

UNIVERSITY OF THESSALY
SCHOOL OF HEALTH SCIENCES



FACULTY OF VETERINARY SCIENCE
CLINIC OF MEDICINE

**STUDY ON THE EPIDEMIOLOGY AND THE CLINICAL
IMPORTANCE OF SELECTED INFECTIOUS,
PARASITIC AND METABOLIC DISEASES IN CATS
FROM GREECE**

KASSIOPI-CHRISTINA G. KOKKINAKI, DVM

DOCTORAL THESIS

KARDITSA 2021

ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΕΣΣΑΛΙΑΣ

ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ



ΤΜΗΜΑ ΚΤΗΝΙΑΤΡΙΚΗΣ

ΠΑΘΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ

**ΜΕΛΕΤΗ ΤΗΣ ΕΠΙΔΗΜΙΟΛΟΓΙΑΣ ΚΑΙ ΤΗΣ
ΚΛΙΝΙΚΗΣ ΣΗΜΑΣΙΑΣ ΕΠΙΛΕΓΜΕΝΩΝ ΛΟΙΜΩΔΩΝ,
ΠΑΡΑΣΙΤΙΚΩΝ ΚΑΙ ΜΕΤΑΒΟΛΙΚΩΝ ΝΟΣΗΜΑΤΩΝ
ΤΗΣ ΓΑΤΑΣ ΣΤΗΝ ΕΛΛΑΔΑ**

ΚΑΣΣΙΟΠΗ-ΧΡΙΣΤΙΝΑ Γ. ΚΟΚΚΙΝΑΚΗ, ΚΤΗΝΙΑΤΡΟΣ

ΔΙΔΑΚΤΟΡΙΚΗ ΔΙΑΤΡΙΒΗ

ΚΑΡΔΙΤΣΑ 2021

UNIVERSITY OF THESSALY
SCHOOL OF HEALTH SCIENCES
FACULTY OF VETERINARY SCIENCE

**STUDY ON THE EPIDEMIOLOGY AND THE CLINICAL
IMPORTANCE OF SELECTED INFECTIOUS,
PARASITIC AND METABOLIC DISEASES IN CATS
FROM GREECE**

KASSIOPI-CHRISTINA G. KOKKINAKI, DVM

**DOCTORAL THESIS CONDUCTED AT THE CLINIC OF MEDICINE,
FACULTY OF VETERINARY SCIENCE, SCHOOL OF HEALTH SCIENCES,
UNIVERSITY OF THESSALY**

ADVISORY COMMITTEE

| | | |
|-----------|------------------------|------------|
| Professor | M. N. Saridomichelakis | Supervisor |
| Professor | M. E. Mylonakis | Member |
| Professor | L. Leontides | Member |

ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΕΣΣΑΛΙΑΣ

ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ

ΤΜΗΜΑ ΚΤΗΝΙΑΤΡΙΚΗΣ

**ΜΕΛΕΤΗ ΤΗΣ ΕΠΙΔΗΜΙΟΛΟΓΙΑΣ ΚΑΙ ΤΗΣ
ΚΛΙΝΙΚΗΣ ΣΗΜΑΣΙΑΣ ΕΠΙΛΕΓΜΕΝΩΝ ΛΟΙΜΩΔΩΝ,
ΠΑΡΑΣΙΤΙΚΩΝ ΚΑΙ ΜΕΤΑΒΟΛΙΚΩΝ ΝΟΣΗΜΑΤΩΝ
ΤΗΣ ΓΑΤΑΣ ΣΤΗΝ ΕΛΛΑΔΑ**

ΚΑΣΣΙΟΠΗ-ΧΡΙΣΤΙΝΑ Γ. ΚΟΚΚΙΝΑΚΗ, ΚΤΗΝΙΑΤΡΟΣ

**ΔΙΔΑΚΤΟΡΙΚΗ ΔΙΑΤΡΙΒΗ ΠΟΥ ΕΚΠΟΝΗΘΗΚΕ ΣΤΗΝ ΠΑΘΟΛΟΓΙΚΗ
ΚΛΙΝΙΚΗ ΤΟΥ ΤΜΗΜΑΤΟΣ ΚΤΗΝΙΑΤΡΙΚΗΣ ΤΗΣ ΣΧΟΛΗΣ
ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ ΤΟΥ ΠΑΝΕΠΙΣΤΗΜΙΟΥ ΘΕΣΣΑΛΙΑΣ**

ΤΡΙΜΕΛΗΣ ΣΥΜΒΟΥΛΕΥΤΙΚΗ ΕΠΙΤΡΟΠΗ

| | | |
|-----------|-----------------------|---------------------|
| Καθηγητής | Μ. Ν. Σαριδομιχελάκης | Επιβλέπων |
| Καθηγητής | Μ. Ε. Μυλωνάκης | Μέλος της Επιτροπής |
| Καθηγητής | Λ. Λεοντίδης | Μέλος της Επιτροπής |

Στους γονείς μου

CONTENTS

| | |
|--|----|
| ΣΥΝΤΟΜΟΓΡΑΦΙΕΣ-ABBREVIATIONS | 8 |
| ΠΡΟΛΟΓΟΣ | 10 |
| PART ONE-REVIEW OF THE LITERATURE | 13 |
| 1. Introduction..... | 13 |
| 2. Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV)..... | 13 |
| 2.1. Transmission and pathogenesis of feline leukemia virus (FeLV)..... | 14 |
| 2.2. Transmission and pathogenesis of feline immunodeficiency virus (FIV)..... | 16 |
| 2.3. Epidemiology of feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV)..... | 17 |
| 2.4. Clinical signs and clinicopathologic abnormalities of feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) infections | 18 |
| 3. Feline coronavirus (FCoV) | 22 |
| 3.1. Transmission..... | 23 |
| 3.2. Pathogenesis | 23 |
| 3.3. Epidemiology..... | 23 |
| 4. <i>Bartonella</i> spp..... | 25 |
| 4.1. Transmission and pathogenesis | 25 |
| 4.2. Epidemiology..... | 26 |
| 4.3. Clinical signs and clinicopathologic abnormalities..... | 27 |
| 5. <i>Mycoplasma</i> spp..... | 28 |
| 5.1. Transmission..... | 28 |
| 5.2. Pathogenesis | 29 |
| 5.3. Epidemiology..... | 30 |
| 5.4. Clinical signs and clinicopathologic abnormalities | 31 |
| 6. <i>Toxoplasma gondii</i> | 31 |
| 6.1. Transmission..... | 32 |
| 6.2. Pathogenesis | 32 |
| 6.3. Epidemiology..... | 33 |
| 7. Feline hyperthyroidism | 34 |
| 7.1. Epidemiology..... | 34 |
| 7.2. Clinical signs and clinicopathologic abnormalities | 36 |
| 8. References..... | 37 |
| PART TWO-OUR STUDY | 66 |
| 1. Aims of the study | 66 |

| | |
|---|-----|
| 2. Article No 1 | 67 |
| 3. Article No 2 | 91 |
| 4. Article No 3 | 104 |
| 5. Article No 4 | 145 |
| 6. Article No 5 | 161 |
| CONCLUSIONS | 179 |
| PROPOSALS FOR FUTURE STUDIES | 181 |
| SUMMARY | 182 |
| ΠΕΡΙΛΗΨΗ | 185 |

ΣΥΝΤΟΜΟΓΡΑΦΙΕΣ-ABBREVIATIONS

A.Π.Θ.: Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης
Γ.Π.Α.: Γεωπονικό Πανεπιστήμιο Αθηνών
Π.Θ.: Πανεπιστήμιο Θεσσαλίας
AG: albumin/globulin
ALP: alkaline phosphatase
ALT: alanine aminotransferase
AST: aspartate aminotransferase
BUN: blood urea nitrogen
CCoV: canine coronavirus
CD: cluster of differentiation
CI: confidence interval
CK: creatine kinase
DNA: deoxyribonucleic acid
EDTA: ethylenediaminetetraacetic acid
ELISA: enzyme-linked immunosorbent assay
FCoV: feline coronavirus
FECV: feline enteric coronavirus
FeLV: feline leukemia virus
FIP: feline infectious peritonitis
FIV: feline immunodeficiency virus
FURTD: feline upper respiratory tract disease
γ-GT: gamma-glutamyl transferase
IFAT: indirect immunofluorescence antibody testing
Ig: immunoglobulin
OR: odds ratio
PCR: polymerase chain reaction
RNA: ribonucleic acid
SARS-CoV: severe acute respiratory syndrome coronavirus
SD: standard deviation
T₃: triiodothyronine
T₄: thyroxine

TAMU: Texas A&M University

ΠΡΟΛΟΓΟΣ

Η έρευνα αυτή αποτελεί τη διδακτορική μου διατριβή, πραγματοποιήθηκε στην Παθολογική Κλινική, του Τμήματος Κτηνιατρικής, της Σχολής Επιστημών Υγείας του Π.Θ. και αποσκοπεί στη μελέτη της επιδημιολογίας και της κλινικής σημασίας επιλεγμένων λοιμωδών, παρασιτικών και μεταβολικών νοσημάτων της γάτας στην Ελλάδα.

Στο σημείο αυτό θα ήθελα να εκφράσω τις θερμότερες ευχαριστίες μου στα μέλη της τριμελούς συμβουλευτικής επιτροπής και συγκεκριμένα:

τον κ. Μανώλη Σαριδομιχελάκη, Καθηγητή της Παθολογίας των Ζώων Συντροφιάς στο Τμήμα Κτηνιατρικής του Π.Θ. και επιβλέποντα της διδακτορικής διατριβής, ο οποίος εκτός από το ότι με τίμησε με την εμπιστοσύνη του και μου έδωσε την ευκαιρία να έρθω σε επαφή με την έρευνα, με την συνεχή στήριξή του, η οποία ήταν τόσο επαγγελματική όσο και ψυχολογική και ηθική, τις συμβουλές και την επιστημονική του καθοδήγηση, συνέβαλε ουσιαστικά τόσο στη διεξαγωγή και την ολοκλήρωση αυτής της διατριβής όσο και στη διαμόρφωση της επαγγελματικής και προσωπικής μου πορείας,

τον κ. Ματθαίο Μυλωνάκη, Καθηγητή της Παθολογίας των Ζώων Συντροφιάς στο Τμήμα Κτηνιατρικής του Α.Π.Θ. για την βοήθειά του στην ένταξη στη μελέτη και τη δειγματοληψία από γάτες που προσκομίζονταν στην Κλινική των Ζώων Συντροφιάς του Τμήματος Κτηνιατρικής του Α.Π.Θ., την στήριξή του, το ενδιαφέρον του καθ' όλη τη διάρκεια της διατριβής και την ουσιαστική συμβολή του στη διόρθωση των ερευνητικών εργασιών που προήλθαν από αυτή,

τον κ. Λεωνίδα Λεοντίδη, Καθηγητή της Επιδημιολογίας στο Τμήμα Κτηνιατρικής του Π.Θ., για την πολύτιμη βοήθεια και καθοδήγηση του στον σχεδιασμό της μελέτης, τη στατιστική επεξεργασία και την ερμηνεία των αποτελεσμάτων.

Στο σημείο αυτό θα ήθελα επίσης να απευθύνω ένα μεγάλο ευχαριστώ στον κ. Παναγιώτη Ξενούλη, Αναπληρωτή Καθηγητή της Παθολογίας των Ζώων Συντροφιάς στο Τμήμα Κτηνιατρικής του Π.Θ., τόσο για την πολύτιμη βοήθεια και την ουσιαστική καθοδήγησή του στην διεξαγωγή και την ολοκλήρωση αυτής της διατριβής όσο και για την ψυχολογική και ηθική στήριξη που μου παρείχε καθ' όλη τη διάρκειά της. Επίσης τον ευχαριστώ για την σημαντική βοήθειά του στην ένταξη στη μελέτη και τη δειγματοληψία μεγάλου αριθμού γατών από την Αττική.

Επιπλέον ευχαριστώ θερμά:

τον κ. Joerg Steiner, Professor, College of Veterinary Medicine and Biomedical Sciences, TAMU και τον κ. Jan Suchodolski, Associate Professor, College of Veterinary Medicine and Biomedical Sciences, TAMU για την πολύτιμη βοήθειά τους στην πραγματοποίηση των βιοχημικών εξετάσεων και στην μέτρηση της συγκέντρωσης της ολικής T₄ και της ελεύθερης T₄,

τον κ. Βασίλη Σκαμπαρδώνη, Διδάκτορα του Τμήματος Κτηνιατρικής του Π.Θ., για τη συμβολή του στη στατιστική επεξεργασία των αποτελεσμάτων,

τον κ. Γεώργιο Καζάκο, Αναπληρωτή Καθηγητή Κτηνιατρικής Χειρουργικής και Εντατικής Θεραπείας του Τμήματος Κτηνιατρικής του Α.Π.Θ., για την συμβολή του στην επιλογή των πρωτοκόλλων χημικής συγκράτησης,

τον κ. Ιωάννη Οικονομόπουλο, Καθηγητή Κτηνιατρικής Μικροβιολογίας στο Τμήμα Επιστήμης Ζωικής Παραγωγής και Υδατοκαλλιεργειών του Γ.Π.Α. για την πολύτιμη βοήθειά του στην εκτέλεση των μοριακών εξετάσεων,

την Κτηνίατρο κ. Χρύσα Σίμου, Διδάκτορα του Πανεπιστημίου Αθηνών και τον Κτηνίατρο κ. Θεόδωρο Μπαμπλένη για τη συμβολή τους στην ένταξη στη μελέτη γατών που προσκομίζονταν στα ιδιωτικά τους κτηνιατρεία στην Αθήνα,

τον κ. Αλέξανδρο Κωνσταντινίδη, Διδάκτορα του Τμήματος Κτηνιατρικής του Α.Π.Θ. για την βοήθειά του στην ένταξη στη μελέτη και τη δειγματοληψία από γάτες που προσκομίζονταν στην Κλινική των Ζώων Συντροφιάς του Τμήματος Κτηνιατρικής του Α.Π.Θ.,

την κ. Αντωνία Ματαράγκα, Διδάκτορα στο Τμήμα Επιστήμης Ζωικής Παραγωγής και Υδατοκαλλιεργειών του Γ.Π.Α. για την πολύτιμη βοήθειά της στην εκτέλεση των μοριακών εξετάσεων,

την κ. Λαμπρινή Αθανασίου, Αναπληρώτρια Καθηγήτρια Κτηνιατρικής Γενικής Παθολογίας στο Τμήμα Κτηνιατρικής του Π.Θ. και την κ. Αθανασία Τζιβάρα, μέλος ΕΔΙΠ του Τμήματος Κτηνιατρικής του Π.Θ. για το ανιδιοτελές ενδιαφέρον τους και την ηθική συμπαράσταση σε όλα τα στάδια της διατριβής. Επίσης ευχαριστώ την κ. Αθανασίου για την βοήθειά της στην εξοικείωσή μου με τη μέθοδο IFAT,

τις συναδέλφους και φίλες μου κ. Ξάνθη Ρούσσου, Ελευθερία Δερμισιάδου και Μαρία Καντερέ για την αδιάκοπη και ουσιαστική στήριξή τους, τη βοήθεια και την ενθάρρυνσή τους και

όλο το προσωπικό της Παθολογικής Κλινικής του Τμήματος Κτηνιατρικής του Π.Θ. που δουλέψαμε παράλληλα για την άψογη συνεργασία και παρέα τους.

Τέλος, θέλω να απευθύνω ένα μεγάλο ευχαριστώ και να εκφράσω την απεριόριστη ευγνωμοσύνη μου στην οικογένειά μου για την αγάπη, την υπομονή και την πίστη τους στις δυνατότητές μου. Ιδιαίτερα ευχαριστώ τους γονείς μου, οι οποίοι εκτός από το ότι με στήριξαν και συνεχίζουν να με στηρίζουν για την επίτευξη των στόχων μου στη ζωή, βοήθησαν έμπρακτα κατά τις δειγματοληψίες από γάτες στην Κρήτη.

PART ONE-REVIEW OF THE LITERATURE

1. Introduction

Infectious and parasitic diseases are common in all mammalian species, including domestic cats (*Felis catus*), who are becoming increasingly popular pets in Greece. Although several studies have investigated the prevalence of certain infectious and parasitic diseases in dogs, little is known about the prevalence and epidemiology of specific infectious agents in cats in Greece. This lack of data represents a major drawback for accurate and effective diagnosis, clinical management and prevention of the diseases caused by these infectious agents.

Vector-borne diseases have global impact on the health of domestic cats and are often of zoonotic importance. Due to the fact that fleas, ticks and mosquitoes are common in Greece, vector-borne disease agents such as *Bartonella* spp. and *Mycoplasma* spp., may also be common. In addition, other infectious and parasitic agents, such as feline leukemia virus (FeLV), feline immunodeficiency virus (FIV), feline coronavirus (FCoV), and *Toxoplasma gondii* are also known to be present in Greece. However, few or no reports exist about their prevalence, epidemiology, and clinical and zoonotic importance of the associated diseases.

Finally, even though feline hyperthyroidism is considered the most common endocrinopathy in cats and, according to epidemiologic studies, the prevalence of the disease is increasing worldwide, no relevant information is available for cats in Greece.

2. Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV)

Feline leukemia virus and FIV are retroviruses, causing significant morbidity and mortality in cats.

Although FeLV and FIV are closely related, they differ in their potential to cause disease, because FeLV is more pathogenic than FIV. Both viruses infect domestic cats. In addition, FIV has been isolated from a variety of non-domestic felids, including pumas, lions, leopards and Pallas cats (Soe et al., 1983; Olmsted et al., 1992; Brown et al., 1994; Carpenter et al., 1996; Barr et al., 1997), while FeLV may infect other small felids, including the wild cat *Felis silvestris* and European and Iberian lynxes.

The first description of FeLV was in 1964 in feline lymphoma tissue (Jarrett et al., 1964), while FIV was first isolated in 1986 following the investigation of an immunodeficiency syndrome in a cat colony (Pedersen et al., 1987). Both are members of the *Orthoretrovirinae* subfamily, with FeLV being a γ -retrovirus and FIV being a lentivirus.

Like all retroviruses, FeLV is an enveloped RNA virus that relies on a DNA intermediate for replication. The viral single-stranded RNA is reverse transcribed, by the reverse transcriptase enzyme, into DNA, the so-called provirus, that is usually integrated into the host's cell genome. FeLV exists in several subgroups, the three most important being FeLV-A, FeLV-B and FeLV-C, which are closely related antigenically to each other (Anderson et al., 2000). However, only FeLV-A is contagious to cats, and it passes horizontally, from one cat to another, in nature.

The FIV is associated with a high degree of genetic diversity, leading to the existence of several subtypes, based on envelope gene sequences. However, five major subtypes (A to E) have been recognized worldwide (Sodora et al., 1994), while a new subtype (subtype F) has been recently described in cats from Texas, Portugal, and New Zealand. Most viruses identified so far belong to either subtype A or B.

2.1. Transmission and pathogenesis of feline leukemia virus (FeLV)

Transmission of FeLV occurs primarily via saliva, where virus is found in highest concentrations compared to blood (Hardy et al., 1976). Although transmission may also occur via milk, nasal secretions, feces and urine, their importance in natural transmission is minor (Pacitti et al., 1986). Thus, the major route of transmission is through bite wounds that introduce saliva containing virus, as well as through friendly contacts among cats, such as mutual grooming, sharing water and food dishes, and using common litters. FeLV is transmitted vertically from infected queens to their offspring, leading to embryonic death or viremic kittens which fade rapidly. Iatrogenic transmission may also occur, via contaminated needles, surgical instruments, or blood transfusion, while transmission via fomites is unlikely. Results of a study have shown that cat fleas are potential vectors (*in vitro* isolation of FeLV RNA) but their vectorial role is probably of minor (Vobis et al., 2003).

Initial infection with FeLV usually takes place in the oropharynx and the virus is first found in the local lymphoid tissue. Then, the virus spreads to the periphery via

monocytes and lymphocytes and, during this primary viraemia, it can infect the bone marrow. After bone marrow infection, salivary glands and intestinal linings are infected, leading to virus shedding in large quantities via saliva and feces (Rojko et al., 1982).

Before the development of very sensitive PCR methods, the outcome of infection with FeLV was controversial. Current research has classified the outcomes of FeLV infection as a) abortive infection (comparable to the former “regressor cats”), b) regressive infection (comparable to the former “latent infection”, with or without previous “transient viremia”), c) progressive infection (comparable to the former “persistent viremia”), and d) focal or atypical infection. These outcomes of FeLV infection can be distinguished through testing blood for FeLV p27 antigen, proviral DNA and antibodies. Each outcome depends on the cat’s immune status, the amount of the virus to which the cat was exposed and the duration of contact with a FeLV-shedding cat.

In abortive infections the cat has negative antigen and PCR tests but positive tests for neutralizing antibodies. In these cats, the virus starts to replicate in the local lymphoid tissue of the oropharyngeal area, but replication is terminated by an effective humoral and cell-mediated immune response. This outcome has been linked to a low amount of virus to which the cat has been exposed.

In regressive forms, an effective immune response limits virus replication prior to or at the time of bone marrow infection. Although these cats terminate the viremia, the proviral DNA does exist in bone marrow stem cells. Thus, the cats cannot eliminate completely the virus from their body. Regressor cats remain latently infected for some time, and, rarely, develop FeLV-associated disease such as lymphoma or bone marrow disorders (Pedersen et al., 1977; Flynn et al., 2000; Flynn et al., 2002; Stutzer et al., 2011). Reactivation can occur by stress and/or high doses of corticosteroids or other immunosuppressive drugs (Helfer-Hungerbuehler et al., 2015).

In progressive infection, virus replication occurs, first in the lymphoid tissues, and then in the bone marrow and in mucosal and glandular tissues. These cats are persistently antigenemic, continuously shed the virus, and develop FeLV-associated diseases.

Focal or atypical infections are rare and occur in cats with FeLV infection restricted into certain tissues, such as the spleen, lymph nodes, small intestine,

mammary glands, urinary bladder, and the eyes (Pacitti et al., 1986; Hayes et al., 1989). This persistent atypical local viral replication can lead to intermittent or low-grade production of p24 antigen. Therefore, these cats may have weakly positive or discordant results in antigen tests, or positive and negative results may alternate over time.

2.2. Transmission and pathogenesis of feline immunodeficiency virus (FIV)

Transmission of FIV occurs via saliva or blood, presumably by bites and fight wounds. Vertical or perinatal transmission is rare; however, primary infection of the queen during pregnancy, may result in infection up to 70% of the embryos. In contrast to FeLV, horizontal transmission of FIV between cats, in stable feline populations, rarely occurs. Iatrogenic transmission, via contaminated needles, surgical instruments, or blood transfusions, can also occur, while sexual transmission has not been documented in nature.

Experimental FIV infection is considered to progress in three stages: a transient primary-acute phase, a clinically asymptomatic phase that can last for many years and a terminal “second stage”. In naturally FIV-infected cats these stages may not be clearly distinguishable, while a large proportion of FIV-infected cats may remain free of significant disease or mild clinical signs might not be noticed by their owners (Hayes et al., 1989; Chen et al., 1998; Stutzer et al., 2010; Nesina et al., 2015).

After experimental inoculation, during the acute phase, FIV replicates in dendritic cells, macrophages and CD4+ T lymphocytes of lymphoid organs including lymph nodes, spleen, thymus, and in organs such as the bone marrow, lung, intestinal tract, brain, and kidney. Moreover, during the acute phase, which lasts 6-8 weeks, FIV can be detected in high concentrations in the blood (by culture and PCR). After peak viremia, an immune response takes place, characterized by the reduction of the circulating viral load and the production of FIV-specific antibodies that occurs 2-4 weeks post-inoculation.

Following the acute phase, the asymptomatic phase begins, which can last for years or be lifelong. During this stage, viremia is absent or in low levels, and for this reason, antigen testing is commonly negative and not recommended in clinical or

epidemiological studies. The infected cat remains free of clinical signs due to successful immune response that inhibits viral replication.

However, at some time point during this stage, a progressive dysfunction of the immune system can occur, and mild or intermittent clinical signs can be seen. In a proportion of infected cats, this can lead to the terminal second stage which is characterized by generalized lymphoid depletion and finally death (Rohn et al., 1994; Tsatsanis et al., 1994; Mendoza et al., 2013).

2.3. Epidemiology of feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV)

Prevalence

The prevalence of these infections varies greatly among countries and regions and depends on the population tested. Studies have reported an overall prevalence of FeLV infection of 2.3-3.3% in North America (Luria et al., 2004; Levy et al., 2006), 0-2.9% in Asia (Nakamura et al., 2000; Maruyama et al., 2003), and 0-15.6% in Europe. A prospective European study on the prevalence of FeLV infection conducted in 32 countries showed an overall prevalence of 2.3% (Studer et al., 2019).

The prevalence of FIV infection has been reported to be 2.5-23% in North America (Little, 2005; Levy et al., 2006), 0-22% in Asia (Miyazawa et al., 1998; Nakamura et al., 2000) and 2.3-11.3% in Europe (Hartmann and Hinze, 1991; Bandecchi et al., 2006).

Risk factors

Several risk factors for FeLV and FIV infections have been reported and they are only slightly different between these two viruses. Risk factors for both infections include male gender, non-neutering, adulthood, outdoor access, and unhealthy status, while overcrowded conditions and crossbred have been reported as risk factors for FeLV and FIV infection, respectively.

From a behavioral perspective, male cats have been shown to be more aggressive than females, leading to a greater risk of bite wounds and FeLV and/or FIV transmission. Similarly, bite wounds are more common in intact than neutered cats. Outdoor access is also a risk factor for both FeLV- and FIV-seropositivity, since

cats living outdoors or having outdoor access have increased chance to interact with infected cats (Yamamoto et al., 1989; Levy et al., 2006; Hosie et al., 2009). Moreover, older cats are more commonly infected with FeLV and FIV, possibly because they have more time to be exposed to these viruses (Levy et al., 2006; Spada et al., 2012; Liem et al., 2013; Stavisky et al., 2017). Illness is also a risk factor for both retroviral infections. In other words, sick cats tend to be more frequently infected by FeLV and/or FIV than healthy cats, as has been reported in several studies (Little et al., 2009; Burling et al., 2017). Both FeLV and FIV are expected to be more prevalent in sick cats than in healthy ones because both viruses can cause immunosuppression and are associated with many clinical manifestations.

Overcrowded environment is also a risk factor for FeLV, as demonstrated in several studies (Polak et al., 2014; Studer et al., 2019). It is known that transmission of the virus can be either through bite wounds or prolonged close contact with infected cats because of nursing, mutual grooming, and sharing of food, water, and litter pans.

Mixed breed cats are more frequently FIV-infected than pedigree cats (Gleich et al., 2009), mainly because the latter are commonly kept indoors, or their outdoor access is limited. In addition, awareness amongst cat breeders of the risks of FIV infection, leads to frequent testing and, thus, most cat-breeding facilities are kept FIV-free.

2.4. Clinical signs and clinicopathologic abnormalities of feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) infections

Clinical manifestations of both retrovirus infections are highly variable and depend on viral and host factors, such as the virus subgroup, the cat's age at the time of infection, since older cats are less susceptible (Hoover et al., 1976), and the exposure to secondary pathogens (Podell et al., 1997; Pedersen et al., 2001). For both retroviruses there is a long asymptomatic phase, even in cats with progressive infection, but eventually clinical signs may occur after months to years.

In the acute phase after experimental infection with FIV, which can last several days to months, clinical signs are mild and include fever, generalized lymph node enlargement (Obert and Hoover, 2000), enteritis, stomatitis, dermatitis, conjunctivitis, and upper respiratory tract disease.

After a long asymptomatic phase, a wide range of disorders are associated with FeLV or FIV infections, including tumors, blood dyscrasias, neurologic dysfunction, immune-mediated diseases, immunosuppression with secondary opportunistic infections, gingivostomatitis, reproductive disorders and fading kitten syndrome (Hoover and Mullins, 1991; Tenorio et al., 1991; Ryan et al., 2005; Hartmann, 2011). The pathomechanism of these disorders is different for each virus. It is also worth mentioning that FeLV potentially causes severe clinical syndromes and progressive infection is associated with a decrease in life expectancy, since 70% to 90% of progressively infected cats will die within 18 months to 3 years (Hardy et al., 1976). On the contrary, most naturally FIV-infected cats do not present severe clinical syndromes, with most of the latter being potentially treatable.

The most common tumors associated with FeLV infection are lymphoma and leukemias, less often other hematopoietic tumors, and rarely non-hematopoietic malignancies, including fibrosarcoma, osteochondroma and neuroblastoma.

The most common tumors associated with FIV infection are lymphoma and leukemia and uncommonly fibrosarcoma, squamous cell carcinoma and mast cell tumor. FIV-infected cats mostly develop B-cell lymphomas, and they have 5-fold increased risk of lymphoma or leukemia compared to non-infected cats (Poli et al., 1994; Callanan et al., 1996). In contrast to FeLV, it is proposed that FIV causes oncogenesis indirectly (Beatty et al., 1998; Wang et al., 2001) due to chronic B-cell hyperplasia or decreased cell-mediated immune surveillance.

Due to immunosuppression, FeLV- and FIV-infected cats are more susceptible to secondary infections and/or to infection by agents to which they would normally be resistant, such as *Salmonella* spp. However, the immunosuppression is more severe for FeLV and infected cats often have concurrent bacterial, viral, protozoal, and/or fungal diseases (Cotter, 1991; Powers et al., 2018), including feline upper respiratory tract disease-FURTD (O'Connor et al., 1991; Barrs et al., 2000; Crawford et al., 2001; Sykes et al., 2007; Bauer et al., 2008; Macieira et al., 2008; Gentilini et al., 2009; Burling et al., 2017; Studer et al., 2019). On the other hand, bacterial skin diseases that have been associated with FIV include folliculitis, superficial spreading pyoderma, abscesses, paronychia, and otitis. Fungal, viral, and parasitic infections, such as dermatophytosis, dermatophyte pseudomycetoma and infections with *Candida*, *Malassezia*, *Demodex cati*, and cow-poxvirus, have also been reported in FIV-positive cats. In addition, idiopathic lymphocytic mural folliculitis, plasma cell

pododermatitis, and generalized miliary dermatitis with alopecia and scaling have been associated with FIV.

Gingivostomatitis is very common in retrovirus-infected cats and is one of the most typical clinical findings of FIV infection, being present in up to 50% of the cases (Hofmann-Lehmann et al., 1995; Knotek et al., 1999; Madhu Ravi, 2010; Ravi et al., 2010; Kornya et al., 2014; Beczkowski et al., 2015). Gingivostomatitis has been attributed to an aberrant immune response against chronic antigenic stimulation or to immune dysregulation (Tenorio et al., 1991).

Immune stimulation caused by retroviruses, may lead to immune-mediated diseases, which more frequently develop in FIV- than FeLV-infected cats. These diseases are caused by loss of T-suppressor cell activity and the formation of antigen-antibody immune complexes, and include immune-mediated hemolytic anemia, glomerulonephritis, uveitis, and polyarthritis (Anderson et al., 1971; Brightman et al., 1991).

Gradually deteriorating neurologic dysfunction is one of the few syndromes that are directly caused by FeLV and FIV. In FeLV-infected cats, most neurologic signs are caused by lymphoma or lymphocytic infiltrations in the central nervous system and the main clinical manifestations include anisocoria, mydriasis, central blindness, Horner's syndrome, urinary incontinence, hyperesthesia, paresis, and paralysis (Carmichael et al., 2002; Forman et al., 2009). Similar signs are present in about 5% of symptomatic FIV-infected cats and they seem to be strain-dependent (Power et al., 1998). They include behavioral changes, disturbed sleep patterns, twitching movements of the face and tongue, compulsive roaming, delayed righting and pupillary reflexes, anisocoria, loss of bladder and rectal control, seizures, ataxia, nystagmus, and intention tremors (Prospero-Garcia et al., 1994; Gunn-Moore et al., 1996; Phillips et al., 1996; Steigerwald et al., 1999).

Reproductive disorders attributed to FeLV include abortion, fetal resorption, and neonatal death. Abortion usually occurs in the late stages of gestation and sometimes is followed by bacterial endometritis, especially if there is concurrent neutropenia. Fading kitten syndrome may develop when kittens are born by infected queens. Thymic atrophy is observed in these kittens, resulting in severe immunosuppression, wasting and early death usually within the first 2 weeks of their life (Dunham and Graham, 2008).

In some FeLV-infected cats a diagnosis of benign peripheral lymphadenopathy has been reported. This sign should be interpreted with caution since it must be differentiated from multicentric lymphoma (Moore et al., 1986).

Both FeLV and FIV infections are associated with a variety of clinicopathologic abnormalities. Blood dyscrasias can occur due to bone marrow suppression and they are more common and more severe in FeLV-infected cats. Hematologic disorders related to FeLV infection include anemia, leukocyte and platelet abnormalities and pancytopenia.

Overall, FeLV-infected cats may develop anemia, usually non-regenerative, through various pathomechanisms. Regenerative anemia is uncommon and may be associated with blood loss (e.g., due to thrombocytopenia) or hemolysis (e.g., concurrent infection by hemoplasmas or immune-mediated hemolytic anemia). Nonregenerative anemia may occur due to bone marrow aplasia, myelophthisis, chronic disease, myelodysplasia, myelofibrosis, and nutritional deficiencies (Shelton and Linenberger, 1995; Shimoda et al., 2000; Hisasue et al., 2001; 2006). Anemia of chronic disease (e.g., concurrent infections or neoplasia), occurs because of excessive inflammatory cytokine production and subsequent abnormal iron utilization and reduced red blood cell survival. Pure red cell aplasia is a severe nonregenerative anemia which is typically due to FeLV subtype C, because this virus interacts and downregulates the cell-surface receptor that functions as heme exporter, resulting in cell death (Tailor et al., 1999; Quigley et al., 2000; George et al., 2002). Nevertheless, the type of this nonregenerative anemia is rare. Thrombocytopenia may occur, due to immune-mediated destruction of platelets or bone marrow suppression. In addition, giant platelets, thrombocytosis, and shorter platelet lifespan, have been observed in some progressively FeLV-infected cats. Neutropenia is present in some cats and can be caused by immune-mediated mechanisms and/or myelosuppression (Brown and Rogers, 2001; Gleich and Hartmann, 2009; Stutzer et al., 2010). Lymphopenia, because of lymphocyte destruction from direct replication of FeLV, may also occur and it is characterized by loss of CD4⁺ helper T cells and inverted CD4/CD8 ratio (as typically seen in FIV infection).

In contrast to FeLV, FIV-associated cytopenias are rather uncommon. The most common hematological abnormality is neutropenia, which is present in about 25% of infected cats. Neutropenia may occur either in the acute phase of infection (and resolve in the asymptomatic phase), or in the later phase of infection when the

cat develops clinical signs. During this phase, patients may also develop other cytopenias including lymphopenia and anemia, which in most cases is mild.

Abnormalities found on serum biochemistry in FeLV and FIV-infected cats are typically mild and, in most cases, reflect concurrent diseases. Nevertheless, FIV-infected cats have a significantly increased risk of hyperglobulinemia (Hofmann-Lehmann et al., 1997; Miro et al., 2007; Gleich and Hartmann, 2009; Stutzer et al., 2010). This is a direct consequence of the virus that triggers polyclonal B cell activation and immunoglobulin production, and has been documented in both natural and experimental infections (Flynn et al., 1994). Less commonly, azotemia has been reported in FIV-infected cats in the absence of other detectable causes of kidney disease (Poli et al., 1993). In a long-term study of experimentally FeLV-infected cats, urea concentrations and serum activities of AST were significantly higher compared to non-infected controls (Soe et al., 1983).

3. Feline coronavirus (FCoV)

Feline coronavirus (FCoV) is a large, spherical, enveloped, single-stranded, positive-sense, RNA virus classified in the order *Nidovirales*; family *Coronaviridae*; genus *Alphacoronavirus*; species *Alphacoronavirus 1*. It is a highly contagious and ubiquitous virus of domestic cats and wild felids and is extremely common in crowded environments. FCoV causes enteric infection and sporadically leads to a fatal, systemic disease, named feline infectious peritonitis (FIP). With the discovery of the severe acute respiratory syndrome coronavirus (SARS-COV) that commonly infects bats, and apparently jumped from civets and raccoon to humans causing the recent and ongoing pandemic, the suspicion that coronaviruses may be responsible for zoonoses has been reinforced. However, FCoV is not infectious for other species (including humans) and is different from the coronavirus which causes COVID-19 in people which is a *Betacoronavirus*.

FCoV strains are subdivided into two distinct biotypes; feline enteric coronavirus (FECV) and feline infectious peritonitis virus (FIPV), which are both divided into two serotypes, I and II. Serotype I FCoV includes unique feline strains, while serotype II appears to have arisen from recombination between type I FCoV and canine coronavirus (CCoV). Although serotype I is most prevalent worldwide, both serotypes I and II can cause FIP.

3.1. Transmission

Transmission of FCoV occurs primarily via the fecal-oral route. The major source of infection is the litter box, and the transmission results from ingestion of infected feces, by paw grooming during litter tray use, or by eating contaminated food. Transplacental transmission and transmission via saliva may occur, but their importance is minor (Addie and Jarrett, 1990, 2001). The virus can persist on fomites for 3-7 weeks (Hartmann, 2005; Pedersen, 2009; Kipar et al., 2010).

3.2. Pathogenesis

Regarding the two biotypes of FCoV, FECV mainly replicates in the intestinal epithelium, causing occasionally mild enteritis, whereas FIPV replicates in the monocytes and macrophages, causing fatal disease. Since all FCoV can be found and replicate systemically (Addie et al., 2009), it is now accepted that these viruses are not different species, but they represent virulence variants of the same virus. Thus, it is suggested to call both biotypes FCoV, including "the less virulent FCoV" and "the FIP-associated FCoV". The most widely accepted hypothesis of developing FIP is the internal mutation theory. Infection with FCoV initially occurs in intestinal epithelial cells, and subsequently, in an unpredictable proportion of cats, the virus mutates and acquires the ability to enter and efficiently replicate in monocytes and macrophages, which allows for the severe disease. The mutations causing this critical change in virulence have been ascribed to numerous genes (spike gene and accessory genes; 3c, 7a and 7b).

Although FCoV infection is typically asymptomatic, mild diarrhea may rarely occur due to replication of the virus in enterocytes (Sabshin et al., 2012; Desmarests et al., 2013). On the contrary, the clinical signs of FIPV infection vary considerably. Two clinical forms of FIP are well-documented: a "wet" or effusive form, characterized by vasculitis and polyserositis, and a "dry" or non-effusive form, characterized by pyogranulomatous lesions in several organs (Kipar et al., 2005). Many cats may, in fact, may share features of both forms of the disease.

3.3. Epidemiology

Prevalence

FCoV infection has been reported worldwide and around 40% of domestic cats are infected. Since FCoV is highly contagious, the prevalence of seropositivity may be up to 90% in crowded environments, like catteries, shelters, and multi-cat households (Addie and Jarrett, 1992b; Addie, 2000). However, only 5% to 12% of infected cats develop FIP (Addie and Jarrett, 1992a; Addie and Jarrett, 1992b; Addie et al., 1995). In addition, studies have reported an overall seroprevalence of FCoV of 0-84% in Europe (Sparkes et al., 1992; Herrewegh et al., 1997; Chatzis et al., 2014), 0-71.6% in America (Pedersen, 1976; Levy et al., 2008), 6.6-28.2% in Asia (An et al., 2011; Wang et al., 2014), 18-40% in Australia (Jones and Hogg, 1974; Watson et al., 1974) and 35% in South Africa (Bland van den Berg and Botha, 1977).

Risk factors

The most well-documented risk factor for FCoV-seropositivity is living in multi-cat environments, such as breeding catteries and shelters. In addition, not only the number of the cats, but also their population density, and the length of time they stay in these environments are associated with the prevalence of FCoV infection. In a study from the United Kingdom, it was reported that cats originating from multi-cat households were approximately two times more likely to be FCoV-seropositive compared to cats from single-cat households (Cave et al., 2004). Similarly, in a preliminary study on the epidemiology of FCoV in cats from Turkey, the reported seroprevalence among cats from multi-cat environments was 62% versus 4% among single-cat households (Pratelli et al., 2009). A study of cats relinquished to a United Kingdom rescue charity indicated that cats spent more than 60 days in a shelter were five times more likely to be FCoV-seropositive (Cave et al., 2004). On the contrary, stray or feral cats are less likely to be FCoV-seropositive compared to pet cats, sheltered cats and cats living in catteries, likely due to lower population densities and because the former have a larger territory and they bury their feces, minimizing the fecal-oral FCoV transmission.

In addition to the risk factors mentioned above, male gender, young age, and purebred have also been suggested as risk factors for developing FIP (Pedersen, 1976; Rohrbach et al., 2001; Cave et al., 2004; Pesteanu-Somogyi et al., 2006; Sharif et al., 2009). In two studies, conducted in Taiwan and North Carolina, 88% and 67% of FIP-confirmed cases, respectively, were less than 2 years old (Rohrbach et al., 2001; Tsai et al., 2011) and, in general, 70% of FIP cases occur in cats younger than 1 year

(Hartmann, 2005). Several breeds have been found to be more susceptible to the disease, including Abyssinian, Bengal, Birman, British Shorthair, Devon Rex, Himalayan, and Ragdoll (Pesteanu-Somogyi et al., 2006; Worthing et al., 2012). In addition, cats with high titers of antibodies against FCoV have a greater risk of developing FIP (Poland et al., 1996; Foley et al., 1997; Pedersen, 2009). Stress experienced by FCoV-infected cats, such as after surgery or moving to a new environment, may precipitate the development of FIP (Riemer et al., 2016) and the same is true for immunosuppressive conditions, such as co-infection with FeLV and FIV (Cotter et al., 1975; Hardy et al., 1976; Foley et al., 1997).

4. *Bartonella* spp.

Bartonellosis is a vector-borne disease with global impact on the health of domestic cats and of zoonotic importance (Boulouis et al., 2005; dos Santos et al., 2008; Lin et al., 2011). *Bartonella* species are small, Gram-negative intracellular bacteria and cats are the main reservoir of *Bartonella henselae*, *B. clarridgeiae* and *B. Koehlerae*, and accidental hosts of *B. quintana*, *B. bovis* and *B. vinsonii* subsp. *berkhoffii*. The most common species infecting cats is *B. henselae*, the main causative agent of cat scratch disease (CSD) in humans (Boulouis et al., 2005), followed by *B. clarridgeiae*. Cat scratch disease is characterized by regional lymphadenopathy and prolonged or relapsing fever, but immunocompromised people may additionally present encephalopathy, osteomyelitis, retinitis, endocarditis, bacillary angiomatosis and parenchymal bacillary peliosis.

4.1. Transmission and pathogenesis

B. henselae is naturally transmitted among cats by the cat flea *Ctenocephalides felis* (Bouhsira et al., 2013). Adult *C. felis* can become infected and support replication of *B. henselae* following ingestion of a blood meal from an infected cat. Experimentally infected adult fleas remain infectious for their entire life, starting from 24 h after ingestion of the blood meal, and the bacteria can be cultured from flea feces up to 9 days after they were fed infected blood (Higgins et al., 1996). The primary mode of transmission to cats is by contamination of open wounds with feces of infected fleas, while other modes could be the ingestion of infected fleas or flea feces and fighting with other cats (Bouhsira et al., 2013). It has been suggested

that ticks may also have a vectorial role, since transstadial transmission of *B. henselae* has been demonstrated in *Ixodes ricinus* (Cotte et al., 2008). Non-vectorial transmission may occur through blood transfusions, since experimentally infected cats develop chronic and persistent bacteremia (Kordick and Breitschwerdt, 1997).

In the infected cat, *Bartonella* inhabits erythrocytes and vascular endothelial cells. Following infection, chronic and recurrent bacteremia occurs mostly in young cats, under the age of two years. Cats experimentally infected by *B. henselae* and *B. clarridgeiae* presented bacteriaemia for as long as 454 days post-infection (Kordick et al., 1999), and bacteremia was intermittent, occurring at irregular intervals ranging between 1 and 4.5 months. Prolonged (for at least 3 years) recurrent bacteremia has also been demonstrated in naturally infected cats, but this was more likely due to their reinfection. The main factor accounting for the persistent bacteremia is the ability of the organism to avoid elimination by the immune system, via intracellular location, frequent genetic rearrangements, and alteration of outer membrane proteins. As the host-adapted reservoir of *Bartonella*, infection of cats usually has minimal health consequences.

4.2. Epidemiology

Prevalence

The prevalence of *Bartonella* spp. infection varies greatly among countries and regions and depends, not only on the feline population tested, but also on the environmental conditions, with highest figures in areas that are favorable for arthropod vectors, mainly fleas. The seroprevalence has been reported to be 0-68% in Europe (Bergh et al., 2002; Mietze et al., 2011), 0-85.2% in the USA (Jameson et al., 1995; Levy et al., 2008), 37% in Australia (Barrs et al., 2010), and 11-59% in Africa (Barrs et al., 2010; Al-Kappany et al., 2011; Tiao et al., 2013). For comparison, epidemiological studies suggest that the overall prevalence of active infection is typically less than 15% (Solano-Gallego et al., 2006; Ishak et al., 2007; Kamrani et al., 2008; Tabar et al., 2008; Gutiérrez et al., 2013; Maia et al., 2014; Silaghi et al., 2014; Otranto et al., 2017), but higher rates have also been reported, such as 67% in Portugal (Alves et al., 2009).

Risk factors

The most well-documented risk factor for *Bartonella* spp. infection is flea infestation (Chomel et al., 1996; Foil et al., 1998; Guptill et al., 2004). In addition, younger cats, especially those under 2 years, are more likely to present bacteremia compared to older cats, while the latter appear to be more likely to become seropositive compared to former (Zangwill et al., 1993; Koehler et al., 1994; Chomel et al., 1995; Jameson et al., 1995; Ueno et al., 1995; Breitschwerdt and Kordick, 2000). Cats with outdoor access are more likely to become infected, due to increased access to flea-infested environment (Chomel et al., 1995; Branley et al., 1996; Chomel et al., 1999; Finkelstein et al., 2002; Guptill et al., 2004; Nutter et al., 2004). Similarly, multi-cat household is a risk factor for *Bartonella* infection due to the increased number of potential hosts (other infected cats) and vectors (Gurfield et al., 2001).

4.3. Clinical signs and clinicopathologic abnormalities

Cats naturally infected with *Bartonella* spp. may have chronic bacteremia but no clinical signs; rarely, they develop endocarditis, myocarditis, osteomyelitis, polyarthritis, and uveitis (Guptill et al., 1997; Kordick et al., 1999). In addition, it has been suggested that *Bartonella* infection could play a role in chronic gingivostomatitis, presumably due to an immune response to chronic antigenic stimulation. However, conflicting data exist regarding the association between gingivostomatitis and *Bartonella* spp. bacteremia and/or seropositivity. In two studies of naturally infected cats, an association between seropositivity and stomatitis was suggested (Ueno et al., 1996; Glaus et al., 1997), while, in another study, an association was found between *Bartonella* spp. bacteremia and oral disease, but not between seropositivity and oral disease (Sykes et al., 2010). Conversely, results of a study in cat shelters, indicated an association between seropositivity, but not bacteremia, and oral lesions (Namekata et al., 2010). The association between gingivostomatitis and *Bartonella* spp. infection requires further investigation.

Most cats experimentally infected with *Bartonella* spp. do not show clinical signs. Occasionally, when signs occur, they are mild and vary depending on the inoculated strain of *B. henselae*. The reported clinical signs include self-limited lethargy and anorexia (Kordick et al., 1999; Namekata et al., 2010), localized or

generalized peripheral lymphadenomegaly, mild neurologic signs, and reproductive failure.

Laboratory abnormalities in naturally infected cats are limited to mild anemia, leukocytosis, eosinophilia, and typically polyclonal hyperglobulinemia due to the prolonged bacteremia (Chomel et al., 2003; Ishak et al., 2007; Whittemore et al., 2012).

5. *Mycoplasma* spp.

Hemoplasmas (hemotropic mycoplasmas) are organisms that infect red blood cells. They can result in hemolytic anemia in a wide variety of mammals, including domestic cats. Many of them are now classified within the genus *Mycoplasma* of the *Mycoplasmataceae* family (Neimark et al., 2001; Messick et al., 2002; Neimark et al., 2004). However, results of a recent study suggest that although hemoplasmas belong to this family, they may comprise their own separate genus (Hicks et al., 2014). The three main species that are known to infect cats, alone or in combination, include, *Mycoplasma haemofelis*, *Candidatus Mycoplasma haemominutum* and *Candidatus Mycoplasma turicensis*. Moreover, a fourth species, *Candidatus Mycoplasma haematoparvum*-like has recently been reported in cats (Martinez-Diaz et al., 2013), but its clinical importance remains unclear (Sykes et al., 2007; Martinez-Diaz et al., 2013).

5.1. Transmission

Although the natural mode of transmission of the infection among cats is not clear, arthropod vectors, including *C. felis*, and interaction with other infected cats have been proposed (Sykes et al., 2007; Museux et al., 2009; Sykes et al., 2010). In particular, *C. felis* has been implicated in feline hemoplasma transmission (Woods et al., 2003; Lappin et al., 2004) and, in a study, cats experimentally infected with *M. haemominutum* transferred the organism to fleas (Woods et al., 2005). Ticks have also been proposed as potential vectors, because feline hemoplasma DNA has been amplified from ticks parasitizing cats (Duplan et al., 2018). However, concrete evidence for their role in the natural transmission of feline hemoplasmas does not exist. It has been suggested that cat fights are involved in transmission and that cat-bite abscesses are the most frequent disorder preceding infection with hemoplasma by

a few weeks. Furthermore, the association between hemoplasma infection and male gender and/or FIV infection, demonstrated in some studies, could also imply that cat fights are a potential route of transmission. Another possible means of transmission is blood transfusion (Pennisi et al., 2015).

5.2. Pathogenesis

M. haemofelis is the most pathogenic feline hemoplasma species. Acute infection may result in severe, and sometimes life-threatening, hemolytic anemia, but, in some cats, the anemia is mild. The acute disease may occur in immunocompetent cats, and irrespectively of the age, although younger cats are more likely to develop clinical illness (Tasker, 2010). Based on studies of experimentally infected cats, clinical signs occur 2-34 days post-infection and anemia lasts from around 18 up to 30 days. In most cases, the anemia is followed by a significant regenerative response with marked reticulocytosis.

Ca. M. haemominutum infection is rarely the causative agent of anemia in the absence of co-infection with another hemoplasma species or of immune compromise. However, rare cases of mild to moderate anemia have been reported in the absence of concurrent infections (Reynolds and Lappin, 2007; Weingart et al., 2016). In general, it is possible that different strains of each of the feline hemoplasma species exist, and that these strains vary in pathogenicity.

Like *Ca. M. haemominutum*, the pathogenicity of *Ca. M. turicensis* is supposed to be mild and that concurrent infections should co-exist to result in hemoplasmosis, although hemolytic anemia has been reported (Willi et al., 2005).

Long-term carrier status can occur with all feline hemoplasmas. Cats with latent *M. haemofelis* infections (carriers) occasionally have low number of organisms visible in blood smears. Their HCT may be normal or slightly to moderately decreased, but typically not lower than 20%. Carrier cats do not show clinical signs, but reactivation can occur and result in disease (Harvey and Gaskin, 1978).

5.3. Epidemiology

Prevalence

The prevalence of hemoplasma infection varies greatly among countries and regions and depends on the feline population tested. Countries with warmer climates appear to have higher prevalence rates.

In general, on the basis of studies that have investigated infection by all three hemoplasma species by PCR, *Ca. M. haemominutum* has been found to be the most common species, with prevalence ranging from 0% to 46.7% (Bauer et al., 2008; Kamrani et al., 2008; Levy et al., 2008; Gentilini et al., 2009; Barrs et al., 2010; Tanahara et al., 2010; Lobetti and Lappin, 2012). *M. haemofelis* and *Ca. M. turicensis* follow with median prevalence of 4.8% and 2%, respectively.

All three hemoplasma species have been described worldwide, sometimes in combined infections. The overall PCR-based prevalence of feline infections with hemoplasmas, has been reported at 32.1% in South Africa (Lobetti and Tasker, 2004), 27.2% in Australia (Tasker et al., 2004), 26.4% in Asia (Tanahara et al., 2010), 12-27% in the USA (Sykes et al., 2008) and 4-43% in Europe (Mifsud et al., 2020).

Risk factors

In several studies, male gender has been reported as a risk factor for hemoplasma species infection (Harrus et al., 2002; Willi et al., 2006; Sykes et al., 2008). From a behavioral perspective, male cats have been shown to be more aggressive than females, leading to a greater risk of bite wounds and hemoplasma transmission. Similarly, outdoor access and cat bite abscesses have been suggested as risk factors (Willi et al., 2006). Cats living outdoors or having outdoor access have an increased chance of aggressive interactions with hemoplasma-infected cats and of exposure to fleas. Non-pedigree cats are more likely to become infected compared to purebred cats (Jenkins et al., 2013). The results of several studies indicate that older cats are more likely to be infected compared to younger cats (Tasker et al., 2003; Willi et al., 2006). A possible explanation of this association could be that older cats have higher chance of acquiring chronic subclinical infections over their lifetime. Finally, some studies have suggested that FIV is a risk factor for hemoplasma infection (Macieira et al., 2008; Gentilini et al., 2009).

As already mentioned, *C. felis* has been implicated in the transmission of feline hemoplasmas, despite the limited evidence for transmission by fleas under experimental or natural conditions (Woods et al., 2006). However, regular use of ectoparasiticides has been associated with decreased risk of hemoplasma infection (Tasker et al., 2018).

5.4. Clinical signs and clinicopathologic abnormalities

The clinical signs of hemoplasma infections are variable and depend on the stage of the infection, the host response to the organism, the health status of the host, and the hemoplasma species involved. Many of the clinical signs of hemoplasmosis result from anemia or the underlying immune-mediated processes. Naturally infected cats may have asymptomatic chronic bacteremia, or they may develop fever, anorexia, weight loss, dehydration and/or splenomegaly (Harrus et al., 2002; Tasker, 2010). Lethargy and weakness have also been reported. In a recent retrospective study, the prevalence of hemoplasma infection in 106 cats with pyrexia was 7.5% (Spencer et al., 2017), and in a study of 22 anemic cats naturally infected with hemoplasma species, 10% of them had fever (Weingart et al., 2016). In experimentally infected cats, only those infected with *Ca. M. haemominutum* showed mild or no clinical signs, with occasional fever (Westfall et al., 2001).

Laboratory abnormalities include mild to severe hemolytic anemia, leukopenia, lymphopenia, eosinopenia, monocytosis, hypergammaglobulinemia, hyperbilirubinemia, and increased activity of alanine aminotransferase (Kewish et al., 2004; Raimundo et al., 2016).

6. *Toxoplasma gondii*

Toxoplasmosis is one of the most important protozoan diseases with a global impact on the health of domestic cats and is also of zoonotic importance (Tenter et al., 2000). The causative agent is *Toxoplasma gondii*, which infects virtually all species of warm-blooded animals. Domestic cats and other felids are the definitive hosts that excrete oocysts (Su et al., 2003).

6.1. Transmission

The main modes of transmission, in both intermediate and definitive hosts, are congenital infection through the placenta, ingestion of oocyst-contaminated food or water and ingestion of infected raw tissue, with the latter being the primary source of infection in cats (Hill and Dubey, 2002). Other minor modes of transmission include blood transfusion, lactation and transplantation of tissues and organs (Bernsteen et al., 1999).

6.2. Pathogenesis

During the life cycle of *T. gondii*, three developmental stages can infect cells: a) tachyzoite (a form of rapid multiplication that is found in acute infections), b) bradyzoite (a form of slow multiplication that is characteristic of chronic infection terminating to tissue cyst formation), and c) sporozoite, which is produced only in the definitive host during the sexual reproduction and is released as oocysts in the feces.

The parasite has two different life cycles, the entero-epithelial that occurs only in the definitive feline host, and the extra-intestinal which occurs in all hosts. Most cats are infected by ingesting intermediated hosts. Following ingestion, bradyzoites are released in the stomach and intestine of the cat from the tissue cysts of the prey. The sexual, entero-epithelial cycle follows and terminates in the shedding of oocysts to the environment through feces. Cats can shed oocysts for only 3-10 days after infection by tissue cysts-bradyzoites (97% of cases), or for up 18 days in the rare case that cats become infected by ingesting oocysts or tachyzoites (Dubey, 1996, 1997, 2002). Once passed to the environment, sporulation occurs in 1-5 days and the sporulated (infectious) oocysts can survive for months to years. After the primary infection of a cat, subsequent re-infections do not usually result in oocyst shedding, and even if this occurs, the load of shed oocysts is low.

The extra-intestinal life cycle of *T. gondii* may occur after the ingestion of tissue cysts or oocysts. After the exposure, sporozoites excyst in the lumen and become tachyzoites by an asexual process. Tachyzoites multiply intracellularly in almost in any cell of the body and eventually encyst. The ensuing tissue cysts contain numerous bradyzoites.

Feline infection with *T. gondii* is usually subclinical, although vertical toxoplasmosis or infection of immunocompromised cats may cause severe disease, and even death (Dubey et al., 2020).

6.3. Epidemiology

Prevalence

The global prevalence of *T. gondii* seropositivity, based on meta-analyses, has been reported to be 35% and 32.9% in cats and humans, respectively (Bigna et al., 2020; Montazeri et al., 2020). Several studies have examined the seroprevalence of *T. gondii* in cats in various countries, and, based on the results, a wide geographical variation is evident. In Europe, seroprevalence has been reported to be 41-60.8% in Northern Europe (Must et al., 2015; Saevik et al., 2015), 10-84.7% in Southern Europe (Millan et al., 2009; Miro et al., 2011), 19.2-65.5% in Western Europe (Bennett et al., 2011; Afonso et al., 2013), 14.7-39.3% in Eastern Europe (Pavlova et al., 2016; Shuralev et al., 2018) and 47-81.3% in Central Europe (Sroka and Szymańska, 2012; Shuralev et al., 2018). In America, studies have reported an overall seroprevalence of 1.1-100% in North America (Bevins et al., 2012; Jimenez-Coello et al., 2013), 0-82.8% in South America and 25% in Central America (Furtado et al., 2015; Teixeira et al., 2016; Rengifo-Herrera et al., 2017). In addition, the reported seroprevalence in North Africa varies from 50% to 97.5%, in West Africa from 4.4% to 36.2% and it is reported to be 3.9% in South Africa (Al-Kappany et al., 2010; Kamani et al., 2010; Ayinmode et al., 2017; Lopes et al., 2017; Yekkour et al., 2017), while in Asia ranges between 2.2% and 82.8% (Hong et al., 2013; Asgari et al., 2018).

Risk factors

The greatest risk factor for *T. gondii* seropositivity is hunting and ingestion of tissue cysts in prey species, including rodents and birds. Also, ingestion of mechanical vectors such as cockroaches and earthworms has been suggested as a possible mode of infection. Outdoor access is a risk factor for seropositivity, and this is obviously associated with the opportunity of an outdoor cat to hunt the intermediate hosts (Miro et al., 2004; Hornok et al., 2008; Opsteegh et al., 2012; Munhoz et al., 2017; Schreiber et al., 2021). Several studies have suggested that older cats are more

commonly infected, possibly because the chances of exposure to the parasite increase over time (Gauss et al., 2003; Maruyama et al., 2003; Vollaire et al., 2005). The results of studies investigated the breed as risk factor are controversial. In a study from Estonia, purebred was a risk factor for seropositivity (Must et al., 2015) and in another study from Finland, Birman and Ocicats were more likely to be seropositive compared to five other breeds (Jokelainen et al., 2012; Must et al., 2017).

7. Feline hyperthyroidism

Hyperthyroidism is a multi-systemic disorder resulting from excessive circulating concentrations of the thyroid hormones, thyroxine (T₄) and triiodothyronine (T₃). It occurs mainly in middle-aged and old-aged cats, with a reported age range of 2-25 years and a median age at the time of diagnosis of 11.5-15.1 years (Milner et al., 2006; Williams et al., 2010; Peterson, 2013; Peterson and Broome, 2015; Puig et al., 2015; Grossi et al., 2019). Benign adenomas or adenomatous hyperplasia affecting one (30%) or both lobes (70%) of the thyroid gland are the most common causes of the disease, accounting for 97-99% of the cases, while thyroid carcinomas are rare (Turrel et al., 1988; Peterson et al., 1994; Naan et al., 2006). To date, the underlying etiology responsible for the thyroid changes has remained unclear and is likely to be multifactorial including genetic, nutritional and environmental influences.

7.1. Epidemiology

Prevalence

Hyperthyroidism is the most common endocrinopathy of cats, with 1-4% prevalence in the general feline population and at least 6% in cats older than 9 years (Milner et al., 2006; Trepanier, 2006; Wakeling et al., 2011). Since its initial description (Holzworth et al., 1980), the prevalence (or the frequency of diagnosis) of the disease has been steadily increased worldwide (McLean et al., 2017) and there is strong evidence that it differs among different geographical areas (Scarlett et al., 1988).

Depending on the selection criteria (mainly the age) of the cats enrolled in each study, reported prevalence rates vary widely, from 0.2% to 21.1% in Europe,

from 0.1 to 2% in North America, and from 3.9% to 8.9% in Asia (Edinboro et al., 2004; De Wet et al., 2009; Wakeling et al., 2011; McLean et al., 2017). Most studies suggest that the overall prevalence of feline hyperthyroidism is 2-4%, and at least 6% when only cats older than 9 years of age are considered, but much higher rates have been reported, such as 20% in Poland (Gójska Zygner et al., 2014). The prevalence of hyperthyroidism in the United Kingdom was noted as 11.9% in a 2005 study of cats >9 years of age and 6% in a 2011 study (Wakeling and Melian, 2005; Wakeling et al., 2011). Two larger subsequent studies in cats from the same country conducted in 2014, reported a prevalence of 3% among 3,584 cats non classified by age and 2.4% or 8.7% in cats older than 10 years of age (O'Neill et al., 2014; Stephens et al., 2014). In North America, the prevalence of feline hyperthyroidism has been reported to increase from 0.1% in 1978-1982 to 2% in 1993-1997 (Edinboro et al., 2004). In New York, the prevalence was 0.3% in 1979 and 4.5% in 1985 (Scarlett et al., 1988). Prevalence studies on feline hyperthyroidism in Germany have also substantiated that the incidence is increasing. In detail, a prevalence of 0.2% was reported in 1987-1994, of 2.6% in 1998, of 11.4% in 2006 in cats older than 8 years of age and of 12.3% in 2016 (Kraft and Buchler, 1999; Sassnau, 2006; Köhler et al., 2016).

Additional epidemiological studies have estimated the prevalence in other countries and suggest a wide geographical variation. In a 2002 study in cats from Japan older than 9 years of age, the prevalence was 8.9% (Miyamoto et al., 2002), and in a 2009 study of cats older than 10 years of age from the same country, it was 3.9% (De Wet et al., 2009). In a 2005 publication from Spain, a prevalence of 1.5% was reported in cats older than 9 years, whilst in Portugal it was 9% among cats with the same age range (Wakeling and Melian, 2005; Dias Neves and Horspool, 2014). In a study from Poland, a prevalence of 20.1% was found among cats older than 10 years of age (Gójska Zygner et al., 2014) and, more recently, a prevalence of 21.1% in Irish cats aged 10 years or older was reported (Bree et al., 2018).

The variability of prevalence among these studies may reflect differences in the demographics and the geographic origin of the cats, in the accuracy of the diagnostic tests, and thyroid hormone concentration cut-offs employed for diagnosing hyperthyroidism and/or the overtime changes in the prevalence of the disease.

Risk factors

In several studies, old age and indoor lifestyle have been reported as risk factors for feline hyperthyroidism (Martin et al., 2000; Edinboro et al., 2004; Olczak et al., 2005). These findings may reflect chronic exposure to goitrogens, which, in turn, increases the risk of genetic mutations in the thyrocytes, resulting in adenomas or adenomatous hyperplasia. Two epidemiological studies have shown that Siamese cats have significantly lower risk of developing hyperthyroidism compared to other breeds (Scarlett et al., 1988; Kass et al., 1999) and three additional studies have demonstrated a decreased risk in purebred cats (Olczak et al., 2005; De Wet et al., 2009; Wakeling et al., 2009). Regarding gender predisposition, conflicting data exist. Most studies found no sex predilection (Scarlett et al., 1988; Broussard et al., 1995; Kass et al., 1999), but in two studies a female predisposition (Edinboro et al., 2004; Olczak et al., 2005), and in one study a male predisposition (Sassnau, 2006) was reported.

Consumption of commercial canned food has been reported as a risk factor (Scarlett et al., 1988; Broussard et al., 1995; Edinboro et al., 2004; Wakeling et al., 2007; Peterson and Broome, 2015; van Hoek et al., 2015) and has been attributed to the plasticizer linings of the cans that can release the thyroid disruptor chemical bisphenol A into the food during the heating process (Hammarling et al., 2000; Kang and Kondo, 2002; Goodson et al., 2004). In addition, regular use of ectoparasiticides applied directly to the cat or to the cat's environment has been identified as risk factor for feline hyperthyroidism (Scarlett et al., 1988; Peter et al., 1991; Kass et al., 1999; Peterson and Ward, 2007). Finally, use of cat litter has also been reported as a risk factor, but a direct cause-effect relationship has not been established (Hoenig et al., 1982; Kass et al., 1999).

7.2. Clinical signs and clinicopathologic abnormalities

A wide range of manifestations is associated with feline hyperthyroidism, reflecting the generalized and multi-systemic nature of the disease. Weight loss is the most common clinical sign, being present in up to 88% of the cases. Weight loss often appears despite increased appetite, which is reported in up to 49% of hyperthyroid cats. In addition polyuria/polydipsia are also common signs being present in up to 36% of the cases (Broussard et al., 1995). Gastrointestinal manifestations of feline

hyperthyroidism include intermittent vomiting (up to 44% of the cases), diarrhea and increased volume and frequency of defecations and steatorrhea (Peterson and Ferguson, 1983; Thoday and Mooney, 1992). Behavioral changes are seen in up to 50% of cases: hyperthyroid cats may appear hyperactive, aggressive, or exhibit signs of anxiety. In addition, panting, impaired stress tolerance, heat intolerance and dermatologic problems have also been reported.

Palpable goiter is present in most cats with hyperthyroidism. In over 90% of cases of feline hyperthyroidism, either unilateral or bilateral thyroid enlargement is present (Peterson, 2013) since all hyperthyroid cats have either adenomas or carcinomas as the underlying cause of the disease.

Less commonly apathetic hyperthyroidism is diagnosed, and it is characterized by lethargy, weakness, and decreased appetite (Thoday and Mooney, 1992; Bucknell, 2000; Peterson, 2013).

The most well-documented hematological and serum biochemistry abnormalities associated with feline hyperthyroidism include mild anemia, increased alanine aminotransferase (ALT) and alkaline phosphatase (ALP) activities, and sometimes mild to moderate increases in blood urea nitrogen (BUN) and creatinine concentrations (Peterson and Ferguson, 1983; Thoday and Mooney, 1992; Broussard et al., 1995).

8. References

- Addie, D., Belak, S., Boucraut-Baralon, C., Egberink, H., Frymus, T., Gruffydd-Jones, T., Hartmann, K., Hosie, M.J., Lloret, A., Lutz, H., Marsilio, F., Pennisi, M.G., Radford, A.D., Thiry, E., Truyen, U., Horzinek, M.C., 2009. Feline infectious peritonitis. ABCD guidelines on prevention and management. *J Feline Med Surg* 11, 594-604.
- Addie, D.D., 2000. Clustering of feline coronaviruses in multicat households. *Vet J* 159, 8-9.
- Addie, D.D., Jarrett, J.O., 1992a. Feline coronavirus antibodies in cats. *Vet Rec* 131, 202-203.
- Addie, D.D., Jarrett, O., 1990. Control of feline coronavirus infection in kittens. *Vet Rec* 126, 164.
- Addie, D.D., Jarrett, O., 1992b. A study of naturally occurring feline coronavirus infections in kittens. *Vet Rec* 130, 133-137.

- Addie, D.D., Jarrett, O., 2001. Use of a reverse-transcriptase polymerase chain reaction for monitoring the shedding of feline coronavirus by healthy cats. *Vet Rec* 148, 649-653.
- Addie, D.D., Toth, S., Murray, G.D., Jarrett, O., 1995. Risk of feline infectious peritonitis in cats naturally infected with feline coronavirus. *Am J Vet Res* 56, 429-434.
- Afonso, E., Germain, E., Poulle, M.L., Ruetten, S., Devillard, S., Say, L., Villena, I., Aubert, D., Gilot-Fromont, E., 2013. Environmental determinants of spatial and temporal variations in the transmission of *Toxoplasma gondii* in its definitive hosts. *Int J Parasitol Parasites Wildl* 2, 278-285.
- Al-Kappany, Y.M., Lappin, M.R., Kwok, O.C., Abu-Elwafa, S.A., Hilali, M., Dubey, J.P., 2011. Seroprevalence of *Toxoplasma gondii* and concurrent *Bartonella* spp., feline immunodeficiency virus, feline leukemia virus, and *Dirofilaria immitis* infections in Egyptian cats. *J Parasitol* 97, 256-258.
- Al-Kappany, Y.M., Rajendran, C., Ferreira, L.R., Kwok, O.C., Abu-Elwafa, S.A., Hilali, M., Dubey, J.P., 2010. High prevalence of toxoplasmosis in cats from Egypt: isolation of viable *Toxoplasma gondii*, tissue distribution, and isolate designation. *J Parasitol* 96, 1115-1118.
- Alves, A.S., Milhano, N., Santos-Silva, M., Santos, A.S., Vilhena, M., de Sousa, R., 2009. Evidence of *Bartonella* spp., *Rickettsia* spp. and *Anaplasma phagocytophilum* in domestic, shelter and stray cat blood and fleas, Portugal. *Clin Microbiol Infect* 15 Suppl 2, 1-3.
- An, D.J., Jeoung, H.Y., Jeong, W., Park, J.Y., Lee, M.H., Park, B.K., 2011. Prevalence of Korean cats with natural feline coronavirus infections. *Virology* 8, 455.
- Anderson, L.J., Jarrett, W.F., Jarrett, O., Laird, H.M., 1971. Feline leukemia-virus infection of kittens: mortality associated with atrophy of the thymus and lymphoid depletion. *J Natl Cancer Inst* 47, 807-817.
- Anderson, M.M., Lauring, A.S., Burns, C.C., Overbaugh, J., 2000. Identification of a cellular cofactor required for infection by feline leukemia virus. *Science* 287, 1828-1830.
- Asgari, Q., Mohammadpour, I., Pirzad, R., Kalantari, M., Motazedian, M.H., Naderi, S., 2018. Molecular and Serological Detection of *Toxoplasma gondii* in Stray Cats in Shiraz, South-central, Iran. *Iran J Parasitol* 13, 430-439.

- Ayinmode, A.B., Oluwayelu, D.O., Babalola, E.T., Lawani, M.A., 2017. Serologic survey of *Toxoplasma gondii* antibodies in cats (*Felis catus*) sold at live animal markets in southwestern Nigeria. *Bulg J Vet Med* 20 20, 58-64.
- Bandecchi, P., Dell'Omodarme, M., Magi, M., Palamidessi, A., Prati, M.C., 2006. Feline leukaemia virus (FeLV) and feline immunodeficiency virus infections in cats in the Pisa district of Tuscany, and attempts to control FeLV infection in a colony of domestic cats by vaccination. *Veterinary Record* 158, 555-557.
- Barr, M.C., Zou, L., Long, F., Hoose, W.A., Avery, R.J., 1997. Proviral organization and sequence analysis of feline immunodeficiency virus isolated from a Pallas' cat. *Virology* 228, 84-91.
- Barrs, V.R., Beatty, J.A., Wilson, B.J., Evans, N., Gowan, R., Baral, R.M., Lingard, A.E., Perkovic, G., Hawley, J.R., Lappin, M.R., 2010. Prevalence of *Bartonella* species, *Rickettsia felis*, haemoplasmas and the Ehrlichia group in the blood of cats and fleas in eastern Australia. *Aust Vet J* 88, 160-165.
- Barrs, V.R., Martin, P., Nicoll, R.G., Beatty, J.A., Malik, R., 2000. Pulmonary cryptococcosis and *Capillaria aerophila* infection in an FIV-positive cat. *Aust Vet J* 78, 154-158.
- Bauer, N., Balzer, H.J., Thure, S., Moritz, A., 2008. Prevalence of feline haemotropic mycoplasmas in convenience samples of cats in Germany. *J Feline Med Surg* 10, 252-258.
- Beatty, J.A., Lawrence, C.E., Callanan, J.J., Grant, C.K., Gault, E.A., Neil, J.C., Jarrett, O., 1998. Feline immunodeficiency virus (FIV)-associated lymphoma: a potential role for immune dysfunction in tumourigenesis. *Vet Immunol Immunopathol* 65, 309-322.
- Beczkowski, P.M., Litster, A., Lin, T.L., Mellor, D.J., Willett, B.J., Hosie, M.J., 2015. Contrasting clinical outcomes in two cohorts of cats naturally infected with feline immunodeficiency virus (FIV). *Veterinary Microbiology* 176, 50-60.
- Bennett, A.D., Gunn-Moore, D.A., Brewer, M., Lappin, M.R., 2011. Prevalence of *Bartonella* species, haemoplasmas and *Toxoplasma gondii* in cats in Scotland. *J Feline Med Surg* 13, 553-557.
- Bergh, K., Bevanger, L., Hanssen, I., Loseth, K., 2002. Low prevalence of *Bartonella henselae* infections in Norwegian domestic and feral cats. *APMIS* 110, 309-314.

- Bernsteen, L., Gregory, C.R., Aronson, L.R., Lirtzman, R.A., Brummer, D.G., 1999. Acute toxoplasmosis following renal transplantation in three cats and a dog. *J Am Vet Med Assoc* 215, 1123-1126.
- Bevins, S.N., Carver, S., Boydston, E.E., Lyren, L.M., Alldredge, M., Logan, K.A., Riley, S.P., Fisher, R.N., Vickers, T.W., Boyce, W., Salman, M., Lappin, M.R., Crooks, K.R., VandeWoude, S., 2012. Three pathogens in sympatric populations of pumas, bobcats, and domestic cats: implications for infectious disease transmission. *PLoS One* 7, e31403.
- Bigna, J.J., Tochie, J.N., Tounouga, D.N., Bekolo, A.O., Ymele, N.S., Youda, E.L., Sime, P.S., Nansseu, J.R., 2020. Global, regional, and country seroprevalence of *Toxoplasma gondii* in pregnant women: a systematic review, modelling and meta-analysis. *Sci Rep* 10, 12102.
- Bland van den Berg, P., Botha, W.S., 1977. Feline infectious peritonitis in South Africa. *J S Afr Vet Assoc* 48, 109-116.
- Bouhsira, E., Ferrandez, Y., Liu, M., Franc, M., Boulouis, H.J., Biville, F., 2013. *Ctenocephalides felis* an in vitro potential vector for five *Bartonella* species. *Comp Immunol Microbiol Infect Dis* 36, 105-111.
- Boulouis, H.J., Chang, C.C., Henn, J.B., Kasten, R.W., Chomel, B.B., 2005. Factors associated with the rapid emergence of zoonotic *Bartonella* infections. *Vet Res* 36, 383-410.
- Branley, J., Wolfson, C., Waters, P., Gottlieb, T., Bradbury, R., 1996. Prevalence of *Bartonella henselae* bacteremia, the causative agent of cat scratch disease, in an Australian cat population. *Pathology* 28, 262-265.
- Bree, L., Gallagher, B.A., Shiel, R.E., Mooney, C.T., 2018. Prevalence and risk factors for hyperthyroidism in Irish cats from the greater Dublin area. *Ir Vet J* 71, 2.
- Breitschwerdt, E.B., Kordick, D.L., 2000. *Bartonella* infection in animals: carriership, reservoir potential, pathogenicity, and zoonotic potential for human infection. *Clin Microbiol Rev* 13, 428-438.
- Brightman, A.H., 2nd, Ogilvie, G.K., Tompkins, M., 1991. Ocular disease in FeLV-positive cats: 11 cases (1981-1986). *J Am Vet Med Assoc* 198, 1049-1051.
- Broussard, J.D., Peterson, M.E., Fox, P.R., 1995. Changes in clinical and laboratory findings in cats with hyperthyroidism from 1983 to 1993. *J Am Vet Med Assoc* 206, 302-305.

- Brown, E.W., Yuhki, N., Packer, C., O'Brien, S.J., 1994. A lion lentivirus related to feline immunodeficiency virus: epidemiologic and phylogenetic aspects. *J Virol* 68, 5953-5968.
- Brown, M.R., Rogers, K.S., 2001. Neutropenia in dogs and cats: a retrospective study of 261 cases. *Journal of the American Animal Hospital Association* 37, 131-139.
- Bucknell, D.G., 2000. Feline hyperthyroidism: spectrum of clinical presentations and response to carbimazole therapy. *Aust Vet J* 78, 462-465.
- Burling, A.N., Levy, J.K., Scott, H.M., Crandall, M.M., Tucker, S.J., Wood, E.G., Foster, J.D., 2017. Seroprevalences of feline leukemia virus and feline immunodeficiency virus infection in cats in the United States and Canada and risk factors for seropositivity. *Journal of the American Veterinary Medical Association* 251, 187-194.
- Callanan, J.J., Jones, B.A., Irvine, J., Willett, B.J., McCandlish, I.A., Jarrett, O., 1996. Histologic classification and immunophenotype of lymphosarcomas in cats with naturally and experimentally acquired feline immunodeficiency virus infections. *Vet Pathol* 33, 264-272.
- Carmichael, K.P., Bienzle, D., McDonnell, J.J., 2002. Feline leukemia virus-associated myelopathy in cats. *Vet Pathol* 39, 536-545.
- Carpenter, M.A., Brown, E.W., Culver, M., Johnson, W.E., Pecon-Slattery, J., Brousset, D., O'Brien, S.J., 1996. Genetic and phylogenetic divergence of feline immunodeficiency virus in the puma (*Puma concolor*). *J Virol* 70, 6682-6693.
- Cave, T.A., Golder, M.C., Simpson, J., Addie, D.D., 2004. Risk factors for feline coronavirus seropositivity in cats relinquished to a UK rescue charity. *J Feline Med Surg* 6, 53-58.
- Chatzis, M.K., Leontides, L., Athanasiou, L.V., Papadopoulos, E., Kasabalis, D., Mylonakis, M., Rallis, T., Koutinas, A.F., Andreadou, M., Ikonopoulou, J., Saridomichelakis, M.N., 2014. Evaluation of indirect immunofluorescence antibody test and enzyme-linked immunosorbent assay for the diagnosis of infection by *Leishmania infantum* in clinically normal and sick cats. *Exp Parasitol* 147, 54-59.

- Chen, H., Bechtel, M.K., Shi, Y., Phipps, A., Mathes, L.E., Hayes, K.A., Roy-Burman, P., 1998. Pathogenicity induced by feline leukemia virus, Rickard strain, subgroup A plasmid DNA (pFRA). *J Virol* 72, 7048-7056.
- Chomel, B.B., Abbott, R.C., Kasten, R.W., Floyd-Hawkins, K.A., Kass, P.H., Glaser, C.A., Pedersen, N.C., Koehler, J.E., 1995. *Bartonella henselae* prevalence in domestic cats in California: risk factors and association between bacteremia and antibody titers. *J Clin Microbiol* 33, 2445-2450.
- Chomel, B.B., Carlos, E.T., Kasten, R.W., Yamamoto, K., Chang, C.C., Carlos, R.S., Abenes, M.V., Pajares, C.M., 1999. *Bartonella henselae* and *Bartonella clarridgeiae* infection in domestic cats from The Philippines. *Am J Trop Med Hyg* 60, 593-597.
- Chomel, B.B., Kasten, R.W., Floyd-Hawkins, K., Chi, B., Yamamoto, K., Roberts-Wilson, J., Gurfield, A.N., Abbott, R.C., Pedersen, N.C., Koehler, J.E., 1996. Experimental transmission of *Bartonella henselae* by the cat flea. *J Clin Microbiol* 34, 1952-1956.
- Chomel, B.B., Wey, A.C., Kasten, R.W., Stacy, B.A., Labelle, P., 2003. Fatal case of endocarditis associated with *Bartonella henselae* type I infection in a domestic cat. *J Clin Microbiol* 41, 5337-5339.
- Cotte, V., Bonnet, S., Le Rhun, D., Le Naour, E., Chauvin, A., Boulouis, H.J., Lecuelle, B., Lilin, T., Vayssier-Taussat, M., 2008. Transmission of *Bartonella henselae* by *Ixodes ricinus*. *Emerg Infect Dis* 14, 1074-1080.
- Cotter, S.M., 1991. Management of healthy feline leukemia virus-positive cats. *Journal of the American Veterinary Medical Association* 199, 1470-1473.
- Cotter, S.M., Hardy, W.D., Jr., Essex, M., 1975. Association of feline leukemia virus with lymphosarcoma and other disorders in the cat. *J Am Vet Med Assoc* 166, 449-454.
- Crawford, P.C., Levy, J.K., Bicknell, J.M., Layton, C.R., Hannaka, T.A., 2001. FeLV, FIV, AND FIP: Epidemiology and clinical disease syndromes. *Journal of Veterinary Internal Medicine* 15, 276.
- De Wet, C.S., Mooney, C.T., Thompson, P.N., Schoeman, J.P., 2009. Prevalence of and risk factors for feline hyperthyroidism in Hong Kong. *J Feline Med Surg* 11, 315-321.
- Desmarets, L.M., Theuns, S., Olyslaegers, D.A., Dedeurwaerder, A., Vermeulen, B.L., Roukaerts, I.D., Nauwynck, H.J., 2013. Establishment of feline intestinal

- epithelial cell cultures for the propagation and study of feline enteric coronaviruses. *Vet Res* 44, 71.
- Dias Neves, R., Horspool, L.J.I., 2014. Prevalence of hyperthyroidism in Portuguese cats. In: *Proceedings of the European College of Veterinary Internal Medicine for Companion Animals Congress, Mainz, Germany*: pp 475.
- dos Santos, A.P., dos Santos, R.P., Biondo, A.W., Dora, J.M., Goldani, L.Z., de Oliveira, S.T., de Sa Guimaraes, A.M., Timenetsky, J., de Moraes, H.A., Gonzalez, F.H., Messick, J.B., 2008. Hemoplasma infection in HIV-positive patient, Brazil. *Emerg Infect Dis* 14, 1922-1924.
- Dubey, J.P., 1996. Infectivity and pathogenicity of *Toxoplasma gondii* oocysts for cats. *J Parasitol* 82, 957-961.
- Dubey, J.P., 1997. Tissue cyst tropism in *Toxoplasma gondii*: a comparison of tissue cyst formation in organs of cats, and rodents fed oocysts. *Parasitology* 115 (Pt 1), 15-20.
- Dubey, J.P., 2002. Tachyzoite-induced life cycle of *Toxoplasma gondii* in cats. *J Parasitol* 88, 713-717.
- Dubey, J.P., Cerqueira-Cezar, C.K., Murata, F.H.A., Kwok, O.C.H., Yang, Y.R., Su, C., 2020. All about toxoplasmosis in cats: the last decade. *Vet Parasitol* 283, 109145.
- Dunham, S.P., Graham, E., 2008. Retroviral infections of small animals. *Vet Clin North Am Small Anim Pract* 38, 879-901, ix.
- Duplan, F., Davies, S., Filler, S., Abdullah, S., Keyte, S., Newbury, H., Helps, C.R., Wall, R., Tasker, S., 2018. *Anaplasma phagocytophilum*, *Bartonella* spp., haemoplasma species and *Hepatozoon* spp. in ticks infesting cats: a large-scale survey. *Parasit Vectors* 11, 201.
- Edinboro, C.H., Scott-Moncrieff, J.C., Janovitz, E., Thacker, H.L., Glickman, L.T., 2004. Epidemiologic study of relationships between consumption of commercial canned food and risk of hyperthyroidism in cats. *J Am Vet Med Assoc* 224, 879-886.
- Finkelstein, J.L., Brown, T.P., O'Reilly, K.L., Wedincamp, J., Jr., Foil, L.D., 2002. Studies on the growth of *Bartonella henselae* in the cat flea (Siphonaptera: Pulicidae). *J Med Entomol* 39, 915-919.

- Flynn, J.N., Cannon, C.A., Lawrence, C.E., Jarrett, O., 1994. Polyclonal B-cell activation in cats infected with feline immunodeficiency virus. *Immunology* 81, 626-630.
- Flynn, J.N., Dunham, S.P., Watson, V., Jarrett, O., 2002. Longitudinal analysis of feline leukemia virus-specific cytotoxic T lymphocytes: correlation with recovery from infection. *J Virol* 76, 2306-2315.
- Flynn, J.N., Hanlon, L., Jarrett, O., 2000. Feline leukaemia virus: protective immunity is mediated by virus-specific cytotoxic T lymphocytes. *Immunology* 101, 120-125.
- Foil, L., Andress, E., Freeland, R.L., Roy, A.F., Rutledge, R., Triche, P.C., O'Reilly, K.L., 1998. Experimental infection of domestic cats with *Bartonella henselae* by inoculation of *Ctenocephalides felis* (Siphonaptera: Pulicidae) feces. *J Med Entomol* 35, 625-628.
- Foley, J.E., Poland, A., Carlson, J., Pedersen, N.C., 1997. Risk factors for feline infectious peritonitis among cats in multiple-cat environments with endemic feline enteric coronavirus. *J Am Vet Med Assoc* 210, 1313-1318.
- Forman, L.W., Pal-Ghosh, R., Spanjaard, R.A., Faller, D.V., Ghosh, S.K., 2009. Identification of LTR-specific small non-coding RNA in FeLV infected cells. *FEBS Lett* 583, 1386-1390.
- Furtado, M.M., Gennari, S.M., Ikuta, C.Y., Jacomo, A.T., de Moraes, Z.M., Pena, H.F., Porfirio, G.E., Silveira, L., Sollmann, R., de Souza, G.O., Torres, N.M., Ferreira Neto, J.S., 2015. Serosurvey of Smooth Brucella, Leptospira spp. and Toxoplasma gondii in Free-Ranging Jaguars (Panthera onca) and Domestic Animals from Brazil. *PLoS One* 10, e0143816.
- Gauss, C.B., Almeria, S., Ortuno, A., Garcia, F., Dubey, J.P., 2003. Seroprevalence of Toxoplasma gondii antibodies in domestic cats from Barcelona, Spain. *J Parasitol* 89, 1067-1068.
- Gentilini, F., Novacco, M., Turba, M.E., Willi, B., Bacci, M.L., Hofmann-Lehmann, R., 2009. Use of combined conventional and real-time PCR to determine the epidemiology of feline haemoplasma infections in northern Italy. *J Feline Med Surg* 11, 277-285.
- George, J.W., Rideout, B.A., Griffey, S.M., Pedersen, N.C., 2002. Effect of preexisting FeLV infection or FeLV and feline immunodeficiency virus

- coinfection on pathogenicity of the small variant of *Haemobartonella felis* in cats. *Am J Vet Res* 63, 1172-1178.
- Glaus, T., Hofmann-Lehmann, R., Greene, C., Glaus, B., Wolfensberger, C., Lutz, H., 1997. Seroprevalence of *Bartonella henselae* infection and correlation with disease status in cats in Switzerland. *J Clin Microbiol* 35, 2883-2885.
- Gleich, S., Hartmann, K., 2009. Hematology and serum biochemistry of feline immunodeficiency virus-infected and feline leukemia virus-infected cats. *Journal of Veterinary Internal Medicine* 23, 552-558.
- Gleich, S.E., Krieger, S., Hartmann, K., 2009. Prevalence of feline immunodeficiency virus and feline leukaemia virus among client-owned cats and risk factors for infection in Germany. *Journal of Feline Medicine and Surgery* 11, 985-992.
- Gójska Zygner, O., Lechowski, R., Zygner, W., 2014. Prevalence of feline hyperthyroidism in mature cats in urban population in Warsaw. *Bull Vet Inst Pulawy* 58, 267-271.
- Goodson, A., Robin, H., Summerfield, W., Cooper, I., 2004. Migration of bisphenol A from can coatings--effects of damage, storage conditions and heating. *Food Addit Contam* 21, 1015-1026.
- Grossi, G., Zoia, A., Palagiano, P., Leoni, N., Bubini-Regini, F., Malerba, E., Peli, A., Biagi, G., Fracassi, F., 2019. Iodine-restricted food versus pharmacological therapy in the management of feline hyperthyroidism: a controlled trial in 34 cats. *Open Vet J* 9, 196-204.
- Gunn-Moore, D.A., Pearson, G.R., Harbour, D.A., Whiting, C.V., 1996. Encephalitis associated with giant cells in a cat with naturally occurring feline immunodeficiency virus infection demonstrated by in situ hybridization. *Vet Pathol* 33, 699-703.
- Guptill, L., Slater, L., Wu, C.C., Lin, T.L., Glickman, L.T., Welch, D.F., HogenEsch, H., 1997. Experimental infection of young specific pathogen-free cats with *Bartonella henselae*. *J Infect Dis* 176, 206-216.
- Guptill, L., Wu, C.C., HogenEsch, H., Slater, L.N., Glickman, N., Dunham, A., Syme, H., Glickman, L., 2004. Prevalence, risk factors, and genetic diversity of *Bartonella henselae* infections in pet cats in four regions of the United States. *J Clin Microbiol* 42, 652-659.
- Gurfield, A.N., Boulouis, H.J., Chomel, B.B., Kasten, R.W., Heller, R., Bouillin, C., Gandoin, C., Thibault, D., Chang, C.C., Barrat, F., Piemont, Y., 2001.

- Epidemiology of Bartonella infection in domestic cats in France. *Vet Microbiol* 80, 185-198.
- Gutiérrez, R., Morick, D., Gross, I., Winkler, R., Abdeen, Z., S., H., 2013. Bartonellae in Domestic and Stray Cats from Israel: Comparison of Bacterial Cultures and High-Resolution Melt Real-Time PCR As Diagnostic Methods. *Vector-Borne and Zoonotic Diseases* 13, 857-864.
- Hammarling, L., Gustavsson, H., Svensson, K., Oskarsson, A., 2000. Migration of bisphenol-A diglycidyl ether (BADGE) and its reaction products in canned foods. *Food Addit Contam* 17, 937-943.
- Hardy, W.D., Jr., Hess, P.W., MacEwen, E.G., McClelland, A.J., Zuckerman, E.E., Essex, M., Cotter, S.M., Jarrett, O., 1976. Biology of feline leukemia virus in the natural environment. *Cancer Res* 36, 582-588.
- Harrus, S., Klement, E., Aroch, I., Stein, T., Bark, H., Lavy, E., Mazaki-Tovi, M., Baneth, G., 2002. Retrospective study of 46 cases of feline haemobartonellosis in Israel and their relationships with FeLV and FIV infections. *Vet Rec* 151, 82-85.
- Hartmann, K., 2005. Feline infectious peritonitis. *Vet Clin North Am Small Anim Pract* 35, 39-79, vi.
- Hartmann, K., 2011. Clinical Aspects of feline immunodeficiency and feline leukemia virus infection. *Veterinary Immunology and Immunopathology* 143, 190-201.
- Hartmann, K., Hinze, K., 1991. Epidemiology and clinical aspects of FIV infection in Bavaria. *Tierärztliche Praxis* 19, 545-551.
- Harvey, J.W., Gaskin, J.M., 1978. Feline haemobartonellosis: attempts to induce relapses of clinical disease in chronically infected cats. *J Am Anim Hosp Assoc* 14, 453-456.
- Hayes, K.A., Rojko, J.L., Tarr, M.J., Polas, P.J., Olsen, R.G., Mathes, L.E., 1989. Atypical localised viral expression in a cat with feline leukaemia. *Vet Rec* 124, 344-346.
- Helfer-Hungerbuehler, A.K., Widmer, S., Kessler, Y., Riond, B., Boretti, F.S., Grest, P., Lutz, H., Hofmann-Lehmann, R., 2015. Long-term follow up of feline leukemia virus infection and characterization of viral RNA loads using molecular methods in tissues of cats with different infection outcomes. *Virus Res* 197, 137-150.

- Hellard, E., Fouchet, D., Santin-Janin, H., Tarin, B., Badol, V., Coupier, C., Leblanc, G., Poulet, H., Pontier, D., 2011. When cats' ways of life interact with their viruses: a study in 15 natural populations of owned and unowned cats (*Felis silvestris catus*). *Prev Vet Med* 101, 250-264.
- Herrewegh, A.A., Mahler, M., Hedrich, H.J., Haagmans, B.L., Egberink, H.F., Horzinek, M.C., Rottier, P.J., de Groot, R.J., 1997. Persistence and evolution of feline coronavirus in a closed cat-breeding colony. *Virology* 234, 349-363.
- Hicks, C.A., Barker, E.N., Brady, C., Stokes, C.R., Helps, C.R., Tasker, S., 2014. Non-ribosomal phylogenetic exploration of Mollicute species: new insights into haemoplasma taxonomy. *Infect Genet Evol* 23, 99-105.
- Higgins, J.A., Radulovic, S., Jaworski, D.C., Azad, A.F., 1996. Acquisition of the cat scratch disease agent *Bartonella henselae* by cat fleas (Siphonaptera:Pulicidae). *J Med Entomol* 33, 490-495.
- Hill, D., Dubey, J.P., 2002. *Toxoplasma gondii*: transmission, diagnosis and prevention. *Clin Microbiol Infect* 8, 634-640.
- Hisasue, M., Okayama, H., Okayama, T., Suzuki, T., Mizuno, T., Fujino, Y., Naganobu, K., Hasegawa, A., Watari, T., Matsuki, N., Masuda, K., Ohno, K., Tsujimoto, H., 2001. Hematologic abnormalities and outcome of 16 cats with myelodysplastic syndromes. *J Vet Intern Med* 15, 471-477.
- Hoening, M., Goldschmidt, M.H., Ferguson, D.C., Koch, K., Eymontt, M.J., 1982. Toxic nodular goitre in the cat. *J Small Anim Pract* 23, 1-12.
- Hofmann-Lehmann, R., Holznagel, E., Aubert, A., Bauer-Pham, K., Lutz, H., 1995. FIV vaccine studies. II. Clinical findings, hematological changes and kinetics of blood lymphocyte subsets. *Veterinary Immunology and Immunopathology* 46, 115-125.
- Hofmann-Lehmann, R., Holznagel, E., Ossent, P., Lutz, H., 1997. Parameters of disease progression in long-term experimental feline retrovirus (feline immunodeficiency virus and feline leukemia virus) infections: hematology, clinical chemistry, and lymphocyte subsets. *Clin Diagn Lab Immunol* 4, 33-42.
- Holzworth, J., Theran, P., Carpenter, J.L., Harpster, N.K., Todoroff, R.J., 1980. Hyperthyroidism in the cat: ten cases. *J Am Vet Med Assoc* 176, 345-353.

- Hong, S.H., Jeong, Y.I., Kim, J.Y., Cho, S.H., Lee, W.J., Lee, S.E., 2013. Prevalence of *Toxoplasma gondii* infection in household cats in Korea and risk factors. *Korean J Parasitol* 51, 357-361.
- Hoover, E.A., Mullins, J.I., 1991. Feline leukemia virus infection and diseases. *Journal of the American Veterinary Medical Association* 199, 1287-1297.
- Hoover, E.A., Olsen, R.G., Hardy, W.D., Jr., Schaller, J.P., Mathes, L.E., 1976. Feline leukemia virus infection: age-related variation in response of cats to experimental infection. *J Natl Cancer Inst* 57, 365-369.
- Hornok, S., Edelhofer, R., Joachim, A., Farkas, R., Berta, K., Repasi, A., Lakatos, B., 2008. Seroprevalence of *Toxoplasma gondii* and *Neospora caninum* infection of cats in Hungary. *Acta Vet Hung* 56, 81-88.
- Hosie, M.J., Addie, D., Belak, S., Boucraut-Baralon, C., Egberink, H., Frymus, T., Gruffydd-Jones, T., Hartmann, K., Lloret, A., Lutz, H., Marsilio, F., Pennisi, M.G., Radford, A.D., Thiry, E., Truyen, U., Horzinek, M.C., 2009. Feline immunodeficiency. ABCD guidelines on prevention and management. *J Feline Med Surg* 11, 575-584.
- Ishak, A.M., Radecki, S., Lappin, M.R., 2007. Prevalence of *Mycoplasma haemofelis*, 'Candidatus *Mycoplasma haemominutum*', *Bartonella* species, *Ehrlichia* species, and *Anaplasma phagocytophilum* DNA in the blood of cats with anemia. *J Feline Med Surg* 9, 1-7.
- Jameson, P., Greene, C., Regnery, R., Dryden, M., Marks, A., Brown, J., Cooper, J., Glaus, B., Greene, R., 1995. Prevalence of *Bartonella henselae* antibodies in pet cats throughout regions of North America. *J Infect Dis* 172, 1145-1149.
- Jarrett, W.F.H., Crawford, E.M., Martin, W.B., Davie, F., 1964. A virus-like particle associated with leukaemia (lymphosarcoma). *Nature* 202, 567-568.
- Jenkins, K.S., Dittmer, K.E., Marshall, J.C., Tasker, S., 2013. Prevalence and risk factor analysis of feline haemoplasma infection in New Zealand domestic cats using a real-time PCR assay. *J Feline Med Surg* 15, 1063-1069.
- Jimenez-Coello, M., Acosta-Viana, K.Y., Guzman- Marin, E., Gutierrez-Ruiz, E.J., Rodriguez-Vivas, R.I., Bolio- González, M.E., Ortega-Pacheco, A., 2013. The occurrence of *Toxoplasma gondii* antibodies in backyard pigs and cats from an endemic tropical area of Mexico. *Trop Subtrop Agroecosyst* 16, 89-92.

- Jokelainen, P., Simola, O., Rantanen, E., Nareaho, A., Lohi, H., Sukura, A., 2012. Feline toxoplasmosis in Finland: cross-sectional epidemiological study and case series study. *J Vet Diagn Invest* 24, 1115-1124.
- Jones, B.R., Hogg, G.G., 1974. Feline infectious peritonitis. *Aust Vet J* 50, 398-402.
- Kamani, J., Mani, A.U., Kumshe, H.A., Yidawi, J.P., Egwu, G.O., 2010. Prevalence of *Toxoplasma gondii* antibodies in cats in Maiduguri, Northeastern Nigeria. *Acta Parasitol* 55, 94-95.
- Kamrani, A., Parreira, V.R., Greenwood, J., Prescott, J.F., 2008. The prevalence of *Bartonella*, hemoplasma, and *Rickettsia felis* infections in domestic cats and in cat fleas in Ontario. *Can J Vet Res* 72, 411-419.
- Kang, J.H., Kondo, F., 2002. Determination of bisphenol A in canned pet foods. *Res Vet Sci* 73, 177-182.
- Kass, P.H., Peterson, M.E., Levy, J., James, K., Becker, D.V., Cowgill, L.D., 1999. Evaluation of environmental, nutritional, and host factors in cats with hyperthyroidism. *J Vet Intern Med* 13, 323-329.
- Kewish, K.E., Appleyard, G.D., Myers, S.L., Kidney, B.A., Jackson, M.L., 2004. *Mycoplasma haemofelis* and *Mycoplasma haemominutum* detection by polymerase chain reaction in cats from Saskatchewan and Alberta. *Can Vet J* 45, 749-752.
- Kipar, A., May, H., Menger, S., Weber, M., Leukert, W., Reinacher, M., 2005. Morphologic features and development of granulomatous vasculitis in feline infectious peritonitis. *Vet Pathol* 42, 321-330.
- Kipar, A., Meli, M.L., Baptiste, K.E., Bowker, L.J., Lutz, H., 2010. Sites of feline coronavirus persistence in healthy cats. *J Gen Virol* 91, 1698-1707.
- Knotek, Z., Hajkova, P., Svoboda, M., Toman, M., Raska, V., 1999. Epidemiology of feline leukaemia and feline immunodeficiency virus infections in the Czech Republic. *Zentralblatt fur Veterinarmedizin. Reihe B* 46, 665-671.
- Koehler, J.E., Glaser, C.A., Tappero, J.W., 1994. *Rochalimaea henselae* infection. A new zoonosis with the domestic cat as reservoir. *JAMA* 271, 531-535.
- Köhler, I., Ballhausen, B.D., Stockhaus, C., Hartmann, K., Wehner, A., 2016. Prevalence of and risk factors for feline hyperthyroidism among a clinic population in Southern Germany. *Tierärztliche Praxis Kleintiere* 44, 149-157.
- Kordick, D.L., Breitschwerdt, E.B., 1997. Relapsing bacteremia after blood transmission of *Bartonella henselae* to cats. *Am J Vet Res* 58, 492-497.

- Kordick, D.L., Brown, T.T., Shin, K., Breitschwerdt, E.B., 1999. Clinical and pathologic evaluation of chronic *Bartonella henselae* or *Bartonella clarridgeiae* infection in cats. *J Clin Microbiol* 37, 1536-1547.
- Kornya, M.R., Little, S.E., Scherk, M.A., Sears, W.C., Bienzle, D., 2014. Association between oral health status and retrovirus test results in cats. *Journal of the American Veterinary Medical Association* 245, 916-922.
- Kraft, W., Buchler, F., 1999. Hyperthyroidism: incidence in the cat. *Tierärztliche Praxis Kleintiere* 27, 386-388.
- Lappin, M.R., Brunt, J., Riley, A., 2004. *Bartonella* spp. and *Mycoplasma haemominutum* DNA in the blood of cats and their fleas Proceedings of the ACVIM meeting, June, 2003. Proceedings of the American College of Internal Medicine (ACVIM) meeting, Charlotte, New York, 4th-7th June 2003 pp. 382.
- Levy, J.K., Crawford, P.C., Lappin, M.R., Dubovi, E.J., Levy, M.G., Alleman, R., Tucker, S.J., Clifford, E.L., 2008. Infectious diseases of dogs and cats on Isabela Island, Galapagos. *J Vet Intern Med* 22, 60-65.
- Levy, J.K., Scott, H.M., Lachtara, J.L., Crawford, P.C., 2006. Seroprevalence of feline leukemia virus and feline immunodeficiency virus infection among cats in North America and risk factors for seropositivity. *Journal of the American Veterinary Medical Association* 228, 371-376.
- Liem, B.P., Dhand, N.K., Pepper, A.E., Barrs, V.R., Beatty, J.A., 2013. Clinical findings and survival in cats naturally infected with feline immunodeficiency virus. *Journal of Veterinary Internal Medicine* 27, 798-805.
- Lin, J.W., Chen, C.M., Chang, C.C., 2011. Unknown fever and back pain caused by *Bartonella henselae* in a veterinarian after a needle puncture: a case report and literature review. *Vector Borne Zoonotic Dis* 11, 589-591.
- Little, S., Sears, W., Lachtara, J., Bienzle, D., 2009. Seroprevalence of feline leukemia virus and feline immunodeficiency virus infection among cats in Canada. *Can Vet J* 50, 644-648.
- Little, S.E., 2005. Feline immunodeficiency virus testing in stray, feral, and client-owned cats of Ottawa. *Canadian Veterinary Journal* 46, 898-901.
- Lobetti, R., Lappin, M.R., 2012. Prevalence of *Toxoplasma gondii*, *Bartonella* species and haemoplasma infection in cats in South Africa. *J Feline Med Surg* 14, 857-862.

- Lobetti, R.G., Tasker, S., 2004. Diagnosis of feline haemoplasma infection using a real-time PCR assay. *J S Afr Vet Assoc* 75, 94-99.
- Lopes, A.P., Oliveira, A.C., Granada, S., Rodrigues, F.T., Papadopoulos, E., Schallig, H., Dubey, J.P., Cardoso, L., 2017. Antibodies to *Toxoplasma gondii* and *Leishmania* spp. in domestic cats from Luanda, Angola. *Vet Parasitol* 239, 15-18.
- Luria, B.J., Levy, J.K., Lappin, M.R., Breitschwerdt, E.B., Legendre, A.M., Hernandez, J.A., Gorman, S.P., Lee, I.T., 2004. Prevalence of infectious diseases in feral cats in Northern Florida. *Journal of Feline Medicine and Surgery* 6, 287-296.
- Macieira, D.B., de Menezes Rde, C., Damico, C.B., Almosny, N.R., McLane, H.L., Daggy, J.K., Messick, J.B., 2008. Prevalence and risk factors for hemoplasmas in domestic cats naturally infected with feline immunodeficiency virus and/or feline leukemia virus in Rio de Janeiro--Brazil. *J Feline Med Surg* 10, 120-129.
- Madhu Ravi, G.A.W., Susan M. Taylor, Marion L. Jackson, 2010. Naturally acquired feline immunodeficiency virus (FIV) infection in cats from western Canada: Prevalence, disease associations, and survival analysis. *Canadian Veterinary Journal* 51, 271-276.
- Maia, C., Ramos, C., Coimbra, M., Bastos, F., Martins, A., Pinto, P., Nunes, M., Vieira, M.L., Cardoso, L., Campino, L., 2014. Bacterial and protozoal agents of feline vector-borne diseases in domestic and stray cats from southern Portugal. *Parasit Vectors* 7, 115.
- Martin, K.M., Rossing, M.A., Ryland, L.M., DiGiacomo, R.F., Freitag, W.A., 2000. Evaluation of dietary and environmental risk factors for hyperthyroidism in cats. *J Am Vet Med Assoc* 217, 853-856.
- Martinez-Diaz, V.L., Silvestre-Ferreira, A.C., Vilhena, H., Pastor, J., Francino, O., Altet, L., 2013. Prevalence and co-infection of haemotropic mycoplasmas in Portuguese cats by real-time polymerase chain reaction. *J Feline Med Surg* 15, 879-885.
- Maruyama, S., Kabeya, H., Nakao, R., Tanaka, S., Sakai, T., Xuan, X., Katsube, Y., Mikami, T., 2003. Seroprevalence of *Bartonella henselae*, *Toxoplasma gondii*, FIV and FeLV infections in domestic cats in Japan. *Microbiology and Immunology* 47, 147-153.

- McLean, J.L., Lobetti, R.G., Mooney, C.T., Thompson, P.N., Schoeman, J.P., 2017. Prevalence of and risk factors for feline hyperthyroidism in South Africa. *J Feline Med Surg* 19, 1103-1109.
- Mendoza, R., Miller, A.D., Overbaugh, J., 2013. Disruption of thiamine uptake and growth of cells by feline leukemia virus subgroup A. *J Virol* 87, 2412-2419.
- Messick, J.B., Walker, P.G., Raphael, W., Berent, L., Shi, X., 2002. 'Candidatus mycoplasma haemodidelphidis' sp. nov., 'Candidatus mycoplasma haemolamae' sp. nov. and *Mycoplasma haemocanis* comb. nov., haemotrophic parasites from a naturally infected opossum (*Didelphis virginiana*), alpaca (*Lama pacos*) and dog (*Canis familiaris*): phylogenetic and secondary structural relatedness of their 16S rRNA genes to other mycoplasmas. *Int J Syst Evol Microbiol* 52, 693-698.
- Mietze, A., Morick, D., Kohler, H., Harrus, S., Dehio, C., Nolte, I., Goethe, R., 2011. Combined MLST and AFLP typing of *Bartonella henselae* isolated from cats reveals new sequence types and suggests clonal evolution. *Vet Microbiol* 148, 238-245.
- Mifsud, M., Takacs, N., Gyurkovszky, M., Solymosi, N., Farkas, R., 2020. Detection of flea-borne pathogens from cats and fleas in a maltese shelter. *Vector Borne Zoonotic Dis* 20, 529-534.
- Millan, J., Cabezon, O., Pabon, M., Dubey, J.P., Almeria, S., 2009. Seroprevalence of *Toxoplasma gondii* and *Neospora caninum* in feral cats (*Felis silvestris catus*) in Majorca, Balearic Islands, Spain. *Vet Parasitol* 165, 323-326.
- Milner, R.J., Channell, C.D., Levy, J.K., Schaer, M., 2006. Survival times for cats with hyperthyroidism treated with iodine 131, methimazole, or both: 167 cases (1996-2003). *J Am Vet Med Assoc* 228, 559-563.
- Miro, G., Domenech, A., Escolar, E., Collado, V.M., Tejerizo, G., De Las Heras, A., Gomez-Lucia, E., 2007. Plasma electrophoretogram in feline immunodeficiency virus (FIV) and/or feline leukaemia virus (FeLV) infections. *Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine* 54, 203-209.
- Miro, G., Hernandez, L., Montoya, A., Arranz-Solis, D., Dado, D., Rojo-Montejo, S., Mendoza-Ibarra, J.A., Ortega-Mora, L.M., Pedraza-Diaz, S., 2011. First description of naturally acquired *Tritrichomonas foetus* infection in a Persian cattery in Spain. *Parasitol Res* 109, 1151-1154.

- Miro, G., Montoya, A., Jimenez, S., Frisuelos, C., Mateo, M., Fuentes, I., 2004. Prevalence of antibodies to *Toxoplasma gondii* and intestinal parasites in stray, farm and household cats in Spain. *Vet Parasitol* 126, 249-255.
- Miyamoto, T., Miyata, I., Kurobane, K., Kamijima, Y., Tani, H., Sasai, K., Baba, E., 2002. Prevalence of Feline Hyperthyroidism in Osaka and the Chugoku Region. *Journal of the Japan Veterinary Medical Association* 55, 289-292.
- Miyazawa, T., Ikeda, Y., Maeda, K., Horimoto, T., Tohya, Y., Mochizuki, M., Vu, D., Vu, G.D., Cu, D.X., Ono, K., Takahashi, E., Mikami, T., 1998. Seroepidemiological survey of feline retrovirus infections in domestic and leopard cats in northern Vietnam in 1997. *Journal of Veterinary Medical Science* 60, 1273-1275.
- Montazeri, M., Mikaeili Galeh, T., Moosazadeh, M., Sarvi, S., Dodangeh, S., Javidnia, J., Sharif, M., Daryani, A., 2020. The global serological prevalence of *Toxoplasma gondii* in felids during the last five decades (1967-2017): a systematic review and meta-analysis. *Parasit Vectors* 13, 82.
- Moore, F.M., Emerson, W.E., Cotter, S.M., DeLellis, R.A., 1986. Distinctive peripheral lymph node hyperplasia of young cats. *Vet Pathol* 23, 386-391.
- Munhoz, A.D., Hage, S.B., Cruz, R.D.S., Calazans, A.P.F., Silva, F.L., Albuquerque, G.R., Lacerda, L.C., 2017. Toxoplasmosis in cats in northeastern Brazil: Frequency, associated factors and coinfection with *Neospora caninum*, feline immunodeficiency virus and feline leukemia virus. *Vet Parasitol Reg Stud Reports* 8, 35-38.
- Museux, K., Boretti, F.S., Willi, B., Riond, B., Hoelzle, K., Hoelzle, L.E., Wittenbrink, M.M., Tasker, S., Wengi, N., Reusch, C.E., Lutz, H., Hofmann-Lehmann, R., 2009. In vivo transmission studies of 'Candidatus *Mycoplasma turicensis*' in the domestic cat. *Vet Res* 40, 45.
- Must, K., Hytonen, M.K., Orro, T., Lohi, H., Jokelainen, P., 2017. *Toxoplasma gondii* seroprevalence varies by cat breed. *PLoS One* 12, e0184659.
- Must, K., Lassen, B., Jokelainen, P., 2015. Seroprevalence of and Risk Factors for *Toxoplasma gondii* Infection in Cats in Estonia. *Vector Borne Zoonotic Dis* 15, 597-601.
- Naan, E.C., Kirpensteijn, J., Kooistra, H.S., Peeters, M.E., 2006. Results of thyroidectomy in 101 cats with hyperthyroidism. *Vet Surg* 35, 287-293.

- Nakamura, K., Miyazawa, T., Ikeda, Y., Sato, E., Nishimura, Y., Nguyen, N.T., Takahashi, E., Mochizuki, M., Mikami, T., 2000. Contrastive prevalence of feline retrovirus infections between northern and southern Vietnam. *Journal of Veterinary Medical Science* 62, 921-923.
- Namekata, D.Y., Kasten, R.W., Boman, D.A., Straub, M.H., Siperstein-Cook, L., Couvelaire, K., Chomel, B.B., 2010. Oral shedding of *Bartonella* in cats: correlation with bacteremia and seropositivity. *Vet Microbiol* 146, 371-375.
- Neimark, H., Hoff, B., Ganter, M., 2004. *Mycoplasma ovis* comb. nov. (formerly *Eperythrozoon ovis*), an epierythrocytic agent of haemolytic anaemia in sheep and goats. *Int J Syst Evol Microbiol* 54, 365-371.
- Neimark, H., Johansson, K.E., Rikihisa, Y., Tully, J.G., 2001. Proposal to transfer some members of the genera *Haemobartonella* and *Eperythrozoon* to the genus *Mycoplasma* with descriptions of '*Candidatus Mycoplasma haemofelis*', '*Candidatus Mycoplasma haemomuris*', '*Candidatus Mycoplasma haemosuis*' and '*Candidatus Mycoplasma wenyonii*'. *Int J Syst Evol Microbiol* 51, 891-899.
- Nesina, S., Katrin Helfer-Hungerbuehler, A., Riond, B., Boretti, F.S., Willi, B., Meli, M.L., Grest, P., Hofmann-Lehmann, R., 2015. Retroviral DNA--the silent winner: blood transfusion containing latent feline leukemia provirus causes infection and disease in naive recipient cats. *Retrovirology* 12, 105.
- Nutter, F.B., Dubey, J.P., Levine, J.F., Breitschwerdt, E.B., Ford, R.B., Stoskopf, M.K., 2004. Seroprevalences of antibodies against *Bartonella henselae* and *Toxoplasma gondii* and fecal shedding of *Cryptosporidium* spp, *Giardia* spp, and *Toxocara cati* in feral and pet domestic cats. *J Am Vet Med Assoc* 225, 1394-1398.
- O'Connor, T.P., Jr., Tonelli, Q.J., Scarlett, J.M., 1991. Report of the National FeLV/FIV Awareness Project. *Journal of the American Veterinary Medical Association* 199, 1348-1353.
- O'Neill, D.G., Church, D.B., McGreevy, P.D., Thomson, P.C., Brodbelt, D.C., 2014. Prevalence of disorders recorded in cats attending primary-care veterinary practices in England. *Vet J* 202, 286-291.
- Obert, L.A., Hoover, E.A., 2000. Relationship of lymphoid lesions to disease course in mucosal feline immunodeficiency virus type C infection. *Vet Pathol* 37, 386-401.

- Olczak, J., Jones, B.R., Pfeiffer, D.U., Squires, R.A., Morris, R.S., Markwell, P.J., 2005. Multivariate analysis of risk factors for feline hyperthyroidism in New Zealand. *N Z Vet J* 53, 53-58.
- Olmsted, R.A., Langley, R., Roelke, M.E., Goeken, R.M., Adger-Johnson, D., Goff, J.P., Albert, J.P., Packer, C., Laurenson, M.K., Caro, T.M., et al., 1992. Worldwide prevalence of lentivirus infection in wild feline species: epidemiologic and phylogenetic aspects. *J Virol* 66, 6008-6018.
- Opsteegh, M., Haveman, R., Swart, A.N., Mensink-Beerepoot, M.E., Hofhuis, A., Langelaar, M.F., van der Giessen, J.W., 2012. Seroprevalence and risk factors for *Toxoplasma gondii* infection in domestic cats in The Netherlands. *Prev Vet Med* 104, 317-326.
- Otranto, D., Napoli, E., Latrofa, M.S., Annoscia, G., Tarallo, V.D., Greco, G., Lorusso, E., Gulotta, L., Falsone, L., Basano, F.S., Pennisi, M.G., Deuster, K., Capelli, G., Dantas-Torres, F., Brianti, E., 2017. Feline and canine leishmaniosis and other vector-borne diseases in the Aeolian Islands: Pathogen and vector circulation in a confined environment. *Vet Parasitol* 236, 144-151.
- Pacitti, A.M., Jarrett, O., Hay, D., 1986. Transmission of feline leukaemia virus in the milk of a non-viraemic cat. *Vet Rec* 118, 381-384.
- Pavlova, E.V., Kirilyuk, E.V., Naidenko, S.V., 2016. Occurrence pattern of influenza A virus, *Coxiella burnetii*, *Toxoplasma gondii* and *Trichinella* sp. in the Pallas cat and domestic cat and their potential prey under arid climate conditions. *Arid Ecosystems* 6, 277-283.
- Pedersen, N.C., 1976. Serologic studies of naturally occurring feline infectious peritonitis. *Am J Vet Res* 37, 1449-1453.
- Pedersen, N.C., 2009. A review of feline infectious peritonitis virus infection: 1963-2008. *J Feline Med Surg* 11, 225-258.
- Pedersen, N.C., Ho, E.W., Brown, M.L., Yamamoto, J.K., 1987. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. *Science* 235, 790-793.
- Pedersen, N.C., Leutenegger, C.M., Woo, J., Higgins, J., 2001. Virulence differences between two field isolates of feline immunodeficiency virus (FIV-APetaluma and FIV-CPGammar) in young adult specific pathogen free cats. *Vet Immunol Immunopathol* 79, 53-67.

- Pedersen, N.C., Theilen, G., Keane, M.A., Fairbanks, L., Mason, T., Orser, B., Che, C.H., Allison, C., 1977. Studies of naturally transmitted feline leukemia virus infection. *Am J Vet Res* 38, 1523-1531.
- Pennisi, M.G., Hartmann, K., Addie, D.D., Lutz, H., Gruffydd-Jones, T., Boucraut-Baralon, C., Egberink, H., Frymus, T., Horzinek, M.C., Hosie, M.J., Lloret, A., Marsilio, F., Radford, A.D., Thiry, E., Truyen, U., Mostl, K., European Advisory Board on Cat, D., 2015. Blood transfusion in cats: ABCD guidelines for minimising risks of infectious iatrogenic complications. *J Feline Med Surg* 17, 588-593.
- Pesteanu-Somogyi, L.D., Radzai, C., Pressler, B.M., 2006. Prevalence of feline infectious peritonitis in specific cat breeds. *J Feline Med Surg* 8, 1-5.
- Peter, H.J., Gerber, H., Studer, H., Peterson, M.E., Becker, D.V., Groscurth, P., 1991. Autonomous growth and function of cultured thyroid follicles from cats with spontaneous hyperthyroidism. *Thyroid* 1, 331-338.
- Peterson, M.E., 2013. Hyperthyroidism in cats. In: *Clinical Endocrinology of Companion Animals* Blackwell, Iowa: pp 295-310.
- Peterson, M.E., Broome, M.R., 2015. Thyroid scintigraphy findings in 2096 cats with hyperthyroidism. *Vet Radiol Ultrasound* 56, 84-95.
- Peterson, M.E., Ferguson, D.C., 1983. Feline hyperthyroidism: Pretreatment clinical and laboratory evaluation of 131 cases. *J Am Vet Med Assoc* 183, 103-110.
- Peterson, M.E., Randolph, J.F., Mooney, C.T., 1994. Endocrine diseases. In: Sherding RG, ed. *The cat: diseases and clinical management*. 2nd ed. Churchill Livingstone, New York: pp 1416-1452.
- Peterson, M.E., Ward, C.R., 2007. Etiopathologic findings of hyperthyroidism in cats. *Vet Clin North Am Small Anim Pract* 37, 633-645, v.
- Phillips, T.R., Prospero-Garcia, O., Wheeler, D.W., Wagaman, P.C., Lerner, D.L., Fox, H.S., Whalen, L.R., Bloom, F.E., Elder, J.H., Henriksen, S.J., 1996. Neurologic dysfunctions caused by a molecular clone of feline immunodeficiency virus, FIV-PPR. *J Neurovirol* 2, 388-396.
- Podell, M., Hayes, K., Oglesbee, M., Mathes, L., 1997. Progressive encephalopathy associated with CD4/CD8 inversion in adult FIV-infected cats. *J Acquir Immune Defic Syndr Hum Retrovirol* 15, 332-340.

- Polak, K.C., Levy, J.K., Crawford, P.C., Leutenegger, C.M., Moriello, K.A., 2014. Infectious diseases in large-scale cat hoarding investigations. *Vet J* 201, 189-195.
- Poland, A.M., Vennema, H., Foley, J.E., Pedersen, N.C., 1996. Two related strains of feline infectious peritonitis virus isolated from immunocompromised cats infected with a feline enteric coronavirus. *J Clin Microbiol* 34, 3180-3184.
- Poli, A., Abramo, F., Baldinotti, F., Pistello, M., Da Prato, L., Bendinelli, M., 1994. Malignant lymphoma associated with experimentally induced feline immunodeficiency virus infection. *J Comp Pathol* 110, 319-328.
- Poli, A., Abramo, F., Taccini, E., Guidi, G., Barsotti, P., Bendinelli, M., Malvaldi, G., 1993. Renal involvement in feline immunodeficiency virus infection: a clinicopathological study. *Nephron* 64, 282-288.
- Power, C., Buist, R., Johnston, J.B., Del Bigio, M.R., Ni, W., Dawood, M.R., Peeling, J., 1998. Neurovirulence in feline immunodeficiency virus-infected neonatal cats is viral strain specific and dependent on systemic immune suppression. *J Virol* 72, 9109-9115.
- Powers, J.A., Chiu, E.S., Kraberger, S.J., Roelke-Parker, M., Lowery, I., Erbeck, K., Troyer, R., Carver, S., VandeWoude, S., 2018. Feline Leukemia Virus (FeLV) Disease Outcomes in a Domestic Cat Breeding Colony: Relationship to Endogenous FeLV and Other Chronic Viral Infections. *Journal of Virology* 92, e00649-00618.
- Pratelli, A., Yesilbag, K., Siniscalchi, M., Yalcin, E., Yilmaz, Z., 2009. Prevalence of feline coronavirus antibodies in cats in Bursa province, Turkey, by an enzyme-linked immunosorbent assay. *J Feline Med Surg* 11, 881-884.
- Prospero-Garcia, O., Herold, N., Phillips, T.R., Elder, J.H., Bloom, F.E., Henriksen, S.J., 1994. Sleep patterns are disturbed in cats infected with feline immunodeficiency virus. *Proc Natl Acad Sci U S A* 91, 12947-12951.
- Puig, J., Cattin, I., Seth, M., 2015. Concurrent diseases in hyperthyroid cats undergoing assessment prior to radioiodine treatment. *J Feline Med Surg* 17, 537-542.
- Quigley, J.G., Burns, C.C., Anderson, M.M., Lynch, E.D., Sabo, K.M., Overbaugh, J., Abkowitz, J.L., 2000. Cloning of the cellular receptor for feline leukemia virus subgroup C (FeLV-C), a retrovirus that induces red cell aplasia. *Blood* 95, 1093-1099.

- Raimundo, J.M., Guimaraes, A., Botelho, C.F., Peixoto, M.P., Pires, M.S., Machado, C.H., Santos, H.A., Massard, C.L., Andre, M.R., Machado, R.Z., Baldani, C.D., 2016. Hematological changes associated with hemoplasma infection in cats in Rio de Janeiro, Brazil. *Rev Bras Parasitol Vet* 25, 441-449.
- Ravagnan, S., Carli, E., Piseddu, E., Da Rold, G., Porcellato, E., Zanardello, C., Carminato, A., Vascellari, M., Capelli, G., 2017. Prevalence and molecular characterization of canine and feline hemotropic mycoplasmas (hemoplasmas) in northern Italy. *Parasit Vectors* 10, 132.
- Ravi, M., Wobeser, G.A., Taylor, S.M., Jackson, M.L., 2010. Naturally acquired feline immunodeficiency virus (FIV) infection in cats from western Canada: Prevalence, disease associations, and survival analysis. *Canadian Veterinary Journal* 51, 271-276.
- Rengifo-Herrera, C., Pile, E., Garcia, A., Perez, A., Perez, D., Nguyen, F.K., de la Guardia, V., McLeod, R., Caballero, Z., 2017. Seroprevalence of *Toxoplasma gondii* in domestic pets from metropolitan regions of Panama. *Parasite* 24, 9.
- Reynolds, C.A., Lappin, M.R., 2007. "Candidatus *Mycoplasma haemominutum*" infections in 21 client-owned cats. *J Am Anim Hosp Assoc* 43, 249-257.
- Riemer, F., Kuehner, K.A., Ritz, S., Sauter-Louis, C., Hartmann, K., 2016. Clinical and laboratory features of cats with feline infectious peritonitis--a retrospective study of 231 confirmed cases (2000-2010). *J Feline Med Surg* 18, 348-356.
- Rohn, J.L., Linenberger, M.L., Hoover, E.A., Overbaugh, J., 1994. Evolution of feline leukemia virus variant genomes with insertions, deletions, and defective envelope genes in infected cats with tumors. *J Virol* 68, 2458-2467.
- Rohrbach, B.W., Legendre, A.M., Baldwin, C.A., Lein, D.H., Reed, W.M., Wilson, R.B., 2001. Epidemiology of feline infectious peritonitis among cats examined at veterinary medical teaching hospitals. *J Am Vet Med Assoc* 218, 1111-1115.
- Rojko, J.L., Hoover, E.A., Quackenbush, S.L., Olsen, R.G., 1982. Reactivation of latent feline leukaemia virus infection. *Nature* 298, 385-388.
- Ryan, G., Grimes, T., Brankin, B., Mabruk, M.J., Hosie, M.J., Jarrett, O., Callanan, J.J., 2005. Neuropathology associated with feline immunodeficiency virus infection highlights prominent lymphocyte trafficking through both the blood-

- brain and blood-choroid plexus barriers. *Journal of Neurovirology* 11, 337-345.
- Sabshin, S.J., Levy, J.K., Tupler, T., Tucker, S.J., Greiner, E.C., Leutenegger, C.M., 2012. Enteropathogens identified in cats entering a Florida animal shelter with normal feces or diarrhea. *J Am Vet Med Assoc* 241, 331-337.
- Saevik, B.K., Krontveit, R.I., Eggen, K.P., Malmberg, N., Thoresen, S.I., Prestrud, K.W., 2015. *Toxoplasma gondii* seroprevalence in pet cats in Norway and risk factors for seropositivity. *J Feline Med Surg* 17, 1049-1056.
- Sassnau, R., 2006. Epidemiological investigation on the prevalence of feline hyperthyroidism in an urban population in Germany. *Tierärztliche Praxis Kleintiere* 34, 450-457.
- Scarlett, J.M., Sydney Moise, N., Rayl, J., 1988. Feline hyperthyroidism: a descriptive and case-control study. *Prev Vet Med* 6, 295-309.
- Schreiber, N., Basso, W., Riond, B., Willi, B., Torgerson, P.R., Deplazes, P., 2021. Antibody kinetics and exposure to *Toxoplasma gondii* in cats: a seroepidemiological study. *Int J Parasitol* 51, 291-299.
- Sharif, S., Arshad, S.S., Hair-Bejo, M., Omar, A.R., Zeenathul, N.A., Hafidz, M.A., 2009. Prevalence of feline coronavirus in two cat populations in Malaysia. *J Feline Med Surg* 11, 1031-1034.
- Shelton, G.H., Linenberger, M.L., 1995. Hematologic abnormalities associated with retroviral infections in the cat. *Semin Vet Med Surg Small Anim* 10, 220-233.
- Shimoda, T., Shiranaga, N., Mashita, T., Hasegawa, A., 2000. Chronic myelomonocytic leukemia in a cat. *J Vet Med Sci* 62, 195-197.
- Shuralev, E.A., Shamaev, N.D., Mukminov, M.N., Nagamune, K., Taniguchi, Y., Saito, T., Kitoh, K., Arleevskaya, M.I., Fedotova, A.Y., Abdulmanova, D.R., Aleksandrova, N.M., Efimova, M.A., Yarullin, A.I., Valeeva, A.R., Khaertynov, K.S., Takashima, Y., 2018. *Toxoplasma gondii* seroprevalence in goats, cats and humans in Russia. *Parasitol Int* 67, 112-114.
- Silaghi, C., Knaus, M., Rapti, D., Kusi, I., Shukullari, E., Hamel, D., Pfister, K., Rehbein, S., 2014. Survey of *Toxoplasma gondii* and *Neospora caninum*, haemotropic mycoplasmas and other arthropod-borne pathogens in cats from Albania. *Parasit Vectors* 7, 62.
- Sodora, D.L., Shpaer, E.G., Kitchell, B.E., Dow, S.W., Hoover, E.A., Mullins, J.I., 1994. Identification of three feline immunodeficiency virus (FIV) env gene

- subtypes and comparison of the FIV and human immunodeficiency virus type 1 evolutionary patterns. *J Virol* 68, 2230-2238.
- Soe, L.H., Devi, B.G., Mullins, J.I., Roy-Burman, P., 1983. Molecular cloning and characterization of endogenous feline leukemia virus sequences from a cat genomic library. *J Virol* 46, 829-840.
- Solano-Gallego, L., Hegarty, B., Espada, Y., Llull, J., Breitschwerdt, E., 2006. Serological and molecular evidence of exposure to arthropod-borne organisms in cats from northeastern Spain. *Vet Microbiol* 118, 274-277.
- Spada, E., Proverbio, D., della Pepa, A., Perego, R., Baggiani, L., DeGiorgi, G.B., Domenichini, G., Ferro, E., Cremonesi, F., 2012. Seroprevalence of feline immunodeficiency virus, feline leukaemia virus and *Toxoplasma gondii* in stray cat colonies in northern Italy and correlation with clinical and laboratory data. *Journal of Feline Medicine and Surgery* 14, 369-377.
- Sparkes, A.H., Gruffydd-Jones, T.J., Harbour, D.A., 1992. Feline coronavirus antibodies in UK cats. *Vet Rec* 131, 223-224.
- Spencer, S.E., Knowles, T., Ramsey, I.K., Tasker, S., 2017. Pyrexia in cats: Retrospective analysis of signalment, clinical investigations, diagnosis and influence of prior treatment in 106 referred cases. *J Feline Med Surg* 19, 1123-1130.
- Sroka, J., Szymańska, J., 2012. Analysis of prevalence of *Toxoplasma gondii* infection in selected rural households in the Lublin Region. *Bull Vet Inst Pulawy* 56, 529-534.
- Stavisky, J., Dean, R.S., Molloy, M.H., 2017. Prevalence of and risk factors for FIV and FeLV infection in two shelters in the United Kingdom (2011-2012). *Veterinary Record* 181, 451.
- Steigerwald, E.S., Sarter, M., March, P., Podell, M., 1999. Effects of feline immunodeficiency virus on cognition and behavioral function in cats. *J Acquir Immune Defic Syndr Hum Retrovirol* 20, 411-419.
- Stephens, M.J., O'Neill, D.G., Church, D.B., McGreevy, P.D., Thomson, P.C., Brodbelt, D.C., 2014. Feline hyperthyroidism reported in primary-care veterinary practices in England: prevalence, associated factors and spatial distribution. *Vet Rec* 175, 458.
- Studer, N., Lutz, H., Saegerman, C., Gonczi, E., Meli, M.L., Boo, G., Hartmann, K., Hosie, M.J., Moestl, K., Tasker, S., Belak, S., Lloret, A., Boucraut-Baralon,

- C., Egberink, H.F., Pennisi, M.G., Truyen, U., Frymus, T., Thiry, E., Marsilio, F., Addie, D., Hochleithner, M., Tkalec, F., Vizi, Z., Brunetti, A., Georgiev, B., Ludwig-Begall, L.F., Tschuor, F., Mooney, C.T., Eliasson, C., Orro, J., Johansen, H., Juuti, K., Krامل, I., Kovalenko, K., Sengaut, J., Sobral, C., Borska, P., Kovarikova, S., Hofmann-Lehmann, R., 2019. Pan-European Study on the Prevalence of the Feline Leukaemia Virus Infection - Reported by the European Advisory Board on Cat Diseases (ABCD Europe). *Viruses* 11, 993.
- Stutzer, B., Muller, F., Majzoub, M., Lutz, H., Greene, C.E., Hermanns, W., Hartmann, K., 2010. Role of latent feline leukemia virus infection in nonregenerative cytopenias of cats. *J Vet Intern Med* 24, 192-197.
- Stutzer, B., Simon, K., Lutz, H., Majzoub, M., Hermanns, W., Hirschberger, J., Sauter-Louis, C., Hartmann, K., 2011. Incidence of persistent viraemia and latent feline leukaemia virus infection in cats with lymphoma. *J Feline Med Surg* 13, 81-87.
- Su, C., Evans, D., Cole, R.H., Kissinger, J.C., Ajioka, J.W., Sibley, L.D., 2003. Recent expansion of *Toxoplasma* through enhanced oral transmission. *Science* 299, 414-416.
- Sykes, J.E., Drazenovich, N.L., Ball, L.M., Leutenegger, C.M., 2007. Use of conventional and real-time polymerase chain reaction to determine the epidemiology of hemoplasma infections in anemic and nonanemic cats. *J Vet Intern Med* 21, 685-693.
- Sykes, J.E., Terry, J.C., Lindsay, L.L., Owens, S.D., 2008. Prevalences of various hemoplasma species among cats in the United States with possible hemoplasmosis. *J Am Vet Med Assoc* 232, 372-379.
- Sykes, J.E., Westropp, J.L., Kasten, R.W., Chomel, B.B., 2010. Association between *Bartonella* species infection and disease in pet cats as determined using serology and culture. *J Feline Med Surg* 12, 631-636.
- Tabar, M.D., Altet, L., Francino, O., Sanchez, A., Ferrer, L., Roura, X., 2008. Vector-borne infections in cats: molecular study in Barcelona area (Spain). *Vet Parasitol* 151, 332-336.
- Taylor, C.S., Willett, B.J., Kabat, D., 1999. A putative cell surface receptor for anemia-inducing feline leukemia virus subgroup C is a member of a transporter superfamily. *J Virol* 73, 6500-6505.

- Tanahara, M., Miyamoto, S., Nishio, T., Yoshii, Y., Sakuma, M., Sakata, Y., Nishigaki, K., Tsujimoto, H., Setoguchi, A., Endo, Y., 2010. An epidemiological survey of feline hemoplasma infection in Japan. *J Vet Med Sci* 72, 1575-1581.
- Tasker, S., 2010. Haemotropic mycoplasmas: what's their real significance in cats? *J Feline Med Surg* 12, 369-381.
- Tasker, S., Binns, S.H., Day, M.J., Gruffydd-Jones, T.J., Harbour, D.A., Helps, C.R., Jensen, W.A., Olver, C.S., Lappin, M.R., 2003. Use of a PCR assay to assess the prevalence and risk factors for *Mycoplasma haemofelis* and '*Candidatus Mycoplasma haemominutum*' in cats in the United Kingdom. *Vet Rec* 152, 193-198.
- Tasker, S., Braddock, J.A., Baral, R., Helps, C.R., Day, M.J., Gruffydd-Jones, T.J., Malik, R., 2004. Diagnosis of feline haemoplasma infection in Australian cats using a real-time PCR assay. *J Feline Med Surg* 6, 345-354.
- Tasker, S., Hofmann-Lehmann, R., Belak, S., Frymus, T., Addie, D.D., Pennisi, M.G., Boucraut-Baralon, C., Egberink, H., Hartmann, K., Hosie, M.J., Lloret, A., Marsilio, F., Radford, A.D., Thiry, E., Truyen, U., Mostl, K., 2018. Haemoplasmosis in cats: European guidelines from the ABCD on prevention and management. *J Feline Med Surg* 20, 256-261.
- Teixeira, J.V., de Oliveira, J.L.S., de Almeida, D.M.P.F., Gonçalves, L.S., de Oliveira, F.L.L., 2016. Seroprevalence of feline toxoplasmosis in Teresina, Piauí, Brazil. *Rev Bras Hig Sanid Anim* 10, 549-555.
- Tenorio, A.P., Franti, C.E., Madewell, B.R., Pedersen, N.C., 1991. Chronic oral infections of cats and their relationship to persistent oral carriage of feline calici-, immunodeficiency, or leukemia viruses. *Veterinary Immunology and Immunopathology* 29, 1-14.
- Tenter, A.M., Heckeroth, A.R., Weiss, L.M., 2000. *Toxoplasma gondii*: from animals to humans. *Int J Parasitol* 30, 1217-1258.
- Thoday, K.L., Mooney, C.T., 1992. Historical, clinical and laboratory features of 126 hyperthyroid cats. *Vet Rec* 131, 257-264.
- Tiao, N., Darrington, C., Molla, B., Saville, W.J., Tilahun, G., Kwok, O.C., Gebreyes, W.A., Lappin, M.R., Jones, J.L., Dubey, J.P., 2013. An investigation into the seroprevalence of *Toxoplasma gondii*, *Bartonella* spp., feline

- immunodeficiency virus (FIV), and feline leukaemia virus (FeLV) in cats in Addis Ababa, Ethiopia. *Epidemiol Infect* 141, 1029-1033.
- Trepanier, L.A., 2006. Medical management of hyperthyroidism. *Clin Tech Small Anim Pract* 21, 22-28.
- Tsai, H.Y., Chueh, L.L., Lin, C.N., Su, B.L., 2011. Clinicopathological findings and disease staging of feline infectious peritonitis: 51 cases from 2003 to 2009 in Taiwan. *J Feline Med Surg* 13, 74-80.
- Tsatsanis, C., Fulton, R., Nishigaki, K., Tsujimoto, H., Levy, L., Terry, A., Spandidos, D., Onions, D., Neil, J.C., 1994. Genetic determinants of feline leukemia virus-induced lymphoid tumors: patterns of proviral insertion and gene rearrangement. *J Virol* 68, 8296-8303.
- Turrel, J.M., Feldman, E.C., Nelson, R.W., Cain, G.R., 1988. Thyroid carcinoma causing hyperthyroidism in cats: 14 cases (1981-1986). *J Am Vet Med Assoc* 193, 359-364.
- Ueno, H., Hohdatsu, T., Muramatsu, Y., Koyama, H., Morita, C., 1996. Does coinfection of *Bartonella henselae* and FIV induce clinical disorders in cats? *Microbiol Immunol* 40, 617-620.
- Ueno, H., Muramatsu, Y., Chomel, B.B., Hohdatsu, T., Koyama, H., Morita, C., 1995. Seroepidemiological survey of *Bartonella (Rochalimaea) henselae* in domestic cats in Japan. *Microbiol Immunol* 39, 339-341.
- van Hoek, I., Hesta, M., Biourge, V., 2015. A critical review of food-associated factors proposed in the etiology of feline hyperthyroidism. *J Feline Med Surg* 17, 837-847.
- Vobis, M., D'Haese, J., Mehlhorn, H., Mencke, N., 2003. Evidence of horizontal transmission of feline leukemia virus by the cat flea (*Ctenocephalides felis*). *Parasitol Res* 91, 467-470.
- Vollaire, M.R., Radecki, S.V., Lappin, M.R., 2005. Seroprevalence of *Toxoplasma gondii* antibodies in clinically ill cats in the United States. *Am J Vet Res* 66, 874-877.
- Wakeling, J., Elliott, J., Syme, H., 2011. Evaluation of predictors for the diagnosis of hyperthyroidism in cats. *J Vet Intern Med* 25, 1057-1065.
- Wakeling, J., Everard, A., Brodbelt, D., Elliott, J., Syme, H., 2009. Risk factors for feline hyperthyroidism in the UK. *J Small Anim Pract* 50, 406-414.

- Wakeling, J., Melian, C.A.F., 2005. Evidence for Differing Incidences of Feline Hyperthyroidism in London, Uk and Spain. In: Proceedings of the European College of Veterinary Internal Medicine for Companion Animals Congress, Glasgow, Scotland: pp 2005.
- Wakeling, J., Smith, K., Scase, T., Kirkby, R., Elliott, J., Syme, H., 2007. Subclinical hyperthyroidism in cats: a spontaneous model of subclinical toxic nodular goiter in humans? *Thyroid* 17, 1201-1209.
- Wang, J., Kyaw-Tanner, M., Lee, C., Robinson, W.F., 2001. Characterisation of lymphosarcomas in Australian cats using polymerase chain reaction and immunohistochemical examination. *Aust Vet J* 79, 41-46.
- Wang, Y.T., Chueh, L.L., Wan, C.H., 2014. An eight-year epidemiologic study based on baculovirus-expressed type-specific spike proteins for the differentiation of type I and II feline coronavirus infections. *BMC Vet Res* 10, 186.
- Watson, A.D., Huxtable, C.R., Bennett, A.M., 1974. feline infectious peritonitis. *Aust Vet J* 50, 393-397.
- Weingart, C., Tasker, S., Kohn, B., 2016. Infection with haemoplasma species in 22 cats with anaemia. *J Feline Med Surg* 18, 129-136.
- Weiss, D.J., 2006. Evaluation of dysmyelopoiesis in cats: 34 cases (1996-2005). *J Am Vet Med Assoc* 228, 893-897.
- Westfall, D.S., Jensen, W.A., Reagan, W.J., Radecki, S.V., Lappin, M.R., 2001. Inoculation of two genotypes of *Hemobartonella felis* (California and Ohio variants) to induce infection in cats and the response to treatment with azithromycin. *Am J Vet Res* 62, 687-691.
- Whittemore, J.C., Hawley, J.R., Radecki, S.V., Steinberg, J.D., Lappin, M.R., 2012. Bartonella species antibodies and hyperglobulinemia in privately owned cats. *J Vet Intern Med* 26, 639-644.
- Willi, B., Boretti, F.S., Baumgartner, C., Tasker, S., Wenger, B., Cattori, V., Meli, M.L., Reusch, C.E., Lutz, H., Hofmann-Lehmann, R., 2006. Prevalence, risk factor analysis, and follow-up of infections caused by three feline hemoplasma species in cats in Switzerland. *J Clin Microbiol* 44, 961-969.
- Willi, B., Boretti, F.S., Cattori, V., Tasker, S., Meli, M.L., Reusch, C., Lutz, H., Hofmann-Lehmann, R., 2005. Identification, molecular characterization, and experimental transmission of a new hemoplasma isolate from a cat with hemolytic anemia in Switzerland. *J Clin Microbiol* 43, 2581-2585.

- Williams, T.L., Peak, K.J., Brodbelt, D., Elliott, J., Syme, H.M., 2010. Survival and the development of azotemia after treatment of hyperthyroid cats. *J Vet Intern Med* 24, 863-869.
- Woods, J.E., Brewer, M.M., Hawley, J.R., Wisnewski, N., Lappin, M.R., 2005. Evaluation of experimental transmission of *Candidatus Mycoplasma haemominutum* and *Mycoplasma haemofelis* by *Ctenocephalides felis* to cats. *Am J Vet Res* 66, 1008-1012.
- Woods, J.E., Hawley, J.R., Lappin, M.R., 2003. Attempted transmission of *Haemobartonella felis* by *Ctenocephalides felis*. Proceedings of the American College of Internal Medicine (ACVIM) meeting, Charlotte, New York, 4th-7th June 2003 pp. 426.
- Woods, J.E., Wisnewski, N., Lappin, M.R., 2006. Attempted transmission of *Candidatus Mycoplasma haemominutum* and *Mycoplasma haemofelis* by feeding cats infected *Ctenocephalides felis*. *Am J Vet Res* 67, 494-497.
- Worthing, K.A., Wigney, D.I., Dhand, N.K., Fawcett, A., McDonagh, P., Malik, R., Norris, J.M., 2012. Risk factors for feline infectious peritonitis in Australian cats. *J Feline Med Surg* 14, 405-412.
- Yamamoto, J.K., Hansen, H., Ho, E.W., Morishita, T.Y., Okuda, T., Sawa, T.R., Nakamura, R.M., Pedersen, N.C., 1989. Epidemiologic and clinical aspects of feline immunodeficiency virus infection in cats from the continental United States and Canada and possible mode of transmission. *Journal of the American Veterinary Medical Association* 194, 213-220.
- Yekkour, F., Aubert, D., Mercier, A., Murat, J.B., Khames, M., Nguewa, P., Ait-Oudhia, K., Villena, I., Bouchene, Z., 2017. First genetic characterization of *Toxoplasma gondii* in stray cats from Algeria. *Vet Parasitol* 239, 31-36.
- Zangwill, K.M., Hamilton, D.H., Perkins, B.A., Regnery, R.L., Plikaytis, B.D., Hadler, J.L., Cartter, M.L., Wenger, J.D., 1993. Cat scratch disease in Connecticut. Epidemiology, risk factors, and evaluation of a new diagnostic test. *N Engl J Med* 329, 8-13.

PART TWO-OUR STUDY

1. Aims of the study

In Greece, there are few or no reports on the prevalence, the risk factors, and the clinical and clinicopathological manifestations of infections with FeLV, FIV, FCoV, *Bartonella* spp., *Mycoplasma* spp. and *T. gondii*, whereas the prevalence of feline hyperthyroidism has not been reported. For this reason, we conducted a prospective, cross-sectional study, in different populations of cats living in various areas of the country, to: a) determine the seroprevalence for FeLV, FIV, FCoV, *B. henselae* and *T. gondii* and the molecular prevalence of *Bartonella* spp. and *Mycoplasma* spp. infections; b) determine the prevalence of feline hyperthyroidism; c) investigate risk factors for FeLV, FIV, FCoV, *B. henselae* and *T. gondii* seropositivity; d) investigate risk factors for *Bartonella* spp. and *Mycoplasma* spp. PCR-positivity; e) determine the clinical signs, hematological and biochemical findings associated with FeLV, FIV, FCoV, *B. henselae* and *T. gondii* seropositivity; f) determine the clinical signs, hematological and biochemical findings associated with PCR-positivity for *Bartonella* spp. and *Mycoplasma* spp.; g) investigate possible associations between seropositivity for *B. henselae*, PCR-positivity for *Bartonella* spp. or PCR-positivity for *Mycoplasma* spp. and seropositivity for other infectious agents, including *T. gondii*, FCoV, FeLV and FIV; h) to compare the clinical signs, hematological and serum biochemical findings between hyperthyroid and non-hyperthyroid cats.

2. Article No 1

K.G. Kokkinaki, M.N. Saridomichelakis, L. Leontides, M.E. Mylonakis, A. O. Konstantinidis, J.M. Steiner, J.S. Suchodolski, P.G. Xenoulis

A prospective epidemiological, clinical, and clinicopathologic study of feline leukemia virus and feline immunodeficiency virus infection in 435 cats from Greece. *Comparative Immunology, Microbiology and Infectious Diseases*, 2021, 78: 101687



Contents lists available at ScienceDirect

Comparative Immunology, Microbiology and Infectious Diseases

journal homepage: www.elsevier.com/locate/cimid

A prospective epidemiological, clinical, and clinicopathologic study of feline leukemia virus and feline immunodeficiency virus infection in 435 cats from Greece

K.G. Kokkinaki^{a,*}, M.N. Saridomichelakis^a, L. Leontides^b, M.E. Mylonakis^c, A. O. Konstantinidis^c, J.M. Steiner^d, J.S. Suchodolski^d, P.G. Xenoulis^{a,d}

^a Clinic of Medicine, Faculty of Veterinary Science, University of Thessaly, 224 Trikalon Str., GR-43132, Karditsa, Greece

^b Laboratory of Epidemiology, Biostatistics and Animal Health Economics, Faculty of Veterinary Science, University of Thessaly, 224 Trikalon Str., GR-43132, Karditsa, Greece

^c Companion Animal Clinic, School of Veterinary Medicine, Aristotle University of Thessaloniki, 11 Stavrou Voutyra Str., GR-54627, Thessaloniki, Greece

^d Gastrointestinal Laboratory, Department of Small Animal Clinical Sciences, College of Veterinary and Biomedical Sciences, Texas A & M University, 4474-77843 TAMU, College Station, TX, USA

ARTICLE INFO

Keywords:

Retrovirus
Infectious diseases
Prevalence
Serology
Risk factors

ABSTRACT

Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) are retroviruses causing significant morbidity and mortality in cats. The aim of this study was to describe the epidemiological, clinical and clinicopathologic aspects of FeLV and FIV infections in different populations of cats in Greece, including client-owned cats, stray cats and cats who live in catteries.

A total of 435 cats were prospectively enrolled. Serological detection of FeLV antigen and FIV antibody was performed using a commercial in-house ELISA test kit.

The results showed that 17 (3.9 %) and 40 (9.2 %) of the 435 cats were positive for FeLV antigen and FIV antibody, respectively, whereas 5 (1.1 %) had concurrent infection with FeLV and FIV. Factors that were associated with FeLV antigenemia, based on multivariate analysis, included vomiting, rhinitis, infection with FIV, neutropenia, decreased blood urea nitrogen and increased serum cholesterol and triglyceride concentrations. Factors associated with FIV seropositivity included male gender, older age, outdoor access, weight loss, fever, gingivostomatitis, skin lesions and/or pruritus and hyperglobulinemia.

Various clinical signs and laboratory abnormalities were found to be significantly associated with retroviral infections, suggesting that current guidelines to test all sick cats should be followed, taking into particular consideration the high-risk groups of cats found in this study.

1. Introduction

Feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) are retroviruses, causing significant morbidity and mortality in cats. A wide range of disorders are associated with FeLV or FIV infections, including lymphoma, blood dyscrasias, neurological dysfunction, immune-mediated diseases, immunosuppression with secondary opportunistic infections, gingivostomatitis, reproductive disorders and fading kitten syndrome [1–4]. Reported risk factors for FeLV antigenemia and FIV seropositivity include male gender, outdoor access and unhealthy status [5–8]. The most well-documented clinicopathologic abnormalities associated with retroviral infections in cats include

anaemia, leukopenia, neutropenia and lymphopenia, reduced serum albumin/globulin ratio (A/G ratio), and hypergammaglobulinemia [9].

Epidemiological data are necessary to design optimal strategies for the control of these viral infections. Based on available data, organizations such as the European Advisory Board on Cat Diseases (ABCD) [10] and the American Association of Feline Practitioners (AAFP) [11] have published guidelines for the prevention and management of FeLV and FIV. The prevalence of FeLV antigenemia and FIV seropositivity varies considerably, ranging from 0% to 22.3 % for FeLV and from 0% to 23 % for FIV, depending on the geographical location and the study population [5,12–21].

Only limited seroepidemiological data are available on the retroviral

* Corresponding author.

E-mail address: kassikokkinaki@yahoo.gr (K.G. Kokkinaki).

<https://doi.org/10.1016/j.cimid.2021.101687>

Received 15 January 2021; Received in revised form 18 June 2021; Accepted 27 June 2021

Available online 29 June 2021

0147-9571/© 2021 Elsevier Ltd. All rights reserved.

infections of cats in Greece, including three studies [22–24] and a preliminary report [25]. Risk factors for FeLV antigenemia and FIV seropositivity and associated clinicopathologic abnormalities were not thoroughly investigated in any of these studies. In addition, they included cats living in certain areas of the country and admitted to veterinary clinics, likely representing the general feline population suboptimally.

The objectives of the present study were: 1) to determine the prevalence of FeLV and FIV infections in different populations of cats living in different parts of Greece; 2) to assess signalment risk factors for FeLV antigenemia and FIV seropositivity; 3) to determine the clinical signs and haematological and biochemical findings associated with FeLV antigenemia and/or FIV seropositivity in cats.

2. Materials and methods

2.1. Ethics approval

The study protocol was reviewed and approved by the Animal Ethics Committee of the Faculty of Veterinary Science, University of Thessaly (13/16-6-15). Handling of these animals was in compliance with the European Communities Council Directive 2010/63/EU and state laws.

2.2. Study population

Cats from four different geographic areas of Greece (i.e., Attica, Thessaly, Crete, and Macedonia) were prospectively enrolled by three clinicians between November 2013 and November 2016 and divided into three groups (i.e., client-owned, stray, and cats living in catteries). Client-owned cats and cats living in catteries were presented by their owners for wellness examination, vaccination, neutering and/or medical treatment. Two volunteer cat-rescue groups provided stray cats from urban and rural areas that were brought in for clinical examination, vaccination, neutering, and/or treatment. The stray cats often originated from cat-dense environments (i.e., cat colonies) and their age was estimated based on body size, dentition and other physical characteristics [26–28].

The sampling size was calculated using the Epi Info 7 software (Centers of Disease Control and Prevention, Atlanta, Georgia) with a confidence interval of 95%, expected prevalence of 50% and maximum error acceptable of 5%. The minimum number of systematically sampled cats was 384 cats.

Inclusion criteria included: a) body weight of ≥ 0.5 kg; and b) an informed consent form signed by the owner or the rescuer. The cats were enrolled randomly and no preference was given to their health status. Signalment and historical data were collected using a standardized questionnaire and a thorough physical examination was performed for each cat by one of three authors (KKG, PGX, AOK).

2.3. Sample collection and laboratory analyses

A total of 5 mL of blood was collected by jugular venipuncture from each cat. One milliliter of blood was immediately transferred into EDTA-anticoagulated tube and was used for haematology, whereas serum was separated and stored at -80°C until biochemical analysis. Haematology was performed utilizing one of three different hematology analyzers (Sysmex poch-100i, ADVIA 2120i Siemens, ADVIA 120 Siemens), depending on the geographic area of sampling and the results were classified as normal, increased, or decreased, based on the reference intervals for each laboratory. For most cats, differential cell count was calculated manually utilizing Diff-Quik (Merc, Germany) stained blood smears, whereas for the remaining cats it was based on the results of analysis using the ADVIA 2120i analyzer. All hematological analyses were performed within 12 h from blood collection. Biochemical analyses were performed using an automated chemistry analyzer (Roche/Hitachi MODULAR ANALYTICS D 2400 module, Roche Diagnostics,

Switzerland, CH).

FeLV antigen and FIV antibody testing were performed using an in-house ELISA assay (SNAP FIV/FeLV Combo test, IDEXX Laboratories, Westbrook, ME, USA) at the time of blood collection, using serum or plasma. The sensitivity and specificity reported by the manufacturer is 98.6% and 98.2%, respectively, for FeLV, and 93.5% and 100%, respectively, for FIV [29].

2.4. Statistical analysis

In the univariate analysis, categorical data regarding signalment, historical information, clinical signs, hematology and biochemistry of FeLV- or FIV- positive cats were compared with those of FeLV or FIV negative cats by either Pearson's χ^2 or Fisher's exact test. The normality of the distribution of the continuous variables was tested using the Kolmogorov-Smirnov test. Normally distributed data are presented as means \pm standard deviation and were compared between infected and non-infected cats using independent sample t-tests. Non-normally distributed data are presented as medians and ranges and were compared between infected and non-infected cats using the Mann Whitney *U* tests.

Variables that were different, at 25% level of significance, between FeLV- or FIV-positive and negative cats in the univariate analysis were selected as initial candidates for four separate logistic regression models using stepwise, forward and backward selection procedures. Variables identified as being associated with infection status of the cat (at $P < 0.05$) were retained in the final models. Odds ratios (OR) derived from the models were interpreted as measures of increased risk of infection.

The analyses were done using Stata 13 (Stata Corp, College Station, TX) and SPSS 23 for Windows (IBM Corp, Armonk, NY).

3. Results

A total of 435 cats were included in the study. The age of these cats ranged from 6 weeks to 17 years (median 2 years). Two hundred and twenty-nine cats (52.6%) were male (91 neutered) and 206 (47.4%) were female (65 neutered). Twenty-one cats (4.8%) were purebred and 399 (91.7%) were crossbreed, while for 15 (3.5%) cats these data were missing. One hundred and twenty-one cats (27.8%) lived exclusively indoors and 292 (67.1%) outdoors, while for 22 cats (5.1%) these data were missing. Three hundred and four cats (69.9%) were living in Attica, 58 (13.3%) in Thessaly, 45 (10.3%) in Crete, and 28 (6.4%) in Macedonia. Two hundred and eighty-six cats (65.7%) were client-owned, 123 (28.3%) were stray and 15 (3.5%) were living in catteries, while for 11 cats (2.5%) these data were missing. Three hundred and seventy-three cats (85.7%) lived in urban areas and 37 (8.5%) in rural areas, while for 25 (5.8%) cats these data were missing. One hundred and fifty-seven cats (36.1%) were clinically healthy and 268 (61.6%) were sick, while for 10 cats (2.3%) these data were missing.

Of the 435 cats, a total of 17 (3.9%) and 40 (9.2%) were found to be positive for FeLV antigen and FIV antibody, respectively. Of these infected cats, 5 (1.1% of the total 435 cats) had concurrent infections with FeLV and FIV. The prevalence for FeLV and FIV infection was 3.9% (12/304; 95%CI 3.8%–4.1%) and 9.9% (30/304; 95%CI 9.7%–10%) for cats living in Attica, 3.4% (2/58; 95%CI 2.8%–4%) and 12.1% (7/58; 95%CI 11%–13.2%) for cats living in Thessaly, 4.4% (2/45; 95%CI 3.5%–5.3%) and 2.2% (1/45; 95%CI 1.6%–2.8%) for cats living in Crete and 3.6% (1/28; 95%CI 2.3%–4.9%) and 7.1% (2/28; 95%CI 5.3%–8.9%) for cats living in Macedonia, respectively. Based on univariate analyses there was no statistically significant difference in the prevalence of FeLV or FIV infection among the four sampling regions. The prevalence for sick cats was 6% (95%CI 3.1%–8.8%) for FeLV infection, 11.2% (95%CI 7.4%–15%) for FIV and 1.5% (95%CI 0.05%–3%) for both viruses. For clinically healthy cats the prevalence was 0% for FeLV and 5.7% (95%CI 2.1%–9.3%) for FIV.

The univariate associations between FeLV antigenemia (Tables S1,

S3, S5, S7) or FIV seropositivity (Tables S2, S4, S6, S8) and signalment-historical data, clinical signs, results of haematology and results of serum biochemistry are presented in supplementary files.

Several factors were found to be significantly associated with FeLV antigenemia in the multivariate analysis (Table 1). Cats with vomiting (OR, 9.25; $P = 0.003$) or rhinitis (OR, 7.33; $P = 0.002$) were significantly more likely to be FeLV-positive compared to cats without vomiting or rhinitis. In addition, infection with FIV increased the risk of infection with FeLV (OR, 3.76; $P = 0.04$). Neutropenic cats (OR, 8.99; $P = 0.005$) and cats with decreased blood urea nitrogen (BUN) concentration (OR, 6.24; $P = 0.009$) were significantly more likely to be FeLV-positive compared to cats with neutrophil counts and BUN concentration within the reference intervals. Finally, cats with increased serum cholesterol (OR, 15.82; $P = 0.03$) or increased serum triglyceride concentration (OR, 9.17; $P = 0.004$) were significantly more likely to be FeLV-positive compared to cats with cholesterol and triglyceride concentrations within the reference intervals.

Multivariate analysis also indicated several factors associated with FIV-seropositivity (Table 2). FIV-positive cats (median age 4.5 years; range 0.13–14 years) were significantly older (OR, 1.17; $P < 0.001$) than FIV-negative cats (median age 2 years; range 0.13–17 years). In addition, male cats (OR, 4.00; $P = 0.002$) and cats living outdoors (OR, 2.67; $P = 0.04$) were significantly more likely to be seropositive than female cats and cats living indoors, respectively. Weight loss (OR, 2.98; $P = 0.013$) and the presence of fever (OR, 5.31; $P = 0.025$), gingivostomatitis (OR, 3.61; $P = 0.005$) and skin lesions and/or pruritus (OR, 2.21; $P = 0.05$) were also significantly associated with FIV-seropositivity. Also, cats with hyperglobulinemia were more likely to be FIV-seropositive (OR, 5.04; $P < 0.001$) compared to cats with normal or reduced serum globulin concentrations.

4. Discussion

This is one of the largest prospective studies on FeLV and FIV infections in cats. The prevalence of these infections varies greatly among countries and regions and depends on the population tested. Studies have reported an overall prevalence of FeLV infection of 22.3% in Latin America [20], 2.3%–3.3% in North America [19,30], 0%–2.9% in Asia [14,15], and 0%–15.6% in Europe. A prospective European study on the prevalence of FeLV infection conducted in 32 countries showed an overall prevalence of 2.3% [21]. The prevalence of FIV infection has been reported to be 5.8% in Latin America [20], 2.5%–23% in North America [17,19], 0%–22% in Asia [13,14], and 2.3%–11.3% in Europe [12,18].

Table 1

Multivariate analysis of historical data, clinical signs, and results of hematology and serum biochemistry, identified as factors associated with feline leukemia virus (FeLV) antigenemia.

| Variables | Categories | OR | CI | <i>P</i> value |
|---------------|---------------------|-----------|---------------|----------------|
| Vomiting | No | Reference | | |
| | Yes | 9.25 | 2.11 – 40.54 | 0.003 |
| Rhinitis | No | Reference | | |
| | Yes | 7.33 | 2.12 – 25.32 | 0.002 |
| FIV infection | No | Reference | | |
| | Yes | 3.76 | 1.03 – 13.67 | 0.04 |
| Neutrophils | Decreased | Reference | | |
| | Normal | 0.11 | 0.02 – 0.52 | 0.005 |
| | Increased | 0.28 | 0.04 – 1.65 | 0.16 |
| BUN | Decreased | Reference | | |
| | Normal | 0.16 | 0.04 – 0.63 | 0.009 |
| | Increased | 0.67 | 0.12 – 3.73 | 0.65 |
| Cholesterol | Normal or decreased | Reference | | |
| | Increased | 15.82 | 1.27 – 196.16 | 0.03 |
| Triglycerides | Normal or decreased | Reference | | |
| | Increased | 9.17 | 2.03 – 41.24 | 0.004 |

OR: odds ratio; CI: confidence interval; FIV: feline immunodeficiency virus; BUN: blood urea nitrogen.

Table 2

Multivariate analysis of signalment, historical data, clinical signs, and the results of hematology and serum biochemistry identified as factors associated with feline immunodeficiency virus (FIV) seropositivity.

| Variables | Categories | OR | CI | <i>P</i> value |
|------------------------------|---------------------|-----------|--------------|----------------|
| Sex | Female | Reference | | |
| | Male | 4 | 1.69 – 9.36 | 0.002 |
| Age (years) | | 1.17 | 1.07 – 1.28 | < 0.001 |
| | | | | |
| Living conditions | Indoors | Reference | | |
| | Outdoors | 2.67 | 1.03 – 6.88 | 0.04 |
| Weight loss | No | Reference | | |
| | Yes | 2.98 | 1.25 – 7.1 | 0.013 |
| Fever | No | Reference | | |
| | Yes | 5.31 | 1.23 – 22.85 | 0.025 |
| Gingivostomatitis | No | Reference | | |
| | Yes | 3.61 | 1.47 – 8.88 | 0.005 |
| Skin lesions and/or pruritus | No | Reference | | |
| | Yes | 2.21 | 0.96 – 5.06 | 0.05 |
| Globulins | Normal or decreased | Reference | | |
| | Increased | 5.04 | 2.37 – 10.69 | < 0.001 |
| | | | | |

OR: odds ratio; CI: confidence interval.

We found an overall prevalence of 3.9% (95%CI 2.1%–5.7%) and 9.2% (95%CI 6.4%–11.9%) for infection with FeLV and FIV, respectively. These percentages are practically the same with those reported in a study from Greece, that assessed the *Leishmania infantum* infection status in 50 clinically healthy cats and 50 sick cats. The authors reported a prevalence of 3% and 8% for FeLV and FIV infection, respectively [24]. In the current study the prevalence for sick cats was 6% for FeLV and 11.2% for FIV infection. These percentages are quite the same with those reported in a Congress presentation of the results of a retrospective study of 422 sick cats admitted to a veterinary teaching hospital [25]. The authors of the above mentioned presentation reported a prevalence of 4.5% for FeLV and 10.2% for FIV.

Our study showed that cats with a history of vomiting were 9.25 times more likely to be FeLV-positive than cats with no such history. To our knowledge, there is no published information suggesting a significant association between vomiting and FeLV infection and the design of our study cannot confirm a causal association. Feline leukemia virus is a potential cause of enteritis, singly or in combination with other enteric pathogens, such as feline panleukopenia virus and coronavirus [31–33].

FeLV-infected cats often have concurrent bacterial, viral, protozoal, and/or fungal infections [31,34,35], including feline upper respiratory tract disease (FURTD). In our study, rhinitis was found to be associated with FeLV antigenemia (OR, 7.33) and this is consistent with the results of a retrospective study of 62,000 cats from the United States and Canada, where FeLV-positive cats were 5 times more likely to have respiratory signs compared to non-infected cats [8]. In addition, in two other studies, FURTD affected 18% or 11% of FeLV-infected cats, respectively [36,37], but no statistically significant association was found. A more recent European study reported a prevalence of 15% for FURTD among FeLV-positive cats [21], again without showing a significant association.

Regression analysis showed that FIV infection was a significant risk factor for FeLV infection, and this is consistent with the results of previous studies [5,38]. This finding could be explained by the fact that FIV can cause immunosuppression, therefore increasing the risk for FeLV infection [39].

FeLV infection is associated with a variety of clinicopathologic abnormalities. An important finding was that cats with neutropenia were 9 times more likely to be FeLV-positive compared to cats with normal neutrophil counts. Neutropenia is a common hematological abnormality in FeLV-infected cats and several studies have showed similar results [9, 40]. Neutropenia can be caused by immune-mediated mechanisms, bone

marrow aplasia, myelodysplasia, myelofibrosis or myelophthisis. In FeLV-infected cats, myeloid hypoplasia of all granulocytic stages and an arrest in bone marrow maturation at the myelocyte and metamyelocyte stages can occur [41,42]. In addition, neutrophil counts of some neutropenic FeLV-infected cats recover with glucocorticoid treatment (glucocorticoid-responsive neutropenia), suggesting an immune-mediated pathogenetic mechanism [43].

The reason for the increased prevalence of low serum BUN concentration in FeLV-infected cats is not clear. Theoretically, chronic consumption of low-protein diets or protein malabsorption can lead to low BUN concentrations. This might be especially applicable for stray cats. Interestingly, univariate analysis showed that anorexia was associated with increased risk of FeLV-antigenemia (Supplementary Table S3). Because prolonged anorexia can also lead to reduced protein intake, low BUN could reflect the anorexia associated with FeLV infection or other comorbidities.

The prevalence of increased cholesterol and triglyceride concentrations was significantly higher in FeLV-positive than in FeLV-negative cats. Fasting was not an inclusion criterion for our study and therefore, these results need to be interpreted with caution. Hyperlipidaemia has been associated with several inflammatory conditions in both humans and dogs (e.g., pancreatitis, parvoviral enteritis) and inflammation due to FeLV could potentially have led to increased serum lipid concentrations [44–46].

Male cats were approximately 4 times more likely to be FIV-positive than female cats. Male sex has also been described as an important risk factor for FIV infection in other studies [5,8,19,47,48]. From a behavioral perspective, male cats have been shown to be more aggressive than female cats, leading to a greater risk of bite wounds and FIV transmission.

In the current study FIV positive cats were significantly older than FIV negative cats and this is consistent with previous studies [19,38,49,50]. Older cats are more commonly infected with FIV possibly due to the fact that compared to FeLV, FIV has a longer incubation period, within which cats could remain in the asymptomatic phase for years with a low impact on morbidity and mortality rates.

Outdoor access was also found to be a risk factor for FIV-seropositivity and this is consistent with results of several previous reports [5,8,19,51,52]. Cats living outdoors or having outdoor access have an increased chance to interact with infected cats.

Weight loss was significantly associated to FIV-seropositivity and this finding is in accordance with the results of previous studies [47,53–55]. Weight loss leading to a poor body condition score may be the result of anorexia associated with the infection or comorbidities that developed as a result of the FIV (e.g., neoplasia, secondary infections).

Fever was also found to be significantly associated with FIV-seropositivity. To our knowledge, this is the first time a significant association between the presence of fever and natural FIV infection has been reported. In the first weeks to months after experimental infection, fever, lasting for a few days to a few weeks, may be observed but it is likely to go unobserved by the owners of many naturally infected cats [47]. However, since fever is a non-specific finding that can be present in several diseases in cats [56] this finding need to be interpreted with caution. Fever could be associated with FIV infection as we mentioned previously, but also could be associated with other comorbidities.

Gingivostomatitis is one of the most typical clinical findings in FIV-infected cats and has been attributed to an immune response to chronic antigenic stimulation or to immune dysregulation [2]. Our study indicates a strong association between FIV-seropositivity and gingivostomatitis (OR 3.6), and this is in agreement with previous reports [53,57–59,55]. Furthermore, among client-owned cats, the prevalence of FIV-seropositivity was 5.7 times higher in the cats with oral disease, including stomatitis and gingivitis [60].

Another finding of our study was the higher prevalence of FIV infection among cats with skin lesions and/or pruritus. This is not surprising because many bacterial, viral, and/or fungal infections have

been associated with FIV [52,61]. Bacterial skin diseases that have been associated with FIV infection include folliculitis, superficial spreading pyoderma, abscesses, paronychia and otitis. Fungal, viral, and parasitic infections, such as dermatophytosis, dermatophyte pseudomycetoma and infections with *Candida*, *Malassezia*, *Demodex cati* and cow-poxvirus, have also been associated with FIV infection. In addition, FIV-infected cats may be at risk for developing immune-mediated vasculitis and auricular chondritis. Idiopathic lymphocytic mural folliculitis, plasma cell pododermatitis, and generalized papulocrustous eruption with alopecia and scaling have been reported in FIV-positive cats. Tumors, such as B-cell lymphomas, squamous cell carcinoma, and mast cell tumors also have been reported in association with FIV infection [8,60,62–64].

Similar to others studies, we found that FIV-infected cats had a significantly increased risk of hyperglobulinemia [9,41,65,66]. This finding is a direct consequence of FIV infection, reflects polyclonal B cell activation and has been documented in both natural and experimental infections [67].

5. Conclusions

This study demonstrates a relatively high prevalence of FeLV antigenemia and FIV seropositivity of cats in Greece. Thus, it is necessary to establish optimal strategies for prevention and management of infection with these viruses, taking into particular consideration the high-risk groups of cats identified in this study. FeLV infection was associated with vomiting, rhinitis, FIV infection, neutropenia, low serum BUN concentration, hypercholesterolemia, and hypertriglyceridemia. Male gender, older age, and outdoor access were risk factors for FIV-seropositivity. Weight loss, fever, gingivostomatitis, skin lesion and/or pruritus and hyperglobulinemia were associated with FIV-seropositivity. These results can be used to focus testing resources on cats at high risk of infection, when it is not feasible to test all cats as recommended.

Declaration of Competing Interest

IDEXX Laboratories and Petline supplied the SNAP FIV/FeLV Combo tests used in this study. IDEXX Laboratories and Petline did not participate in the study design, sample collection and analysis, or interpretation of data, and in the decision to submit the manuscript for publication. None of the authors has any financial or personal relationships that could inappropriately influence or bias the content of the paper.

Acknowledgements

Preliminary results were presented as an abstract at the 28th Annual Congress of the European College of Veterinary Internal Medicine Companion Animals (ECVIM-CA, Rotterdam, 6-8 September 2018) and the proceedings were published in the Journal of Veterinary Internal Medicine. The authors wish to thank Dr. Chrisi Simou and Dr. Theodoros Bamplenis for helping with the enrolment of cats into the study and Dr. George Kazakos for his advice on the protocol for the chemical restraint of the cats.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.cimid.2021.101687>.

References

- [1] E.A. Hoover, J.I. Mullins, Feline leukemia virus infection and diseases, *J. Am. Vet. Med. Assoc.* 199 (1991) 1287–1297.
- [2] A.P. Tenorio, C.E. Franti, B.R. Madewell, N.C. Pedersen, Chronic oral infections of cats and their relationship to persistent oral carriage of feline calicivirus, immunodeficiency, or leukemia viruses, *Vet. Immunol. Immunopathol.* 29 (1991) 1–14.

- [3] G. Ryan, T. Grimes, B. Brankin, M.J. Mabruk, M.J. Hosie, O. Jarrett, J.J. Callanan, Neuropathology associated with feline immunodeficiency virus infection highlights prominent lymphocyte trafficking through both the blood-brain and blood-choroid plexus barriers, *J. Neurovirol.* 11 (2005) 337–345.
- [4] K. Hartmann, Clinical aspects of feline immunodeficiency and feline leukemia virus infection, *Vet. Immunol. Immunopathol.* 143 (2011) 190–201.
- [5] S.E. Gleich, S. Krieger, K. Hartmann, Prevalence of feline immunodeficiency virus and feline leukaemia virus among client-owned cats and risk factors for infection in Germany, *J. Feline Med. Surg.* 11 (2009) 985–992.
- [6] B.K. Chhetri, O. Berke, D.L. Pearl, D. Bienzle, Comparison of risk factors for seropositivity to feline immunodeficiency virus and feline leukemia virus among cats: a case-case study, *BMC Vet. Res.* 11 (2015) 30.
- [7] M.E. Westman, A. Paul, R. Malik, P. McDonagh, M.P. Ward, E. Hall, J.M. Norris, Seroprevalence of feline immunodeficiency virus and feline leukaemia virus in Australia: risk factors for infection and geographical influences (2011–2013), *J. Feline Med. Surg. Open Rep.* 2 (2016) 1–11.
- [8] A.N. Burling, J.K. Levy, H.M. Scott, M.M. Crandall, S.J. Tucker, E.G. Wood, J. D. Foster, Seroprevalences of feline leukemia virus and feline immunodeficiency virus infection in cats in the United States and Canada and risk factors for seropositivity, *J. Am. Vet. Med. Assoc.* 251 (2017) 187–194.
- [9] S. Gleich, K. Hartmann, Hematology and serum biochemistry of feline immunodeficiency virus-infected and feline leukemia virus-infected cats, *J. Vet. Intern. Med.* 23 (2009) 552–558.
- [10] K. Möstl, D.D. Addie, C. Boucraut-Baralon, H. Egberink, T. Frymus, T. Gruffydd-Jones, K. Hartmann, M.J. Hosie, A. Lloret, H. Lutz, F. Marsilio, M.G. Pennisi, A. D. Radford, E. Thiry, U. Truyen, M.C. Horzinek, European Advisory Board on Cat, D. Something old, something new: update of the 2009 and 2013 ABCD guidelines on prevention and management of feline infectious diseases, *J. Feline Med. Surg.* 17 (2015) 570–582.
- [11] S. Little, J. Levy, K. Hartmann, R. Hofmann-Lehmann, M. Hosie, G. Olah, K. S. Denis, 2020 AAEP feline retrovirus testing and management guidelines, *J. Feline Med. Surg.* 22 (2020) 5–30.
- [12] K. Hartmann, K. Hinze, Epidemiology and clinical aspects of FIV infection in Bavaria, *Tierärztliche Praxis* 19 (1991) 545–551.
- [13] T. Miyazawa, Y. Ikeda, K. Maeda, T. Horimoto, Y. Tohya, M. Mochizuki, D. Vu, G. D. Vu, D.X. Cu, K. Ono, E. Takahashi, T. Mikami, Seroepidemiological survey of feline retrovirus infections in domestic and leopard cats in northern Vietnam in 1997, *J. Vet. Med. Sci.* 60 (1998) 1273–1275.
- [14] K. Nakamura, T. Miyazawa, Y. Ikeda, E. Sato, Y. Nishimura, N.T. Nguyen, E. Takahashi, M. Mochizuki, T. Mikami, Contrastive prevalence of feline retrovirus infections between northern and southern Vietnam, *J. Vet. Med. Sci.* 62 (2000) 921–923.
- [15] S. Maruyama, H. Kabeya, R. Nakao, S. Tanaka, T. Sakai, X. Xuan, Y. Katsube, T. Mikami, Seroprevalence of *Bartonella henselae*, *Toxoplasma gondii*, FIV and FeLV infections in domestic cats in Japan, *Microbiol. Immunol.* 47 (2003) 147–153.
- [16] B.J. Luria, J.K. Levy, M.R. Lappin, E.B. Breitschwerdt, A.M. Legendre, J. A. Hernandez, S.P. Gorman, I.T. Lee, Prevalence of infectious diseases in feral cats in Northern Florida, *J. Feline Med. Surg.* 6 (2004) 287–296.
- [17] S.E. Little, Feline immunodeficiency virus testing in stray, feral, and client-owned cats of Ottawa, *Can. Vet. J.* 46 (2005) 898–901.
- [18] P. Bandecchi, M. Dell’Omodarme, M. Magi, A. Palamidessi, M.C. Prati, Feline leukaemia virus (FeLV) and feline immunodeficiency virus infections in cats in the Pisa district of Tuscany, and attempts to control FeLV infection in a colony of domestic cats by vaccination, *Vet. Rec.* 158 (2006) 555–557.
- [19] J.K. Levy, H.M. Scott, J.L. Lachlari, P.C. Crawford, Seroprevalence of feline leukemia virus and feline immunodeficiency virus infection among cats in North America and risk factors for seropositivity, *J. Am. Vet. Med. Assoc.* 228 (2006) 371–376.
- [20] G. Biezus, G. Machado, P.E. Ferian, U.M. da Costa, L. Pereira, J.A. Withoef, I.A. C. Nunes, T.R. Muller, T.G. de Cristo, R.A. Casagrande, Prevalence of and factors associated with feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) in cats of the state of Santa Catarina, Brazil, *Comp. Immunol. Microbiol. Infect. Dis.* 63 (2019) 17–21.
- [21] N. Studer, H. Lutz, C. Saegerman, E. Gonczi, M.L. Meli, G. Boo, K. Hartmann, M. J. Hosie, K. Moestl, S. Tasker, S. Belak, A. Lloret, C. Boucraut-Baralon, H. F. Egberink, M.G. Pennisi, U. Truyen, T. Frymus, E. Thiry, F. Marsilio, D. Addie, M. Hochleitner, F. Tkalec, Z. Vizi, A. Brunetti, B. Georgiev, L.F. Ludwig-Begall, F. Tschuor, C.T. Mooney, C. Eliasson, J. Orro, H. Johansen, K. Juuti, I. Krampfl, K. Kovalenko, J. Sengaut, C. Sobral, P. Borska, S. Kovarikova, R. Hofmann-Lehmann, Pan-European study on the prevalence of the feline leukaemia virus infection – reported by the European advisory board on cat diseases (ABCD Europe), *Viruses* 11 (2019) 993.
- [22] A. Koutinas, G. Koptopoulos, Low prevalence of feline viral infections in northern Greece, *Vet. Rec.* 133 (1993) 245–247.
- [23] I.E. Maher, S. Tasker, Z. Polizopoulou, A. Dasopoulou, K. Egan, C.R. Helps, K. Papanolioti, Polymerase chain reaction survey of feline haemoplasma infections in Greece, *J. Feline Med. Surg.* 12 (2010) 601–605.
- [24] M.K. Chatzis, L. Leontides, L.V. Athanasiou, E. Papadopoulos, D. Kasabalas, M. Mylonakis, T. Rallis, A.F. Koutinas, M. Andreadou, J. Ikononopoulos, M. N. Saridomichelakis, Evaluation of indirect immunofluorescence antibody test and enzyme-linked immunosorbent assay for the diagnosis of infection by *Leishmania infantum* in clinically normal and sick cats, *Exp. Parasitol.* 147 (2014) 54–59.
- [25] T.K. Tzoloufi, A. Theodoridis, V. Lantzaki, N. Filos, I.L. Oikonomidis, M. Kritsepi-Konstantinou, S. Papadimitriou, M.E. Mylonakis, Clinical and clinicopathologic indicators of feline leukemia virus and feline immunodeficiency virus infections in sick cats, in: Proceedings of the Annual Meeting of the European Society of Veterinary Clinical Pathology (ESVCP)/European College of Veterinary Clinical Pathology (ECVCP), Nantes, France, 20th–22th October 2016, 2016, p. 197.
- [26] F.A. Hale, Juvenile veterinary dentistry, *Vet. Clin. North Am. Small Anim. Pract.* 35 (2005) 789–817.
- [27] J. Bellows, S. Center, L. Daristotle, A.H. Estrada, E.A. Flickinger, D.F. Horwitz, B. D. Lascelles, A. Lepine, S. Perea, M. Scherck, A.K. Shoveller, Aging in cats: common physical and functional changes, *J. Feline Med. Surg.* 18 (2016) 533–550.
- [28] B.A. DiGangi, J. Graves, C.M. Budke, J.K. Levy, S. Tucker, N. Isaza, Assessment of body weight for age determination in kittens, *J. Feline Med. Surg.* 22 (2020) 322–328.
- [29] J. Levy, Performance of point-of-care assays for FeLV and FIV, in: Proceedings of the Annual Forum of the American College of Veterinary Internal Medicine (ACVIM), Denver, Colorado, 9th–10th June 2016, 2016, p. 1475.
- [30] B.J. Luria, J.K. Levy, M.R. Lappin, E.B. Breitschwerdt, A.M. Legendre, J. A. Hernandez, S.P. Gorman, I.T. Lee, Prevalence of infectious diseases in feral cats in Northern Florida, *J. Feline Med. Surg.* 6 (2004) 287–296.
- [31] S.M. Cotter, Management of healthy feline leukemia virus-positive cats, *J. Am. Vet. Med. Assoc.* 199 (1991) 1470–1473.
- [32] H. Lutz, I. Castelli, F. Ehrensperger, A. Pospischil, M. Roskopf, G. Siegl, M. Grob, S. Martinod, Panleukopenia-like syndrome of FeLV caused by co-infection with FeLV and feline panleukopenia virus, *Vet. Immunol. Immunopathol.* 46 (1995) 21–33.
- [33] A. Kipar, J. Kremendahl, M.L. Jackson, M. Reinacher, Comparative examination of cats with feline leukemia virus-associated enteritis and other relevant forms of feline enteritis, *Vet. Pathol.* 38 (2001) 359–371.
- [34] P. Sierra, J. Guillot, H. Jacob, S. Bussieras, R. Chermette, Fungal flora on cutaneous and mucosal surfaces of cats infected with feline immunodeficiency virus or feline leukemia virus, *Am. J. Vet. Res.* 61 (2000) 158–161.
- [35] J.A. Powers, E.S. Chiu, S.J. Kraberger, M. Roelke-Parker, I. Lowery, K. Erbeck, R. Troyer, S. Carver, S. VandeWoude, Feline leukemia virus (FeLV) disease outcomes in a domestic cat breeding colony: relationship to endogenous FeLV and other chronic viral infections, *J. Virol.* 92 (2018) e00649–00618.
- [36] T.P. O’Connor Jr., Q.J. Tonelli, J.M. Scarlett, Report of the national FeLV/FIV awareness project, *J. Am. Vet. Med. Assoc.* 199 (1991) 1348–1353.
- [37] P.C. Crawford, J.K. Levy, J.M. Bicknell, C.R. Layton, T.A. Hannaka, FeLV, FIV, AND FIP: epidemiology and clinical disease syndromes, *J. Vet. Intern. Med.* 15 (2001) 276.
- [38] E. Spada, D. Proverbio, A. della Pepa, R. Perego, L. Baggiani, G.B. DeGiorgi, G. Domenichini, E. Ferro, F. Cremonesi, Seroprevalence of feline immunodeficiency virus, feline leukaemia virus and *Toxoplasma gondii* in stray cat colonies in northern Italy and correlation with clinical and laboratory data, *J. Feline Med. Surg.* 14 (2012) 369–377.
- [39] D.D. Addie, J.M. Dennis, S. Toth, J.J. Callanan, S. Reid, O. Jarrett, Long-term impact on a closed household of pet cats of natural infection with feline coronavirus, feline leukaemia virus and feline immunodeficiency virus, *Vet. Rec.* 146 (2000) 419–424.
- [40] M.R. Brown, K.S. Rogers, Neutropenia in dogs and cats: a retrospective study of 261 cases, *J. Am. Anim. Hosp. Assoc.* 37 (2001) 131–139.
- [41] G.H. Shelton, M.L. Linenberger, Hematologic abnormalities associated with retroviral infections in the cat, *Semin. Vet. Med. Surg.* 10 (1995) 220–233.
- [42] B. Stutzer, F. Muller, M. Majzoub, H. Lutz, C.E. Greene, W. Hermanns, K. Hartmann, Role of latent feline leukemia virus infection in nonregenerative cytopenias of cats, *J. Vet. Intern. Med.* 24 (2010) 192–197.
- [43] E.M. Stavroulaki, M.E. Mylonakis, E. Papanikolaou, A. Hatzis, P.G. Xenoulis, Steroid-responsive neutropenia in a cat with progressive feline leukemia virus infection, *Vet. Clin. Pathol.* 49 (2020) 389–393.
- [44] P.G. Xenoulis, J.M. Steiner, Lipid metabolism and hyperlipidemia in dogs, *Vet. J.* 183 (2010) 12–21.
- [45] P.G. Xenoulis, J.M. Steiner, Canine hyperlipidaemia, *J. Small Anim. Pract.* 56 (2015) 595–605.
- [46] P.G. Xenoulis, P.J. Cammarata, R.L. Walzem, J.S. Suchodolski, J.M. Steiner, Serum triglyceride and cholesterol concentrations and lipoprotein profiles in dogs with naturally occurring pancreatitis and healthy control dogs, *J. Vet. Intern. Med.* 34 (2020) 644–652.
- [47] C. Luckman, M.C. Gates, Epidemiology and clinical outcomes of feline immunodeficiency virus and feline leukaemia virus in client-owned cats in New Zealand, *J. Feline Med. Surg. Open Rep.* 3 (2017) 1–9.
- [48] A. Sivagurunathan, A.M. Atwa, R. Lobetti, Prevalence of feline immunodeficiency virus and feline leukaemia virus infection in Malaysia: a retrospective study, *J. Feline Med. Surg. Open Rep.* 4 (2018) 1–5.
- [49] B.P. Liem, N.K. Dhand, A.E. Pepper, V.R. Barrs, J.A. Beatty, Clinical findings and survival in cats naturally infected with feline immunodeficiency virus, *J. Vet. Intern. Med.* 27 (2013) 798–805.
- [50] J. Stavisky, R.S. Dean, M.H. Molloy, Prevalence of and risk factors for FIV and FeLV infection in two shelters in the United Kingdom (2011–2012), *Vet. Rec.* 181 (2017) 451.
- [51] J.K. Yamamoto, H. Hansen, E.W. Ho, T.Y. Morishita, T. Okuda, T.R. Sawa, R. M. Nakamura, N.C. Pedersen, Epidemiologic and clinical aspects of feline immunodeficiency virus infection in cats from the continental United States and Canada and possible mode of transmission, *J. Am. Vet. Med. Assoc.* 194 (1989) 213–220.
- [52] M.J. Hosie, D. Addie, S. Belak, C. Boucraut-Baralon, H. Egberink, T. Frymus, T. Gruffydd-Jones, K. Hartmann, A. Lloret, H. Lutz, F. Marsilio, M.G. Pennisi, A. D. Radford, E. Thiry, U. Truyen, M.C. Horzinek, Feline immunodeficiency. ABCD

- guidelines on prevention and management, *J. Feline Med. Surg.* 11 (2009) 575–584.
- [53] R. Hofmann-Lehmann, E. Holznagel, A. Aubert, K. Bauer-Pham, H. Lutz, FIV vaccine studies. II. Clinical findings, hematological changes and kinetics of blood lymphocyte subsets, *Vet. Immunol. Immunopathol.* 46 (1995) 115–125.
- [54] A. Ortega-Pacheco, A.J. Aguilar-Caballero, R.F. Colín-Flores, K.Y. Acosta-Viana, E. Guzmán-Marin, M. Jiménez-Coello, Seroprevalence of feline leukemia virus, feline immunodeficiency virus and heartworm infection among owned cats in tropical Mexico, *J. Feline Med. Surg.* 16 (2014) 460–464.
- [55] P.M. Beczkowski, A. Lítster, T.L. Lin, D.J. Mellor, B.J. Willett, M.J. Hosie, Contrasting clinical outcomes in two cohorts of cats naturally infected with feline immunodeficiency virus (FIV), *Vet. Microbiol.* 176 (2015) 50–60.
- [56] S.E. Spencer, T. Knowles, I.K. Ramsey, S. Tasker, Pyrexia in cats: retrospective analysis of signalment, clinical investigations, diagnosis and influence of prior treatment in 106 referred cases, *J. Feline Med. Surg.* 19 (2017) 1123–1130.
- [57] Z. Knotek, P. Hajkova, M. Svoboda, M. Toman, V. Raska, Epidemiology of feline leukaemia and feline immunodeficiency virus infections in the Czech Republic, *Zentralblatt Veterinärmedizin Reihe B* 46 (1999) 665–671.
- [58] G.A.W. Madhu Ravi, Susan M. Taylor, Marion L. Jackson, Naturally acquired feline immunodeficiency virus (FIV) infection in cats from western Canada: prevalence, disease associations, and survival analysis, *Can. Vet. J.* 51 (2010) 271–276.
- [59] M.R. Kornya, S.E. Little, M.A. Scherk, W.C. Sears, D. Bienzle, Association between oral health status and retrovirus test results in cats, *J. Am. Vet. Med. Assoc.* 245 (2014) 916–922.
- [60] M. Ravi, G.A. Wobeser, S.M. Taylor, M.L. Jackson, Naturally acquired feline immunodeficiency virus (FIV) infection in cats from western Canada: prevalence, disease associations, and survival analysis, *Can. Vet. J.* 51 (2010) 271–276.
- [61] M.S. Hughes, N.W. Ball, D.N. Love, P.J. Canfield, D.L. Wigney, D. Dawson, P. E. Davis, R. Malik, Disseminated Mycobacterium genavense infection in a FIV-positive cat, *J. Feline Med. Surg.* 1 (1999) 23–29.
- [62] J.J. Callanan, B.A. Jones, J. Irvine, B.J. Willett, I.A. McCandlish, O. Jarrett, Histologic classification and immunophenotype of lymphosarcomas in cats with naturally and experimentally acquired feline immunodeficiency virus infections, *Vet. Pathol.* 33 (1996) 264–272.
- [63] C.E. Goldkamp, J.K. Levy, C.H. Edinboro, J.L. Lachtara, Seroprevalences of feline leukemia virus and feline immunodeficiency virus in cats with abscesses or bite wounds and rate of veterinarian compliance with current guidelines for retrovirus testing, *J. Am. Vet. Med. Assoc.* 232 (2008) 1152–1158.
- [64] A. Reche Jr., A.G. Daniel, T.C. Lazaro Strauss, C.P. Tabora, S.A. Vieira Marques, K. Haipek, L.J. Oliveira, J.M. Monteiro, J.R. Kfoury Jr., Cutaneous mycoflora and CD4:CD8 ratio of cats infected with feline immunodeficiency virus, *J. Feline Med. Surg.* 12 (2010) 355–358.
- [65] R. Hofmann-Lehmann, E. Holznagel, P. Ossent, H. Lutz, Parameters of disease progression in long-term experimental feline retrovirus (feline immunodeficiency virus and feline leukemia virus) infections: hematology, clinical chemistry, and lymphocyte subsets, *Clin. Diagn. Lab. Immunol.* 4 (1997) 33–42.
- [66] G. Miro, A. Domenech, E. Escolar, V.M. Collado, G. Tejerizo, A. De Las Heras, E. Gomez-Lucia, Plasma electrophoretogram in feline immunodeficiency virus (FIV) and/or feline leukaemia virus (FeLV) infections, *J. Vet. Med. A Physiol. Pathol. Clin. Med.* 54 (2007) 203–209.
- [67] J.N. Flynn, C.A. Cannon, C.E. Lawrence, O. Jarrett, Polyclonal B-cell activation in cats infected with feline immunodeficiency virus, *Immunology* 81 (1994) 626–630.

Supplementary data-Table S1. Univariable associations between the infection status of 435 cats tested for feline leukemia virus (FeLV) and signalment and historical data.

| Variables | Categories | Missing data | FeLV infection status | | P value |
|-----------------------------|--------------|--------------|-----------------------|------------------|---------|
| | | | Infected (%) | Non-infected (%) | |
| Sex | Male | 0 | 10/17 (58.8%) | 219/418 (52.4%) | 0.603 |
| | Female | | 7/17 (41.2%) | 199/418 (47.6%) | |
| Neutered | | 8 | 7/15 (46.7%) | 150/412 (36.4%) | 0.418 |
| Breed | Purebred | 15 | 0/16 (0%) | 21/404 (5.2%) | 1 |
| | Crossbreed | | 16/16 (100%) | 383/404 (94.8%) | |
| Age (years) | | 29 | 3 (0.33-12) | 2 (0.1-17) | 0.119 |
| Body weight (kg) | | 45 | 2.5 (1.5-5.7) | 3.3 (0.5-9) | 0.123 |
| Cat acquisition | Client-owned | 73 | 3/16 (18.8%) | 52/346 (15%) | 0.809 |
| | Stray | | 13/16 (81.3%) | 272/346 (78.6%) | |
| | Cattery | | 0/16 (0%) | 19/346 (5.5%) | |
| | Pet shop | | 0/16 (0%) | 3/346 (0.9%) | |
| Current ownership | Client-owned | 11 | 12/17 (70.6%) | 274/407 (67.3%) | 1 |
| | Stray | | 5/17 (29.4%) | 118/407 (29%) | |
| | Cattery | | 0/17 (0%) | 15/407 (3.7%) | |
| Living conditions | Indoors | 22 | 2/16 (12.5%) | 118/397 (29.7%) | 0.168 |
| | Outdoors | | 14/16 (87.5%) | 279/397 (70.3%) | |
| Living area | Urban | 25 | 13/16 (81.3%) | 359/394 (91.1%) | 0.177 |
| | Rural | | 3/16 (18.8%) | 35/394 (8.9%) | |
| Geographic region | Attica | 0 | 12/17 (70.6%) | 292/418 (69.9%) | 0.967 |
| | Thessaly | | 2/17 (11.8%) | 55/418 (13.2%) | |
| | Crete | | 2/17 (11.8%) | 43/418 (10.3%) | |
| | Macedonia | | 1/17 (5.9%) | 28/418 (13.2%) | |
| Contact with other cats | | 66 | 12/14 (85.7%) | 284/355 (80%) | 1 |
| Number of in-contact cats | | 118 | 7 (0-30) | 4 (0-46) | 0.532 |
| History of cat-fight trauma | | 243 | 3/7 (42.9%) | 43/185 (23.2%) | 0.361 |

| | | | | | |
|--------------------|---------|-----|---------------|-----------------|-------|
| Vaccinated CHPR | against | 96 | 10/14 (71.4%) | 185/325 (56.9%) | 0.282 |
| Vaccinated FeLV | against | 101 | 0/14 (0%) | 14/320 (4.4%) | 1 |

CHPR: calicivirus, herpesvirus-1, panleukopenia, rabies.

Supplementary data-Table S2. Univariable associations between the infection status of 435 cats tested for feline immunodeficiency virus (FIV) and signalment and historical data.

| Variables | Categories | Missing data | FIV infection status | | P value |
|-----------------------------|--------------|--------------|----------------------|------------------|---------|
| | | | Infected (%) | Non-infected (%) | |
| Sex | Male | 0 | 31/40 (77.5%) | 198/395 (50.1%) | 0.001 |
| | Female | | 9/40 (22.5%) | 197/395 (49.9%) | |
| Neutered | | 8 | 22/38 (57.9%) | 135/389 (34.7%) | 0.005 |
| Breed | Purebred | 15 | 2/37 (5.4%) | 19/383 (5%) | 0.706 |
| | Crossbreed | | 35/37 (94.6%) | 364/383 (95%) | |
| Age (years) | | 29 | 4.5 (0.13-15) | 2 (0.1-17) | <0.001 |
| Body weight (kg) | | 45 | 4 (0.58-9) | 3.2 (0.5-8.5) | 0.026 |
| Cat acquisition | Client-owned | 73 | 2/33 (6.1%) | 53/329 (16.1%) | 0.118 |
| | Stray | | 27/33 (81.8%) | 258/329 (78.4%) | |
| | Cattery | | 4/33 (12.1%) | 15/329 (4.6%) | |
| | Pet shop | | 0/33 (0%) | 3/329 (0.9%) | |
| Current ownership | Client-owned | 11 | 24/39 (61.5%) | 262/385 (68.1%) | 0.307 |
| | Stray | | 12/39 (30.8%) | 111/385 (28.8%) | |
| | Cattery | | 3/39 (7.7%) | 12/385 (3.1) | |
| Living conditions | Indoors | 22 | 6/36 (16.7%) | 114/377 (30.2%) | 0.087 |
| | Outdoors | | 30/36 (83.3%) | 263/377 (69.5%) | |
| Living area | Urban | 25 | 36/36 (100%) | 336/374 (89.8%) | 0.037 |
| | Rural | | 0/36 (0%) | 38/374 (10.2%) | |
| Geographic region | Attica | 0 | 30/40 (75%) | 274/395 (69.4%) | 0.297 |
| | Thessaly | | 7/40 (17.5%) | 50/395 (12.7%) | |
| | Crete | | 1/40 (2.5%) | 44/395 (11.1%) | |
| | Macedonia | | 2/40 (5%) | 27/395 (6.8%) | |
| Contact with other cats | | 66 | 24/30 (80%) | 272/339 (80.2%) | 0.975 |
| Number of in-contact cats | | 118 | 4.5 (0-32) | 4 (0-46) | 0.318 |
| History of cat-fight trauma | | 243 | 5/13 (38.5%) | 41/179 (22.9%) | 0.309 |

| | | | | | |
|--------------------|---------|----|---------------|-----------------|-------|
| Vaccinated CHPR | against | 96 | 18/29 (62.1%) | 177/310 (57.1%) | 0.604 |
|--------------------|---------|----|---------------|-----------------|-------|

CHPR: calicivirus, herpesvirus-1, panleukopenia, rabies.

Supplementary data-Table S3. Univariable associations between the infection status of 435 cats tested for feline leukemia virus (FeLV) and clinical signs.

| Clinical sign | Missing data | FeLV infection status | | P value |
|-----------------------------|--------------|-----------------------|------------------|---------|
| | | Infected (%) | Non-infected (%) | |
| Weight loss | 99 | 4/13 (30.8%) | 42/323 (13%) | 0.087 |
| Anorexia (previous 3 weeks) | 66 | 7/15 (46.7%) | 66/354 (18.6%) | 0.015 |
| Depression-lethargy | 6 | 4/16 (25%) | 49/413 (11.9%) | 0.112 |
| Weakness | 6 | 1/16 (6.3%) | 13/413 (3.1%) | 0.418 |
| Dehydration | 7 | 5/16 (31.3%) | 35/412 (8.5%) | 0.011 |
| Fever | 12 | 0/16 (0%) | 13/407 (3.2%) | 1 |
| Lymphadenomegaly | 8 | 2/16 (12.5%) | 24/411 (5.8%) | 0.254 |
| Abnormal lung sounds | 7 | 1/16 (6.3%) | 9/412 (2.2%) | 0.320 |
| Cough | 4 | 0/16 (0%) | 6/415 (1.4%) | 1 |
| Dyspnea | 7 | 0/16 (0%) | 8/412 (1.9%) | 1 |
| Signs of rhinitis | 7 | 5/16 (31.3%) | 30/412 (7.3%) | 0.006 |
| Ocular signs | 16 | 2/15 (13.3%) | 41/404 (10.1%) | 0.659 |
| Gingivostomatitis | 6 | 3/16 (18.8%) | 53/413 (12.8%) | 0.451 |
| Glossitis | 6 | 1/16 (6.3%) | 14/413 (3.4%) | 0.44 |
| Vomiting | 88 | 3/15 (20%) | 16/332 (4.8%) | 0.042 |
| Diarrhea | 93 | 2/15 (13.3%) | 13/327 (4%) | 0.136 |
| Constipation | 104 | 0/14 (0%) | 3/317 (0.9%) | 1 |
| Abdominal pain | 6 | 0/16 (0%) | 11/413 (2.7%) | 1 |
| Abdominal mass | 7 | 0/16 (0%) | 3/412 (0.7%) | 1 |
| Abdominal effusion | 6 | 0/16 (0%) | 6/413 (1.5%) | 1 |
| Hepatomegaly | 7 | 0/16 (0%) | 5/412 (1.2%) | 1 |
| Splenomegaly | 7 | 0/16 (0%) | 2/412 (0.5%) | 1 |
| Decreased kidney size | 7 | 0/16 (0%) | 2/412 (0.5%) | 1 |
| Increased kidney size | 7 | 0/16 (0%) | 4/412 (1%) | 1 |
| Non-smooth kidney surface | 7 | 1/16 (6.3%) | 2/412 (0.5%) | 0.108 |
| Polyuria-polydipsia | 109 | 0/14 (0%) | 6/312 (1.9%) | 1 |
| Dysuria | 104 | 0/14 (0%) | 5/317 (1.6%) | 1 |
| Pyometra or penile swelling | 6 | 0/16 (0%) | 2/413 (0.5%) | 1 |

| | | | | |
|---|----|--------------|-----------------|-------|
| Skin lesions and/or pruritus | 13 | 6/16 (37.5%) | 83/406 (20.4%) | 0.118 |
| Neurological signs | 7 | 0/16 (0%) | 19/412 (4.6%) | 1 |
| Musculoskeletal signs | 6 | 0/16 (0%) | 16/413 (3.9%) | 1 |
| At least one clinical sign | 10 | 16/16 (100%) | 252/409 (61.6%) | 0.002 |
| At least one clinical sign compatible with FeLV | 10 | 12/16 (75%) | 158/409 (38.6%) | 0.004 |
| FIV infection | 0 | 5/17 (29.4%) | 35/418 (8.4%) | 0.014 |

FIV: feline immunodeficiency virus.

Supplementary data-Table S4. Univariable associations between the infection status of 435 cats tested for feline immunodeficiency virus (FIV) and clinical signs.

| Clinical sign | Missing data | FIV infection status | | P value |
|------------------------------|--------------|----------------------|------------------|---------|
| | | Infected (%) | Non-infected (%) | |
| Weight loss | 99 | 11/30 (36.7%) | 35/306 (11.4%) | 0.001 |
| Anorexia (previous 3 weeks) | 66 | 15/33 (45.5%) | 58/336 (17.3%) | <0.001 |
| Depression-lethargy | 6 | 9/39 (23.1%) | 44/390 (11.3%) | 0.042 |
| Weakness | 6 | 2/39 (5.1%) | 12/390 (3.1%) | 0.369 |
| Dehydration | 7 | 8/38 (21.1%) | 32/390 (8.2%) | 0.017 |
| Fever | 12 | 3/38 (7.9%) | 10/385 (2.6%) | 0.102 |
| Lymphadenomegaly | 8 | 2/38 (5.3%) | 24/389 (6.2%) | 1 |
| Abnormal lung sounds | 7 | 0/38 (0%) | 10/390 (2.6%) | 1 |
| Cough | 4 | 0/39 (0%) | 6/392 (1.5%) | 1 |
| Dyspnea | 7 | 2/38 (5.3%) | 6/390 (1.5%) | 0.153 |
| Signs of rhinitis | 7 | 5/39 (12.8%) | 30/389 (7.7%) | 0.351 |
| Ocular signs | 16 | 6/38 (15.8%) | 37/381 (9.7%) | 0.258 |
| Gingivostomatitis | 6 | 12/39 (30.8%) | 44/390 (11.3%) | 0.001 |
| Glossitis | 6 | 3/39 (7.7%) | 12/390 (3.1%) | 0.147 |
| Vomiting | 88 | 1/33 (3%) | 18/314 (5.7%) | 1 |
| Diarrhea | 93 | 2/33 (6.1%) | 13/309 (4.2%) | 0.646 |
| Constipation | 104 | 0/30 (0%) | 3/301 (1%) | 1 |
| Abdominal pain | 6 | 0/39 (0%) | 11/390 (2.8%) | 0.609 |
| Abdominal mass | 7 | 0/39 (0%) | 3/389 (0.8%) | 1 |
| Abdominal effusion | 6 | 1/39 (2.6%) | 5/390 (1.3%) | 0.438 |
| Hepatomegaly | 7 | 0/39 (0%) | 5/389 (1.3%) | 1 |
| Splenomegaly | 7 | 0/39 (0%) | 2/389 (0.5%) | 1 |
| Decreased kidney size | 7 | 0/39 (0%) | 2/389 (0.5%) | 1 |
| Increased kidney size | 7 | 0/39 (0%) | 4/389 (1%) | 1 |
| Non-smooth kidney surface | 7 | 1/39 (2.6%) | 2/389 (0.5%) | 0.25 |
| Polyuria-polydipsia | 109 | 0/30 (0%) | 6/296 (2%) | 1 |
| Dysuria | 104 | 0/30 (0%) | 5/301 (1.7%) | 1 |
| Pyometra or penile swelling | 6 | 0/39 (0%) | 2/390 (0.5%) | 1 |
| Skin lesions and/or pruritus | 13 | 14/39 (35.9%) | 75/383 (19.6%) | 0.017 |

| | | | | |
|--|----|---------------|-----------------|-------|
| Neurological signs | 7 | 1/39 (2.6%) | 18/389 (4.6%) | 1 |
| Musculoskeletal signs | 6 | 2/39 (5.1%) | 14/390 (3.6%) | 0.648 |
| At least one clinical sign | 10 | 30/39 (76.9%) | 238/386 (61.7%) | 0.06 |
| At least one clinical sign compatible with FIV | 10 | 23/39 (59%) | 148/386 (38.3%) | 0.012 |
| FeLV infection | 0 | 5/40 (12.5%) | 12/395 (3%) | 0.014 |

FeLV: feline leukemia virus.

Supplementary data-Table S5. Laboratory values and univariable associations between the infection status of 303 cats tested for feline leukemia virus (FeLV) and haematology.

| Variable | Categories | Missing data | FeLV infection status | | P value |
|---|------------|--------------|-----------------------|-------------------|---------|
| | | | Infected (%) | Non-infected (%) | |
| HCT | Decreased | | 4/9 (44.4%) | 84/294 (28.6%) | 0.29 |
| HCT (%; mean; SD) | | 0 | 25.96; 8.6 | 31.86; 7 | |
| WBC | Decreased | | 3/9 (33.3%) | 18/294 (6.1%) | 0.018 |
| | Increased | | 2/9 (22.2%) | 76/294 (25.9%) | |
| WBC (x10 ³ /μL, median; range) | | 0 | 12.45; 1.33-20.87 | 12.24; 33-65.98 | |
| Neutrophils | Decreased | | 4/9 (44.4%) | 31/294 (10.5%) | 0.008 |
| | Increased | | 2/9 (22.2%) | 54/294 (18.4%) | |
| Neutrophils (x10 ³ /μL, median; range) | | 0 | 6.85; 1.1-14.47 | 6.91; 0.46-57.64 | |
| Lymphocytes | Decreased | | 2/9 (22.2%) | 45/294 (15.3%) | 0.811 |
| | Increased | | 0/9 (0%) | 20/294 (6.8%) | |
| Lymphocytes (x10 ³ /μL, median; range) | | 0 | 34.85; 0.09-5.12 | 34.84; 0.92-14.96 | |
| Monocytes | Increased | | 0/9 (0%) | 9/294 (3.1%) | 1 |
| Monocytes (x10 ³ /μL, median; range) | | 0 | 0.27; 0-0.64 | 0.268; 0-2.1 | |
| Eosinophils | Decreased | | 2/9 (22.2%) | 10/294 (3.4%) | 0.074 |
| | Increased | | 1/9 (11.1%) | 59/294 (20.1%) | |
| Eosinophils (x10 ³ /μL, median; range) | | 0 | 0.98; 0.05-3.51 | 0.9; 0-75.10 | |
| Platelets | Decreased | | 3/9 (33.3%) | 52/294 (17.7%) | 0.433 |
| | Increased | | 0/9 (0%) | 18/294 (6.1%) | |
| Platelets (x10 ³ /μL, median; range) | | 0 | 304; 11-607 | 303; 18-94.2 | |

HCT: haematocrit; SD: standard deviation; WBC: white blood cells

Supplementary data-Table S6. Laboratory values and univariable associations between the infection status of 303 cats tested for feline immunodeficiency virus (FIV) and haematology

| Variable | Categories | Missing data | FIV infection status | | P value |
|---|------------|--------------|----------------------|-------------------|---------|
| | | | Infected (%) | Non-infected (%) | |
| HCT | Decreased | | 10/24 (41.7%) | 78/279 (28%) | 0.156 |
| HCT (%; mean; SD) | | 0 | 29.6; 7 | 31.87; 7.2 | |
| WBC | Decreased | | 3/24 (12.5%) | 18/279 (6.5%) | 0.45 |
| | Increased | | 7/24 (29.2%) | 71/279 (25.4%) | |
| WBC (x10 ³ /μL, median; range) | | 0 | 12.19; 4.6-26.15 | 12.2; 1.33-65.98 | |
| Neutrophils | Decreased | | 4/24 (16.7%) | 31/279 (11.1%) | 0.198 |
| | Increased | | 7/24 (29.2%) | 49/279 (17.6%) | |
| Neutrophils (x10 ³ /μL, median; range) | | 0 | 6.84; 0.46-20.75 | 6.885; 1.1-57.64 | |
| Lymphocytes | Decreased | | 6/24 (25%) | 41/279 (14.7%) | 0.184 |
| | Increased | | 0/24 (0%) | 20/279 (7.2%) | |
| Lymphocytes (x10 ³ /μL, median; range) | | 0 | 3.54; 0.09-10.63 | 3.487; 0.09-14.96 | |
| Monocytes | Increased | | 0/24 (0%) | 9/279 (3.2%) | 1 |
| Monocytes (x10 ³ /μL, median; range) | | 0 | 0.268; 0-0.67 | 0.266; 0-2.1 | |
| Eosinophils | Decreased | | 2/24 (8.3%) | 10/279 (3.6%) | 0.344 |
| | Increased | | 5/24 (20.8%) | 55/279 (19.7%) | |
| Eosinophils (x10 ³ /μL, median; range) | | 0 | 0.95; 0-3.92 | 0.918; 0-7.51 | |
| Platelets | Decreased | | 5/24 (20.8%) | 50/279 (17.9%) | 0.73 |
| | Increased | | 2/24 (8.3%) | 16/279 (5.7%) | |
| Platelets (x10 ³ /μL, median; range) | | 0 | 303; 18-812 | 304; 11-942 | |

HCT: haematocrit; SD: standard deviation; WBC: white blood cells.

Supplementary data-Table S7. Laboratory values and univariable associations between the infection status of 435 cats tested for feline leukemia virus (FeLV) and serum biochemistry.

| Variable | Categories | Missing data | FeLV infection status | | P value |
|----------------|------------------------|--------------|-----------------------|----------------------|---------|
| | | | Infected (%) | Non-infected (%) | |
| Total proteins | Decreased | | 1/13 (7.7%) | 28/386 (7.3%) | 0.128 |
| | Increased | | 2/13 (15.4%) | 16/386 (4.1%) | |
| Total proteins | (g/dL, median; range) | 36 | 6.75; 3.94-10.34 | 6.72; 4.23-11.9 | |
| Albumins | Decreased | | 12/13 (92.3%) | 290/390 (74.4%) | 0.199 |
| Albumins | (g/dL, mean; SD) | 32 | 2.71; 0.48 | 2.91; 0.43 | |
| Globulins | Decreased | | 1/13 (7.7%) | 15/386 (3.9%) | 0.113 |
| | Increased | | 7/13 (53.8%) | 122/386 (31.6%) | |
| Globulins | (g/dL, median; range) | 36 | 3.71; 2.26-8.43 | 3.71; 2.1-9.82 | |
| Urea nitrogen | Decreased | | 4/13 (30.8%) | 43/383 (11.2%) | 0.008 |
| | Increased | | 3/13 (23.1%) | 29/383 (7.6%) | |
| Urea nitrogen | (mg/dL, median; range) | 39 | 22.61; 13.72-96.74 | 22.68; 9.22-1300 | |
| Creatinine | Decreased | | 0/13 (0%) | 38/387 (9.8%) | 0.338 |
| | Increased | | 1/13 (7.7%) | 13/387 (3.4%) | |
| Creatinine | (mg/dL, median; range) | 35 | 1.02; 0.6-3.07 | 1.04; 0.2-10.73 | |
| Glucose | Decreased | | 1/13 (7.7%) | 11/383 (2.9%) | 0.344 |
| | Increased | | 5/13 (38.5%) | 214/383 (55.9%) | |
| Glucose | (mg/dL, median; range) | 39 | 150.28; 59.26-194.17 | 148.46; 10.11-423.13 | |
| Cholesterol | Decreased | | 0/13 (0%) | 38/381 (10%) | 0.105 |
| | Increased | | 1/13 (7.7%) | 3/381 (0.8%) | |
| Cholesterol | (mg/dL, median; range) | 41 | 112.83; 81.88-259.83 | 112.4; 42.68-268.98 | |
| Triglycerides | Decreased | | 0/13 (0%) | 7/386 (1.8%) | 0.041 |
| | Increased | | 3/13 (23.1%) | 17/386 (4.4%) | |

| | | | | | |
|-----------------|---------------------------|----|---------------------------|-----------------------|-------|
| Triglycerides | (mg/dL, median; range) | 36 | 57.08; 35.53- 191.5 | 56.2; 16.73-231.57 | |
| Total bilirubin | Increased | | 1/13 (7.7%) | 18/389 (4.6%) | 0.472 |
| Total bilirubin | (mg/dL, median; range) | 33 | 0.16; 0.01-2.56 | 0.15; 0-8.49 | |
| ALP | Increased | | 0/13 (0%) | 32/390 (8.2%) | 0.611 |
| ALP | (U/L, median; range) | 32 | 26.86; 5.15- 89.41 | 26.53; 5.29-794.28 | |
| ALT | Increased | | 1/13 (7.7%) | 13/379 (3.4%) | 0.381 |
| ALT | (U/L, median; range) | 43 | 17.28; 3.21- 144.75 | 18.77; 3.05-5000 | |
| AST | Increased | | 1/13 (7.7%) | 41/389 (10.5%) | 1 |
| AST | (U/L, median; range) | 33 | 18.08; 9.16- 568.19 | 19.825; 4.46-577 | |
| GGT | Increased | | 0/13 (0%) | 4/381 (1%) | 1 |
| GGT | (U/L, median; range) | 41 | 3; 3 | 3; 0.35-9.72 | |
| Calcium | Decreased | | 1/13 (7.7%) | 19/388 (4.9%) | |
| | Increased | | 0/13 (0%) | 4/388 (1%) | 0.557 |
| Calcium | (mg/dL, median; range) | 34 | 9.44; 6.7-10.49 | 9.36; 4.51-40 | |
| Phosphorus | Increased | | 5/13 (38.5%) | 167/382 (43.7%) | 0.707 |
| Phosphorus | (mg/dL, median; range) | 40 | 6.33; 4.64-9.47 | 6.01; 2.79-200 | |
| Potassium | Decreased | | 0/13 (0%) | 7/388 (1.8%) | |
| | Increased | | 4/13 (30.8%) | 90/388 (23.2) | 0.619 |
| Potassium | (mEq/L, median; range) | 34 | 4.81; 4.01-5.92 | 4.77; 2.53-100 | |
| Sodium | Decreased | | 3/13 (23.1%) | 57/389 (14.7%) | |
| | Increased | | 1/13 (7.7%) | 39/389 (10%) | 0.564 |
| Sodium | (mEq/L, median; range) | 33 | 152.99; 130.19- 168.32 | 152.75; 134.85-186.16 | |
| Chloride | Decreased | | 5/13 (38.5%) | 127/389 (32.6%) | |

| | | | | | |
|----------|--|----|---|---------------------------------------|-------|
| Chloride | Increased (mEq/L, median; range) | 33 | 1/13 (7.7%) 117.42; 98.08- 135.56 | 6/389 (1.5%) 117.41; 102.39-144.53 | 0.176 |
|----------|--|----|---|---------------------------------------|-------|

SD: standard deviation; ALP: alkaline phosphatase; ALT: alanine aminotransferase;
AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase

Supplementary data-Table S8. Laboratory values and univariable associations between the infection status of 435 cats tested for feline immunodeficiency virus (FIV) and serum biochemistry

| Variable | Categories | Missing data | FIV infection status | | P value |
|----------------|------------------------|--------------|----------------------|----------------------|---------|
| | | | Infected (%) | Non-infected (%) | |
| Total proteins | Decreased | | 1/37 (2.7%) | 28/362 (7.7%) | 0.112 |
| | Increased | | 4/37 (10.8%) | 14/362 (3.9%) | |
| Total proteins | (g/dL, median; range) | 36 | 6.72; 5.69-10.35 | 6.72; 3.94-11.9 | |
| Albumins | Decreased | | 36/38 (94.7%) | 266/365 (72.9%) | 0.003 |
| Albumins | (g/dL, mean; SD) | 32 | 2.66; 0.41 | 2.93; 0.42 | |
| Globulins | Decreased | | 0/37 (0%) | 16/362 (4.4%) | <0.001 |
| | Increased | | 26/37 (70.3%) | 103/362 (28.5%) | |
| Globulins | (g/dL, median; range) | 36 | 3.71; 2.85-8.43 | 3.7; 2.1-9.82 | |
| Urea nitrogen | Decreased | | 5/37 (13.5%) | 42/359 (11.7%) | 0.282 |
| | Increased | | 5/37 (13.5%) | 27/359 (7.5%) | |
| Urea nitrogen | (mg/dL, median; range) | 39 | 22.67; 13.48-1300 | 22.68; 9.22-1300 | |
| Creatinine | Decreased | | 2/38 (5.3%) | 36/362 (9.9%) | 0.174 |
| | Increased | | 3/38 (7.9%) | 11/362 (3%) | |
| Creatinine | (mg/dL, median; range) | 35 | 1.03; 0.25-7.92 | 1.04; 0.2-10.73 | |
| Glucose | Decreased | | 1/38 (2.6%) | 11/358 (3.1%) | 0.754 |
| | Increased | | 19/38 (50%) | 200/358 (55.9%) | |
| Glucose | (mg/dL, median; range) | 39 | 149.14; 58.66-408.5 | 148.46; 10.11-423.13 | |
| Cholesterol | Decreased | | 2/38 (5.3%) | 36/356 (10.1%) | 0.708 |
| | Increased | | 0/38 (0%) | 4/356 (1.1%) | |
| | | 41 | | | |
| Cholesterol | (mg/dL, median; range) | | 112.4; 62.49-247.97 | 112.4; 42.68-268.98 | |
| Triglycerides | Decreased | | 0/38 (0%) | 7/361 (1.9%) | |

| | | | | | |
|-----------------|--|----|--|---|-------|
| Triglycerides | Increased (mg/dL, median; range) | 36 | 2/38 (5.3%) 55.79; 29.45- 162.54 | 18/361 (5%) 56.32; 16.73-231.57 | 1 |
| Total bilirubin | Increased | | 2/38 (5.3%) | 17/364 (4.7%) | 0.698 |
| Total bilirubin | (mg/dL, median; range) | 33 | 0.15; 0-0.46 | 0.15; 0-8.49 | |
| ALP | Increased | | 0/38 (0%) | 32/365 (8.8%) | 0.058 |
| ALP | (U/L, median; range) | 32 | 26.53; 5.15- 85.34 | 26.53; 5.29-794.28 | |
| ALT | Increased | | 0/36 (0%) | 14/356 (3.9%) | 0.628 |
| ALT | (U/L, median; range) | 43 | 18.91; 3.21- 53.91 | 18.77; 3.05-5000 | |
| AST | Increased | | 2/38 (5.3%) | 40/364 (11%) | 0.404 |
| AST | (U/L, median; range) | 33 | 19.76; 4.46- 58.99 | 19.82; 5.18-577 | |
| GGT | Increased | | 0/38 (0%) | 4/356 (1.1%) | 1 |
| GGT | (U/L, median; range) | 41 | 3; 3 | 3; 0.35-9.72 | |
| Calcium | Decreased | | 2/38 (5.3%) | 18/363 (5%) | |
| Calcium | Increased (mg/dL, median; range) | 34 | 1/38 (2.6%) 9.35; 7.86-40 | 3/363 (0.8%) 9.36; 4.51-15.1 | 0.405 |
| Phosphorus | Increased | | 7/38 (18.4%) | 165/357 (46.2%) | 0.001 |
| Phosphorus | (mg/dL, median; range) | 40 | 6.01; 3.06-200 | 6.01; 2.79-18.77 | |
| Potassium | Decreased | | 2/38 (5.3%) | 5/363 (1.4%) | |
| Potassium | Increased (mEq/L, median; range) | 34 | 8/38 (21.1%) 4.77; 3.06-100 | 86/363 (23.7%) 4.775; 2.53-8.95 | 0.214 |
| Sodium | Decreased | | 9/38 (23.7%) | 51/364 (14%) | |
| Sodium | Increased (mEq/L, median; range) | 33 | 3/38 (7.9%) 152.75; 143.76- 163.99 | 37/364 (10.2%) 152.75; 130.19-186.16 | 0.274 |

| | | | | | |
|----------|---------------------------|----|--------------------------|----------------------|-------|
| Chloride | Decreased | | 16/38 (42.1%) | 116/364 (31.9%) | |
| | Increased | | 0/38 (0%) | 7/364 (1.9%) | 0.334 |
| Chloride | (mEq/L, median; range) | 33 | 117.38; 109.72- 127.2 | 117.41; 98.08-144.53 | |

SD: standard deviation; ALP: alkaline phosphatase; ALT: alanine aminotransferase;
AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase

3. Article No 2

Seroprevalence and risk factors for feline coronavirus infection in cats from Greece. Under review

Short Communication

Seroprevalence and risk factors for feline coronavirus infection in cats from Greece

Abstract

Feline coronavirus (FCoV) is a highly contagious and ubiquitous virus of domestic cats and wild felids. Feline infectious peritonitis (FIP) is a fatal, systemic disease caused by FCoV when spontaneous mutations of its genome take place.

The aims of this study were to determine the prevalence of seropositivity for FCoV in different populations of cats in Greece and to assess risk factors for seropositivity.

A total of 453 cats were prospectively enrolled and a commercially available IFAT was used for the detection of FCoV IgG in their serum.

Overall, 55 (12.1%) of the 453 cats were seropositive for FCoV. Based on multivariate analysis, risk factors for seropositivity included the cat being adopted as stray and be in contact with other cats.

This is the first extensive study on the epidemiology of FCoV in cats from Greece and one of the largest worldwide. Feline coronavirus seropositivity was found to be common. Therefore, it is necessary to establish optimal strategies for the prevention of FCoV infection, considering the high-risk groups of cats identified in this study.

Keywords: cat, infectious peritonitis, prevalence, seropositivity

Introduction

Feline coronavirus (FCoV) is a highly contagious and ubiquitous virus of domestic cats and wild felids. Feline infectious peritonitis (FIP) is a fatal, systemic disease caused by mutated strains of FCoV.

FCoV strains are subdivided into two biotypes; feline enteric coronavirus (FECV) and feline infectious peritonitis virus (FIPV) (Pedersen, 1987). It is now accepted that these biotypes are not different species, but they represent variants of the same virus. Thus, it has been suggested to call the biotypes of FCoV as "the less virulent FCoV" and "the FIP-associated FCoV". The most widely accepted hypothesis of developing FIP is the internal mutation theory. Based on this theory, the less virulent FCoV converts to FIP-associated FCoV in individual cats by genetic modifications that induce, among others, a change in virus tropism from the enterocytes to the macrophages (Barker et al., 2013; Decaro et al., 2021).

FCoV is shed in the feces, and the transmission results from direct ingestion of infected feces or from contaminated litter and other fomites. Reported risk factors for FCoV-seropositivity and FIP include multi-cat environments, young age, being purebred and male (Pedersen, 1976; Rohrbach et al., 2001; Cave et al., 2004; Sharif et al., 2009).

FCoV infection has been reported worldwide and around 40% of domestic cats are infected, although the seroprevalence may be as high as 90% in multi-cat households (Addie and Jarrett, 1992b; Addie, 2000). Furthermore, approximately 5-12% of infected cats will develop FIP (Addie and Jarrett, 1992a; Addie and Jarrett, 1992b; Addie et al., 1995). Therefore, current epidemiological data are necessary to design optimal strategies for the control of the infection. Based on available data, organizations, such as the European Advisory Board on Cat Diseases (ABCD), have published guidelines on the prevention and management of FCoV infection (Addie et al., 2009).

Only limited data are available on FCoV seroprevalence of cats in Greece (Koutinas and Koptopoulos, 1993; Chatzis et al., 2014), and there is no information on the risk factors for seropositivity. Thus, the objectives of the present study are to determine the prevalence of seropositivity for FCoV in different populations of cats living in various regions of Greece, and to investigate the signalment and historical information to identify risk factors for seropositivity.

Materials and methods

Ethics approval

The study protocol was reviewed and approved by the Animal Ethics Committee of the Faculty of Veterinary Science, University of Thessaly (13/16-6-15). Handling of these animals was in compliance with the European Communities Council Directive 2010/63/EU and state laws.

Study population

Cats from four different geographic areas of Greece (i.e., Attica, Thessaly, Crete and Macedonia) were prospectively enrolled by three clinicians between November 2013 and November 2016, as part of a previous study (Kokkinaki et al., 2021), and they were divided into three groups: client-owned cats, stray cats, and cats living in breeding catteries. Cats were presented by their owners (client-owned or cattery cats) or by two cat-rescue groups (stray cats) for wellness examination, vaccination, neutering and/or medical treatment. Stray cats often originated from cat-dense environments (i.e., rescue colonies), and their age was estimated based on body size, dentition and other physical characteristics (Hale, 2005; Bellows et al., 2016; DiGangi et al., 2020).

Inclusion criteria were: a) body weight of ≥ 0.5 kg; and b) an informed consent form signed by the owner or the rescuer. The cats were enrolled randomly, and no preference was given to their health status. Signalment and historical data were collected using a standardized questionnaire.

Sample collection and laboratory analyses

A total of 5 mL of blood was collected by jugular venipuncture from each cat. Serum was harvested following centrifugation at 3000 rpm for 20 min and stored at -80°C until an indirect fluorescent antibody test (IFAT) was done.

FCoV IgG antibodies were detected using a commercially available IFAT kit (Biopronix Product Line, Agrilolabo S.p.a., Italy) and performed according to the manufacturer's instructions. Transmissible gastroenteritis virus (TGEV; a porcine coronavirus) was used in IFAT slides as antigen substrate. The cut-off value was 1/100, and all slides were examined by fluorescence microscopy (Olympus, Japan) at 400x magnification.

Statistical analysis

For univariate analysis, the categorical data from signalment and historical information of FCoV seropositive cats were compared to those of seronegative cats using Pearson's χ^2 or Fisher's exact tests. The normality of the distribution of the continuous variables was tested using the Kolmogorov-Smirnov test. Normally distributed data are presented as means \pm standard deviation and were compared between seropositive cats and seronegative cats using independent sample t-tests. Not normally distributed data are presented as medians and ranges and were compared between seropositive cats and seronegative cats using Mann Whitney U tests.

Variables that were different in the univariate analysis, at 25% level of significance, between seropositive and seronegative cats were selected as candidates for an initial logistic regression model. The initial model was subsequently reduced in a stepwise manner until only significant at $P < 0.05$ variables remained. Odds ratios (OR) derived from the reduced model were interpreted as measures of risk of seropositivity.

The analyses were performed using Stata 13 (Stata Corp, College Station, TX) and SPSS 23 for Windows (IBM Corp, Armonk, NY).

Results

A total of 453 cats were included in the study. The age of these cats ranged from 6 weeks to 17 years (median: two years). Two hundred and forty cats (53%) were male (86 neutered; 35.8% of the male cats), and 213 (47%) were female (52 neutered; 24.4% of the female cats). Fifteen cats (3.3%) were purebred, and 423 (93.4%) were common European cats, while for fifteen (3.3%) cats the breed was not recorded. Ninety-eight cats (21.6%) lived exclusively indoors and 333 (73.5%) outdoors, while for 22 cats (4.9%) living status was not recorded. Two hundred and fifty-four cats (56.1%) were living in Attica, 73 (16.1%) in Thessaly, 79 (17.4%) in Crete, and 47 (10.4%) in Macedonia. Two hundred and sixty-seven cats (58.9%) were client-owned, 156 (34.4%) were stray, and 21 (4.6%) were living in catteries, while for nine cats (2%) the current ownership was not recorded.

Of the 453 cats, a total of 55 (12.1%) were seropositive for FCoV. The univariate associations between seropositivity for FCoV and the signalment or the historical information are presented in Table 1.

Multivariate analysis indicated factors associated with FCoV-seropositivity (Table 2). Cats adopted as strays were significantly more likely (OR, 2.94) to be FCoV-seropositive compared to cats that were adopted as non-stray cats. In addition, cats who had contact with other cats were significantly more likely (OR, 4.54) to be seropositive compared to cats who were not in contact with other cats.

Discussion

This is one of the most extensive prospective studies on seropositivity against FCoV in cats, and the first study reporting risk factors for seropositivity in Greece. Overall, 12.1% of the cats were seropositive and the risk factors identified included adoption as strays and contact with other cats.

The seroprevalence identified here is considerably higher than the one reported in a previous seroepidemiological study, including 202 cats from Macedonia, Greece, where it was only 5.9% (Koutinas and Koptopoulos, 1993). Even more, in a recent study from Greece, that investigated *Leishmania infantum* infection in 100 cats, reported a 0% prevalence of anti-FCoV seropositivity (Chatzis et al., 2014). Other studies have reported an overall seroprevalence of 0-84% in Europe (Sparkes et al., 1992; Herrewegh et al., 1997), 0-71.6% in America (Pedersen, 1976; Levy et al., 2008), 6.6-28.2% in Asia (An et al., 2011; Wang et al., 2014), 18-40% in Australia (Jones and Hogg, 1974; Watson et al., 1974) and 35% in South Africa (Bland van den Berg and Botha, 1977). The variability of seroprevalence among these studies may reflect differences in the demographics and the geographic origin of the cats, in the accuracy of the diagnostic tests, or the overtime changes in the frequency of exposure of the cats to FCoV.

In our study, cats that were in contact with other cats, either on a permanent basis (constant contact) or occasionally, were significantly more likely to be seropositive, compared to those that were not in contact with other cats. This finding is consistent with the results of several previous reports (Pedersen, 1976; Cave et al., 2004; Bell et al., 2006; Drechsler et al., 2011). In a study from the United Kingdom, authors reported that cats originating from multi-cat households were approximately two times more likely to be FCoV-seropositive compared to cats from single-cat households (Cave et al., 2004). In addition, in a preliminary study on the epidemiology of FCoV in cats from Turkey, the reported seroprevalence rate among cats from multi-cat environments was 62% versus 4% among cats living in single-cat

households (Pratelli et al., 2009). It is well documented that the virus is transmitted via the fecal-oral route; thus, the prevalence of exposure to FCoV increases in parallel with the number and density of in-contact cats (Drechsler et al., 2011).

Cats that had been adopted as strays were significantly more likely to be seropositive compared to cats that were adopted as non-stray cats (i.e., from private owners or from catteries). This finding is in agreement with the results of a study in the United Kingdom, where free-roaming cats were more likely to be FCoV-seropositive compared to indoor cats (Cave et al., 2004). Similarly, in an earlier study from the same country, feral or semi-feral cats were almost twice as likely to be seropositive compared to household cats (Muirden, 2002). On the contrary, many other studies conclude that outdoor access reduces the risk of exposure to FCoV, possibly because outdoor cats have a larger territory and they bury their feces in the soil, thus minimizing fecal-oral transmission of FCoV. However, in urban environments with high cat population densities, communal use of soiling areas may occur, and stray cat movement through several territories may lead to a higher risk of exposure to FCoV.

Conclusions

Feline coronavirus infection is relatively common in Greece. Cats adopted as strays and those in contact with other cats are at increased risk of seropositivity. These risk factors should be taken into consideration in order to establish optimal strategies for the prevention of FCoV infection.

References

- Addie, D., Belak, S., Boucraut-Baralon, C., Egberink, H., Frymus, T., Gruffydd-Jones, T., Hartmann, K., Hosie, M.J., Lloret, A., Lutz, H., Marsilio, F., Pennisi, M.G., Radford, A.D., Thiry, E., Truyen, U., Horzinek, M.C., 2009. Feline infectious peritonitis. ABCD guidelines on prevention and management. *J Feline Med Surg* 11, 594-604.
- Addie, D.D., 2000. Clustering of feline coronaviruses in multicat households. *Vet J* 159, 8-9.
- Addie, D.D., Jarrett, J.O., 1992a. Feline coronavirus antibodies in cats. *Vet Rec* 131, 202-203.

- Addie, D.D., Jarrett, O., 1992b. A study of naturally occurring feline coronavirus infections in kittens. *Vet Rec* 130, 133-137.
- Addie, D.D., Toth, S., Murray, G.D., Jarrett, O., 1995. Risk of feline infectious peritonitis in cats naturally infected with feline coronavirus. *Am J Vet Res* 56, 429-434.
- An, D.J., Jeoung, H.Y., Jeong, W., Park, J.Y., Lee, M.H., Park, B.K., 2011. Prevalence of Korean cats with natural feline coronavirus infections. *Virology* 43, 455.
- Barker, E.N., Tasker, S., Gruffydd-Jones, T.J., Tuplin, C.K., Burton, K., Porter, E., Day, M.J., Harley, R., Fewes, D., Helps, C.R., Siddell, S.G., 2013. Phylogenetic analysis of feline coronavirus strains in an enzootic outbreak of feline infectious peritonitis. *J Vet Intern Med* 27, 445-450.
- Bell, E.T., Toribio, J.A., White, J.D., Malik, R., Norris, J.M., 2006. Seroprevalence study of feline coronavirus in owned and feral cats in Sydney, Australia. *Aust Vet J* 84, 74-81.
- Bellows, J., Center, S., Daristotle, L., Estrada, A.H., Flickinger, E.A., Horwitz, D.F., Lascelles, B.D., Lepine, A., Perea, S., Scherk, M., Shoveller, A.K., 2016. Aging in cats: Common physical and functional changes. *Journal of Feline Medicine and Surgery* 18, 533-550.
- Bland van den Berg, P., Botha, W.S., 1977. Feline infectious peritonitis in South Africa. *J S Afr Vet Assoc* 48, 109-116.
- Cave, T.A., Golder, M.C., Simpson, J., Addie, D.D., 2004. Risk factors for feline coronavirus seropositivity in cats relinquished to a UK rescue charity. *J Feline Med Surg* 6, 53-58.
- Chatzis, M.K., Leontides, L., Athanasiou, L.V., Papadopoulos, E., Kasabalis, D., Mylonakis, M., Rallis, T., Koutinas, A.F., Andreadou, M., Ikonopoulou, J., Saridomichelakis, M.N., 2014. Evaluation of indirect immunofluorescence antibody test and enzyme-linked immunosorbent assay for the diagnosis of infection by *Leishmania infantum* in clinically normal and sick cats. *Exp Parasitol* 147, 54-59.
- Decaro, N., Mari, V., Lanave, G., Lorusso, E., Lucente, M.S., Desario, C., Colaianni, M.L., Elia, G., Ferringo, F., Alfano, F., Buonavoglia, C., 2021. Mutation analysis of the spike protein in Italian feline infectious peritonitis virus and feline enteric coronavirus sequences. *Res Vet Sci* 135, 15-19.

- DiGangi, B.A., Graves, J., Budke, C.M., Levy, J.K., Tucker, S., Isaza, N., 2020. Assessment of body weight for age determination in kittens. *Journal of Feline Medicine and Surgery* 22, 322-328.
- Drechsler, Y., Alcaraz, A., Bossong, F.J., Collisson, E.W., Diniz, P.P., 2011. Feline coronavirus in multicat environments. *Vet Clin North Am Small Anim Pract* 41, 1133-1169.
- Hale, F.A., 2005. Juvenile veterinary dentistry. *Veterinary Clinics of North America: Small Animal Practice* 35, 789-817.
- Herrewegh, A.A., Mahler, M., Hedrich, H.J., Haagmans, B.L., Egberink, H.F., Horzinek, M.C., Rottier, P.J., de Groot, R.J., 1997. Persistence and evolution of feline coronavirus in a closed cat-breeding colony. *Virology* 234, 349-363.
- Jones, B.R., Hogg, G.G., 1974. Feline infectious peritonitis. *Aust Vet J* 50, 398-402.
- Kokkinaki, K.G., Saridomichelakis, M.N., Leontides, L., Mylonakis, M.E., Konstantinidis, A.O., Steiner, J.M., Suchodolski, J.S., Xenoulis, P.G., 2021. A prospective epidemiological, clinical, and clinicopathologic study of feline leukemia virus and feline immunodeficiency virus infection in 435 cats from Greece. *Comp Immunol Microbiol Infect Dis* 78, 101687.
- Koutinas, A., Koptopoulos, G., 1993. Low prevalence of feline viral infections in northern Greece. *Veterinary Record* 133, 245-247.
- Levy, J.K., Crawford, P.C., Lappin, M.R., Dubovi, E.J., Levy, M.G., Alleman, R., Tucker, S.J., Clifford, E.L., 2008. Infectious diseases of dogs and cats on Isabela Island, Galapagos. *J Vet Intern Med* 22, 60-65.
- Muirden, A., 2002. Prevalence of feline leukaemia virus and antibodies to feline immunodeficiency virus and feline coronavirus in stray cats sent to an RSPCA hospital. *Vet Rec* 150, 621-625.
- Pedersen, N.C., 1976. Serologic studies of naturally occurring feline infectious peritonitis. *Am J Vet Res* 37, 1449-1453.
- Pedersen, N.C., 1987. Virologic and immunologic aspects of feline infectious peritonitis virus infection. *Adv Exp Med Biol* 218, 529-550.
- Pratelli, A., Yesilbag, K., Siniscalchi, M., Yalcin, E., Yilmaz, Z., 2009. Prevalence of feline coronavirus antibodies in cats in Bursa province, Turkey, by an enzyme-linked immunosorbent assay. *J Feline Med Surg* 11, 881-884.
- Rohrbach, B.W., Legendre, A.M., Baldwin, C.A., Lein, D.H., Reed, W.M., Wilson, R.B., 2001. Epidemiology of feline infectious peritonitis among cats examined

- at veterinary medical teaching hospitals. *J Am Vet Med Assoc* 218, 1111-1115.
- Sharif, S., Arshad, S.S., Hair-Bejo, M., Omar, A.R., Zeenathul, N.A., Hafidz, M.A., 2009. Prevalence of feline coronavirus in two cat populations in Malaysia. *J Feline Med Surg* 11, 1031-1034.
- Sparkes, A.H., Gruffydd-Jones, T.J., Harbour, D.A., 1992. Feline coronavirus antibodies in UK cats. *Vet Rec* 131, 223-224.
- Wang, Y.T., Chueh, L.L., Wan, C.H., 2014. An eight-year epidemiologic study based on baculovirus-expressed type-specific spike proteins for the differentiation of type I and II feline coronavirus infections. *BMC Vet Res* 10, 186.
- Watson, A.D., Huxtable, C.R., Bennett, A.M., 1974. feline infectious peritonitis. *Aust Vet J* 50, 393-397.

Table 1. Univariable associations between seropositivity of 453 cats against feline coronavirus (FCoV), and the signalment and historical information that were collected using a standardized questionnaire. Variables that were used in the logistic regression model (P value <0.25) are highlighted with an asterisk

| Variables | Categories | Missing data | Serology for FCoV | | <i>P</i> value |
|----------------------------|------------------------|--------------|-------------------|-----------------|----------------|
| | | | Positive (%) | Negative (%) | |
| Sex | Male | 0 | 30/55 (54.5%) | 210/398 (52.8%) | 0.804 |
| | Female | | 25/55 (45.5%) | 188/398 (47.2%) | |
| Neutered | | 6 | 18/55 (32.7%) | 120/392 (30.6%) | 0.751 |
| Breed | Purebred | 15 | 2/54 (3.7%) | 13/384 (3.4%) | 1 |
| | Crossbreed | | 52/54 (96.3%) | 371/384 (96.6%) | |
| Age (years) | | 23 | 1.75 (0.38-12) | 2 (0.13-17) | 0.597 |
| Body weight (kg) | | 45 | 3.3 (1-7.2) | 3.2 (0.5-9) | 0.559 |
| Cat acquisition | Stray | 93 | 39/45 (86.7%) | 219/315 (69.5%) | 0.017* |
| | Non-stray [†] | | 6/45 (13.3%) | 96/315 (30.5%) | |
| Current ownership | Client-owned | | 26/53 (49.1) | 241/391 (61.6%) | |
| | Stray | 9 | 23/53 (43.4%) | 133/391 (34%) | 0.139* |
| | Cattery | | 4/53 (7.5%) | 17/391 (4.3%) | |
| Living conditions | Indoors | 22 | 10/52 (19.2%) | 88/379 (23.2%) | 0.52 |
| | Outdoors | | 42/52 (80.8%) | 291/379 (76.8%) | |
| Contact with other cats | | 58 | 44/46 (95.7%) | 295/349 (84.5%) | 0.042* |
| History of cat-bite wounds | | 256 | 3/20 (15%) | 41/177 (23.2%) | 0.574 |
| Flea infestation | | 11 | 9/53 (17%) | 80/389 (20.6%) | 0.542 |
| Tick infestation | | 12 | 0/52 (0%) | 7/389 (1.8%) | 1 |

[†] Non-stray category includes client-owned cats and cats lived in catteries

Table 2. Multivariate analysis of risk factors for seropositivity against feline coronavirus (FCoV) among 453 cats

| Variables | Categories | Odds Ratio | Confidence Interval | P value |
|-------------------------|-------------------|-------------------|----------------------------|----------------|
| Cat acquisition | Non-stray† | Reference | | |
| | Stray | 2.94 | 1.26 - 8.03 | 0.019 |
| Contact with other cats | | 4.54 | 1.32 - 28.57 | 0.042 |

† Non-stray category includes client-owned cats and cats lived in catteries

4. Article No 3

Prospective epidemiological, clinical, and clinicopathologic evaluation of cats with *Bartonella* spp. and haemoplasma infections. Submitted for publication

Original Article

Prospective epidemiological, clinical, and clinicopathologic evaluation of cats with *Bartonella* spp. and haemoplasma infections

Abstract

The aim of this study was to describe the epidemiological, clinical, and clinicopathologic aspects of various populations of cats infected with *Bartonella* spp. or haemoplasma species. The populations evaluated included client-owned cats, stray cats and cats that live in catteries in Greece.

A total of 452 cats were prospectively enrolled into the study. A commercially available IFAT kit was used for the detection of *B. henselae* IgG antibodies in serum. PCRs for the detection of *Bartonella* spp. and haemoplasma species DNA in the blood were performed in a subgroup of 242 cats.

Overall, 160 (35.4%) of the 452 cats were seropositive for *B. henselae*. Seven (2.9%) and 46 (19%) of the 242 cats were PCR-positive for *Bartonella* spp. and haemoplasma species, respectively. Factors associated with *B. henselae*-seropositivity based on multivariate analysis, included higher body weight, stray or client-owned cats, outdoor access, higher number of in-contact cats, flea infestation, gingivostomatitis and hyperglobulinaemia. Factors associated with *Bartonella* spp. infection included living in rural areas, non-smooth kidney surface and hypercalcaemia. Factors associated with haemoplasma species infection included non-administration of ectoparasiticides, fever, ocular signs, exposure to *Toxoplasma gondii* and thrombocytopenia. Clinically healthy cats were more likely to be PCR-positive for haemoplasma species compared to sick cats.

This study shows a high prevalence of seropositivity for *B. henselae* and a relatively high prevalence of infection with haemoplasma species. Various clinical signs and laboratory abnormalities were identified to be significantly associated with exposure to and/or infection with *Bartonella* spp. and haemoplasma species.

Keywords: feline, molecular, prevalence, risk factors, serology, vector-borne

Introduction

Bartonellosis and haemoplasmosis are vector-borne diseases with global impact on the health of domestic cats and of zoonotic importance.

Bartonella species are small, Gram-negative intracellular bacteria and cats are the main reservoir of *Bartonella henselae*, *B. clarridgeiae* and *B. koehlerae* and accidental hosts for *B. quintana*, *B. bovis* and *B. vinsonii* subsp. *berkhoffii*. The most common species infecting cats is *B. henselae*, which is the main causative agent of cat scratch disease in humans. The major mode of transmission among cats, is by exposure to flea bites (*Ctenocephalides felis*) or faeces, and uncommonly by aggressive interactions among cats (Bouhsira et al., 2013).

Haemoplasmas are haemotropic mycoplasmas that infect erythrocytes. The main haemoplasma species currently known to infect cats are *Mycoplasma haemofelis*, *Candidatus Mycoplasma haemominutum* and *Candidatus Mycoplasma turicensis*. Although the natural mode of transmission of haemoplasma species among cats is not clear, arthropod vectors, including *C. felis* and interaction with infected cats have been suggested (Sykes et al., 2007).

The reported serological and molecular prevalence of *Bartonella* spp. varies considerably, ranging between 0-85% and 0-83.5% (Bergh et al., 2002), respectively, depending on the geographical location and study population, while the molecular prevalence of haemoplasma species infection ranges between 4-43% (Attipa et al., 2017; Mifsud et al., 2020).

Cats naturally infected with *Bartonella* spp. and haemoplasma species may have chronic bacteraemia but no clinical signs. Uncommonly, cats naturally infected with *Bartonella* spp. may develop endocarditis, myocarditis, osteomyelitis, polyarthritis, uveitis and/or gingivostomatitis, while after natural infection with haemoplasma species they may develop fever, anorexia, weight loss, dehydration and/or splenomegaly. Various laboratory abnormalities have been reported in cats infected with *Bartonella* spp. or haemoplasma species, typically including anaemia, leukocytosis or leukopenia and hyperglobulinaemia (Ishak et al., 2007; Whittemore et al., 2012).

Only limited data are available on the epidemiology of *Bartonella* spp. and haemoplasma species in cats from Greece, and there is no study investigating the possible associations between infection and clinical or laboratory abnormalities in this country. Globally, limited prospective studies have been published to investigate both

risk factors (including, though not limited to, exposure to other common feline infectious agents) and the clinical and clinicopathologic findings of these two vector-borne pathogens in naturally infected cats.

The objectives of the present study were to: 1) determine the seroprevalence of *B. henselae* and the molecular prevalence of *Bartonella* spp. and haemoplasma species in different populations of cats living in different regions of Greece; 2) assess risk factors for seropositivity and/or PCR-positivity; 3) investigate possible associations between seropositivity for *B. henselae*, PCR-positivity for *Bartonella* spp. or PCR-positivity for haemoplasma species and seropositivity for other infectious agents, including *Toxoplasma gondii*, feline coronavirus (FCoV), feline leukaemia virus (FeLV) and feline immunodeficiency virus (FIV); 4) determine the clinical signs and haematological and biochemical findings associated with seropositivity and PCR-positivity for *Bartonella* spp. and PCR-positivity for haemoplasma species.

Materials and methods

Ethics approval

The study protocol was reviewed and approved by the Animal Ethics Committee of the Faculty of Veterinary Science, University of Thessaly (13/16-6-15). Handling of these animals was in compliance with the European Communities Council Directive 2010/63/EU and state laws.

Study population

Cats from 4 different geographic areas of Greece (i.e., Attica, Thessaly, Crete and Macedonia) were prospectively enrolled by three clinicians between November 2013 and November 2016 and divided into three groups: client-owned cats, stray cats, and cats living in breeding catteries (Kokkinaki et al., 2021). Cats were presented by their owners (client-owned or cattery cats) or by two cat-rescue groups (stray cats) for wellness examination, vaccination, neutering and/or medical treatment. Stray cats often originated from cat-dense environments (i.e., rescue colonies) and their age was estimated based on body size, dentition and other physical characteristics.

Inclusion criteria for cats in all groups included: a) a body weight of ≥ 0.5 kg; and b) an informed consent form signed by the owner or the rescuer. Both healthy and diseased cats were randomly included into the study. Cats were considered healthy based on a normal physical examination and no recent history of disease. Cats

presented with systemic clinical (anorexia, depression, lethargy), gastrointestinal (vomiting, diarrhoea), ocular, neurological or dermatological signs (skin lesions and/or pruritus) were considered sick.

For the serological detection of *B. henselae* IgG antibodies, cats that fulfilled the above two criteria were enrolled on a sequential basis, regardless of their health status. For the molecular detection of *Bartonella* spp. and haemoplasma species, anaemic and non-anaemic cats were randomly selected from the initially enrolled cats at a 1:1 ratio, using a randomization table.

Signalment and historical data were collected using a standardized questionnaire and a thorough physical examination was performed for each cat by one of three authors (K GK, PGX, MEM). Historical information included: a) signalment; b) geographic origin and travel history; c) prior and current ownership; d) living conditions (indoors, outdoors); e) diet (dry food, canned food, home-cooked food, raw meat); f) vaccination status (fully vaccinated, partially vaccinated, unvaccinated); g) parasite prevention status (regular use of ectoparasiticides, intermittent use, non-use); h) prior medical problems; i) previous treatments; j) chief presenting complaint; k) present health status (e.g., weight loss, reduced appetite, faecal characteristics).

Sample collection and laboratory analyses

A total of 5 mL of blood was collected by jugular venipuncture from each cat. One mL of blood was sequentially transferred into two EDTA-anticoagulated tubes. One sample was used for haematology, while the other was stored at -80°C for PCR. The remaining blood was transferred in an anticoagulant-free tube, and serum was harvested following centrifugation at 3000 rpm for 20 min. Serum aliquots were stored at -80°C until biochemical analysis and indirect fluorescent antibody test (IFAT) were done.

Haematology was performed using one of three different haematology analyzers (Sysmex pocH-100i, ADVIA 2120i Siemens, ADVIA 120 Siemens), depending on the geographic area of sampling and the results were classified as normal, increased, or decreased, based on the reference intervals of each laboratory. For most cats, differential white blood cell count was calculated manually, and inspection for platelet aggregates was done in Diff-Quik (Merck, Germany) stained blood smears, whereas for the remaining cats (n=25) it was based on the results of analysis using the ADVIA 2120i analyzer. All haematologic analyses were performed

within 12 hours of blood collection. Biochemical analyses were performed using an automated chemistry analyzer (Roche/Hitachi MODULAR ANALYTICS D 2400 module, Roche Diagnostics, Switzerland, CH).

Serologic testing

Bartonella henselae IgG antibodies, *T. gondii* IgG antibodies and FCoV IgG antibodies were detected using commercially available IFAT kits (Biopronix Product Line, Agrilolabo S.p.a., Italy). The tests were performed according to manufacturer's instructions as previously described (Spada et al., 2016). Cut-off values were 1/64 for *B. henselae*, 1/50 for *T. gondii* and 1/100 for FCoV. All slides were examined by fluorescence microscopy at 40x magnification (Olympus, Japan)

Testing for FeLV antigen and FIV antibody was performed using an in-house ELISA assay (SNAP FIV/FeLV Combo test, IDEXX Laboratories, Westbrook, ME, USA) at the time of blood collection, using serum or plasma.

Molecular analyses

DNA was extracted from whole blood using the Nucleospin Tissue Kit (Macherey-Nagel GmbH & Co. KG, Germany), based on the instructions provided by the manufacturer and stored at -20°C until use.

The quality of the DNA was assessed for purity and integrity by submerged gel electrophoresis followed by image analysis using a Bio-Rad ChemiDoc XRS+ Molecular Imager (Bio-Rad Laboratories Inc., U.S.A.), and by spectrophotometry at 260/280 nm, using a NanoDrop 8000 Spectrophotometer (Thermo Fisher Scientific Inc., U.S.A.). The presence of inhibitors in the samples was assessed by a PCR assay targeting a housekeeping gene (actin).

PCR was performed in an Applied Biosystems Verity 96-well Thermal Cycler (Thermo Fisher Scientific Inc., U.S.A.). Real-time PCR was performed in a Roche LightCycler 2.0 (Roche, Germany). PCR products were analyzed by submerged electrophoresis using 2% agarose gels stained with ethidium bromide (0.5 µg/mL) and visualized using a Bio-Rad ChemiDoc XRS+ Molecular Imager (Bio-Rad Laboratories Inc., U.S.A.). For confirmation of the specificity of the amplification products, approximately 20% of the PCR products were submitted for sequence analysis, which was conducted on both strands using the Applied Biosystems BigDye Terminator Cycle Sequencing Kit and PRISM 377 DNA Sequencer (Thermo Fisher

Scientific Inc., U.S.A.). Results were analyzed and compared to deposited sequences in the GenBank database using the Basic Local Alignment Search Tool (BLAST) of the National Center for Biotechnology Information (NCBI).

PCR protocol for detection of Bartonella spp.

The target sequence was a 209 base-pair fragment of the *Bartonella ssrA* gene (Forward: GCTATGGTAATAAATGGACAATGAAATAA, Reverse: GACGTGCTTCCGCATAGTTGTC) (Mylonakis et al., 2018). A 25 µl mixture for each PCR reaction was performed with the Kapa Taq PCR kit following the standard protocol suggested by the manufacturer. The amplification profile consisted of an initial denaturation step at 95°C for 5 min followed by 30 cycles of incubation at 95°C for 30 sec, 60°C for 45 sec and a final elongation step at 72°C for 5 min.

PCR protocol for detection of Mycoplasma spp.

The target sequence was a fragment of the *Mycoplasma* 16S-rRNA gene (Forward: ACGAAAGTCTGATGGAGCAATA, Reverse: ACGCCCAATAAATCCGRATAAT) (Jensen et al., 2001). A 25 µl mixture for each PCR reaction was performed with the Kapa Taq PCR kit, following the standard protocol suggested by the manufacturer. A hot-start PCR was performed, starting with 5 min at 95°C. The amplification profile consisted of an initial denaturation step at 95°C for 5 min followed by 30 cycles of incubation at 95°C for 30 sec, 60°C for 45 sec and a final elongation step at 72°C for 5 min.

Statistical analysis

For univariate analysis, categorical data regarding signalment, historical information, clinical signs, haematology and biochemistry in *Bartonella* spp. or haemoplasma species PCR-positive cats were compared to those of *Bartonella* spp. or haemoplasma species PCR-negative cats by either Pearson's χ^2 or Fisher's exact test. The same variables were compared between *B. henselae* seropositive and seronegative cats. The normality of the distribution of the continuous variables was tested using the Kolmogorov-Smirnov test. Normally distributed data are presented as means \pm standard deviation and were compared between PCR-positive or seropositive cats and PCR-negative or seronegative cats using independent sample t-tests. Not normally distributed data are presented as medians and ranges and were compared

between PCR-positive or seropositive cats and PCR-negative or seronegative cats using Mann Whitney *U* tests.

Variables that were different at 25% level of significance, between *Bartonella* spp. or haemoplasma species PCR-positive and PCR-negative cats in the univariate analysis were selected as candidates for 3 initial logistic regression models. The first model included significant signalment and history variables, the second model included significant clinical examination and testing for other agents variables and the third model included significant haematology and biochemistry variables. These 3 initial models were subsequently reduced in a stepwise manner until only significant at $P < 0.05$ variables remained.

Similarly, variables that were different at $P < 0.25$ between *B. henselae* seropositive and seronegative cats in the univariate analysis were selected as candidates for 4 initial logistic regression models relating to: a) signalment and history variables, b) clinical examination and testing for other infectious agents variables, c) haematology variables and d) biochemistry variables. The initial models were subsequently reduced in a stepwise manner until only significant at $P < 0.05$ variables remained. Odds ratios (OR) derived from the reduced models were interpreted as measures of increased risk of seropositivity or PCR-positivity. The analyses were done using Stata 13 (Stata Corp, College Station, TX) and SPSS 23 for Windows (IBM Corp, Armonk, NY).

Results

Serology

A total of 452 cats were enrolled. The age of the cats ranged from 6 weeks to 17 years (median 2 years). Two hundred and forty-one cats (53.3%) were males (86 neutered; 35.7% of the male cats) and 211 (46.7%) were females (52 neutered; 24.6% of the female cats). Fifteen cats (3.3%) were purebred and 422 (93.4%) were common European cats, while for 15 (3.3%) cats the breed was not recorded. Ninety-seven cats (21.5%) lived exclusively indoors and 333 (73.7%) outdoors (exclusively or partially), while for 22 cats (4.9%) the status was unknown. Two hundred and fifty-five cats (56.4%) lived in Attica, 79 (17.5%) in Crete, 73 (16.2%) in Thessaly and 45 (10%) in Macedonia. Two hundred and sixty-seven cats (59.1%) were client-owned, 155 (34.3%) were stray and 21 (4.6%) lived in catteries, while for 9 cats (2%) these data were missing. Three hundred and sixty-one cats (79.9%) lived in urban areas and

68 (15%) in rural areas, while for 23 (5.1%) the area was unknown. One hundred and sixty-seven cats (36.9%) were clinically healthy and 274 (60.6%) were sick, while the health status was unknown for 11 cats (2.4%).

Of the 452 cats, 160 (35.4%) were found to be seropositive for *B. henselae*. Univariate associations between seropositivity for *B. henselae* and signalment-historical data, clinical signs, results of haematology and serum biochemistry results are presented in supplementary Tables S1, S2, S3, S4.

Several factors were found to be significantly associated with *B. henselae*-seropositivity in the multivariate analysis (Table 1). Seropositive cats weighed significantly more than seronegative cats. In addition, a higher number of in-contact cats and flea infestation were risk factors for seropositivity. Stray and client-owned cats were significantly more likely to be seropositive than cats living in catteries; also, cats living outdoors were significantly more likely to be seropositive than cats living indoors. Gingivostomatitis was also significantly associated with seropositivity. Cats with hyperglobulinaemia were more likely to be seropositive compared to cats with a normal or decreased serum globulin concentration, while cats with an increased serum phosphorus concentration were significantly less likely to be *B. henselae*-seropositive compared to cats with a normal serum phosphorus concentration.

PCR

A total of 242 cats were selected for molecular detection of *Bartonella* spp. and *Mycoplasma* spp. infections. The age of these cats ranged from 6 weeks to 15 years (median 1 year). One hundred and thirty cats (53.7%) were male (49 neutered) and 112 (46.3%) were female (22 neutered). Two cats (0.8%) were purebred and 234 (96.7%) were common European cats, while for 6 (2.5%) cats the breed was not recorded. Thirty cats (12.4%) lived exclusively indoors and 205 (84.7%) outdoors (exclusively or partially), while for 7 cats (2.9%) the status was unknown. Ninety-four cats (38.8%) lived in Attica, 70 (28.9%) in Crete, 60 (24.8%) in Thessaly, and 18 (7.4%) in Macedonia. One hundred and thirty-seven cats (56.6%) were client-owned, 91 (37.6%) were stray and 12 (5%) were living in catteries, while for 2 cats (0.8%) these data were missing. One hundred and seventy-six cats (72.7%) lived in urban areas and 58 (24%) in rural areas, while for 8 cats (3.3%) the area was unknown. Seventy-four cats (30.6%) were clinically healthy and 165 (68.2%) were sick, while the health status was unknown for 3 cats (1.2%).

Of the 242 cats, a total of 7 (2.9%) and 46 (19%) were found to be PCR-positive for *Bartonella* spp. and haemoplasma species, respectively. Of the PCR-positive cats, 3 (1.2% of the total 242 cats) had concurrent PCR-positive results for *Bartonella* spp. and haemoplasma species. The univariate associations between PCR-positivity for *Bartonella* spp. (Tables S5, S6, S7) or haemoplasma species (Tables S8, S9, S10) and signalment-historical data, clinical signs, results of serology, haematology and serum biochemistry are presented in supplementary files.

Factors significantly associated with PCR-positivity for *Bartonella* spp. in the multivariate analysis are presented in Table 2. Cats living in rural areas were significantly more likely to be positive than cats living in urban areas. Non-smooth kidney surface was also significantly associated with PCR-positivity for *Bartonella* spp. In addition, cats with hypercalcemia were more likely to be *Bartonella* spp.-positive compared to cats with normal or reduced serum calcium concentrations.

Multivariate analysis also indicated several factors associated with PCR-positivity for *Mycoplasma* spp. (Table 3). Clinically healthy cats and cats who had not been treated with a preventative ectoparasiticide were significantly more likely to be haemoplasma species-positive than sick cats and cats who had been treated with ectoparasiticides, respectively. The presence of fever and ocular signs was also significantly associated with PCR-positivity for haemoplasma species. In addition, seropositivity for *Toxoplasma gondii* was associated with an increased risk for PCR-positivity for haemoplasma species. Finally, cats with thrombocytopenia were significantly more likely to be PCR-positive for haemoplasma species compared to cats with a normal platelet count.

Discussion

This is one of the largest prospective studies on natural infection with *Bartonella* spp. and *haemoplasma* species in cats. Overall, 35.4% of the cats were seropositive for *B. henselae*, while 2.9% and 19% of the cats were PCR-positive for *Bartonella* spp. and haemoplasma species, respectively. Flea infestation, access to outdoor or multi-cat environments, gingivostomatitis and hyperglobulinaemia were significant predictors of *B. henselae*-seropositivity. Non-smooth kidney surface and hypercalcemia were associated with PCR-positivity for *Bartonella* spp., while fever, ocular signs, seropositivity to *T. gondii* and thrombocytopenia were associated with PCR-positivity for haemoplasma species.

The haemoplasma species prevalence by PCR identified here is similar to results from a previous prospective study in cats from Greece, where the prevalence was reported to be 20.6% (Maher et al., 2010). However, in another study in cats from Greece, the authors reported a seroprevalence of *B. henselae* of only 4% (Chatzis et al., 2014). More recently, in a retrospective study of 100 cats from Greece, 8.5% and 14.9% were PCR-positive for *Bartonella* spp. and haemoplasma species, respectively (Mylonakis et al., 2018). Seroprevalence for *Bartonella* spp. in cats has been reported to be 0%-68% in Europe (Mietze et al., 2011), 0%-85.2% in the USA (Jameson et al., 1995), 37% in Australia (Barrs et al., 2010) and 11%-59% in Africa (Tiao et al., 2013). Studies have reported an overall PCR-based prevalence of feline infection with haemoplasma species, of 32.1% in South Africa (Lobetti and Tasker, 2004), 27.2% in Australia (Tasker et al., 2004), 26.4% in Asia (Tanahara et al., 2010), 12%-27% in the USA (Sykes et al., 2008), and 4%-43% in Europe (Mifsud et al., 2020). The variability of serologic and molecular prevalence among these studies may reflect differences in the demographics and the geographic origin of the cats, in the accuracy of the diagnostic tests and/or the overtime changes in the prevalence of these infections.

Our study showed that stray cats and cats with outdoor access were more likely to be *B. henselae*-seropositive compared to cats living in catteries and cats living strictly indoors, respectively and this is in agreement with previous reports likely reflecting increased access to flea-infested environments (Guptill et al., 2004). Interestingly, client-owned cats were more likely to be seropositive than cats living in catteries. Although the reason for this is not known, it may partially reflect on the high awareness amongst cat breeders of the risks of vector-borne infections and the implementation of strict flea control measures.

A significant association was established between *Bartonella* spp. seropositivity and the number of in-contact cats. These cats are expected to have a higher prevalence of *B. henselae*-seropositivity, as they are exposed to more cats and pathogen vectors. This finding is in accordance with the results of a previous study in 436 client-owned cats in France, where the prevalence of bacteremia and seropositivity increased as the number of cats increased (Gurfield et al., 2001).

Cats infested with fleas were more likely to be *B. henselae*-seropositive compared to cats without flea infestation. Many studies have documented that *B. henselae* is naturally transmitted among cats by the flea *C. felis* or by flea faeces

(Bouhsira et al., 2013). *C. felis* is the major flea species affecting cats in Greece (Koutinas et al., 1995).

Body weight was significantly higher in *B. henselae*-seropositive cats compared to seronegative cats. However, because body weight increases during growth and because univariate analysis showed that older age was associated with increased risk of *B. henselae*-seropositivity, this finding most likely reflects the older age of seropositive cats.

Our study indicates a significant association between *B. henselae*-seropositivity and gingivostomatitis. However, conflicting data exist regarding associations between gingivostomatitis and *Bartonella* spp. bacteraemia and/or seropositivity. In two studies of naturally infected cats, an association between seropositivity and stomatitis was suggested (Ueno et al., 1996; Glaus et al., 1997), while in another study an association was reported between *Bartonella* spp. bacteraemia and oral disease, but not between seropositivity and oral disease (Sykes et al., 2010). The association between gingivostomatitis and *Bartonella* spp. requires further investigation.

Similar to other studies, we found that *B. henselae*-seropositive cats had a significantly increased risk of hyperglobulinaemia (Ishak et al., 2007; Whittemore et al., 2012). Hyperglobulinaemia in *Bartonella* spp.-seropositive cats is typically a polyclonal gammopathy due to the prolonged bacteraemia (Whittemore et al., 2012).

Cats with an increased serum phosphorus concentration were significantly more likely to be *B. henselae*-seronegative than cats with a normal serum phosphorus concentration. Because serum concentration of phosphorus is increased in young healthy animals, this finding most likely reflects the younger age of *B. henselae*-seronegative cats found in the univariate analysis.

Cats living in rural areas were more likely to be PCR-positive for *Bartonella* spp. than cats living in urban areas. This is consistent with a recent study, where a significant association was found between infection with feline vector-borne pathogens, including *B. henselae*, and a rural habitat (Attipa et al., 2017), likely because *C. felis* is more prevalent in rural habitats.

A non-smooth surface of the kidneys on abdominal palpation was more prevalent in *Bartonella* spp.-PCR positive compared to PCR-negative cats. This has not been previously reported and should be interpreted with caution as this was seen in a single PCR-positive cat. Experimentally-induced feline bartonellosis causes

granulomatous inflammation of the kidneys, which may account for the kidney surface distortion (Kordick et al., 1999). However, in our study the single positive cat had concurrent infections with FeLV and FIV and was seropositive for FCoV. Therefore, this clinical finding may not be associated with bartonellosis but rather with infection with these concomitant infections.

Hypercalcaemic cats were significantly more likely to be *Bartonella* spp. PCR-positive than cats with a normal serum calcium concentration. Again, this finding should be interpreted cautiously as only one PCR-positive cat had hypercalcaemia. Due to the fact that this cat also had an increased serum creatinine concentration, hypercalcemia was most likely associated with chronic kidney disease. Also, idiopathic hypercalcaemia, which is an important differential diagnosis in cats, cannot be ruled out.

Cats that had not been on a preventative ectoparasiticide were more likely to be PCR-positive for haemoplasmas than cats previously treated with an ectoparasiticide. It is known that haemoplasmas are mainly transmitted through arthropod vectors and *C. felis* has been implicated in feline haemoplasma transmission (Woods et al., 2003). Also, ticks have been proposed as potential vectors since feline haemoplasma species have been found in ticks collected from cats (Duplan et al., 2018).

Fever was also found to be significantly associated with haemoplasma species PCR-positivity and this is consistent with the results of another study, where an association between *M. haemofelis* and fever in cats without anaemia was found (Lappin et al., 2020). In a recent retrospective study, the prevalence of haemoplasma infection in 106 cats with pyrexia was 7.5% (Spencer et al., 2017). In addition, a study of 22 anaemic cats naturally infected with haemoplasma species, reported that 10% of those cats had a fever (Weingart et al., 2016).

Ocular signs were significantly associated with haemoplasma species PCR-positivity and this is the first time such an association has been reported. In our study, exposure to *T. gondii* was significantly associated with haemoplasma infection. It is well documented that the eye is the most commonly affected organ in feline toxoplasmosis. Furthermore, in our study all haemoplasma species-positive cats with ocular signs were affected by upper respiratory track disease (URTD) that is commonly accompanied by ocular discharge and lesions. Therefore this association

was most likely due to *T. gondii* infection or URTD and less likely due to haemoplasmosis.

Another finding of our study was the higher prevalence of haemoplasma species PCR-positivity among clinically healthy cats compared to sick cats. This finding could reflect the fact that the group of sick cats was quite inhomogeneous. There were cats with severe systemic clinical signs but also cats with skin lesions, reproductive and musculoskeletal disorders or neurological and ocular signs. This fact could have influenced the results. Indeed, when only sick cats with compatible clinical signs of mycoplasmosis were compared with clinically healthy cats, no statistically significant difference was identified.

Seropositivity for *T. gondii* was found to be significantly associated to haemoplasma species PCR-positivity. Although the natural mode of transmission of haemoplasma infection has not been clearly established, one possible explanation could be a similar mode of transmission of the two agents. Similarly to congenital infection with *Toxoplasma gondii*, it has been suggested that *M. haemofelis* can be transmitted from queens with clinical disease to their kittens (Fisher et al., 1983).

Thrombocytopenia was found to be associated with haemoplasma species PCR-positivity. In a retrospective study in 102 cats from South Africa, the prevalence of thrombocytopenia was significantly higher in *M. haemofelis*-infected cats than in non-infected cats (Lobetti and Lappin, 2012). Similarly, in a subsequent study of naturally haemoplasma-infected cats from Brazil, thrombocytopenia was statistically associated with infection by *M. haemofelis* (Raimundo et al., 2016). In our study, low platelet count was confirmed by blood smear quantification of platelets in 26/30 sick cats with thrombocytopenia.

A limitation of our study is that some cats had not undergone an extensive diagnostic investigation to establish the underlying cause(s) of their illness. In addition, the lack of identification of *Bartonella* spp. and haemoplasmas on a species level in this study, prevented the potential expansion of the spectrum of these agents affecting felines in Greece and the investigation of the clinical and clinicopathologic relevance of different species of *Bartonella* and haemoplasmas.

Conclusion

This study showed a high prevalence of seropositivity for *B. henselae* and a relatively high prevalence of haemoplasma species infection. Stray cats, outdoor

access, multiple in-contact cats and flea infestation were identified as risk factors for *B. henselae* seropositivity. Living in rural areas and lack of ectoparasiticide use were identified as risk factors for *Bartonella* spp. and haemoplasma species PCR-positivity, respectively. Gingivostomatitis and hyperglobulinaemia were associated with *B. henselae*-seropositivity. Clinically healthy cats were more likely to be haemoplasma species PCR-positive, while fever, exposure to *T. gondii* and thrombocytopenia were associated with haemoplasma species PCR-positivity.

Future prospective studies in naturally infected cats are warranted in order to investigate the clinical and clinicopathologic relevance of different species of *Bartonella* and haemoplasmas in cats in Greece and other geographic locations.

Conflict of interest statement

IDEXX Laboratories and Petline supplied the SNAP FIV/FeLV Combo tests used in this study. IDEXX Laboratories and Petline did not participate in the study design, sample collection, analysis, interpretation of data, or in the decision to submit the manuscript for publication. None of the authors have any financial or personal relationships that could inappropriately influence or bias the content of the paper.

References

- Attipa, C., Papasouliotis, K., Solano-Gallego, L., Baneth, G., Nachum-Biala, Y., Sarvani, E., Knowles, T.G., Mengi, S., Morris, D., Helps, C., Tasker, S., 2017. Prevalence study and risk factor analysis of selected bacterial, protozoal and viral, including vector-borne, pathogens in cats from Cyprus. *Parasit Vectors* 10, 1-14.
- Barrs, V.R., Beatty, J.A., Wilson, B.J., Evans, N., Gowan, R., Baral, R.M., Lingard, A.E., Perkovic, G., Hawley, J.R., Lappin, M.R., 2010. Prevalence of *Bartonella* species, *Rickettsia felis*, haemoplasmas and the Ehrlichia group in the blood of cats and fleas in eastern Australia. *Aust Vet J* 88, 160-165.
- Bergh, K., Bevanger, L., Hanssen, I., Loseth, K., 2002. Low prevalence of *Bartonella henselae* infections in Norwegian domestic and feral cats. *APMIS* 110, 309-314.

- Bouhsira, E., Ferrandez, Y., Liu, M., Franc, M., Boulouis, H.J., Biville, F., 2013. *Ctenocephalides felis* an in vitro potential vector for five *Bartonella* species. *Comp Immunol Microbiol Infect Dis* 36, 105-111.
- Chatzis, M.K., Leontides, L., Athanasiou, L.V., Papadopoulos, E., Kasabalis, D., Mylonakis, M., Rallis, T., Koutinas, A.F., Andreadou, M., Ikonopoulou, J., Saridomichelakis, M.N., 2014. Evaluation of indirect immunofluorescence antibody test and enzyme-linked immunosorbent assay for the diagnosis of infection by *Leishmania infantum* in clinically normal and sick cats. *Exp Parasitol* 147, 54-59.
- Duplan, F., Davies, S., Filler, S., Abdullah, S., Keyte, S., Newbury, H., Helps, C.R., Wall, R., Tasker, S., 2018. *Anaplasma phagocytophilum*, *Bartonella* spp., haemoplasma species and Hepatozoon spp. in ticks infesting cats: a large-scale survey. *Parasit Vectors* 11, 201.
- Fisher, E.W., Toth, S., Colliers, W.O., 1983. Anaemia in a litter of Siamese kittens. *J Small Anim Pract* 24, 215-219.
- Glaus, T., Hofmann-Lehmann, R., Greene, C., Glaus, B., Wolfensberger, C., Lutz, H., 1997. Seroprevalence of *Bartonella henselae* infection and correlation with disease status in cats in Switzerland. *J Clin Microbiol* 35, 2883-2885.
- Guptill, L., Wu, C.C., HogenEsch, H., Slater, L.N., Glickman, N., Dunham, A., Syme, H., Glickman, L., 2004. Prevalence, risk factors, and genetic diversity of *Bartonella henselae* infections in pet cats in four regions of the United States. *J Clin Microbiol* 42, 652-659.
- Gurfield, A.N., Boulouis, H.J., Chomel, B.B., Kasten, R.W., Heller, R., Bouillin, C., Gandoin, C., Thibault, D., Chang, C.C., Barrat, F., Piemont, Y., 2001. Epidemiology of *Bartonella* infection in domestic cats in France. *Vet Microbiol* 80, 185-198.
- Ishak, A.M., Radecki, S., Lappin, M.R., 2007. Prevalence of *Mycoplasma haemofelis*, 'Candidatus *Mycoplasma haemominutum*', *Bartonella* species, Ehrlichia species, and *Anaplasma phagocytophilum* DNA in the blood of cats with anemia. *J Feline Med Surg* 9, 1-7.
- Jameson, P., Greene, C., Regnery, R., Dryden, M., Marks, A., Brown, J., Cooper, J., Glaus, B., Greene, R., 1995. Prevalence of *Bartonella henselae* antibodies in pet cats throughout regions of North America. *J Infect Dis* 172, 1145-1149.

- Jensen, W.A., Lappin, M.R., Kamkar, S., Reagan, W.J., 2001. Use of a polymerase chain reaction assay to detect and differentiate two strains of *Haemobartonella felis* in naturally infected cats. *Am J Vet Res* 62, 604-608.
- Kokkinaki, K.G., Saridomichelakis, M.N., Leontides, L., Mylonakis, M.E., Konstantinidis, A.O., Steiner, J.M., Suchodolski, J.S., Xenoulis, P.G., 2021. A prospective epidemiological, clinical, and clinicopathologic study of feline leukemia virus and feline immunodeficiency virus infection in 435 cats from Greece. *Comp Immunol Microbiol Infect Dis* 78, 101687.
- Kordick, D.L., Brown, T.T., Shin, K., Breitschwerdt, E.B., 1999. Clinical and pathologic evaluation of chronic *Bartonella henselae* or *Bartonella clarridgeiae* infection in cats. *J Clin Microbiol* 37, 1536-1547.
- Koutinas, A.F., Papazahariadou, M.G., Rallis, T.S., Tzivara, N.H., Himonas, C.A., 1995. Flea species from dogs and cats in northern Greece: environmental and clinical implications. *Vet Parasitol* 58, 109-115.
- Lappin, M.R., Tasker, S., Roura, X., 2020. Role of vector-borne pathogens in the development of fever in cats: 1. Flea-associated diseases. *J Feline Med Surg* 22, 31-39.
- Lobetti, R., Lappin, M.R., 2012. Prevalence of *Toxoplasma gondii*, *Bartonella* species and haemoplasma infection in cats in South Africa. *J Feline Med Surg* 14, 857-862.
- Lobetti, R.G., Tasker, S., 2004. Diagnosis of feline haemoplasma infection using a real-time PCR assay. *J S Afr Vet Assoc* 75, 94-99.
- Maher, I.E., Tasker, S., Polizopoulou, Z., Dasopoulou, A., Egan, K., Helps, C.R., Papasouliotis, K., 2010. Polymerase chain reaction survey of feline haemoplasma infections in Greece. *J Feline Med Surg* 12, 601-605.
- Mietze, A., Morick, D., Kohler, H., Harrus, S., Dehio, C., Nolte, I., Goethe, R., 2011. Combined MLST and AFLP typing of *Bartonella henselae* isolated from cats reveals new sequence types and suggests clonal evolution. *Vet Microbiol* 148, 238-245.
- Mifsud, M., Takacs, N., Gyurkovszky, M., Solymosi, N., Farkas, R., 2020. Detection of flea-borne pathogens from cats and fleas in a maltese shelter. *Vector Borne Zoonotic Dis* 20, 529-534.

- Mylonakis, M.E., Schreeg, M., Chatzis, M.K., Pearce, J., Marr, H.S., Saridomichelakis, M.N., Birkenheuer, A.J., 2018. Molecular detection of vector-borne pathogens in Greek cats. *Ticks Tick Borne Dis* 9, 171-175.
- Raimundo, J.M., Guimaraes, A., Botelho, C.F., Peixoto, M.P., Pires, M.S., Machado, C.H., Santos, H.A., Massard, C.L., Andre, M.R., Machado, R.Z., Baldani, C.D., 2016. Hematological changes associated with hemoplasma infection in cats in Rio de Janeiro, Brazil. *Rev Bras Parasitol Vet* 25, 441-449.
- Spada, E., Proverbio, D., Perego, R., Canzi, I., Baggiani, L., De Maria, C., Marino, F., Caracappa, S., 2016. Screening Feline Blood Donors for *Bartonella henselae* Infection: Comparison between Indirect Immunofluorescent Antibody Test (IFAT) and Polymerase Chain Reaction (PCR) Results. *J Vet Clin Pract Pet Care* 1, 1-9.
- Spencer, S.E., Knowles, T., Ramsey, I.K., Tasker, S., 2017. Pyrexia in cats: Retrospective analysis of signalment, clinical investigations, diagnosis and influence of prior treatment in 106 referred cases. *J Feline Med Surg* 19, 1123-1130.
- Sykes, J.E., Drazenovich, N.L., Ball, L.M., Leutenegger, C.M., 2007. Use of conventional and real-time polymerase chain reaction to determine the epidemiology of hemoplasma infections in anemic and nonanemic cats. *J Vet Intern Med* 21, 685-693.
- Sykes, J.E., Terry, J.C., Lindsay, L.L., Owens, S.D., 2008. Prevalences of various hemoplasma species among cats in the United States with possible hemoplasmosis. *J Am Vet Med Assoc* 232, 372-379.
- Sykes, J.E., Westropp, J.L., Kasten, R.W., Chomel, B.B., 2010. Association between *Bartonella* species infection and disease in pet cats as determined using serology and culture. *J Feline Med Surg* 12, 631-636.
- Tanahara, M., Miyamoto, S., Nishio, T., Yoshii, Y., Sakuma, M., Sakata, Y., Nishigaki, K., Tsujimoto, H., Setoguchi, A., Endo, Y., 2010. An epidemiological survey of feline hemoplasma infection in Japan. *J Vet Med Sci* 72, 1575-1581.
- Tasker, S., Braddock, J.A., Baral, R., Helps, C.R., Day, M.J., Gruffydd-Jones, T.J., Malik, R., 2004. Diagnosis of feline haemoplasma infection in Australian cats using a real-time PCR assay. *J Feline Med Surg* 6, 345-354.

- Tiao, N., Darrington, C., Molla, B., Saville, W.J., Tilahun, G., Kwok, O.C., Gebreyes, W.A., Lappin, M.R., Jones, J.L., Dubey, J.P., 2013. An investigation into the seroprevalence of *Toxoplasma gondii*, *Bartonella* spp., feline immunodeficiency virus (FIV), and feline leukaemia virus (FeLV) in cats in Addis Ababa, Ethiopia. *Epidemiol Infect* 141, 1029-1033.
- Ueno, H., Hohdatsu, T., Muramatsu, Y., Koyama, H., Morita, C., 1996. Does coinfection of *Bartonella henselae* and FIV induce clinical disorders in cats? *Microbiol Immunol* 40, 617-620.
- Weingart, C., Tasker, S., Kohn, B., 2016. Infection with haemoplasma species in 22 cats with anaemia. *J Feline Med Surg* 18, 129-136.
- Whittemore, J.C., Hawley, J.R., Radecki, S.V., Steinberg, J.D., Lappin, M.R., 2012. *Bartonella* species antibodies and hyperglobulinemia in privately owned cats. *J Vet Intern Med* 26, 639-644.
- Woods, J.E., Hawley, J.R., Lappin, M.R., 2003. Attempted transmission of *Haemobartonella felis* by *Ctenocephalides felis*. Proceedings of the American College of Internal Medicine (ACVIM) meeting, Charlotte, New York, 4th-7th June 2003 pp. 426.

Table 1. Multivariate analysis of signalment, historical data, clinical signs, and the results of haematology and serum biochemistry identified as factors associated with *Bartonella henselae* seropositivity

| Variables | Categories | Seropositivity (%) | OR | CI | <i>P</i> value |
|---------------------------|-------------------|---------------------------|-----------|---------------|-----------------------|
| Body weight (kg) | | | 1.42 | 1.18 - 1.7 | < 0.001 |
| Current ownership | Cattery | 3/21 (14.3%) | Reference | | |
| | Stray | 60/155 (38.7%) | 8.38 | 1.04 - 67.42 | 0.04 |
| | Client-owned | 94/267 (35.2%) | 12.47 | 1.56 - 99.47 | 0.01 |
| Living conditions | Indoors | 21/97 (21.6%) | Reference | | |
| | Outdoors | 129/333 (38.7%) | 2.47 | 1.15 - 5.32 | 0.02 |
| Number of in-contact cats | | | 1.45 | 1.07 - 1.97 | 0.01 |
| Flea infestation | No | 113/354 (31.9%) | Reference | | |
| | Yes | 43/87 (49.4%) | 2 | 1.05 – 3.82 | 0.03 |
| Gingivostomatitis | No | 122/380 (32.1%) | Reference | | |
| | Yes | 34/64 (53.1%) | 2.39 | 1.4 - 4.09 | 0.001 |
| Globulins | Normal | 84/281 (29.9%) | Reference | | |
| | Increased | 74/140 (52.8%) | 2.38 | 1.55 - 3.65 | < 0.001 |
| Globulins | Decreased | 1/19 (5.2%) | Reference | | |
| | Increased | 74/140 (52.8%) | 14.09 | 1.79 - 111.02 | 0.012 |
| Inorganic phosphorus | Normal | 97/224 (43.3%) | Reference | | |
| | Increased | 61/213 (28.6%) | 0.56 | 0.36 - 0.87 | 0.01 |

OR: odds ratio; CI: confidence interval

Table 2. Multivariate analysis of historical data, clinical signs, and results of haematology and serum biochemistry, identified as factors associated with *Bartonella* spp. PCR-positive status

| Variables | Categories | Positive cats (%) | OR | CI | <i>P</i> value |
|---------------------------|------------|-------------------|-----------|-------------|----------------|
| Living area | Urban | 2/176 (1.1%) | Reference | | |
| | Rural | 5/58 (8.6%) | 8.2 | 1.54-43.53 | 0.01 |
| Non-smooth kidney surface | No | 6/238 (2.5%) | Reference | | |
| | Yes | 1/3 (33.3%)* | 19.33 | 1.53-243.56 | 0.02 |
| Calcium | Normal | 6/218 (2.7%) | Reference | | |
| | Increased | 1/3 (33.3%)** | 18.5 | 1.46-233.11 | 0.024 |

OR: odds ratio; CI: confidence interval

* The single *Bartonella* spp. PCR-positive cat with irregular kidney surface had concurrent infections with FeLV and FIV and was seropositive for FCoV

** The single *Bartonella* spp. PCR-positive cat with hypercalcemia had also increased serum creatinine

Table 3. Multivariate analysis of historical data, clinical signs and results of serology and haematology identified as factors associated with *Mycoplasma* spp. PCR-positive status

| Variables | Categories | Positive cats (%) | OR | CI | <i>P</i> value |
|---|-------------------|--------------------------|-----------|-------------|-----------------------|
| Use of ectoparasiticides | | 8/83 (9.6%) | 0.29 | 0.12 - 0.72 | 0.007 |
| Fever | | 3/6 (50%) | 6.85 | 1.2 - 39.12 | 0.03 |
| Ocular signs | | 13/50 (26%)* | 3.14 | 1.27 - 7.75 | 0.013 |
| At least one clinical sign | | 28/165 (16.9%) | 0.42 | 0.18 - 0.96 | 0.04 |
| <i>Toxoplasma gondii</i> IgG antibodies | | 17/53 (32%) | 3.18 | 1.48 - 6.82 | 0.003 |
| Platelets | Normal | 27/176 (15.3%) | Reference | | |
| | Decreased | 16/49 (32.6%) | 2.67 | 1.29 - 3.22 | 0.008 |

OR: odds ratio; CI: confidence interval

*All haemoplasma species-positive cats with ocular signs were affected by upper respiratory track disease (URTD)

Supplementary data-Table S1. Univariable associations between *Bartonella henselae* seropositivity and the signalment and historical data that were collected using a standardized questionnaire. Variables that were used in the logistic regression model (P value < 0.25) are highlighted with an asterisk

| Variables | Categories | Missing data | <i>Bartonella henselae</i> IgG antibodies | | |
|---------------------------|----------------------------|--------------|---|------------------|-----------|
| | | | Seropositive (%) | Seronegative (%) | P value |
| Sex | Male | 0 | 78/160 (48.8%) | 163/292 (55.8%) | 0.15* |
| | Female | | 82/160 (51.2%) | 129/292 (44.2%) | |
| Neutered | | 6 | 49/157 (31.2%) | 89/289 (30.8%) | 0.928 |
| Breed | Purebred | | 2/154 (1.3%) | 13/283 (4.6%) | |
| | Common European breed | 15 | 152/154 (98.7%) | 270/283 (95.4%) | 0.071* |
| Age (years) | | 23 | 2 (0.13-17) | 1 (0.13-15) | <0.001* |
| Body weight (kg) | | 45 | 3.4 (0.5-8) | 3.15 (0.5-9) | 0.014* |
| Cat acquisition | Stray | 93 | 87/118 (73.7%) | 170/241 (70.5%) | 0.529 |
| | Non-stray | | 31/118 (26.3%) | 71/241 (29.5%) | |
| Current ownership | Client-owned | | 94/157 (59.9%) | 173/286 (60.5%) | |
| | Stray | 9 | 60/157 (38.2%) | 95/286 (33.2%) | 0.081* |
| | Cattery | | 3/157 (1.9%) | 18/286 (6.3%) | |
| Living conditions | Indoors | 22 | 21/150 (14%) | 76/280 (27.1%) | 0.002* |
| | Outdoors | | 129/150 (86%) | 204/280 (72.9%) | |
| Living area | Urban | 23 | 120/149 (80.5%) | 241/280 (86.1%) | 0.135* |
| | Rural | | 29/149 (19.5%) | 39/280 (13.9%) | |
| Contact with other cats | | 57 | 131/141 (92.9%) | 208/254 (81.8%) | 0.003* |
| | 1-2 cats | | 18/112 (16.1%) | 38/213 (17.8%) | |
| | 3 cats | 127 | 5/112 (4.5%) | 6/213 (2.8%) | 0.01* |
| Number of in-contact cats | >3 cats | | 79/112 (70.5%) | 121/213 (56.8%) | |
| | History of cat-bite wounds | 253 | 15/55 (27.3%) | 31/144 (21.5%) | 0.39 |
| Use of ectoparasiticides | | 187 | 56/91 (61.5%) | 101/174 (58%) | 0.583 |
| Flea infestation | | 11 | 43/156 (27.6%) | 44/285 (15.4%) | 0.002* |

| | | | | |
|------------------|----|--------------|--------------|--------|
| Tick infestation | 12 | 5/156 (3.2%) | 2/284 (0.7%) | 0.103* |
|------------------|----|--------------|--------------|--------|

Supplementary data-Table S2. Univariable associations between *Bartonella henselae* seropositivity, the presence of clinical signs, the results of PCR for *Bartonella* spp. and for *Mycoplasma* spp. and the results of serology for *Toxoplasma gondii*, feline coronavirus, feline leukemia virus and feline immunodeficiency virus. Variables with that were used in the logistic regression model (P value <0.25) are highlighted with an asterisk

| Clinical sign | Missing data | <i>Bartonella henselae</i> IgG antibodies | | |
|-----------------------------|--------------|---|------------------|---------|
| | | Seropositive (%) | Seronegative (%) | P value |
| Weight loss | 128 | 11/102 (10.8%) | 32/222 (14.4%) | 0.371 |
| Anorexia (previous 3 weeks) | 96 | 16/117 (13.7%) | 47/239 (19.7%) | 0.164* |
| Depression-lethargy | 8 | 16/156 (10.3%) | 33/288 (11.5%) | 0.7 |
| Weakness | 8 | 4/156 (2.6%) | 6/288 (2.1%) | 0.746 |
| Dehydration | 10 | 10/155 (6.5%) | 22/287 (7.7%) | 0.638 |
| Fever | 12 | 3/153 (2%) | 9/287 (3.1%) | 0.555 |
| Lymphadenomegaly | 10 | 8/155 (5.2%) | 15/287 (5.2%) | 0.977 |
| Abnormal lung sounds | 10 | 1/155 (0.6%) | 9/287 (3.1%) | 0.176* |
| Cough | 5 | 2/158 (1.3%) | 5/289 (1.7%) | 1 |
| Dyspnea | 9 | 2/155 (1.3%) | 2/288 (0.7%) | 0.614 |
| Signs of rhinitis | 9 | 12/156 (7.7%) | 25/287 (8.7%) | 0.711 |
| Ocular signs | 18 | 13/153 (8.5%) | 38/281 (13.5%) | 0.12* |
| Gingivostomatitis | 8 | 34/156 (21.8%) | 30/288 (10.4%) | 0.001* |
| Vomiting | 130 | 4/100 (4%) | 15/222 (6.8%) | 0.331 |
| Diarrhea | 135 | 2/98 (2%) | 14/219 (6.4%) | 0.163* |
| Constipation | 146 | 1/92 (1.1%) | 1/214 (0.5%) | 0.512 |
| Abdominal pain | 8 | 2/156 (1.3%) | 6/288 (2.1%) | 0.719 |
| Abdominal mass | 10 | 1/156 (0.6%) | 1/286 (0.3%) | 1 |
| Abdominal effusion | 8 | 2/156 (1.3%) | 4/288 (1.4%) | 1 |
| Splenomegaly | 9 | 0/156 (0%) | 2/287 (0.7%) | 0.543 |
| Decreased kidney size | 9 | 1/156 (0.6%) | 1/287 (0.3%) | 1 |
| Increased kidney size | 9 | 2/156 (1.3%) | 3/287 (1%) | 1 |
| Non-smooth kidney surface | 9 | 3/156 (1.9%) | 1/287 (0.3%) | 0.128* |
| Polyuria-polydipsia | 150 | 0/88 (0%) | 4/214 (1.9%) | 0.326 |
| Dysuria | 145 | 0/90 (0%) | 5/217 (2.3%) | 0.326 |

| | | | | |
|--|-----|----------------|-----------------|--------|
| Pyometra or penile swelling | 8 | 0/156 (0%) | 3/288 (1%) | 0.555 |
| Skin lesions and/or pruritus | 14 | 40/155 (25.8%) | 54/283 (19.1%) | 0.101* |
| Neurological signs | 9 | 7/156 (4.5%) | 10/287 (3.5%) | 0.6 |
| Musculoskeletal signs | 8 | 4/156 (2.6%) | 14/288 (4.9%) | 0.241* |
| At least one clinical sign | 11 | 97/155 (62.6%) | 177/286 (61.9%) | 0.886 |
| At least one clinical sign compatible with bartonellosis | 11 | 48/155 (31%) | 77/286 (26.9%) | 0.368 |
| <i>Bartonella</i> spp. infection (PCR) | 228 | 3/81 (3.7%) | 4/143 (2.8%) | 0.705 |
| <i>Mycoplasma</i> spp. infection (PCR) | 228 | 18/81 (22.2%) | 26/143 (18.2%) | 0.465 |
| <i>Toxoplasma gondii</i> IgG antibodies (IFAT) | 0 | 46/160 (28.7%) | 48/292 (16.4%) | 0.002* |
| Feline coronavirus IgG antibodies (IFAT) | 3 | 23/159 (14.5%) | 31/290 (10.7%) | 0.239* |
| Feline leukemia virus infection | 91 | 5/121 (4.1%) | 5/240 (2.1%) | 0.313 |
| Feline immunodeficiency virus infection | 91 | 14/121 (11.6%) | 19/240 (7.9%) | 0.256* |

IFAT: immunofluorescence antibody test; PCR: polymerase chain reaction

Supplementary data-Table S3. Univariable associations between *Bartonella henselae* seropositivity and the abnormal results of haematology. Variables that were used in the logistic regression model (P value <0.25) are highlighted with an asterisk

| Variable | Categories | Missing data | <i>Bartonella henselae</i> IgG antibodies | | P value |
|-------------------|------------|--------------|---|------------------|-----------|
| | | | Seropositive (%) | Seronegative (%) | |
| HCT | Decreased | 0 | 33/138 (23.9%) | 76/231 (32.9%) | 0.067* |
| White blood cells | Decreased | | 6/138 (4.3%) | 15/231 (6.5%) | 0.156* |
| White blood cells | Increased | 0 | 34/138 (24.6%) | 75/231 (32.5%) | |
| Neutrophils | Decreased | | 13/138 (9.4%) | 24/231 (10.4%) | 0.983 |
| Neutrophils | Increased | 0 | 22/138 (15.9%) | 37/231 (16%) | |
| Lymphocytes | Decreased | | 17/138 (12.3%) | 31/231 (13.4%) | 0.498 |
| Lymphocytes | Increased | 0 | 9/138 (6.5%) | 23/231 (10%) | |
| Monocytes | Increased | 0 | 4/138 (2.9%) | 11/231 (4.8%) | 0.38 |
| Eosinophils | Decreased | | 7/138 (5.1%) | 4/231 (1.7%) | 0.086* |
| Eosinophils | Increased | 0 | 42/138 (30.4%) | 59/231 (25.5%) | |
| Platelets | Decreased | | 26/138 (18.8%) | 50/231 (21.6%) | 0.06* |
| Platelets | Increased | 0 | 3/138 (2.2%) | 17/231 (7.4%) | |

HCT: haematocrit

Supplementary data-Table S4. Univariable associations between *Bartonella henselae* seropositivity and the abnormal results of serum biochemistry. Variables that were used in the logistic regression model (P value <0.25) are highlighted with an asterisk

| Variable | Categories | Missing data | <i>Bartonella henselae</i> IgG antibodies | | |
|----------------------|------------|--------------|---|------------------|--------------------|
| | | | Seropositive (%) | Seronegative (%) | P value |
| Total proteins | Decreased | 12 | 7/159 (4.4%) | 33/281 (11.7%) | $<0.001^*$ |
| Total proteins | Increased | | 14/159 (8.8%) | 5/281 (1.8%) | |
| Albumins | Decreased | 8 | 124/160 (77.5%) | 210/284 (73.9%) | 0.405 |
| Globulins | Decreased | 12 | 1/159 (0.6%) | 18/281 (6.4%) | $<0.001^*$ |
| Globulins | Increased | | 74/159 (46.5%) | 66/281 (23.5%) | |
| Urea nitrogen | Decreased | 15 | 18/158 (11.4%) | 40/280 (14.3%) | 0.689 |
| Urea nitrogen | Increased | | 10/158 (6.3%) | 19/280 (6.8%) | |
| Creatinine | Decreased | 10 | 9/159 (5.7%) | 41/283 (14.5%) | 0.013 [*] |
| Creatinine | Increased | | 6/159 (3.8%) | 7/283 (2.5%) | |
| Glucose | Decreased | 15 | 7/158 (4.4%) | 13/280 (4.6%) | 0.756 |
| Glucose | Increased | | 91/158 (57.6%) | 151/280 (53.9%) | |
| Cholesterol | Decreased | 16 | 20/158 (12.7%) | 22/279 (7.9%) | 0.231 [*] |
| Cholesterol | Increased | | 1/158 (0.6%) | 3/279 (1.1%) | |
| Triglycerides | Decreased | 12 | 3/159 (1.9%) | 4/281 (1.4%) | 0.431 |
| Triglycerides | Increased | | 10/159 (6.3%) | 11/281 (3.9%) | |
| Total bilirubin | Increased | 9 | 6/159 (3.8%) | 8/284 (2.8%) | 0.581 |
| ALP | Increased | 8 | 10/160 (6.3%) | 30/284 (10.6%) | 0.127 [*] |
| ALT | Increased | 16 | 3/155 (1.9%) | 11/281 (3.9%) | 0.396 |
| AST | Increased | 8 | 18/160 (11.3%) | 29/284 (10.2%) | 0.733 |
| Calcium | Decreased | 8 | 8/160 (5%) | 10/284 (3.5%) | 0.568 |
| Calcium | Increased | | 2/160 (1.3%) | 2/284 (0.7%) | |
| Inorganic phosphorus | Increased | 16 | 61/158 (38.6%) | 152/279 (54.5%) | 0.001 [*] |
| Potassium | Decreased | 10 | 3/160 (1.9%) | 2/282 (0.7%) | 0.364 |
| Potassium | Increased | | 39/160 (24.4%) | 80/282 (28.4%) | |
| Sodium | Decreased | 9 | 19/160 (11.9%) | 30/283 (10.6%) | 0.49 |
| Sodium | Increased | | 13/160 (8.1%) | 33/183 (11.7%) | |
| Chloride | Decreased | 9 | 56/160 (35%) | 89/283 (31.4%) | 0.34 |

| | | | |
|----------|-----------|--------------|--------------|
| Chloride | Increased | 1/160 (0.6%) | 7/283 (2.5%) |
|----------|-----------|--------------|--------------|

ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase

Supplementary data-Table S5. Univariable associations between the infection status of 242 cats tested for *Bartonella* spp. by PCR and the signalment and historical data that were collected using a standardized questionnaire. Variables that were used in the logistic regression model (*P* value <0.25) are highlighted with an asterisk

| Variables | Categories | Missing data | <i>Bartonella</i> spp. PCR-positive status | | <i>P</i> value |
|----------------------------|-----------------------|--------------|--|-----------------|----------------|
| | | | Positive (%) | Negative (%) | |
| Sex | Male | 0 | 4/7 (57.1%) | 126/235 (53.6%) | 1 |
| | Female | | 3/7 (42.9%) | 109/235 (46.5%) | |
| Neutered | | 3 | 1/7 (14.3%) | 70/232 (30.2%) | 0.677 |
| Breed | Purebred | | 0/7 (0%) | 2/229 (0.9%) | |
| | Common European Breed | 6 | 7/7 (100%) | 227/229 (99.1%) | 1 |
| Age (years) | | 9 | 0.42 (0.33-3.5) | 1 (0.13-15) | 0.338 |
| Body weight (kg) | | 19 | 2.1 (1.5-3.8) | 3 (0.5-8) | 0.365 |
| Cat acquisition | Stray | 58 | 1/6 (16.7%) | 111/178 (62.4%) | 0.035* |
| | Non-stray | | 5/6 (83.3%) | 67/178 (37.6%) | |
| Current ownership | Stray | 2 | 2/7 (28.6%) | 89/233 (38.2%) | 0.712 |
| | Non-stray | | 5/7 (71.4%) | 144/233 (61.8%) | |
| Living conditions | Indoors | 7 | 0/7 (0%) | 30/228 (13.2%) | 0.6 |
| | Outdoors | | 7/7 (100%) | 198/228 (86.8%) | |
| Living area | Urban | 8 | 2/7 (28.6%) | 174/227 (76.7%) | 0.011* |
| | Rural | | 5/7 (71.4%) | 53/227 (23.3%) | |
| Contact with other cats | | 11 | 7/7 (100%) | 210/224 (93.8%) | 1 |
| Number of in-contact cats | ≤ 2 cats | 56 | 0/6 (0%) | 34/180 (18.9%) | 0.594 |
| | > 2 cats | | 6/6 (100%) | 146/180 (81.1%) | |
| History of cat-bite wounds | | 120 | 0/5 (0%) | 28/117 (23.9%) | 0.588 |
| Flea infestation | | 6 | 1/7 (14.3%) | 62/229 (27.1%) | 0.678 |
| Tick infestation | | 7 | 0/7 (0%) | 5/228 (2.2%) | 1 |

PCR: polymerase chain reaction

Supplementary data-Table S6. Univariable associations between the infection status of 242 cats tested for *Bartonella* spp. by PCR and the presence of clinical signs, the results of serology for *Bartonella henselae* and of PCR for *Mycoplasma* spp. and the results of serology for *Toxoplasma gondii*, feline coronavirus, feline leukemia virus and feline immunodeficiency virus. Variables that were used in the logistic regression model (P value <0.25) are highlighted with an asterisk

| Clinical sign | Missing data | <i>Bartonella</i> spp. PCR status | | P value |
|-----------------------------|--------------|-----------------------------------|----------------|---------|
| | | Positive (%) | Negative (%) | |
| Weight loss | 76 | 0/5 (0%) | 32/161 (19.9%) | 0.584 |
| Anorexia (previous 3 weeks) | 66 | 1/6 (16.7%) | 31/170 (18.2%) | 1 |
| Depression-lethargy | 1 | 1/7 (14.3%) | 29/234 (12.4%) | 1 |
| Weakness | 1 | 0/7 (0%) | 6/234 (2.6%) | 1 |
| Dehydration | 2 | 1/7 (14.3%) | 17/233 (7.3%) | 0.425 |
| Fever | 5 | 1/7 (14.3%) | 5/230 (2.2%) | 0.166* |
| Lymphadenomegaly | 3 | 0/7 (0%) | 11/232 (4.7%) | 1 |
| Abnormal lung sounds | 3 | 0/7 (0%) | 11/232 (4.7%) | 1 |
| Cough | 0 | 0/7 (0%) | 8/235 (3.4%) | 1 |
| Dyspnea | 2 | 0/7 (0%) | 3/233 (1.3%) | 1 |
| Signs of rhinitis | 2 | 0/7 (0%) | 31/233 (13.3%) | 0.599 |
| Ocular signs | 5 | 0/7 (0%) | 50/230 (21.7%) | 0.35 |
| Gingivostomatitis | 1 | 0/7 (0%) | 38/234 (16.2%) | 0.6 |
| Glossitis | 1 | 1/7 (14.3%) | 16/234 (6.8%) | 0.405 |
| Vomiting | 89 | 0/3 (0%) | 5/150 (3.3%) | 1 |
| Abdominal pain | 1 | 0/7 (0%) | 5/234 (2.1%) | 1 |
| Abdominal mass | 2 | 0/7 (0%) | 2/233 (0.9%) | 1 |
| Abdominal effusion | 1 | 0/7 (0%) | 1/234 (0.4%) | 1 |
| Hepatomegaly | 1 | 0/7 (0%) | 1/234 (0.4%) | 1 |
| Splenomegaly | 1 | 0/7 (0%) | 1/234 (0.4%) | 1 |
| Decreased kidney size | 1 | 0/7 (0%) | 1/234 (0.4%) | 1 |
| Increased kidney size | 1 | 1/7 (14.3%) | 3/234 (1.3%) | 1 |
| Non-smooth kidney surface | 1 | 1/7 (14.3%) | 2/234 (0.9%) | 0.085* |
| Polyuria-polydipsia | 105 | 0/1 (0%) | 3/136 (2.2%) | 1 |
| Dysuria | 98 | 0/1 (0%) | 3/143 (2.1%) | 1 |

| | | | | |
|--|----|-------------|-----------------|--------|
| Pyometra or penile swelling | 1 | 0/7 (0%) | 1/234 (0.4%) | 1 |
| Skin lesions and/or pruritus | 5 | 0/7 (0%) | 53/230 (23%) | 0.354 |
| Neurological signs | 1 | 0/7 (0%) | 0/234 (3.8%) | 1 |
| Musculoskeletal signs | 1 | 0/7 (0%) | 7/234 (3%) | 1 |
| At least one clinical sign | 3 | 6/7 (85.7%) | 159/232 (68.5%) | 0.441 |
| At least one clinical sign compatible with bartonellosis | 3 | 1/7 (14.3%) | 67/232 (28.9%) | 0.676 |
| <i>Bartonella henselae</i> IgG antibodies (IFAT) | 18 | 3/7 (42.9%) | 78/217 (35.9%) | 0.705 |
| <i>Mycoplasma</i> spp. infection (PCR) | 0 | 3/7 (42.9%) | 43/235 (18.3%) | 0.128* |
| <i>Toxoplasma gondii</i> IgG antibodies (IFAT) | 17 | 3/7 (42.9%) | 50/218 (22.9%) | 0.360 |
| Feline leukemia virus infection | 63 | 1/7 (14.3%) | 6/172 (3.5%) | 0.247* |
| Feline immunodeficiency virus infection | 63 | 1/7 (14.3%) | 19/172 (11%) | 0.57 |
| Feline Coronavirus IgG antibodies (IFAT) | 19 | 1/7 (14.3%) | 32/216 (14.8%) | 1 |

PCR: polymerase chain reaction; IFAT: immunofluorescence antibody test

Supplementary data-Table S7. Univariable associations between the infection status of 242 cats tested for *Bartonella* spp. by PCR and the results of haematology and biochemistry. Variables that were used in the logistic regression model (P value <0.25) are highlighted with an asterisk

| Variable | Categories | Missing data | <i>Bartonella</i> spp. PCR status | | P value |
|-------------------|------------|--------------|-----------------------------------|-----------------|---------|
| | | | Positive (%) | Negative (%) | |
| HCT | Decreased | 0 | 5/7 (71.4%) | 116/235 (49.4%) | 0.446 |
| White blood cells | Decreased | | 0/7 (0%) | 16/235 (6.8%) | 0.816 |
| White blood cells | Increased | 0 | 2/7 (28.6%) | 94/235 (40%) | |
| Neutrophils | Decreased | | 2/7 (28.6%) | 20/235 (8.5%) | 0.127* |
| Neutrophils | Increased | 0 | 2/7 (28.6%) | 52/235 (22.1%) | |
| Lymphocytes | Decreased | | 0/7 (0%) | 35/235 (14.9%) | 0.518 |
| Lymphocytes | Increased | 0 | 1/7 (14.3%) | 23/235 (9.8%) | |
| Monocytes | Increased | 0 | 0/7 (0%) | 14/235 (6%) | 1 |
| Eosinophils | Decreased | | 1/7 (14.3%) | 6/235 (2.6%) | 0.007* |
| Eosinophils | Increased | 0 | 5/7 (71.4%) | 69/235 (29.4%) | |
| Platelets | Decreased | | 1/7 (14.3%) | 48/235 (20.4%) | 0.613 |
| Platelets | Increased | 0 | 1/7 (14.3%) | 16/235 (6.8%) | |
| Total proteins | Decreased | 14 | 1/7 (14%) | 31/221 (14%) | 0.386 |
| Total proteins | Increased | | 1/7 (14.3%) | 12/221 (5.4%) | |
| Albumins | Decreased | 11 | 7/7 (100%) | 188/224 (83.9) | 0.6 |
| Globulins | Decreased | 14 | 0/7 (0%) | 10/221 (4.5%) | 0.782 |
| Globulins | Increased | | 3/7 (42.9%) | 74/221 (33.5%) | |
| Urea nitrogen | Decreased | 17 | 1/7 (14.3%) | 35/218 (16.1%) | 0.641 |
| Urea nitrogen | Increased | | 1/7 (14.3%) | 17/218 (7.8%) | |
| Creatinine | Increased | 12 | 1/7 (14.3%) | 6/223 (2.7%) | 0.197* |
| Glucose | Decreased | 15 | 1/7 (14.3%) | 14/220 (6.4%) | 0.28 |
| Glucose | Increased | | 2/7 (28.6%) | 109/220 (49.5%) | |
| Cholesterol | Decreased | 16 | 0/7 (0%) | 21/219 (9.6%) | 1 |
| Cholesterol | Increased | | 0/7 (0%) | 2/219 (0.9%) | |
| Triglycerides | Decreased | 14 | 0/7 (0%) | 4/221 (1.8%) | 0.403 |

| | | | | | |
|----------------------|-----------|----|-------------|-----------------|--------|
| Triglycerides | Increased | | 1/7 (14.3%) | 11/221 (5%) | |
| Total bilirubin | Increased | 11 | 1/7 (14.3%) | 8/224 (3.6%) | 0.246* |
| ALP | Increased | 11 | 2/7 (28.6%) | 22/224 (9.8%) | 0.157* |
| ALT | Increased | 12 | 0/7 (0%) | 4/223 (1.8%) | 1 |
| AST | Increased | 11 | 1/7 (14.3%) | 29/224 (12.9%) | 1 |
| GGT | Increased | 15 | 0/7 (0%) | 4/220 (1.8%) | 1 |
| Calcium | Increased | 11 | 1/7 (14.3%) | 2/224 (0.9%) | 0.089* |
| Inorganic phosphorus | Increased | 15 | 4/7 (57.1%) | 111/220 (50.5%) | 1 |
| Potassium | Increased | 13 | 1/7 (14.3%) | 66/222 (29.7%) | 0.677 |
| Sodium | Decreased | 12 | 1/7 (14.3%) | 30/223 (13.5%) | 1 |
| Sodium | Increased | | 0/7 (0%) | 18/223 (8.1%) | |

PCR: polymerase chain reaction; HCT: haematocrit; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase

Supplementary data-Table S8. Univariable associations between the infection status of 242 cats tested for haemoplasma species by PCR and the signalment and historical data that were collected using a standardized questionnaire. Variables that were used in the logistic regression model (P value <0.25) are highlighted with an asterisk

| Variables | Categories | Missing data | Haemoplasma species PCR status | | P value |
|----------------------------|--------------|--------------|--------------------------------|-----------------|---------|
| | | | Positive (%) | Negative (%) | |
| Sex | Male | 0 | 25/46 (54.3%) | 105/196 (53.6%) | 0.924 |
| | Female | | 21/46 (45.7%) | 91/196 (46.4%) | |
| Neutered | | 3 | 11/45 (24.4%) | 60/194 (30.9%) | 0.391 |
| Breed | Purebred | 6 | 0/44 (0%) | 44/44 (100%) | 1 |
| | Crossbreed | | 2/190 (1%) | 190/192 (99%) | |
| Age (years) | | 9 | 2 (0.13-8) | 1 (0.13-15) | 0.705 |
| Body weight (kg) | | 19 | 3 (0.5-7.2) | 3 (0.5-8) | 0.992 |
| Cat acquisition | Client-owned | 58 | 9/32 (28.1%) | 47/152 (30.9%) | 0.879 |
| | Stray | | 20/32 (62.5%) | 92/152 (60.5%) | |
| | Cattery | | 3/32 (9.4%) | 11/152 (7.2%) | |
| | Pet shop | | 0/32 (0%) | 2/152 (1.3%) | |
| Current ownership | Client-owned | 2 | 22/45 (48.9%) | 115/195 (59%) | 0.453 |
| | Stray | | 20/45 (44.4%) | 71/195 (36.4%) | |
| | Cattery | | 3/45 (6.7%) | 9/195 (4.6%) | |
| Living conditions | Indoors | 7 | 2/44 (4.5%) | 28/191 (14.7%) | 0.07* |
| | Outdoors | | 42/44 (95.5%) | 163/191 (85.3%) | |
| Living area | Urban | 8 | 31/44 (70.5%) | 145/190 (76.3%) | 0.417 |
| | Rural | | 13/44 (29.5%) | 45/190 (23.7%) | |
| Contact with other cats | | 11 | 43/44 (97.7%) | 174/187 (93%) | 0.479 |
| Number of in-contact cats | 1-2 cats | 56 | 1/31 (3.2%) | 18/155 (11.6%) | 0.189* |
| | 3 cats | | 3/31 (9.7%) | 6/155 (3.9%) | |
| | > 3 cats | | 26/31 (83.9%) | 117/155 (75.5%) | |
| History of cat-bite wounds | | 120 | 4/19 (21.1%) | 24/103 (23.3%) | 1 |
| Vaccinated against CHPR | | 69 | 7/32 (21.9%) | 56/141 (39.7%) | 0.058* |

| | | | | | |
|-------------------|----|---------------|----------------|--------|--|
| Use of | | | | | |
| ectoparasiticides | 79 | 8/29 (27.6%) | 75/134 (56%) | 0.006* | |
| Flea infestation | 6 | 14/45 (31.1%) | 49/191 (25.7%) | 0.457 | |
| Tick infestation | 7 | 1/45 (2.2%) | 4/190 (2.1%) | 1 | |

PCR: polymerase chain reaction; CHPR: calicivirus, herpesvirus-1, panleukopenia, rabies

Supplementary data-Table S9. Univariable associations between the infection status of 242 cats tested for haemoplasma species by PCR and the presence of clinical signs, the results of serology for *Bartonella henselae* and of PCR for *Bartonella* spp. and the results of serology for *Toxoplasma gondii*, feline coronavirus, feline leukemia virus and feline immunodeficiency virus. Variables that were used in the logistic regression model (P value <0.25) are highlighted with an asterisk

| Clinical sign | Missing data | Haemoplasma species PCR status | | P value |
|-----------------------------|--------------|--------------------------------|----------------|---------|
| | | Positive (%) | Negative (%) | |
| Weight loss | 76 | 7/26 (26.9%) | 25/140 (17.9%) | 0.282 |
| Anorexia (previous 3 weeks) | 66 | 8/27 (29.6%) | 24/149 (16.1%) | 0.107* |
| Depression-lethargy | 1 | 6/46 (13%) | 24/195 (12.3%) | 0.892 |
| Weakness | 1 | 2/46 (4.3%) | 4/195 (2.1%) | 0.322 |
| Dehydration | 2 | 4/46 (8.7%) | 14/194 (7.2%) | 0.756 |
| Fever | 5 | 3/46 (6.5%) | 3/191 (1.6%) | 0.089* |
| Lymphadenomegaly | 3 | 3/45 (6.7%) | 8/194 (4.1%) | 0.438 |
| Abnormal lung sounds | 3 | 2/46 (4.3%) | 9/193 (4.7%) | 1 |
| Cough | 0 | 3/46 (6.5%) | 5/196 (2.6%) | 0.179* |
| Dyspnea | 2 | 1/46 (2.2%) | 2/194 (1%) | 0.473 |
| Signs of rhinitis | 2 | 10/46 (21.7%) | 21/194 (10.8%) | 0.047* |
| Ocular signs | 5 | 13/46 (28.3%) | 37/191 (19.4%) | 0.185* |
| Gingivostomatitis | 1 | 8/46 (17.4%) | 30/195 (15.4%) | 0.737 |
| Glossitis | 1 | 3/46 (6.5%) | 14/195 (7.2%) | 1 |
| Vomiting | 89 | 1/25 (4%) | 4/128 (3.1%) | 1 |
| Diarrhea | 94 | 1/23 (4.3%) | 5/125 (4%) | 1 |
| Constipation | 98 | 0/22 (0%) | 2/122 (1.6%) | 1 |
| Abdominal pain | 1 | 1/46 (2.2%) | 4/195 (2.1%) | 1 |
| Abdominal mass | 2 | 0/46 (0%) | 2/194 (1%) | 1 |
| Abdominal effusion | 1 | 0/46 (0%) | 1/195 (0.5%) | 1 |
| Hepatomegaly | 1 | 0/46 (0%) | 1/195 (0.5%) | 1 |
| Splenomegaly | 1 | 0/46 (0%) | 1/195 (0.5%) | 1 |
| Decreased kidney size | 1 | 0/46 (0%) | 1/195 (0.5%) | 0.657 |
| Increased kidney size | 1 | 1/46 (2.2%) | 3/195 (1.5%) | |
| Non-smooth kidney surface | 1 | 1/46 (2.2%) | 2/195 (1%) | 0.472 |

| | | | | |
|---|-----|---------------|----------------|--------|
| Polyuria-polydipsia | 105 | 0/19 (0%) | 3/118 (2.5%) | 1 |
| Dysuria | 98 | 0/21 (0%) | 3/123 (2.4%) | 1 |
| Pyometra or penile swelling | 1 | 0/46 (0%) | 1/195 (0.5%) | 1 |
| Skin lesions and/or pruritus | 5 | 11/46 (23.9%) | 42/191 (22%) | 0.779 |
| Musculoskeletal signs | 1 | 1/46 (2.2%) | 6/195 (3.1%) | 1 |
| At least one clinical sign | 3 | 28/46 (60.9%) | 137/193 (71%) | 0.182* |
| At least one clinical sign compatible with haemoplasmosis | 3 | 9/46 (19.6%) | 37/193 (19.2%) | 0.951 |
| <i>Bartonella</i> spp. infection (PCR) | 0 | 3/46 (6.5%) | 4/196 (2%) | 0.128* |
| <i>Bartonella henselae</i> IgG antibodies (IFAT) | 18 | 18/44 (40.9%) | 63/180 (35%) | 0.465 |
| <i>Toxoplasma gondii</i> IgG antibodies (IFAT) | 17 | 17/45 (37.8%) | 36/180 (20%) | 0.012* |
| Feline leukemia virus infection | 63 | 0/32 (0%) | 7/147 (4.8%) | 0.355 |
| Feline immunodeficiency virus infection | 63 | 6/32 (18.8%) | 14/147 (9.5%) | 0.210* |
| Feline Coronavirus IgG antibodies (IFAT) | 19 | 8/45 (17.8%) | 25/178 (14%) | 0.529 |

PCR: polymerase chain reaction; IFAT: immunofluorescence antibody test

Supplementary data-Table S10. Univariable associations between the infection status of 242 cats tested for haemoplasma species by PCR and the results of haematology and biochemistry. Variables that were used in the logistic regression model (P value <0.25) are highlighted with an asterisk

| Variable | Categories | Missing data | Haemoplasma species PCR-positive status | | |
|-------------------|------------|--------------|---|-----------------|---------|
| | | | Positive (%) | Negative (%) | P value |
| HCT | Decreased | 0 | 27/46 (58.7%) | 94/196 (48%) | 0.19* |
| White blood cells | Decreased | | 1/46 (2.2%) | 15/196 (7.7%) | 0.166* |
| White blood cells | Increased | 0 | 23/46 (50%) | 73/196 (37.2%) | |
| Neutrophils | Decreased | | 4/46 (8.7%) | 18/196 (9.2%) | 0.336 |
| Neutrophils | Increased | 0 | 14/46 (30.4%) | 40/196 (20.4%) | |
| Lymphocytes | Decreased | | 6/46 (13%) | 29/196 (14.8%) | 0.719 |
| Lymphocytes | Increased | 0 | 6/46 (13%) | 18/196 (9.2%) | |
| Monocytes | Increased | 0 | 4/46 (8.7%) | 10/196 (5.1%) | 0.312 |
| Eosinophils | Decreased | | 2/46 (4.3%) | 5/196 (2.6%) | 0.742 |
| Eosinophils | Increased | 0 | 15/46 (32.6%) | 59/196 (30.1%) | |
| Platelets | Decreased | | 16/46 (34.8%) | 33/196 (16.8%) | 0.024* |
| Platelets | Increased | 0 | 3/46 (6.5%) | 14/196 (7.1%) | |
| Total proteins | Decreased | | 7/45 (15.6%) | 25/183 (13.7%) | 0.444 |
| Total proteins | Increased | 14 | 4/45 (8.9%) | 9/183 (4.9%) | |
| Albumins | Decreased | 11 | 41/45 (91.1%) | 154/186 (82.8%) | 0.168* |
| Globulins | Decreased | | 1/45 (2.2%) | 9/183 (4.9%) | 0.418 |
| Globulins | Increased | 14 | 19/45 (42.2%) | 58/183 (31.7%) | |
| Urea nitrogen | Decreased | | 8/45 (17.8%) | 28/180 (15.6%) | 0.802 |
| Urea nitrogen | Increased | 17 | 4/45 (8.9%) | 14/180 (7.8%) | |
| Creatinine | Decreased | | 9/45 (20%) | 33/185 (17.8%) | 0.936 |
| Creatinine | Increased | 12 | 1/45 (2.2%) | 6/185 (3.2%) | |
| Glucose | Decreased | | 3/45 (6.7%) | 12/182 (6.6%) | 0.931 |
| Glucose | Increased | 15 | 21/45 (46.7%) | 90/182 (49.5%) | |
| Cholesterol | Decreased | | 2/45 (4.4%) | 19/181 (10.5%) | 0.528 |
| Cholesterol | Increased | 16 | 0/45 (0%) | 2/181 (1.1%) | |
| Triglycerides | Decreased | | 1/45 (2.2%) | 3/183 (1.6%) | 0.561 |
| Triglycerides | Increased | 14 | 1/45 (2.2%) | 11/183 (6%) | |

| | | | | | |
|----------------------|-----------|----|---------------|----------------|-------|
| Total bilirubin | Increased | 11 | 2/45 (4.4%) | 7/186 (3.8%) | 0.689 |
| ALP | Increased | 11 | 3/45 (6.7%) | 21/186 (11.3%) | 0.585 |
| ALT | Increased | 12 | 1/45 (2.2%) | 3/185 (1.6%) | 0.584 |
| AST | Increased | 11 | 5/45 (11.1%) | 25/186 (13.4%) | 0.677 |
| GGT | Increased | 15 | 1/45 (2.2%) | 3/182 (1.6%) | 1 |
| Calcium | Decreased | 11 | 1/45 (2.2%) | 9/186 (4.8%) | 0.839 |
| Calcium | Increased | | 0/45 (0%) | 3/186 (1.6%) | |
| Inorganic phosphorus | Increased | 15 | 22/45 (48.9%) | 93/182 (51.1%) | 0.791 |
| Potassium | Increased | 13 | 11/45 (24.4%) | 56/184 (30.4%) | 0.429 |
| Sodium | Decreased | 12 | 7/45 (15.6%) | 24/185 (13%) | 0.717 |
| Sodium | Increased | | 2/45 (4.4%) | 16/185 (8.6%) | |
| Chloride | Decreased | 12 | 17/45 (37.8%) | 70/185 (37.8%) | 1 |
| Chloride | Increased | | 0/45 (0%) | 2/185 (1.1%) | |

PCR: polymerase chain reaction; HCT: haematocrit; ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyl transpeptidase

5. Article No 4

Seroprevalence and risk factors for *Toxoplasma gondii* infection in cats from Greece. Under review

Short Communication

Seroprevalence and risk factors for *Toxoplasma gondii* infection in cats from Greece

Abstract

Toxoplasmosis is one of the most important protozoan diseases with a global impact on the health of domestic cats and with zoonotic significance. The aims of this study were to determine the prevalence of seropositivity for *Toxoplasma gondii* in different populations of cats in Greece and to assess risk factors for seropositivity.

A total of 457 cats were prospectively enrolled and a commercially available IFAT kit was used for the detection of anti-*T. gondii* IgG in serum.

Overall, 95 (20.8%) of the 457 cats were seropositive for *T. gondii*. Based on multivariate analysis, factors associated with seropositivity included older age, a history of cat-fight trauma, and lack of vaccination against calicivirus, herpesvirus-1, panleukopenia, and rabies.

This study shows a high prevalence of seropositivity for *T. gondii* in cats in Greece. This implies that toxoplasmosis is still a major public health concern and that optimal strategies for the prevention of infection with *T. gondii* in cats should be established.

Keywords: feline, prevalence, protozoan, public health, seropositivity

Introduction

Toxoplasmosis is one of the most important zoonotic protozoan diseases, with a global impact on the health of domestic cats (Tenter et al., 2000). The causative agent is *Toxoplasma gondii* which infects virtually all warm-blooded animals (intermediate hosts). Domestic cats and other felids are the definitive hosts that excrete oocysts (Su et al., 2003).

The main modes of transmission, to both intermediate and definitive hosts, are congenital infection through the placenta, ingestion of oocyst-contaminated food or water and ingestion of raw infected tissues, with the latter being the primary source of infection in cats (Hill and Dubey, 2002). Other, less important, modes of transmission include blood transfusion, lactation and organ transplantation (Bernsteen et al., 1999; Powell et al., 2001).

Reported risk factors for *T. gondii* seropositivity in cats include male gender, older age, being non-purebred, and hunting and eating intermediate hosts (rodents and birds) or mechanical vectors such as cockroaches and earthworms (Gauss et al., 2003; Maruyama et al., 2003; Voltaire et al., 2005; López et al., 2011).

The global prevalence of seropositivity against *T. gondii*, based on meta-analyses, has been reported to be 35% and 32.9% in cats and in humans, respectively (Bigna et al., 2020; Montazeri et al., 2020). Because of the vital role of cats for human infection, the high seropositivity rate highlights the need for current and comprehensive data on the epidemiology of *T. gondii* infection in cats. Only limited seroepidemiological data are available on *T. gondii* infection of cats in Greece (Chatzis et al., 2014), and there is no study investigating the risk factors for seropositivity. The objectives of the present study were to determine the prevalence of seropositivity against *T. gondii* in different populations of cats living in different areas of Greece and to assess risk factors related to signalment and history.

Materials and methods

Ethics approval

The study protocol was reviewed and approved by the Animal Ethics Committee of the Faculty of Veterinary Science, University of Thessaly (13/16-6-15). Handling of these animals was in compliance with the European Communities Council Directive 2010/63/EU and state laws.

Study population

Cats from four different geographic areas of Greece (Attica, Thessaly, Crete, and Macedonia) were prospectively enrolled, between November 2013 and November 2016, as part of a previous study (Kokkinaki et al., 2021), and they were divided into three groups: client-owned cats, stray cats, and cats living in breeding catteries. These cats were presented for wellness examination, vaccination, neutering and/or medical treatment. Stray cats often originated from cat-dense environments (i.e., rescue colonies) and their age was estimated based on body size, dentition and other physical characteristics (Hale, 2005; Bellows et al., 2016; DiGangi et al., 2020).

Inclusion criteria included: a) body weight of ≥ 0.5 kg, and b) an informed consent form signed by the owner or the rescuer. The cats were enrolled randomly, and no preference was given to their health status. Signalment and historical data were collected using a standardized questionnaire.

Sample collection and laboratory analyses

A total of 5 mL of blood was collected by jugular venipuncture from each cat. Serum was harvested following centrifugation at 3000 rpm for 20 min and stored at -80°C until indirect fluorescent antibody test (IFAT) for anti-*T. gondii* IgG was performed.

Anti-*T. gondii* IgG antibodies were detected using a commercially available IFAT kit (Biopronix Product Line, Agrilolabo S.p.a., Italy) according to the manufacturer's instructions. The cut-off value was 1/50, and all slides were examined by fluorescence microscopy (Olympus, Japan) at 400x magnification.

Statistical analysis

For univariate analysis, categorical data, regarding signalment and historical information, were compared between *T. gondii* seropositive and seronegative cats using Pearson's χ^2 or Fischer's exact tests. The normality of the distribution of the continuous variables was tested using the Kolmogorov-Smirnov test. Normally distributed data are presented as means \pm standard deviation and were compared between seropositive cats and seronegative cats using independent sample t-tests. Not normally distributed data are presented as medians and ranges and were compared between seropositive cats and seronegative cats using Mann Whitney U tests.

Variables that, in the univariate analysis, were different at 25% level of significance, between seropositive and seronegative cats were selected as candidates for an initial logistic regression model. The initial model was subsequently reduced in a stepwise manner until only significantly different ($P < 0.05$) variables remained. Odds ratios (OR) derived from the reduced model were interpreted as measures of the risk of seropositivity.

The analyses were performed using Stata 13 (Stata Corp, College Station, TX) and SPSS 23 for Windows (IBM Corp, Armonk, NY).

Results

A total of 457 cats were prospectively enrolled in the study. The age of these cats ranged from 6 weeks to 17 years (median: 2 years). Two hundred and forty-two cats (53%) were males (86 neutered; 35.5% of the male cats), and 215 (47%) were females (52 neutered; 24.2% of the female cats). Fifteen cats (3.3%) were purebred, 427 (93.4%) were crossbred, and for 15 (3.3%) cats the breed was not recorded. Ninety-nine cats (21.7%) lived exclusively indoors, 336 (73.5%) outdoors, and for 22 cats (4.8%) living status was not recorded. Two hundred and fifty-eight cats (56.5%) were living in Attica, 73 (16%) in Thessaly, 79 (17.3%) in Crete, and 47 (10.3%) in Macedonia. Two hundred and sixty-nine cats (58.9%) were client-owned, 158 (34.6%) were stray, 21 (4.6%) were living in catteries, and for nine cats (2%) current ownership was not recorded. Three hundred and sixty-six cats (80.1%) lived in urban areas, 68 (14.9%) in rural areas, while for 23 (5%) cats their habitat was not recorded.

Of the 457 cats, a total of 95 (20.8%) were seropositive for *T. gondii*. The univariate associations between seropositivity and signalment or historical data are presented in Table 1.

Multivariate analysis indicated three factors that were independently associated with *T. gondii*-seropositivity (Table 2). *Toxoplasma gondii*-seropositive cats were older, were more likely to have history of cat-fight trauma, and more likely to be unvaccinated against calicivirus, herpesvirus-1, panleukopenia and rabies (CHPR), compared to seronegative cats.

Discussion

This is one of the most extensive prospective studies on natural infection with *T. gondii* in cats, and the first study reporting risk factors for seropositivity in Greece.

Overall, 20.8% of the cats were seropositive for *T. gondii*. In addition, older age, history of cat-fight trauma and non-vaccination against calicivirus, herpesvirus-1, panleukopenia and rabies were positively associated with *T. gondii*-seropositivity.

The seroprevalence identified here is similar to that from a previous prospective study in Greece, where it was reported to be 21% (Chatzis et al., 2014). In addition, the seroprevalence in our study is similar to that reported in other countries, including Italy, Portugal, United Kingdom, the Netherlands, Argentina, Brazil and China (Bennett et al., 2011; López et al., 2011; Opsteegh et al., 2012; Spada et al., 2013; Esteves et al., 2014; Liu et al., 2014; Pereira et al., 2018).

Globally, studies evaluating the seroprevalence for *T. gondii* have shown a wide variation. Seroprevalence has been reported to be 41-60.8% in Northern Europe (Must et al., 2015; Saevik et al., 2015), 10-84.7% in Southern Europe (Millan et al., 2009; Miro et al., 2011), 19.2-65.5% in Western Europe (Bennett et al., 2011; Afonso et al., 2013), 14.7-39.3% in Eastern Europe (Pavlova et al., 2016; Shuralev et al., 2018), 47-81.3% in Central Europe (Sroka and Szymańska, 2012; Shuralev et al., 2018), 1.1-100% in North America (Bevins et al., 2012; Jimenez-Coello et al., 2013), 0-82.8% in South America, 25% in Central America (Furtado et al., 2015; Teixeira et al., 2016; Rengifo-Herrera et al., 2017), 50-97.5% in North Africa, 4.4-36.2% in West Africa, 3.9% in South Africa (Al-Kappany et al., 2010; Kamani et al., 2010; Ayinmode et al., 2017; Lopes et al., 2017; Yekkour et al., 2017), and 2.2-82.8% in Asia (Hong et al., 2013; Asgari et al., 2018). This tremendous variability may reflect differences in the demographics and the geographic origin of the cats, the accuracy of the diagnostic tests and/or the overtime changes in the prevalence of these infections.

In our study, *T. gondii*-seropositive cats were significantly older than *T. gondii*-seronegative cats. This finding is consistent with previous studies, and may be explained by the fact that older cats have more time to be exposed to the parasite (Gauss et al., 2003; Maruyama et al., 2003; Voltaire et al., 2005).

Our study showed that cats with a history of cat-bite wounds were more likely to be *T. gondii*-seropositive than cats with no such history. To our knowledge, this is the first time that a significant association between cat-bite wounds and seropositivity to *T. gondii* is reported. The major route of transmission among cats is the ingestion of bradyzoites within tissue cysts. However, transmission through bite wounds that introduce saliva containing tachyzoites may also occur (Frenkel, 1973). In this case, the biting cat must be in the acute phase of infection, in order to have tachyzoites in

blood (parasitemia) and body secretions (Terragna et al., 1984; Burney et al., 1999; Hill and Dubey, 2002). However, cats with history of cat-bite wounds are more likely to live outside and thus to hunt and eat intermediate hosts, which is a well-established risk factor for *T. gondii*-seropositivity. Therefore, we suggest that the association between cat-bite wounds and seropositivity most likely reflects the consumption of the intermediate hosts by the cats.

Lack of vaccination against CHPR was found to be an independent risk factor for *T. gondii*-seropositivity. This is consistent with the results of a recent study on the epidemiology of *T. gondii* in 155 cats from Cyprus (Attipa et al., 2021) and presumably, reflects the better quality of life and veterinary care of the vaccinated cats compared to unvaccinated ones. Unvaccinated cats have an increased chance to become infected by calicivirus, herpesvirus-1 and/or panleukopenia virus, and to develop clinical illness. Concomitant illnesses render cats more susceptible to *T. gondii* infection. Also, they may lead to reactivation of tissue cysts in chronically infected but seronegative cats, with subsequent release of bradyzoites and seroconversion (Dubey and Lappin, 2012). Finally, unvaccinated cats are more likely to be stray and thus to be more prone to eat intermediate hosts.

Conclusions

This study shows a high prevalence of seropositivity for *T. gondii* among cats in Greece. Thus, feline toxoplasmosis should be considered a major public health concern in this country, necessitating the establishment of optimal prevention strategies, taking into consideration the high-risk groups of cats identified in this study.

References

- Afonso, E., Germain, E., Poulle, M.L., Ruetten, S., Devillard, S., Say, L., Villena, I., Aubert, D., Gilot-Fromont, E., 2013. Environmental determinants of spatial and temporal variations in the transmission of *Toxoplasma gondii* in its definitive hosts. *Int J Parasitol Parasites Wildl* 2, 278-285.
- Al-Kappany, Y.M., Rajendran, C., Ferreira, L.R., Kwok, O.C., Abu-Elwafa, S.A., Hilali, M., Dubey, J.P., 2010. High prevalence of toxoplasmosis in cats from Egypt: isolation of viable *Toxoplasma gondii*, tissue distribution, and isolate designation. *J Parasitol* 96, 1115-1118.

- Asgari, Q., Mohammadpour, I., Pirzad, R., Kalantari, M., Motazedian, M.H., Naderi, S., 2018. Molecular and Serological Detection of *Toxoplasma gondii* in Stray Cats in Shiraz, South-central, Iran. *Iran J Parasitol* 13, 430-439.
- Attipa, C., Yiapanis, C., Tasker, S., Diakou, A., 2021. Seroprevalence of *Toxoplasma gondii* in Cats from Cyprus. *Pathogens* 10.
- Ayinmode, A.B., Oluwayelu, D.O., Babalola, E.T., Lawani, M.A., 2017. Serologic survey of *Toxoplasma gondii* antibodies in cats (*Felis catus*) sold at live animal markets in southwestern Nigeria. *Bulg J Vet Med* 20 20, 58-64.
- Bellows, J., Center, S., Daristotle, L., Estrada, A.H., Flickinger, E.A., Horwitz, D.F., Lascelles, B.D., Lepine, A., Perea, S., Scherk, M., Shoveller, A.K., 2016. Aging in cats: Common physical and functional changes. *Journal of Feline Medicine and Surgery* 18, 533-550.
- Bennett, A.D., Gunn-Moore, D.A., Brewer, M., Lappin, M.R., 2011. Prevalence of *Bartonella* species, haemoplasmas and *Toxoplasma gondii* in cats in Scotland. *J Feline Med Surg* 13, 553-557.
- Bernsteen, L., Gregory, C.R., Aronson, L.R., Lirtzman, R.A., Brummer, D.G., 1999. Acute toxoplasmosis following renal transplantation in three cats and a dog. *J Am Vet Med Assoc* 215, 1123-1126.
- Bevins, S.N., Carver, S., Boydston, E.E., Lyren, L.M., Alldredge, M., Logan, K.A., Riley, S.P., Fisher, R.N., Vickers, T.W., Boyce, W., Salman, M., Lappin, M.R., Crooks, K.R., VandeWoude, S., 2012. Three pathogens in sympatric populations of pumas, bobcats, and domestic cats: implications for infectious disease transmission. *PLoS One* 7, e31403.
- Bigna, J.J., Tochie, J.N., Tounouga, D.N., Bekolo, A.O., Ymele, N.S., Youda, E.L., Sime, P.S., Nansseu, J.R., 2020. Global, regional, and country seroprevalence of *Toxoplasma gondii* in pregnant women: a systematic review, modelling and meta-analysis. *Sci Rep* 10, 12102.
- Burney, D.P., Lappin, M.R., Spilker, M., McReynolds, L., 1999. Detection of *Toxoplasma gondii* parasitemia in experimentally inoculated cats. *J Parasitol* 85, 947-951.
- Chatzis, M.K., Leontides, L., Athanasiou, L.V., Papadopoulos, E., Kasabalis, D., Mylonakis, M., Rallis, T., Koutinas, A.F., Andreadou, M., Ikonomopoulos, J., Saridomichelakis, M.N., 2014. Evaluation of indirect immunofluorescence antibody test and enzyme-linked immunosorbent assay for the diagnosis of

- infection by *Leishmania infantum* in clinically normal and sick cats. *Exp Parasitol* 147, 54-59.
- DiGangi, B.A., Graves, J., Budke, C.M., Levy, J.K., Tucker, S., Isaza, N., 2020. Assessment of body weight for age determination in kittens. *Journal of Feline Medicine and Surgery* 22, 322-328.
- Dubey, J.P., Lappin, M.R., 2012. Toxoplasmosis and Neosporosis. In: Green CE, ed. *Infectious diseases of the dog and cat*. 4th ed, Elsevier, USA: pp 806-821.
- Esteves, F., Aguiar, D., Rosado, J., Costa, M.L., de Sousa, B., Antunes, F., Matos, O., 2014. *Toxoplasma gondii* prevalence in cats from Lisbon and in pigs from centre and south of Portugal. *Vet Parasitol* 200, 8-12.
- Frenkel, J.K., 1973. Toxoplasmosis: parasite life cycle, pathology and immunity. In: Hammond DM and Long PL, ed. *The Coccidia. Eimeria, Isospora, Toxoplasma, and related genera*. University Park Press, Baltimore: pp 344-410.
- Furtado, M.M., Gennari, S.M., Ikuta, C.Y., Jacomo, A.T., de Morais, Z.M., Pena, H.F., Porfirio, G.E., Silveira, L., Sollmann, R., de Souza, G.O., Torres, N.M., Ferreira Neto, J.S., 2015. Serosurvey of Smooth Brucella, Leptospira spp. and *Toxoplasma gondii* in Free-Ranging Jaguars (*Panthera onca*) and Domestic Animals from Brazil. *PLoS One* 10, e0143816.
- Gauss, C.B., Almeria, S., Ortuno, A., Garcia, F., Dubey, J.P., 2003. Seroprevalence of *Toxoplasma gondii* antibodies in domestic cats from Barcelona, Spain. *J Parasitol* 89, 1067-1068.
- Hale, F.A., 2005. Juvenile veterinary dentistry. *Veterinary Clinics of North America: Small Animal Practice* 35, 789-817.
- Hill, D., Dubey, J.P., 2002. *Toxoplasma gondii*: transmission, diagnosis and prevention. *Clin Microbiol Infect* 8, 634-640.
- Hong, S.H., Jeong, Y.I., Kim, J.Y., Cho, S.H., Lee, W.J., Lee, S.E., 2013. Prevalence of *Toxoplasma gondii* infection in household cats in Korea and risk factors. *Korean J Parasitol* 51, 357-361.
- Jimenez-Coello, M., Acosta-Viana, K.Y., Guzman- Marin, E., Gutierrez-Ruiz, E.J., Rodriguez-Vivas, R.I., Bolio- González, M.E., Ortega-Pacheco, A., 2013. The occurrence of *Toxoplasma gondii* antibodies in backyard pigs and cats from an endemic tropical area of Mexico. *Trop Subtrop Agroecosyst* 16, 89-92.

- Kamani, J., Mani, A.U., Kumshe, H.A., Yidawi, J.P., Egwu, G.O., 2010. Prevalence of *Toxoplasma gondii* antibodies in cats in Maiduguri, Northeastern Nigeria. *Acta Parasitol* 55, 94-95.
- Kokkinaki, K.G., Saridomichelakis, M.N., Leontides, L., Mylonakis, M.E., Konstantinidis, A.O., Steiner, J.M., Suchodolski, J.S., Xenoulis, P.G., 2021. A prospective epidemiological, clinical, and clinicopathologic study of feline leukemia virus and feline immunodeficiency virus infection in 435 cats from Greece. *Comp Immunol Microbiol Infect Dis* 78, 101687.
- Liu, Q.X., Wang, S., Wang, L.Q., Xing, J., Gao, W.J., Liu, G.F., Zhao, B., Zhang, H.B., Gao, L.H., 2014. Seroprevalence of *Toxoplasma gondii* infection in dogs and cats in Zhenjiang City, Eastern China. *Asian Pac J Trop Biomed* 4, 725-728.
- Lopes, A.P., Oliveira, A.C., Granada, S., Rodrigues, F.T., Papadopoulos, E., Schallig, H., Dubey, J.P., Cardoso, L., 2017. Antibodies to *Toxoplasma gondii* and *Leishmania* spp. in domestic cats from Luanda, Angola. *Vet Parasitol* 239, 15-18.
- López, C., Daprato, B., Zampolini, S., Mazzeo, C., Cardillo, N., Sommerfelt, I., 2011. Risk factors and prevalence of IgG antibodies to *Toxoplasma gondii* in domestic cats: La Matanza, Buenos Aires, Argentina. *Rev Ibero-Latinoam Parasitol* 70, 29-34.
- Maruyama, S., Kabeya, H., Nakao, R., Tanaka, S., Sakai, T., Xuan, X., Katsube, Y., Mikami, T., 2003. Seroprevalence of *Bartonella henselae*, *Toxoplasma gondii*, FIV and FeLV infections in domestic cats in Japan. *Microbiology and Immunology* 47, 147-153.
- Millan, J., Cabezón, O., Pabon, M., Dubey, J.P., Almeria, S., 2009. Seroprevalence of *Toxoplasma gondii* and *Neospora caninum* in feral cats (*Felis silvestris catus*) in Majorca, Balearic Islands, Spain. *Vet Parasitol* 165, 323-326.
- Miro, G., Hernandez, L., Montoya, A., Arranz-Solis, D., Dado, D., Rojo-Montejo, S., Mendoza-Ibarra, J.A., Ortega-Mora, L.M., Pedraza-Diaz, S., 2011. First description of naturally acquired *Tritrichomonas foetus* infection in a Persian cattery in Spain. *Parasitol Res* 109, 1151-1154.
- Montazeri, M., Mikaeili Galeh, T., Moosazadeh, M., Sarvi, S., Dodangeh, S., Javidnia, J., Sharif, M., Daryani, A., 2020. The global serological prevalence

- of *Toxoplasma gondii* in felids during the last five decades (1967-2017): a systematic review and meta-analysis. *Parasit Vectors* 13, 82.
- Must, K., Lassen, B., Jokelainen, P., 2015. Seroprevalence of and Risk Factors for *Toxoplasma gondii* Infection in Cats in Estonia. *Vector Borne Zoonotic Dis* 15, 597-601.
- Opsteegh, M., Haveman, R., Swart, A.N., Mensink-Beerepoot, M.E., Hofhuis, A., Langelaar, M.F., van der Giessen, J.W., 2012. Seroprevalence and risk factors for *Toxoplasma gondii* infection in domestic cats in The Netherlands. *Prev Vet Med* 104, 317-326.
- Pavlova, E.V., Kirilyuk, E.V., Naidenko, S.V., 2016. Occurrence pattern of influenza A virus, *Coxiella burnetii*, *Toxoplasma gondii* and *Trichinella* sp. in the Pallas cat and domestic cat and their potential prey under arid climate conditions. *Arid Ecosystems* 6, 277-283.
- Pereira, P.F., Barbosa, A.D.S., Santos, A.L.C., Bolais, P.F., Darde, M.L., Amendoeira, M.R.R., 2018. *Toxoplasma gondii*: infection among shelter and stray cats in Rio de Janeiro, Brazil. *Rev Bras Parasitol Vet* 27, 401-408.
- Powell, C.C., Brewer, M., Lappin, M.R., 2001. Detection of *Toxoplasma gondii* in the milk of experimentally infected lactating cats. *Vet Parasitol* 102, 29-33.
- Rengifo-Herrera, C., Pile, E., Garcia, A., Perez, A., Perez, D., Nguyen, F.K., de la Guardia, V., McLeod, R., Caballero, Z., 2017. Seroprevalence of *Toxoplasma gondii* in domestic pets from metropolitan regions of Panama. *Parasite* 24, 9.
- Saevik, B.K., Krontveit, R.I., Eggen, K.P., Malmberg, N., Thoresen, S.I., Prestrud, K.W., 2015. *Toxoplasma gondii* seroprevalence in pet cats in Norway and risk factors for seropositivity. *J Feline Med Surg* 17, 1049-1056.
- Shuralev, E.A., Shamaev, N.D., Mukminov, M.N., Nagamune, K., Taniguchi, Y., Saito, T., Kitoh, K., Arleevskaya, M.I., Fedotova, A.Y., Abdulmanova, D.R., Aleksandrova, N.M., Efimova, M.A., Yarullin, A.I., Valeeva, A.R., Khaertynov, K.S., Takashima, Y., 2018. *Toxoplasma gondii* seroprevalence in goats, cats and humans in Russia. *Parasitol Int* 67, 112-114.
- Spada, E., Proverbio, D., Della Pepa, A., Domenichini, G., Bagnagatti De Giorgi, G., Traldi, G., Ferro, E., 2013. Prevalence of faecal-borne parasites in colony stray cats in northern Italy. *J Feline Med Surg* 15, 672-677.

- Sroka, J., Szymańska, J., 2012. Analysis of prevalence of *Toxoplasma gondii* infection in selected rural households in the Lublin Region. *Bull Vet Inst Pulawy* 56, 529-534.
- Su, C., Evans, D., Cole, R.H., Kissinger, J.C., Ajioka, J.W., Sibley, L.D., 2003. Recent expansion of *Toxoplasma* through enhanced oral transmission. *Science* 299, 414-416.
- Teixeira, J.V., de Oliveira, J.L.S., de Almeida, D.M.P.F., Gonçalves, L.S., de Oliveira, F.L.L., 2016. Seroprevalence of feline toxoplasmosis in Teresina, Piauí, Brazil. *Rev Bras Hig Sanid Anim* 10, 549-555.
- Tenter, A.M., Heckeroth, A.R., Weiss, L.M., 2000. *Toxoplasma gondii*: from animals to humans. *Int J Parasitol* 30, 1217-1258.
- Terragna, A., Morandi, N., Canessa, A., Pellegrino, C., 1984. The occurrence of *toxoplasma gondii* in saliva. *Tropenmed Parasitol* 35, 9-10.
- Vollaire, M.R., Radecki, S.V., Lappin, M.R., 2005. Seroprevalence of *Toxoplasma gondii* antibodies in clinically ill cats in the United States. *Am J Vet Res* 66, 874-877.
- Yekkour, F., Aubert, D., Mercier, A., Murat, J.B., Khames, M., Nguewa, P., Ait-Oudhia, K., Villena, I., Bouchene, Z., 2017. First genetic characterization of *Toxoplasma gondii* in stray cats from Algeria. *Vet Parasitol* 239, 31-36.

Table 1. Univariable associations between seropositivity for *Toxoplasma gondii* among 457 cats and the signalment and historical data that were collected using a standardized questionnaire. Variables that were used in the logistic regression model (*P* value <0.25) are highlighted with an asterisk

| Variables | Categories | Missing data | Anti- <i>T. gondii</i> IgG antibodies | | <i>P</i> value |
|----------------------------|--------------|--------------|---------------------------------------|-----------------|----------------|
| | | | Positive (%) | Negative (%) | |
| Sex | Male | 0 | 39/95 (41.1%) | 203/362 (56.1%) | 0.009* |
| | Female | | 56/95 (58.9%) | 159/362 (43.9%) | |
| Neutering | | 6 | 26/93 (28%) | 112/358 (31.3%) | 0.535 |
| Breed | Purebred | 15 | 1/91 (1.1%) | 14/351 (4%) | 0.326 |
| | Crossbreed | | 90/91 (98.9%) | 337/351 (96%) | |
| Age (years) | | 23 | 2.5 (0.13-17) | 1.05 (0.13-15) | <0.001* |
| Body weight (kg) | | 46 | 3.5 (0.85-7.2) | 3.2 (0.5-9) | 0.173* |
| Cat acquisition | Client-owned | 95 | 14/75 (18.7%) | 61/287 (21.3%) | 0.625 |
| | Stray | | 58/75 (77.3%) | 202/287 (70.4%) | |
| | Cattery | | 3/75 (4%) | 21/287 (7.3%) | |
| | Pet shop | | 0/75 (0%) | 3/287 (1%) | |
| Current ownership | Client-owned | 9 | 51/93 (54.8%) | 218/355 (61.4%) | 0.433 |
| | Stray | | 38/93 (40.9%) | 120/355 (33.8%) | |
| | Cattery | | 4/93 (4.3%) | 17/355 (4.8%) | |
| Living conditions | Indoors | 22 | 9/90 (10%) | 90/345 (26.1%) | 0.001* |
| | Outdoors | | 81/90 (90%) | 255/345 (73.9%) | |
| Living area | Urban | 23 | 72/90 (80%) | 294/344 (85.5%) | 0.204* |
| | Rural | | 18/90 (20%) | 50/344 (14.5%) | |
| Contact with other cats | | 57 | 72/80 (90%) | 272/320 (85%) | 0.249* |
| Number of in-contact cats | 0 cats | 131 | 8/56 (14.3%) | 48/270 (17.8%) | 0.669 |
| | 1-2 cats | | 9/56 (16.1%) | 48/270 (17.8%) | |
| | 3 cats | | 3/56 (5.4%) | 8/270 (3%) | |
| | >3 cats | | 36/56 (64.3%) | 166/270 (61.5%) | |
| History of cat-bite wounds | | 256 | 12/29 (41.4%) | 35/172 (20.3%) | 0.013* |
| Vaccinated against CHPR | | 119 | 25/72 (34.7%) | 138/266 (51.9%) | 0.01* |

| | | | | |
|--|-----|---------------|-----------------|--------|
| Use of ectoparasiticide | 190 | 27/53 (50.9%) | 132/214 (61.7%) | 0.154* |
| Flea infestation | 11 | 27/92 (29.3%) | 63/354 (17.8%) | 0.014* |
| Tick infestation | 12 | 1/92 (1.1%) | 6/353 (1.7%) | 1 |
| Consumption of prey, raw meat, and/or unpasteurized milk | 245 | 24/35 (68.6%) | 70/177 (39.5%) | 0.002* |

IFAT: immunofluorescence antibody test; CHPR: calicivirus, herpesvirus-1, panleukopenia, rabies

Table 2. Multivariate analysis of risk factors for *Toxoplasma gondii* seropositivity

| Variables | Odds Ratio | Confidence Interval | P value |
|----------------------------|-------------------|----------------------------|----------------|
| Age (years) | 1.33 | 1.15 - 1.54 | < 0.001 |
| History of cat-bite wounds | 3.88 | 1.54 - 9.81 | 0.004 |
| Vaccinated against CHPR | 0.1 | 0.07 - 0.55 | 0.002 |

CHPR: calicivirus, herpesvirus-1, panleukopenia, rabies

6. Article No 5

Prevalence of feline hyperthyroidism in Greece. Under review

Short Communication

Prevalence of feline hyperthyroidism in Greece

Abstract

Hyperthyroidism is the most common endocrine disease of cats and usually occurs in middle-aged to older animals. The primary aim of this study was to determine the prevalence of feline hyperthyroidism in Greece, and the secondary aim was to compare the clinical signs, haematological and serum biochemical findings between hyperthyroid and non-hyperthyroid cats.

A total of 80 cats, six years or older, were prospectively enrolled. The diagnosis of hyperthyroidism was based on serum concentration of total thyroxine and of free thyroxin (both measured by solid-phase chemiluminescent competitive immunoassays).

Hyperthyroidism was diagnosed in 4/80 (5%) of the cats. Clinical and laboratory findings that were significantly more common in these hyperthyroid cats compared to the non-hyperthyroid cats included a palpable thyroid nodule, depression-lethargy, dyspnoea and decreased blood urea nitrogen concentration.

Feline hyperthyroidism is quite common in Greece and routine measurement of thyroid hormone concentrations in serum should be considered in all middle-aged and older cats.

Keywords: biochemistry; clinical signs; haematology; hormone; epidemiology; thyroid

Introduction

Hyperthyroidism is a multi-systemic disorder resulting from excessive circulating concentrations of thyroid hormones, namely thyroxine (T₄) and triiodothyronine (T₃). It occurs mainly in middle-aged and older cats, with a reported age range of 2-25 years and a median age at the time of diagnosis of 11.5-15.1 years (Milner et al., 2006; Williams et al., 2010; Peterson, 2013a; Peterson and Broome, 2015; Puig et al., 2015; Grossi et al., 2019). Benign adenoma or adenomatous hyperplasia of the thyroid gland are the most common causes of the disease, accounting for 97-99% of the cases (Turrel et al., 1988; Peterson et al., 1994; Naan et al., 2006).

A wide range of clinical signs is seen in hyperthyroid cats, including weight loss, increased appetite, polyuria/polydipsia, vomiting, diarrhoea, hyperactivity, tachypnoea, tachycardia, and palpable goitre (Broussard et al., 1995; Frenais et al., 2009; Nussbaum et al., 2015; Grossi et al., 2019). Less commonly, cats present with the apathetic form of the disease, that is characterized by lethargy, weakness and decreased appetite, which is usually accompanied by concurrent severe systemic diseases (Thoday and Mooney, 1992; Bucknell, 2000; Frenais et al., 2009; Nussbaum et al., 2015; Grossi et al., 2019).

The most common haematologic and serum biochemistry abnormalities associated with feline hyperthyroidism include anaemia, leucocytosis, increased activities of alanine aminotransferase (ALT) and alkaline phosphatase (ALP), decreased calcium and increased inorganic phosphorous concentrations and decreased potassium osmolalities (Peterson and Ferguson, 1983; Thoday and Mooney, 1992; Broussard et al., 1995; Milner et al., 2006; Naan et al., 2006; Frenais et al., 2009; Williams et al., 2013; Hiebert et al., 2020).

Hyperthyroidism is the most common endocrinopathy of cats, with 1-4% prevalence in the general feline population and at least 6% in cats older than 9 years of age (Milner et al., 2006; Trepanier, 2006; Wakeling et al., 2011). Since its initial description (Holzworth et al., 1980), the prevalence (or the frequency of diagnosis) of the disease has been steadily increasing worldwide (McLean et al., 2017), and there is strong evidence that its prevalence differs among geographical locations (Scarlett et al., 1988). Depending on the selection criteria (mainly the age) of the cats enrolled in each study, reported prevalence rates vary widely, from 0.2% to 21.1% in Europe, from 0.1 to 2% in North America, and from 3.9% to 8.9% in Asia (Edinboro et al.,

2004; De Wet et al., 2009; Wakeling et al., 2011; McLean et al., 2017). Until now, the prevalence of feline hyperthyroidism in Greece remains unknown.

The primary aim of this study was to determine the prevalence of feline hyperthyroidism in Greece. The secondary aim was to compare the clinical signs as well as the haematological and serum biochemical findings between hyperthyroid and non-hyperthyroid cats.

Materials and Methods

Ethics approval

The study protocol was reviewed and approved by the Animal Ethics Committee of the Faculty of Veterinary Science, University of Thessaly (licence No: 13/16-6-15). Handling of the cats was in compliance with the European Communities Council Directive 2010/63/EU and State laws.

Study population

Cats from four different areas of Greece (i.e. Attica, Thessaly, Crete, and Macedonia) were prospectively enrolled, by three clinicians (KCGK, PGX, MEM), between March 2014 and July 2016. Client-owned cats, cats living in catteries, and stray cats that were presented by their owners or by volunteer cat-rescue groups for wellness examination, vaccination, neutering and/or medical treatment, were enrolled if they were at least 6 years old [the age of stray cats was estimated based on body size, dentition and other physical characteristics (Hale, 2005; Bellows et al., 2016; DiGangi et al., 2020)] and an informed consent form was signed by the owner or the rescuer. The only exclusion criterion was previous diagnosis and/or treatment of hyperthyroidism.

Signalment and historical data were collected using a standardized questionnaire followed by a thorough physical examination and blood sampling.

Sample collection and laboratory analyses

A total of 5 ml of blood was collected from the jugular vein. One ml was immediately transferred into a EDTA-anticoagulated tube and was used for haematology, whereas the remaining blood was centrifuged, and serum was separated and stored at -80 °C until further use for hormone assays and biochemistry analysis.

Serum total T₄ (tT₄) concentration was measured by a solid-phase chemiluminescent competitive assay (Immulite 2000 Canine Total T₄, Siemens Healthcare Diagnostics, Deerfield, IL) with a reference interval of 0.78-3.82 µg/dl. Serum free T₄ (fT₄) concentration was measured by a solid-phase chemiluminescent competitive immunoassay (Immulite 2000 Veterinary Free T₄, Siemens Healthcare Diagnostics, Llanberis, Gwynedd, UK) with a reference interval of 0.7-2.6 ng/dl. A cat was considered hyperthyroid if: a) tT₄ concentration was increased or b) tT₄ concentration was in the upper half of the reference interval (i.e. >2.3 µg/dl), fT₄ concentration was increased and there was a palpable goitre (Peterson and Broome, 2015).

Complete blood count (CBC) was performed within 12 h of blood collection, with one of three different analysers (Sysmex pochH-100i, ADVIA 2120i Siemens, ADVIA 120 Siemens), depending on sampling area. The results for each haematology parameter were classified as increased, normal, or decreased, based on the reference intervals determined for the specific analyser.

Complete serum biochemistry panels was performed using an automated analyser (Roche/Hitachi MODULAR ANALYTICS D 2400 module, Roche Diagnostics, Switzerland, CH).

Statistical analysis

Categorical data from signalment, history, clinical examination, haematology, and serum biochemistry were compared between hyperthyroid and euthyroid cats by either Pearson's χ^2 or Fisher's exact test. The distribution of continuous variables was tested by a Kolmogorov-Smirnov test. Normally distributed variables are presented as mean \pm standard deviation (SD) and were compared between hyperthyroid and euthyroid cats by independent samples *t*-test. Non-normally distributed variables are presented as median and range and were compared between hyperthyroid and euthyroid cats by the Mann Whitney *U* test. Analyses were done using SPSS 23 for Windows (IBM Corp, Armonk, NY) and the level of significance was set at $P < 0.05$.

Results

A total of 80 cats were included, 70 (87.5%) of them were sick and 10 (12.5%) were clinically healthy.

A total of 4/80 (5%) cats were diagnosed with hyperthyroidism. All of them were sick, and 3/4 (75%) had increased tT₄ (5.39 µg/dl, 6.32 µg/dl, and 8.49 µg/dl, respectively) and fT₄ (4.73 ng/dl, 5.56 ng/dl and >6 ng/dl, respectively) concentration. In addition, two of these three cats with the increased tT₄ and fT₄ presented the apathetic form of hyperthyroidism, while the third cat presented the classical clinical signs of the disease. The fourth cat had tT₄ concentration in the upper half of the reference range (2.35 µg/dl), increased fT₄ concentration (3.26 ng/dl), palpable goitre and presented the apathetic form of hyperthyroidism. This cat also presented with clinical signs of upper respiratory infection, laboratory investigation revealed anaemia, decreased serum albumin and increased serum globulin concentration, it was seropositive for feline immunodeficiency virus, *Toxoplasma gondii* IgG antibodies and *Bartonella* spp. IgG antibodies and it was blood PCR-positive for *Mycoplasma* spp.

Of the remaining 76/80 (95%) euthyroid cats 66 (86.8%) were sick and 10 (13.2%) were clinically healthy. Their tT₄ (0.63-3.27 µg/dl) and fT₄ (0.4-2.29 ng/dl) concentrations were below the upper limit of the reference interval, respectively.

The age of the four hyperthyroid cats ranged from 6 to 13 years (median: 9 years). Two (50%) of them were neutered males, and 2 (50%) spayed females. All were DSH and their body weight was 2.75 ± 0.35 kg. The age of the 76 euthyroid cats ranged from 6 to 17 years (median: 8 years). Thirty-nine (51.3%) of them were males (29 castrated) and 37 (48.7%) females (26 spayed). Four (5.3%) were purebred, 70 (92.1%) DSH, and the breed of 2 (2.6%) cats was not recorded. Their body weight was 4.35 ± 1.41 kg. There was no significant difference in the age ($P = 0.975$), sex ($P = 1$) or body weight ($P = 0.115$) between hyperthyroid and euthyroid cats (P value > 0.05).

The frequency of clinical manifestations, based on history and clinical examination (Table 1), and of haematology and serum biochemistry abnormalities (Table 2) were compared between hyperthyroid and euthyroid cats. The frequency of palpable goitre, depression-lethargy and dyspnoea was significantly higher in hyperthyroid compared to euthyroid cats (Table 1). Also, decreased blood urea nitrogen (BUN) concentration was more common in the hyperthyroid cats (Table 2).

Discussion

This is the first study reporting the prevalence of feline hyperthyroidism in Greece. The prevalence was found to be 5% among cats with an age range of 6 to 17 years. Palpable goitre, depression-lethargy, dyspnoea and decreased BUN concentration were more common in hyperthyroid compared to age-matched euthyroid cats.

The diagnostic sensitivity of tT_4 for feline hyperthyroidism varies from 90% to 95.2% but can be as low as 65% in the early stages of the disease and in cats with concurrent systemic illness (Milner et al., 2006; Peterson, 2013b; Peterson and Broome, 2015; Peterson et al., 2015). However, the diagnostic sensitivity of fT_4 in hyperthyroid cats with tT_4 concentration within the reference interval is approximately 95% (Peterson, 2006). Since all 76 cats that were considered euthyroid had tT_4 and fT_4 concentrations within the reference interval, the possibility of having misclassified some hyperthyroid cats as euthyroid is small, although it cannot be definitively excluded.

The reported diagnostic specificity of tT_4 is very high, typically varying between 98% and 100% (Peterson, 2006, 2013b; Peterson and Broome, 2015). Also, the diagnostic specificity of increased fT_4 in cats with high-normal tT_4 and palpable goitre is high (Peterson, 2013b) and for this reason the single cat with normal tT_4 and an increased serum fT_4 concentration was considered hyperthyroid. The authors acknowledge that it would have been ideal, for this particular cat, to have the measurement of thyroid hormones repeated and/or to perform alternative diagnostic tests (e.g. scintigraphy, T_3 suppression test) to definitively confirm the diagnosis. Unfortunately, this was not feasible due to the design of the study and the long time period between the enrolment of this cat and the measurement of its thyroid hormone concentrations.

Our results are comparable with those of most previous studies, where the prevalence of hyperthyroidism in middle-aged and older cats was found to vary between 2% and 12% (Kraft and Buchler, 1999; Wakeling and Melian, 2005; Sassnau, 2006; Wakeling et al., 2011; Dias Neves and Horspool, 2014; O'Neill et al., 2014; Stephens et al., 2014; Köhler et al., 2016). However, higher figures have also been reported, such as 20% in Poland (Gójska Zygnier et al., 2014) and 21.1% in Ireland (Bree et al., 2018), and the prevalence of the disease is increasing worldwide, thus necessitating routine clinical (neck palpation for goitre) and laboratory

(measurement of tT₄ concentration) testing for hyperthyroidism in all middle-aged and old-aged cats.

The reported diagnostic sensitivity of the palpation of one or two enlarged thyroid nodules varies from 71% to 96% (Paepe et al., 2008; Hibbert et al., 2009), depending on the palpation technique (classical and/or as described Norsworthy) (Norsworthy et al., 2002) the conformation of the neck of the cat, the size of the thyroid nodule (very small nodules may not be palpable and large nodules may descent and enter into the thoracic cavity) and the source of excessive thyroid hormone production (thyroid gland or ectopic thyroid tissue) (Broome, 2006; Peterson, 2013b; Peterson and Broome, 2015). The above may explain why goitre was not palpable in 1/4 hyperthyroid cats in the present study. In contrast to the sensitivity, the diagnostic specificity of this examination is considered poor because a palpable nodule may represent non-functional thyroid tissue (e.g. thyroid cyst, thyroiditis), early stages of functional thyroid tissue that does not produce enough hormones to result in clinical hyperthyroidism, enlarged parathyroid glands, enlarged lymph nodes, and also because of misinterpretation of the finding by an inexperienced examiners (Peterson, 2006; Paepe et al., 2008; Wakeling et al., 2011; Peterson, 2013b). Even when 30 hyperthyroid and euthyroid cats were examined, independently, by three experienced clinicians, that were blinded to the thyroid status of each cat, the specificity of palpation ranged from 63.3% to 66.7% (Paepe et al., 2008). In light of these data, the high specificity (98.7%) of thyroid palpation (Table 1) was a surprising finding of our study. Furthermore, we confirmed previous statements that cats with palpable nodules in the ventral neck region are significantly more likely to be hyperthyroid compared to cats without such palpable nodules (McLean et al., 2017; Bree et al., 2018).

The majority (3/4) of the hyperthyroid cats in our study presented the apathetic form of the disease with depression or lethargy instead of hyperactivity and aggressiveness (Thoday and Mooney, 1992; Bucknell, 2000). Most likely the apathetic form occurred due to comorbidities or due to severe complications of hyperthyroidism, such as heart failure that could also explain the increased prevalence of dyspnoea. The unexpected high prevalence of apathetic hyperthyroidism was probably the result of the inclusion and exclusion criteria of the study: cats with the classical clinical signs of the disease (hyperactivity, aggression, etc.) are more likely

to be tested and diagnosed with hyperthyroidism by their primary care veterinarian and such a previous diagnosis was an exclusion criterion for our study.

In the current study, dyspnoea was more common in hyperthyroid compared to euthyroid cats. The same has been reported in a prospective study of 508 cats from Ireland (Gallagher and Mooney, 2013) and the prevalence of dyspnoea among hyperthyroid cats was reported to range from 11% and 32% (Peterson and Ferguson, 1983; Grossi et al., 2019). Dyspnoea in hyperthyroid cats has been attributed to congestive heart failure, heat intolerance, and/or various respiratory comorbidities (Syme, 2007; Sangster et al., 2013).

Finally, the increased frequency of significantly lower BUN concentration in hyperthyroid than in euthyroid cats, although not previously reported, can be explained by the increased glomerular filtration rate, which is present in cats with hyperthyroidism (Syme, 2007).

Limitations of this study include the relatively small number of cats tested, and the inability to definitively confirm hyperthyroidism in the cat with normal tT_4 and high fT_4 concentration. Future prospective studies, addressing a larger number of cats and using additional diagnostic modalities to confirm the diagnosis in equivocal cases, are warranted to determine the risk factors for the appearance of the disease in Greece and to investigate further its clinical and clinicopathologic manifestations.

Conclusion

The results of this study indicate that hyperthyroidism is relatively common in cats in Greece, from the age of 6 years and above. The disease must be considered in any sick middle-aged and old-aged cat, especially if it presents palpable goitre, depression-lethargy, dyspnoea and/or decreased BUN concentration.

References

- Bellows, J., Center, S., Daristotle, L., Estrada, A.H., Flickinger, E.A., Horwitz, D.F., Lascelles, B.D., Lepine, A., Perea, S., Scherk, M., Shoveller, A.K., 2016. Aging in cats: Common physical and functional changes. *Journal of Feline Medicine and Surgery* 18, 533-550.
- Bree, L., Gallagher, B.A., Shiel, R.E., Mooney, C.T., 2018. Prevalence and risk factors for hyperthyroidism in Irish cats from the greater Dublin area. *Ir Vet J* 71, 2.

- Broome, M.R., 2006. Thyroid scintigraphy in hyperthyroidism. *Clin Tech Small Anim Pract* 21, 10-16.
- Broussard, J.D., Peterson, M.E., Fox, P.R., 1995. Changes in clinical and laboratory findings in cats with hyperthyroidism from 1983 to 1993. *J Am Vet Med Assoc* 206, 302-305.
- Bucknell, D.G., 2000. Feline hyperthyroidism: spectrum of clinical presentations and response to carbimazole therapy. *Aust Vet J* 78, 462-465.
- De Wet, C.S., Mooney, C.T., Thompson, P.N., Schoeman, J.P., 2009. Prevalence of and risk factors for feline hyperthyroidism in Hong Kong. *J Feline Med Surg* 11, 315-321.
- Dias Neves, R., Horspool, L.J.I., 2014. Prevalence of hyperthyroidism in Portuguese cats. In: *Proceedings of the European College of Veterinary Internal Medicine for Companion Animals Congress, Mainz, Germany*: pp 475.
- DiGangi, B.A., Graves, J., Budke, C.M., Levy, J.K., Tucker, S., Isaza, N., 2020. Assessment of body weight for age determination in kittens. *Journal of Feline Medicine and Surgery* 22, 322-328.
- Edinboro, C.H., Scott-Moncrieff, J.C., Janovitz, E., Thacker, H.L., Glickman, L.T., 2004. Epidemiologic study of relationships between consumption of commercial canned food and risk of hyperthyroidism in cats. *J Am Vet Med Assoc* 224, 879-886.
- Frenais, R., Rosenberg, D., Burgaud, S., Horspool, L.J., 2009. Clinical efficacy and safety of a once-daily formulation of carbimazole in cats with hyperthyroidism. *J Small Anim Pract* 50, 510-515.
- Gallagher, B., Mooney, C.T., 2013. Prevalence and risk factors for hyperthyroidism in Irish cats from the greater Dublin area. In: *Proceedings of the European College of Veterinary Internal Medicine Congress, Seattle, Washington*: pp 689.
- Gójska Zygner, O., Lechowski, R., Zygner, W., 2014. Prevalence of feline hyperthyroidism in mature cats in urban population in Warsaw. *Bull Vet Inst Pulawy* 58, 267-271.
- Grossi, G., Zoia, A., Palagiano, P., Leoni, N., Bubini-Regini, F., Malerba, E., Peli, A., Biagi, G., Fracassi, F., 2019. Iodine-restricted food versus pharmacological therapy in the management of feline hyperthyroidism: a controlled trial in 34 cats. *Open Vet J* 9, 196-204.

- Hale, F.A., 2005. Juvenile veterinary dentistry. *Veterinary Clinics of North America: Small Animal Practice* 35, 789-817.
- Hibbert, A., Gruffydd-Jones, T., Barrett, E.L., Day, M.J., Harvey, A.M., 2009. Feline thyroid carcinoma: diagnosis and response to high-dose radioactive iodine treatment. *J Feline Med Surg* 11, 116-124.
- Hiebert, E.C., Panciera, D.L., Boes, K.M., Bartl, L., 2020. Platelet function in cats with hyperthyroidism. *J Feline Med Surg* 22, 1214-1218.
- Holzworth, J., Theran, P., Carpenter, J.L., Harpster, N.K., Todoroff, R.J., 1980. Hyperthyroidism in the cat: ten cases. *J Am Vet Med Assoc* 176, 345-353.
- Köhler, I., Ballhausen, B.D., Stockhaus, C., Hartmann, K., Wehner, A., 2016. Prevalence of and risk factors for feline hyperthyroidism among a clinic population in Southern Germany. *Tierärztliche Praxis Kleintiere* 44, 149-157.
- Kraft, W., Buchler, F., 1999. Hyperthyroidism: incidence in the cat. *Tierärztliche Praxis Kleintiere* 27, 386-388.
- McLean, J.L., Lobetti, R.G., Mooney, C.T., Thompson, P.N., Schoeman, J.P., 2017. Prevalence of and risk factors for feline hyperthyroidism in South Africa. *J Feline Med Surg* 19, 1103-1109.
- Milner, R.J., Channell, C.D., Levy, J.K., Schaer, M., 2006. Survival times for cats with hyperthyroidism treated with iodine 131, methimazole, or both: 167 cases (1996-2003). *J Am Vet Med Assoc* 228, 559-563.
- Naan, E.C., Kirpensteijn, J., Kooistra, H.S., Peeters, M.E., 2006. Results of thyroidectomy in 101 cats with hyperthyroidism. *Vet Surg* 35, 287-293.
- Norsworthy, G.D., Adams, V.J., McElhaney, M.R., Milios, J.A., 2002. Relationship between semi-quantitative thyroid palpation and total thyroxine concentration in cats with and without hyperthyroidism. *J Feline Med Surg* 4, 139-143.
- Nussbaum, L.K., Scavelli, T.D., Scavelli, D.M., Pintar, J., Henderson, A.K., DeMarco, J.A., Worwag, S., Bastian, R.P., Kittner, H.S., 2015. Abdominal Ultrasound Examination Findings in 534 Hyperthyroid Cats Referred for Radioiodine Treatment Between 2007-2010. *J Vet Intern Med* 29, 1069-1073.
- O'Neill, D.G., Church, D.B., McGreevy, P.D., Thomson, P.C., Brodbelt, D.C., 2014. Prevalence of disorders recorded in cats attending primary-care veterinary practices in England. *Vet J* 202, 286-291.

- Paepe, D., Smets, P., van Hoek, I., Saunders, J., Duchateau, L., Daminet, S., 2008. Within- and between-examiner agreement for two thyroid palpation techniques in healthy and hyperthyroid cats. *J Feline Med Surg* 10, 558-565.
- Peterson, M.E., 2006. Diagnostic tests for hyperthyroidism in cats. *Clin Tech Small Anim Pract* 21, 2-9.
- Peterson, M.E., 2013a. Hyperthyroidism in cats. In: *Clinical Endocrinology of Companion Animals* Blackwell, Iowa: pp 295-310.
- Peterson, M.E., 2013b. More than just T(4): diagnostic testing for hyperthyroidism in cats. *J Feline Med Surg* 15, 765-777.
- Peterson, M.E., Broome, M.R., 2015. Thyroid scintigraphy findings in 2096 cats with hyperthyroidism. *Vet Radiol Ultrasound* 56, 84-95.
- Peterson, M.E., Ferguson, D.C., 1983. Feline hyperthyroidism: Pretreatment clinical and laboratory evaluation of 131 cases. *J Am Vet Med Assoc* 183, 103-110.
- Peterson, M.E., Guterl, J.N., Nichols, R., Rishniw, M., 2015. Evaluation of Serum Thyroid-Stimulating Hormone Concentration as a Diagnostic Test for Hyperthyroidism in Cats. *J Vet Intern Med* 29, 1327-1334.
- Peterson, M.E., Randolph, J.F., Mooney, C.T., 1994. Endocrine diseases. In: *Sherding RG, ed. The cat: diseases and clinical management*. 2nd ed. Churchill Livingstone, New York: pp 1416-1452.
- Puig, J., Cattin, I., Seth, M., 2015. Concurrent diseases in hyperthyroid cats undergoing assessment prior to radioiodine treatment. *J Feline Med Surg* 17, 537-542.
- Sangster, J.K., Panciera, D.L., Abbott, J.A., 2013. Cardiovascular effects of thyroid disease. *Compend Contin Educ Vet* 35, E5.
- Sassnau, R., 2006. Epidemiological investigation on the prevalence of feline hyperthyroidism in an urban population in Germany. *Tierärztliche Praxis Kleintiere* 34, 450-457.
- Scarlett, J.M., Sydney Moise, N., Rayl, J., 1988. Feline hyperthyroidism: a descriptive and case-control study. *Prev Vet Med* 6, 295-309.
- Stephens, M.J., O'Neill, D.G., Church, D.B., McGreevy, P.D., Thomson, P.C., Brodbelt, D.C., 2014. Feline hyperthyroidism reported in primary-care veterinary practices in England: prevalence, associated factors and spatial distribution. *Vet Rec* 175, 458.

- Syme, H.M., 2007. Cardiovascular and renal manifestations of hyperthyroidism. *Vet Clin North Am Small Anim Pract* 37, 723-743, vi.
- Thoday, K.L., Mooney, C.T., 1992. Historical, clinical and laboratory features of 126 hyperthyroid cats. *Vet Rec* 131, 257-264.
- Trepanier, L.A., 2006. Medical management of hyperthyroidism. *Clin Tech Small Anim Pract* 21, 22-28.
- Turrel, J.M., Feldman, E.C., Nelson, R.W., Cain, G.R., 1988. Thyroid carcinoma causing hyperthyroidism in cats: 14 cases (1981-1986). *J Am Vet Med Assoc* 193, 359-364.
- Wakeling, J., Elliott, J., Syme, H., 2011. Evaluation of predictors for the diagnosis of hyperthyroidism in cats. *J Vet Intern Med* 25, 1057-1065.
- Wakeling, J., Melian, C.A.F., 2005. Evidence for Differing Incidences of Feline Hyperthyroidism in London, Uk and Spain. In: *Proceedings of the European College of Veterinary Internal Medicine for Companion Animals Congress, Glasgow, Scotland*: pp 2005.
- Williams, T.L., Elliott, J., Berry, J., Syme, H.M., 2013. Investigation of the pathophysiological mechanism for altered calcium homeostasis in hyperthyroid cats. *J Small Anim Pract* 54, 367-373.
- Williams, T.L., Peak, K.J., Brodbelt, D., Elliott, J., Syme, H.M., 2010. Survival and the development of azotemia after treatment of hyperthyroid cats. *J Vet Intern Med* 24, 863-869.

Table 1. Comparison of the frequency of clinical manifestations, based on history and clinical examination, between four hyperthyroid and 76 euthyroid cats (asterisks indicate variables that differ significantly between the two groups of cats)

| Clinical sign | Missing data | Hyperthyroid (%) | Euthyroid (%) | <i>P</i> value |
|-----------------------------|--------------|------------------|---------------|----------------|
| Weight loss | 9 | 2/3 (66.7%) | 15/68 (22.1%) | 0.14 |
| Anorexia (previous 3 weeks) | 6 | 2/4 (50%) | 22/70 (31.4%) | 0.591 |
| Increased appetite | 9 | 0/4 (0%) | 2/67 (3%) | 1 |
| Depression-lethargy | 0 | 3/4 (75%) | 15/76 (19.7%) | 0.034* |
| Weakness | 0 | 1/4 (25%) | 3/76 (3.9%) | 0.189 |
| Dehydration | 0 | 2/4 (50%) | 15/76 (19.7%) | 0.197 |
| Fever | 0 | 0/4 (0%) | 4/76 (5.3%) | 1 |
| Lymphadenomegaly | 0 | 0/4 (0%) | 7/76 (9.2%) | 1 |
| Abnormal lung sounds | 0 | 0/4 (0%) | 3/76 (3.9%) | 1 |
| Cough | 0 | 1/4 (25%) | 0/76 (0%) | 0.05 |
| Dyspnoea | 0 | 2/4 (50%) | 2/76 (2.6%) | 0.011* |
| Ocular signs | 0 | 1/4 (25%) | 12/76 (15.8%) | 0.515 |
| Gingivostomatitis | 0 | 2/4 (50%) | 22/76 (28.9%) | 0.579 |
| Vomiting | 6 | 0/3 (0%) | 8/71 (11.3%) | 1 |
| Diarrhoea | 6 | 0/3 (0%) | 4/71 (5.6%) | 1 |
| Constipation | 8 | 0/3 (0%) | 1/69 (1.4%) | 1 |
| Abdominal pain | 0 | 0/4 (0%) | 2/76 (2.6%) | 1 |
| Abdominal mass | 0 | 0/4 (0%) | 2/76 (2.6%) | 1 |
| Abdominal effusion | 0 | 0/4 (0%) | 2/76 (2.6%) | 1 |
| Hepatomegaly | 0 | 0/4 (0%) | 1/76 (1.3%) | 1 |
| Splenomegaly | 0 | 1/4 (25%) | 0/76 (0%) | 0.05 |
| Increased kidney size | 0 | 1/4 (25%) | 2/76 (2.6%) | 0.144 |

| | | | | |
|--|----|------------|---------------|---------|
| Non-smooth kidney surface | 0 | 0/4 (0%) | 2/76 (2.6%) | 1 |
| Polyuria-polydipsia | 10 | 0/3 (0%) | 6/67 (9%) | 1 |
| Dysuria | 7 | 0/3 (0%) | 3/70 (4.3%) | 1 |
| Skin lesions and/or pruritus | 0 | 2/4 (50%) | 24/76 (31.6%) | 0.592 |
| Neurological signs | 0 | 0/4 (0%) | 2/76 (2.6%) | 1 |
| Musculoskeletal signs | 0 | 0/4 (0%) | 4/76 (5.3%) | 1 |
| Palpable goitre | 0 | 3/4 (75%) | 1/76 (1.3%) | <0.001* |
| At least one clinical sign/symptom | 0 | 4/4 (100%) | 66/76 (86.8%) | 1 |
| At least one clinical sign/symptom compatible with hyperthyroidism | 0 | 4/4 (100%) | 42/76 (55.3%) | 0.133 |

Table 2. Comparison of the frequency of haematology and serum biochemistry abnormalities between four hyperthyroid and 76 euthyroid cats (asterisks indicate variables that differ significantly between the two groups of cats)

| Variable | Categories | Missing data | Hyperthyroid (%) | Euthyroid (%) | <i>P</i> value |
|-------------------|------------|--------------|------------------|---------------|----------------|
| HCT | Decreased | 26 | 1/4 (25%) | 16/50 (32%) | 1 |
| White blood cells | Decreased | 26 | 0/4 (0%) | 7/50 (14%) | 1 |
| White blood cells | Increased | | 1/4 (25%) | 11/50 (22%) | |
| Neutrophils | Decreased | 26 | 1/4 (25%) | 6/50 (12%) | 0.306 |
| Neutrophils | Increased | | 1/4 (25%) | 7/50 (14%) | |
| Lymphocytes | Decreased | 26 | 1/4 (25%) | 14/50 (28%) | 1 |
| Monocytes | Increased | 26 | 0/4 (0%) | 1/50 (2%) | 1 |
| Eosinophils | Decreased | 26 | 0/4 (0%) | 3/50 (6%) | 1 |
| Eosinophils | Increased | | 1/4 (25%) | 9/50 (18%) | |
| Platelets | Decreased | 26 | 1/4 (25%) | 13/50 (26%) | 1 |
| Platelets | Increased | | 0/4 (0%) | 4/50 (8%) | |
| Total proteins | Decreased | 2 | 0/3 (0%) | 2/75 (2.7%) | 0.28 |
| Total proteins | Increased | | 1/3 (33.3%) | 5/75 (6.7%) | |
| Albumins | Decreased | 0 | 4/4 (100%) | 63/76 (82.9%) | 1 |
| Globulins | Decreased | 2 | 0/3 (0%) | 1/75 (1.3%) | 0.612 |
| Globulins | Increased | | 2/3 (66.7%) | 34/75 (45.3%) | |
| Urea nitrogen | Decreased | 3 | 2/3 (66.7%) | 7/74 (9.5%) | 0.017* |
| Urea nitrogen | Increased | | 1/3 (33.3%) | 10/74 (13.5%) | |
| Creatinine | Increased | 2 | 1/4 (25%) | 7/74 (9.5%) | 0.346 |
| Glucose | Increased | 2 | 2/3 (66.7%) | 41/75 (54.7%) | 1 |
| Cholesterol | Increased | 3 | 1/3 (33.3%) | 1/74 (1.4%) | 0.111 |
| Triglycerides | Decreased | 2 | 0/3 (0%) | 3/75 (4%) | 1 |

| | | | | | |
|----------------------|-----------|---|-------------|---------------|-------|
| Triglycerides | Increased | | 0/3 (0%) | 4/75 (5.3%) | |
| Total bilirubin | Increased | 1 | 1/4 (25%) | 3/75 (4%) | 0.191 |
| ALP | Increased | 0 | 1/4 (25%) | 3/76 (3.9%) | 0.189 |
| ALT | Increased | 4 | 0/4 (0%) | 0/72 (0%) | |
| AST | Increased | 1 | 1/4 (25%) | 8/75 (10.7%) | 0.39 |
| γGT | Increased | 5 | 0/3 (0%) | 1/72 (1.4%) | 1 |
| Calcium | Decreased | 2 | 0/4 (0%) | 6/74 (8.1%) | 1 |
| Calcium | Increased | | 0/4 (0%) | 1/74 (1.4%) | |
| Inorganic phosphorus | Increased | 3 | 2/4 (50%) | 8/73 (11%) | 0.08 |
| Potassium | Decreased | 1 | 0/3 (0%) | 1/76 (1.3%) | 1 |
| Potassium | Increased | | 0/3 (0%) | 10/76 (13.2%) | |
| Sodium | Decreased | 1 | 1/3 (33.3%) | 15/76 (19.7%) | 0.63 |
| Sodium | Increased | | 0/3 (0%) | 6/76 (7.9%) | |
| Chloride | Decreased | 1 | 2/3 (66.7%) | 27/76 (35.5%) | 0.569 |
| Chloride | Increased | | 0/3 (0%) | 1/76 (1.3%) | |

ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; γGT: gamma-glutamyl transpeptidase; HCT: haematocrit

CONCLUSIONS

1. The prevalence of FeLV infection in cats from Greece was found to be 3.9%.
2. Cats with a history of vomiting or rhinitis are significantly more likely to be FeLV-positive compared to cats without vomiting and rhinitis, respectively.
3. Infection with FIV increases the risk of infection with FeLV.
4. Neutropenic cats are significantly more likely to be FeLV-positive compared to cats with neutrophil counts within the reference intervals.
5. Cats with decreased BUN concentration are significantly more likely to be FeLV-positive compared to cats with BUN concentration within the reference intervals.
6. Cats with increased serum cholesterol or increased serum triglyceride concentration are significantly more likely to be FeLV-positive compared to cats with cholesterol and triglyceride concentrations within the reference intervals.
7. The prevalence of FIV infection in cats from Greece was found to be 9.2%.
8. Male gender, older age, and outdoor access have been identified as risk factors for FIV seropositivity.
9. Weight loss and the presence of fever, gingivostomatitis and skin lesions and/or pruritus are significantly associated with FIV-seropositivity.
10. Cats with hyperglobulinemia are more likely to be FIV-seropositive compared to cats with normal or reduced serum globulin concentrations.
11. The seroprevalence of FCoV infection in cats from Greece was found to be 12.1%.
12. Cats adopted as strays and in contact with other cats are more likely to be seropositive for FCoV.
13. The prevalence of seropositivity for *B. henselae* was found to be 35.4%.
14. Stray cats, cats with outdoor access, multiple in-contact cats and flea infestation are risk factors for *B. henselae*-seropositivity.
15. Gingivostomatitis is significantly associated with *B. henselae*-seropositivity.
16. Hyperglobulinemia is significantly associated with *B. henselae*-seropositivity.
17. Cats with an increased serum phosphorus concentration are significantly more likely to be *B. henselae*-seronegative than cats with a normal serum phosphorus concentration.

18. The molecular prevalence of *Bartonella* spp. infection in cats from Greece was found to be 2.9%.
19. Living in rural areas is a risk factor for *Bartonella* spp. PCR-positivity.
20. Non-smooth surface of the kidneys on abdominal palpation is significantly associated with PCR-positivity for *Bartonella* spp.
21. Cats with hypercalcemia are more likely to be *Bartonella* spp.-positive compared to cats with normal or reduced serum calcium concentrations.
22. The prevalence of hemoplasma species infection in cats from Greece was found to be 19%.
23. The lack of ectoparasiticide use is a risk factor for hemoplasma species infection.
24. Seropositivity for *T. gondii* has been found to be significantly associated to hemoplasma species PCR-positivity.
25. The presence of fever and ocular signs are significantly associated with PCR-positivity for hemoplasma species.
26. The prevalence of hemoplasma species PCR-positivity in clinically healthy cats is higher compared to sick cats.
27. Cats with thrombocytopenia are significantly more likely to be PCR-positive for hemoplasma species compared to cats with a normal platelet count.
28. The seroprevalence of *T. gondii* infection in cats from Greece was found to be 20.8%.
29. Older age is a risk factor for *T. gondii*-seropositivity.
30. Cats with a history of cat-bite wounds are significantly more likely to be *T. gondii*-seropositive compared to cats with no such history.
31. Cats that have not been vaccinated against calicivirus, herpesvirus-1, panleukopenia and rabies are significantly more likely to be seropositive to *T. gondii* compared to vaccinated cats.
32. The prevalence of feline hyperthyroidism among cats from Greece with an age of at least 6 years was found to be 5%.
33. The frequency of palpable goiter, depression-lethargy and dyspnea was significantly higher in hyperthyroid compared to euthyroid cats.
34. Decreased BUN concentration was more common in the hyperthyroid compared to euthyroid cats.

PROPOSALS FOR FUTURE STUDIES

The results of this study provide important information regarding the prevalence, the risk factors, the clinical picture and the clinicopathologic abnormalities of FeLV, FIV, FCoV, *Bartonella* spp., hemoplasma species, *Toxoplasma gondii* infections and feline hyperthyroidism. Future research could:

1. Determine the prevalence of feline infectious peritonitis in cats from Greece and investigate the risk factors for the appearance of the disease.
2. Investigate the clinical and clinicopathologic relevance of the infection by the different species of *Bartonella* and of hemoplasmas in cats.
3. Investigate the mechanisms underlying the positive association between gingivostomatitis and *Bartonella* spp. infection.
4. Investigate the role of fleas and ticks as vectors for hemoplasma species.
5. Determine the prevalence of feline toxoplasmosis in Greece and assess the risk factors for the appearance of the disease.
6. Determine the risk factors for the appearance of feline hyperthyroidism in Greece and further investigate its clinical and clinicopathologic manifestations, addressing a larger number of cats and using additional examinations to confirm the diagnosis in equivocal cases.

SUMMARY

STUDY ON THE EPIDEMIOLOGY AND THE CLINICAL IMPORTANCE OF SELECTED INFECTIOUS, PARASITIC AND METABOLIC DISEASES IN CATS FROM GREECE

Kassiopi-Christina G. Kokkinaki

Doctoral Thesis 2021

Infectious and parasitic diseases are common in all mammalian species, including domestic cats (*Felis catus*), who are becoming increasingly popular pets in Greece. Although several studies have investigated the prevalence of certain infectious and parasitic diseases in dogs, little is known about the prevalence and epidemiology of specific infectious agents in cats from Greece. This lack of data represents a major drawback for accurate and effective diagnosis, clinical management, and prevention of the diseases caused by these agents.

Vector-borne diseases, not only impact the health of domestic cats, but they are often of zoonotic importance. Since fleas, ticks and mosquitos are common in Greece, vector-borne agents such as *Bartonella* spp. and hemoplasma species, may also be common. Other infectious and parasitic agents such as *Toxoplasma gondii*, feline leukemia virus (FeLV), feline immunodeficiency virus (FIV) and feline coronavirus (FCoV) are also known to be present in Greece but reports on their prevalence, epidemiology, and clinical manifestations are scarce or absent.

Feline hyperthyroidism is worldwide the most common endocrinopathy in cats and its prevalence is increasing over time. No data on the prevalence of feline hyperthyroidism in Greece are available.

The aims of this study are to: a) determine the seroprevalence for FeLV, FIV, FCoV, *B. henselae* and *T. gondii* and the molecular prevalence of *Bartonella* spp. and *Mycoplasma* spp. infections; b) determine the prevalence of feline hyperthyroidism; c) investigate risk factors for FeLV, FIV, FCoV, *B. henselae* and *T. gondii* seropositivity; d) investigate risk factors for *Bartonella* spp. and *Mycoplasma* spp. PCR-positivity; e) determine the clinical signs, hematological and biochemical

findings associated with FeLV, FIV, FCoV, *B. henselae* and *T. gondii* seropositivity; f) determine the clinical signs, hematological and biochemical findings associated with PCR-positivity for *Bartonella* spp. and *Mycoplasma* spp.; g) investigate possible associations between seropositivity for *B. henselae*, PCR-positivity for *Bartonella* spp. or PCR-positivity for *Mycoplasma* spp. and seropositivity for other infectious agents, including *T. gondii*, FCoV, FeLV and FIV; h) to compare the clinical signs, hematological and serum biochemical findings between hyperthyroid and non-hyperthyroid cats.

A total of 547 clinically healthy and sick cats were prospectively enrolled in the study. The age of the cats ranged from 6 weeks to 17 years, they lived in Attica, Crete, Thessaly, and Macedonia and were client-owned, stray, or cattery cats. Four subgroups of 435, 453, 452 and 457 cats were selected to investigate the epidemiology and the clinical importance of infection with FeLV/FIV, FCoV, *Bartonella* spp./hemoplasma species, and *T. gondii*, respectively, while a fifth subgroup of 80 cats was selected for the investigation of the prevalence of hyperthyroidism. After history and physical examination, blood sampling was performed. Laboratory examinations included: a) hematology; b) serum biochemistry; c) serology for the detection of FeLV antigen and anti-FIV IgG antibodies using a commercial in-house ELISA test kit; d) serology (IFAT) for the detection of anti-FCoV, anti-*B. henselae* and anti-*T. gondii* IgG antibodies; e) blood PCR for detection of *Bartonella* spp. and hemoplasma species DNA; f) solid-phase chemiluminescent competitive assays for measurement of serum total T₄ and free T₄ concentration.

The seroprevalence of FeLV, FIV, FCoV, *B. henselae* and *T. gondii* infection was found to be 3.9%, 9.2%, 12.1%, 35.4% and 20.8%, respectively. The molecular prevalence of *Bartonella* spp. and hemoplasma species infection was found to be 2.9% and 19%, respectively. Finally, the prevalence of feline hyperthyroidism was found to be 5%.

Independent risk factors for FeLV seropositivity included vomiting, rhinitis, infection with FIV, neutropenia, decreased BUN and increased serum cholesterol and triglyceride concentrations.

Male gender, older age, outdoor access, weight loss, fever, gingivostomatitis, presence of skin lesions and/or pruritus, and hyperglobulinemia were independent risk factors for FIV seropositivity.

Cats adopted as stray cats and being in contact with other cats were at increased risk for FCoV seropositivity.

Independent risk factors for *B. henselae* seropositivity included being a stray cat, having outdoor access, having multiple in-contact cats, history of flea infestation, gingivostomatitis, hyperglobulinemia, and increased serum inorganic phosphorus concentration. Living in rural areas, non-smooth kidney surface on abdominal palpation and hypercalcemia were risk factor for *Bartonella* spp. PCR-positivity.

Independent risk factors for positive blood PCR for hemoplasma species included the lack of use ectoparasiticides, seropositivity for *T. gondii*, fever, presence of ocular signs, thrombocytopenia, and being clinically healthy cat.

Older age, history of cat-bite wounds, and no vaccination against calicivirus, herpesvirus-1, panleukopenia and rabies were risk factors for *T. gondii*-seropositivity.

The frequency of palpable goitre, depression-lethargy, dyspnea, and decreased BUN concentration was significantly higher in hyperthyroid compared to euthyroid cats.

In conclusion, the results of this study indicate a relative high prevalence of FeLV, FIV, FCoV, *Bartonella* spp., hemoplasma species and *T. gondii* seropositivity and/or PCR positivity in cats in Greece. Various factors related to the signalment and history, clinical examination findings, and laboratory abnormalities were found to be associated with the exposure and/or infection with these organisms. Thus, it is necessary to establish optimal strategies for prevention and management of these infections, taking into consideration the high-risk groups of cats identified in this study. Finally, hyperthyroidism is relatively common in cats in Greece, from the age of 6 years and above and should be considered especially in cats with palpable goiter, depression-lethargy, dyspnea and/or decreased BUN concentration.

ΠΕΡΙΛΗΨΗ

ΜΕΛΕΤΗ ΤΗΣ ΕΠΙΔΗΜΙΟΛΟΓΙΑΣ ΚΑΙ ΤΗΣ ΚΛΙΝΙΚΗΣ ΣΗΜΑΣΙΑΣ ΕΠΙΛΕΓΜΕΝΩΝ ΛΟΙΜΩΔΩΝ, ΠΑΡΑΣΙΤΙΚΩΝ ΚΑΙ ΜΕΤΑΒΟΛΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΗΣ ΓΑΤΑΣ ΣΤΗΝ ΕΛΛΑΔΑ

Κασσιόπη-Χριστίνα Γ. Κοκκινάκη

Διδακτορική Διατριβή 2021

Όλα τα ζωικά είδη μπορεί να εκτεθούν και να νοσήσουν από μεγάλο αριθμό μικροοργανισμών, συμπεριλαμβανομένης της γάτας (*Felis catus*), ενός είδους που απαντάται όλο και συχνότερα στην καθημερινή κλινική πράξη. Παρ' όλο που στην Ελλάδα υπάρχουν αρκετές έρευνες για τη συχνότητα και τους παράγοντες επικινδυνότητας για την εμφάνιση λοιμωδών και παρασιτικών νοσημάτων στο σκύλο, οι αντίστοιχες μελέτες για τη γάτα είναι λιγιστές, γεγονός που αποτελεί τροχοπέδη για τον σχεδιασμό κατάλληλων διαγνωστικών, θεραπευτικών και προληπτικών παρεμβάσεων, τόσο στις οικόσιτες γάτες όσο σε εκείνες που ζουν σε εκτροφεία και καταφύγια ή είναι αδέσποτες. Επιπλέον, στη χώρα μας δεν υπάρχει δημοσιευμένη μελέτη για τη συχνότητα του υπερθυρεοειδισμού, που διεθνώς θεωρείται η συχνότερη ενδοκρινοπάθεια της γάτας.

Τα λοιμώδη νοσήματα της γάτας που μεταδίδονται με ενδιάμεσους ξενιστές έχουν παγκόσμια εξάπλωση, ενώ συχνά προσβάλλουν και τον άνθρωπο. Οι βιολογικοί ή μηχανικοί μεταδότες είναι αρθρόποδα, όπως ψύλλοι, κρότωνες και κουνούπια, τα οποία αφθονούν στην Ελλάδα και είναι ικανά να μεταδώσουν διάφορους λοιμογόνους παράγοντες, όπως για παράδειγμα η *Bartonella* spp. και το *Mycoplasma* spp. Ορισμένοι άλλοι μικροοργανισμοί, όπως είναι ο ιός της λευχαιμίας (FeLV), ο ιός της επίκτητης ανοσοανεπάρκειας (FIV) και ο κορονοϊός (FCoV) της γάτας, είναι γνωστό ότι υπάρχουν στην Ελλάδα, αλλά η επιδημιολογική και η κλινική τους σημασία παραμένει αδιευκρίνιστη. Τέλος, σε επιδημιολογικές μελέτες, από διάφορες χώρες, έχει βρεθεί ότι το ποσοστό των γατών και των ανθρώπων που είναι ορολογικά θετικοί για το *Toxoplasma gondii* μπορεί να ξεπερνάει το 30%, γεγονός που καταδεικνύει την

αναγκαιότητα σύγχρονων δεδομένων για τη συχνότητα της τοξοπλάσμωσης της γάτας στην Ελλάδα και των παραγόντων επικινδυνότητας.

Οι στόχοι της μελέτης αυτής ήταν: α) η διερεύνηση της συχνότητας της οροθετικότητας της γάτας στην Ελλάδα έναντι των FeLV, FIV, FCoV, *B. henselae* και *T. gondii* και της συχνότητας μόλυνσης από *Bartonella* spp. και *Mycoplasma* spp., β) ο προσδιορισμός της συχνότητας του υπερθυρεοειδισμού, γ) η διερεύνηση των παραγόντων επικινδυνότητας για την οροθετικότητα έναντι των FeLV, FIV, FCoV, *B. henselae* και *T. gondii*, δ) η διερεύνηση των παραγόντων επικινδυνότητας για τη μόλυνση από *Bartonella* spp. και *Mycoplasma* spp., ε) η διερεύνηση των συμπτωμάτων, των αιματολογικών και βιοχημικών διαταραχών που σχετίζονται με την οροθετικότητα έναντι των FeLV, FIV, FCoV, *B. henselae* και *T. gondii*, στ) η διερεύνηση των συμπτωμάτων, των αιματολογικών και βιοχημικών διαταραχών που σχετίζονται με την μόλυνση από *Bartonella* spp. και *Mycoplasma* spp., ζ) η διερεύνηση πιθανών συσχετισμών μεταξύ της οροθετικότητας για *B. henselae*, της μόλυνσης από *Bartonella* spp. ή της μόλυνσης από *Mycoplasma* spp. και της οροθετικότητας για FeLV, FIV, FCoV, και *T. gondii*, η) η σύγκριση της κλινικής εικόνας και των αποτελεσμάτων της γενικής εξέτασης του αίματος και των βιοχημικών εξετάσεων μεταξύ των υπερθυρεοειδικών και ευθυρεοειδικών γατών.

Στην μελέτη περιλήφθηκαν συνολικά 547 κλινικά υγιείς και άρρωστες γάτες. Η ηλικία τους κυμαινόταν μεταξύ 6 εβδομάδων και 17 ετών και ζούσαν στην Αττική, την Κρήτη, τη Θεσσαλία και τη Μακεδονία. Οι γάτες της μελέτης ήταν δεσποζόμενες, αδέσποτες ή ζούσαν σε εκτροφές. Από τις 547 γάτες, επιλέχθηκαν οι 435, 453, 452 και 457 για τη μελέτη της επιδημιολογίας και της κλινικής σημασίας της μόλυνσης από FeLV/FIV, FCoV, *Bartonella* spp./*Mycoplasma* spp. και *T. gondii* αντίστοιχα, ενώ στη μελέτη του υπερθυρεοειδισμού χρησιμοποιήθηκαν 80 γάτες ηλικίας ≥ 6 ετών. Μετά την λήψη του ιστορικού και την κλινική εξέταση ακολούθησε η λήψη ολικού αίματος. Οι εξετάσεις που πραγματοποιήθηκαν ήταν: α) γενική εξέταση αίματος, β) βιοχημικές εξετάσεις στον ορό αίματος, γ) ορολογική εξέταση για την ανίχνευση του αντιγόνου του FeLV και των αντισωμάτων έναντι του FIV, δ) ορολογικές εξετάσεις (IFAT) για την ανίχνευση IgG αντισωμάτων έναντι της *B. henselae*, του *T. gondii* και του FCoV, ε) PCR από το αίμα για την ανίχνευση του DNA των *Bartonella* spp. και *Mycoplasma* spp., και στ) προσδιορισμός της συγκέντρωσης της ολικής T₄ και της ελεύθερης T₄.

Η συχνότητα της οροθετικότητας για FeLV, FIV, FCoV, *B. henselae* και *T. gondii* ήταν 3,9%, 9,2%, 12,1%, 35,4% and 20,8%, αντίστοιχα, η συχνότητα της μόλυνσης από *Bartonella* spp. και *Mycoplasma* spp. ήταν 2,9% και 19%, αντίστοιχα και η συχνότητα του υπερθυρεοειδισμού ήταν 5%.

Οι παράγοντες επικινδυνότητας για τη μόλυνση από FeLV ήταν η διαπίστωση εμέτου ή ρινίτιδας, η ταυτόχρονη μόλυνση από FIV, η ουδετεροπενία, η μειωμένη συγκέντρωση ουρείκού αζώτου (BUN) στον ορό αίματος και η αυξημένη συγκέντρωση χολοστερόλης και τριγλυκεριδίων.

Οι παράγοντες επικινδυνότητας για την οροθετικότητα στον FIV ήταν το αρσενικό φύλο, η μεγαλύτερη ηλικία, η διαμονή σε εξωτερικούς χώρους, η απώλεια βάρους, ο πυρετός, η διαπίστωση δερματικών αλλοιώσεων ή/και κνησμού και η υπερσφαιριναίμια.

Οι παράγοντες επικινδυνότητας για την οροθετικότητα στον FCoV ήταν η υιοθέτηση προηγουμένως αδέσποτης γάτας και η επαφή με άλλες γάτες.

Παράγοντες επικινδυνότητας για την οροθετικότητα στην *B. henselae* ήταν το να είναι η γάτα αδέσποτη, να ζει σε εξωτερικούς χώρους, να έρχεται σε επαφή με αυξημένο αριθμό γατών, να έχει ιστορικό παρασίτωσης από ψύλλους, να εμφανίζει ουλοστοματίτιδα ή υπερσφαιριναίμια και να μην εμφανίζει υπερφωσφαταιμία.

Η διαβίωση σε αγροτικές περιοχές, η ανώμαλη επιφάνεια των νεφρών κατά την ψηλάφησης της κοιλίας και η υπερασβεστιαίμια ήταν οι παράγοντες επικινδυνότητας για τη μόλυνση από *Bartonella* spp.

Στους παράγοντες επικινδυνότητας για τη μόλυνση από *Mycoplasma* spp. περιλαμβάνονται η μη χρήση εξωπαρασιτοκτόνων, η οροθετικότητα στο *T. gondii*, ο πυρετός, οι αλλοιώσεις από τους οφθαλμούς, η μη διαπίστωση παθολογικών ευρημάτων κατά την κλινική εξέταση και η θρομβοκυτταροπενία.

Οι παράγοντες επικινδυνότητας για την οροθετικότητα στο *T. gondii* ήταν η αυξημένη ηλικία, τα δαγκώματα από άλλες γάτες και ο μη εμβολιασμός έναντι του καλυκοϊού, του ερπητοϊού, της πανλευκοπενίας και της λύσσας.

Η συχνότητα βρογχοκίλης, κατάπτωσης ή ληθαργικότητας, δύσπνοιας και μειωμένης συγκέντρωσης BUN ήταν μεγαλύτερη στις υπερθυρεοειδικές γάτες σε σχέση με τις ευθυρεοειδικές.

Συμπερασματικά, από τα αποτελέσματα της μελέτης προκύπτει ότι η συχνότητα οροθετικότητας ή/και μόλυνσης της γάτας στην Ελλάδα από FeLV, FIV, FCoV, *Bartonella* spp., *Mycoplasma* spp. και *T. gondii* είναι σχετικά μεγάλη και

σχετίζεται με διάφορα συμπτώματα και εργαστηριακές διαταραχές, ανάλογα με το μικροοργανισμό. Για το λόγο αυτό, είναι απαραίτητο να σχεδιαστούν κατάλληλα διαγνωστικά, θεραπευτικά και προληπτικά μέτρα, που θα λαμβάνουν υπόψη του παράγοντες αυξημένου κινδύνου. Τέλος, ο υπερθυρεοειδισμός της γάτας φαίνεται να είναι συχνός στην Ελλάδα στις γάτες ηλικίας ≥ 6 ετών και πρέπει να ελέγχεται, ιδιαίτερα στις μεσήλικες και υπερήλικες γάτες με βρογχοκήλη, κατάπτωση ή ληθαργικότητα και μειωμένη συγκέντρωση BUN.